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Deoxyribonucleic acid (DNA) The DNA double helix was first described by Watson and Crick in 1953.[1] Since then, the scientific advances based in DNA have been prodigious and far beyond expectations in many fields, reaching areas as diverse as medicine, basic biology, genetics, forensics, archeology among others, and culminating in the sequencing of the human genome.[2] Deoxyribonucleic acid is a self-assembling biopolymer that encodes the genetic information used in the development and functioning of all known living organisms and many viruses. DNA, together with proteins and carbohydrates, compose the three major macromolecules essential for all forms of life. DNA forms double helices directed by canonical Watson-Crick base pairing and is stabilized by hydrogen bonds, π-π stacking and hydrophobic interactions.[1] The two DNA strands are composed of simpler units called nucleotides. Each nucleotide is composed of a nitrogen-containing nucleobase—either guanine (G), adenine (A), thymine (T), or cytosine (C)—as well as a monosaccharide sugar called deoxyribose and a phosphate group. The four nucleobases are classified in pyrimidines and purines, depending on their structure: pyrimidines (T and C) consist of a single heterocycle of six atoms and purines (A and G) are composed by a pyrimidine ring fused to an imidazole ring (figure 1). Nucleotides are joined to one another by covalent bonds between the sugar of one nucleotide and the phosphate of the next, resulting in a chain formed by an alternating sugar-phosphate backbone. According to base pairing rules (A with T and C with G), hydrogen bonds bind the nitrogenous bases of the two separate polynucleotide strands to make double-stranded DNA. This double helix is further stabilized by π-π stacking and hydrophobic interactions. 
 
Figure 1. 1A. Representation of the four nucleotides, covalently linked by phosphate bonds. 1B. Watson-Crick canonical base pairing, C-G and A-T. Non-covalent hydrogen bonds between the pairs are shown as dashed lines. Adapted from ref [3].[3]  
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DNA structures DNA exists in many possible conformations that include A-DNA, B-DNA, and Z-DNA forms (figure 2), although only B-DNA and Z-DNA have been directly observed in functional organisms.[4] The conformation adopted by DNA depends on its hydration level, its sequence, the amount and direction of supercoiling, the chemical modifications of its bases, the type and concentration of metal ions, as well as the presence of polyamines in solution.[5] The more compact A form of DNA has 11 base pairs per turn and exhibits a large tilt of the base pairs with respect to the helix axis. In addition, the A form has a central whole (figure 2, left). This helical form is adopted by RNA–DNA and RNA–RNA helices.[6] The B-form of DNA, usually found in cells, consists of well-defined structures 
that	 are	 repeated	 along	 the	 strands:	 the	 helical	 turn	 measures	 	̴ 3.4 nm, the	 helical	
diameter	 	̴ 2.0 nm and the twist angle between base-pairs in solution 	 ̴ 34.3º (figure 2, centre).[1] In contrast, the Z-DNA helix is left-handed and has a structure that is repeated every 2 base pairs (figure 2, right). The major and minor grooves, unlike A- and B-DNA, show little difference in width.[7] Formation of this structure is generally unfavourable, as it is a form of higher energy than B-DNA, although certain conditions can promote it, such as alternating purine-pyrimidine sequence, negative DNA supercoiling or high salt and some cations, all requiring physiological conditions. Z-DNA can form a junction with B-DNA (called a "B-to-Z junction box") in a structure which involves the extrusion of a base pair.[8] The Z-DNA conformation has been difficult to study because it does not exist as a stable feature of the double helix. Instead, it is a transient structure that is occasionally induced by biological activity and then quickly disappears.[9] 
 
Figure 2. Different types of DNA conformation. A-DNA is the more compact form of DNA, with 11 base-pairs per turn, and it is typical of RNA-DNA and RNA-RNA lattices. B-DNA, the most common conformation of DNA in 
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nature, is right-handed and possesses a well-defined structure. Z-DNA is conferred as a zig-zag and is a form of higher energy than B-DNA.  The remarkable flexibility of nucleic acids allows them to form a great variety of structures, in addition to the double helix described above, as for example triplexes, i-
motifs and G-quadruplexes. This flexibility is caused mainly by the high degree of freedom of the deoxyribose ring, and secondly, by the rotation of the glycosidic bond and the phosphate backbone. Triplex forming oligonucleotides (TFOs)[10] bind in the major groove of duplex DNA with high specificity and affinity. A DNA triplex is formed when pyrimidine or purine bases occupy the major groove of the DNA double helix forming Hoogsteen pairs with purines of the Watson-Crick base-pairs. Intermolecular triplexes are formed between triplex forming oligonucleotides (TFO) and target sequences on duplex DNA[11] (figure 3).[12] TFO should have the identical sequence of the complementary strand of the associating strand in the DNA duplex, while the direction of the TFO relies on the type of DNA triplex. Depending on which bases (pyrimidine or purine) of the TFO interact with the purine base of the duplex, there are two kinds of DNA triplexes: parallel and anti-parallel, respectively.[12] Because of these characteristics, TFOs have been proposed as homing devices for genetic manipulation in vivo to alter gene expression and mediate genome modification.[13]  
 
Figure 3. Parallel triplex which consists of T × A·T and C+ × G·C triads (light green). Triplex forming oligonucleotide (TFO), bound at the major groove of the DNA duplex, is coloured in pink. Adapted from ref. [12]. In contrast, the i-motif is an intercalated structure formed by association in a head to tail orientation of two parallel duplexes whose strands are held together by hemiprotonated C:C(+) pairs [14] (figure 4). Due to the hemiprotonated nature of the C:C(+) pairs, the formation of i-motifs often requires acidic conditions. However, depending on 
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particular C-rich sequences, i-motifs can fold close to neutral pH.[15] The i-motif may be formed by a single strand containing four cytidine repeats, by association of two strands containing two cytidine repeats or by four strands containing a single cytidine stretch. In 
vivo, intramolecular i-motifs can be found in C-rich sequences of centromeric and telomeric sequences in the chromosome. 
 
Figure 4. Representation of an i-motif quadruplex structure, with its hemiprotonated C:C+ base pair in cyan. Adapted from ref. [12]. 
 
G-quadruplexes and TBA G-quadruplexes are a family of four-stranded DNA structures stabilized by the stacking of guanine tetrads, in which four planar guanines form a cyclic array of Hoogsteen hydrogen bonds stabilized by the presence of monovalent cations[16] (figure 5A). However, most divalent cations have the capacity to induce the dissociation of G-quadruplex structures.[17] These G-rich regions are connected by lateral, central or diagonal loops of diverse sizes and composition that form base-pairing alignments, which in turn stack with the terminal G-tetrads, thus further stabilizing G-quadruplex structures.[18] G-quadruplexes can be folded from a single G-rich sequence intramolecularly or by the intermolecular association of two (dimeric) or four (tetrameric) separate strands (figure 5B). In addition, quadruplexes can adopt different topologies with varying loop configurations, depending on how the guanine bases are arranged.[16d] In the case of intermolecular quadruplexes, if the 5'-3’ direction of all the strands is the same, the quadruplex is termed parallel (figure 5C). In contrast, intermolecular G-quadruplexes are antiparallel if the strands are arranged in different directions. For intramolecular quadruplexes, if one or more of the runs of guanine bases has a 5’-3’ direction opposite to the other runs of guanine bases, the quadruplex is said to have adopted an antiparallel topology (figure 5C).  
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Figure 5. A. Structure of a G-quadruplex structure with the square and planar arrangement of four guanines forming a G-quartet. Adapted from ref. [12] B. Schematic representation of intermolecular quadruplexes, tetra and bimolecular. C. Schematic representation of intramolecular quadruplexes, antiparallel and parallel respectively. Adapted from ref. [19][19] Modifications in the base composition of the tetrads are poorly tolerated by these structures. As an example, inosine [20] and O6-methylguanosine [21], (figure 6) both nucleosides containing non-natural bases, can form a smaller number of hydrogen bonds, provoking the loss of the quadruplex conformation.[22] 
 
Figure 6. Chemical structure of methylguanosine and inosine. There is evidence that G-quadruplexes can be formed in vivo[23] and present great biological relevance. They can be found in the telomere, the final region of the chromosome composed by repetitions of non-coding G-rich sequences, which protects the end of the chromosome from deterioration or from fusion with neighbouring chromosomes.[24] In addition, these sequences can be found in gene promoters regions, suggesting that their function may be related with gene regulation at the transcription level.[25] Furthermore, a great variety of proteins can recognize and interact with 
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oligonucleotide aptamers that possess a G-quadruplex structure, as the G-quadruplex aptamers that inhibit the HIV integrase.[26]  In particular, the α-thrombin binding aptamers (TBA) are well characterized chair-like, antiparallel quadruplex structures that bind specifically to α-thrombin at nanomolar concentrations and therefore have interesting anticoagulant properties.[27] α-thrombin is able to interact with two different TBAs in two binding sites of the protein.[28] These two sequences are known to bind specifically and cooperatively to two specific and almost opposite epitopes of α-thrombin when folded into their quadruplex structure.[28b] TBA1 is a 15mer nucleotide composed of two G-tetrads that are connected by three edge-wise loops, forming a well-characterized intramolecular chair-like, antiparallel quadruplex which binds α-thrombin in its primarily fibrinogen exosite.[28a] In contrast, TBA2, a 29mer nucleotide that forms a combined quadruplex/duplex structure, interacts with α-thrombin in its heparin-binding exosite, placed in the opposite side of the protein[28b] (figure 7).  
 
Figure 7. α-thrombin interaction with the α-thrombin binding aptamers. The fibrinogen exosite (I) of α-thrombin interacts with the 15mer aptamer while the heparine exosite (II) is recognized by the longer aptamer (29mer).  
DNA stability, damage and repair DNA may suffer structural damage that can alter or eliminate the cell's ability to transcribe the encoded genes.[29] DNA damage occurs at a rate of 10,000 to 1,000,000 molecular lesions per cell per day, which constitutes only 0.000165% of the human genome,[30] and plays a major role in mutagenesis, carcinogenesis and ageing. These reactions are triggered by exposure to environmental factors and exogenous chemicals, or they can result from metabolic processes inside the cell.[31] Environmental and exogenous DNA damage can be caused by the UV radiation of the sun,[32] other radiation frequencies, as X-
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rays and gamma radiation,[33] and human-made mutagenic chemicals,[34] specially aromatic compounds that act as intercalating agents.[35] Some viruses can also cause mutations in DNA during their replication cycle inside the host cell.[36] In contrast, endogenous damage is caused by spontaneous mutations and replication errors,[37] or by reactive oxygen species produced from normal metabolic byproducts.[38] There are several types of damage to DNA due to exogenous factors and endogenous cellular processes:[39] oxidation of bases, as for example 8-oxo-7,8-dihydroguanine (8-oxoG);[40] alkylation of bases[41] (usually methylation), such as formation of 7-N-methylguanine,[42] 3-N-methyladenine[43] and 6-O-methylguanine;[44] or hydrolysis of bases, such as deamination,[45] depurination,[46] and depyrimidination.[47] Other damage includes bulky adduct formation, mismatch of bases due to errors in DNA replication and crosslinks of different types.[48] 
 Cells must repair DNA damage to prevent mutations from propagating and accumulating, and to maintain genome integrity and stability. The persistence of unrepaired DNA damage results in accumulation of mutations, cell cycle arrest and apoptosis.[49] DNA damage alters the spatial configuration of the helix and such alterations can be detected by the cell, inducing several mechanisms for DNA repair.[50] The ATM and ATR genes often initiate the DNA damage response, activating signal transduction pathways that arrest the cell cycle and increase the expression of DNA repair genes.[51] Enzymes involved in different pathways as the base-excision, the nucleotide excision, the mismatch repair, the double-strand break, and other DNA repair processes (figure 8) all respond in a pre- and post-transcriptionally regulated fashion to DNA damage. Nevertheless, cells unable to sense and repair DNA damage may continue to grow and divide, eventually causing cellular dysfunction and death, a hallmark of diseases such as neurological defects and infertility. In addition, deregulation of DNA damage sensing can also yield an increased mutation rate, potentially causing uncontrolled cell growth and cancer.  
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Figure 8. Scheme of the different types of damage that DNA can suffer with their according DNA repair pathways. Adapted from ref. [52]  The base excision repair (BER) pathway is a major mechanism for dealing with a variety of lesions in DNA produced by alkylation.[53] This pathway is initiated by specific DNA glycosylases, which recognize and excise the damaged base to generate an apurinic/apyrimidinic (AP) site. AP endonuclease 1 (Ape1)[54] cleaves the phosphodiester backbone adjacent to the 5’ site of the AP site, generating a 3’ hydroxyl and 5’-deoxyribose phosphate termini.[54d] Polymerase	β	 removes	 the	 5’-deoxy ribose phosphate, fills in the one-nucleotide gap, and the consequent nick is ligated by DNA ligase I or by DNA ligase III/XRCC1[47, 55] (figure 9). Ape1 is a fundamental protein in this essential repair pathway and it is thought to be responsible for 95% of total AP endonuclease activity in human cell lines.[56] 
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Figure 9. Schematic representation of the enzymes involved in the base excision repair pathway. Other DNA repair mechanisms are based on a single reaction modulated by a single enzyme. For example, the DNA repair O6-alkylguanine DNA alkyltransferase (AGT or MGMT) is in charge of repairing alkylating damage, removing alkyl adducts from the O6 position of guanines. The human AGT (hAGT), the most thoroughly characterized AGT protein, repairs alkylated DNA by flipping the damaged base out of the helix, and the alkyl group is transferred from the point of lesion to the active site Cys145 residue to be repaired.[57] Once alkylated, this protein is degraded by the ubiquitin pathway.[58] hAGT is normally present in all cells, but its overexpression can be triggered in tumoral cells that are being attacked by alkylating chemotherapeutic agents.  
 
DNA alkylating agents as chemotherapy for cancer  Alkylating agents are chemotherapeutic anticancer drugs that produce their cytotoxic effect by generating alkylation and adducts at multiple sites in DNA.[59] DNA repair pathways induced by chemotherapeutic drugs as alkylating agents have a key role in the prognosis and evolution of multiple cancers. [60] The simultaneous treatment with alkylating agents and inhibitors of DNA repair proteins sensitizes tumoral cells to chemotherapy and results in a better outcome and prognosis.[61] An example of it is the identification and characterization of small molecules that inhibit the repair endonuclease activity of APE-1,[62] including methoxyamine (MX), lucanthone and 7-nitroindole-2-carboxilic acid (NCA). All three compounds were able to enhance the effects of 
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methylmethane sulfonate (MMS) or temozolamide (TMZ) in ovarian,[63] breast,[63b, 64] colon[65] and HT1080 fibrosarcoma cancer cells.[66] Another subset of alkylating agents, which includes nitrosoureas and temozolamide, have a preference for alkylating guanine at the O6 position, which is the most important in terms of mutagenesis and carcinogenesis.[42, 44, 67] In particular, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) attacks initially at the O6 guanine position, causing its rearrangement in a cyclic intermediate due to the attack at the N1 position of guanine, giving rise to N1,O6-ethanoguanine.[68] Finally, a cross-link with the opposite cytosine is formed (figure 10) and, as a consequence, DNA replication is blocked, producing G2/M arrest.[69] 
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Figure 10. Mechanism of action of 1,3-bis-(2-chloroethyl)-1-nitrosourea, which alkylates the O6 position of guanines, causing a crosslink with the opposite cytosine. The DNA-repair O6-alkylguanine DNA alkyltransferase (hAGT) is in charge of removing alkyl adducts from the O6 position of guanines, blocking their cytotoxic effects and playing an important role as a chemotherapy resistance mechanism (figure 11).[70]  
 
Figure 11. Mechanism of action of the repair reaction of hAGT. A. Carmustine or BCNU (bis-chloroethylnitrosourea) introduces alkyl groups in the O6 position of guanines. B. The active site cystine 145 removes the alkylation through a nucleophilic attack SN2. C. The guanine is restored while the active site of hAGT remains covalently linked to the alkyl group and the protein undergoes a process of ubiquitination and degradation.  
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It is well established that tumor cells frequently express higher levels of this protein, which appears to be predictive of poor response to chemotherapeutic drugs. This effect has been observed in a large number of cancers, ranging from colon cancer, lung tumors, breast cancer, pancreatic tumors, non-Hodgkin’s lymphoma, myeloma and glioblastoma multiforme, among others.[71] Additionally, methylation of hAGT promoter and consequently hAGT complete depletion has been associated with longer survival in patients with gliomas under radiation-chemotherapy combining treatment.[72] Therefore, pharmacological inhibition of hAGT has the potential to enhance cytotoxicity of a diverse range of anticancer agents.[73] Adducts formed at the O6 position of the guanine are of major importance in both the initiation of mutations and in the cytotoxic effects of these agents. For all these reasons, hAGT is considered relevant as a prognosis marker of cancer and represents a potential therapeutic target.[70c] Several research groups have focussed their research on the identification of small molecules capable of inhibiting hAGT activity and enhancing the cytotoxic effect of the alkylating agents in tumour cells.[74]  Over the last years, a number of drugs have been shown to inactivate hAGT in cells, human tumour models and cancer patients, and O6-benzylguanine and O6-[4-bromothenyl]guanine have been used in clinical trials. These agents also inactivate MGMT in normal tissues and hence exacerbate the toxic side effects of the alkylating drugs, requiring dose reduction.[75] In addition, they possess poor pharmacokinetic conditions[76] and also produce myelosupression.[77] 
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DNA Nanotechnology At the end of the XX century, Ned Seeman set the bases for the use of DNA as a scaffold for nanoscale building material.[78] The remarkable specificity of the molecular recognition between complementary nucleotides in the DNA base pairing has made it an attractive molecule for scientists and engineers interested in micro- and nano-fabrication. Its predictability, rigidity, and precise structural control, as well as the creation of algorithms for de novo design of new self-assembled structures,[79] make it a useful building material to develop different kinds of nanotechnological platforms. Compared to other self-assembling molecules, DNA nanostructures offer programmable interactions and surface features for the precise positioning of other nanoparticles and biomolecules.[80]  Seeman’s original goal was the creation of regular 3D lattices of DNA which could be used as scaffolding for the rapid, orderly binding of biological macromolecules to speed the formation of suitable crystals for 3D protein structure elucidation in x-ray diffraction studies.[78] This concept gave rise to the tile-based assembly method, used to synthesize two-dimensional periodic lattices[81] and three-dimensional architectures as for example a cube in solution[82] and different polyhedra in solid phase.[83] Some examples of 3D DNA constructs are represented in figure 12.[84] 
 
Figure 12. A. Schematic representation of a tridimensional cube, containing twelve equal-length double-helical edges arranged around eight vertices. Adapted from ref. [82] B. Double-helical representation of an ideal truncated octahedron. Adapted from ref. [83b] C. Schematic representation of a DNA tetrahedron. Adapted from ref. [83c] D. Reconstituted 3D image of an octahedron. Secondary structures of the octahedron consisted of different DNA motifs for 3D formation. Adapted from ref. [83a] E. Scheme of the polyhedral structures: a tetrahedron, a dodecahedron and a bucky ball were assembled from three-point star building blocks. Adapted from reference [83d]. 
 
 DNA Origami Another important breakthrough in the structural DNA nanotechnology field has been the development of DNA origami by Paul Rothemund,[85] where a long scaffold strand of 7 
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kilobase, the M13 phage genome, is folded with the help of hundreds of short ‘staples’ to create a rational desired two-dimensional shape (figure 13). Since then, various DNA motifs have been designed in 2D and 3D, and extensive studies are currently ongoing to apply these nanostructures to a large amount of biomedical, computational and molecular motor purposes.  
 
Figure 13. Scheme of the formation of a DNA origami by the annealing of a viral circular scaffold and the complementary staple strands. Adapted from ref [87]. DNA origami is a versatile tool for the self-assembly of other molecular species[86] and constitutes an excellent platform to create a variety of new nanoscale devices[87] with great biological potential and applications.[88] As examples, Yao and co-workers have used the DNA origami as an addressable support for label-free detection of RNA hybridization[89] and later, Seeman and co-workers have developed a nanosensor to detect single nucleotide polymorphism (SNP).[90] Both strategies represent an innovative way to use the DNA origami methodology to create a nanosensor for biomedical applications at the single molecule level using atomic force microscopy (AFM) (figure 14A). In addition, DNA origami has been applied for the study of DNA repair proteins, as represented in figure 14B, where the methyl transfer reaction of EcoRI is visualized in a frame-like DNA origami. In this particular case, Sugiyama and collaborators studied by AFM the regulation of DNA methylation using different tensions of double strands. They introduced two different double helical tensions (tense and relaxed) into an origami frame, to control the methyl transfer reaction of EcoRI and examine the structural effect of this methylation.[91] Endo et 
al. further evolved this idea to create a versatile nanochip for direct analysis of DNA base-excision repair. In this case, the studied enzymes were 8-oxoguanine glycosylase (hOgg1) and t4 pyrimidine dimer glycosylase (PDG).[92] The exact positioning and displacement of the enzymes in the reaction can be monitored and analyzed. Another relevant application of the DNA origami is its potential use as drug delivery systems with high biocompatibility: for example, a logic-gated DNA nano-pill was designed for the selective delivery of molecular payloads to the cell and is represented in figure 14C.[93] These nanopills are capable of inducing a great variety of responses in cell behavior. Another cutting-edge design of DNA origami related with cellular biology was 
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the design of DNA-based channel that can punch pores into the lipidic cell membrane which are able to discriminate single DNA molecules (figure 14D).[94] This could be of great interest for the delivery of oligonucleotide-based drugs for gene therapy, which do not enter the cell easily due to their chemical features. 
 
Figure 14. A. Detection of single molecule polymorphisms via atomic force microscopy over an origami surface. Adapted from ref. [90]. B. Methyl transfer reaction of EcoRI and analysis of the structural effect of this methylation using a same frame-like design of DNA origami. Adapted from ref. [91] C. DNA-origami based channel that can punch pores into the lipidic cell membrane, with ability to discriminate single DNA molecules. Adapted from ref. [93]. D. Logic-gated DNA nano-pill for the selective delivery of molecular payloads to the cell. Adapted from ref. [94]. Further development of DNA nanotechnology holds great potential for biological applications, hopefully for biomedical approaches with highly programmable and controllable abilities in the very near future. 
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DNA Nanoparticles In recent years, a great variety of chemical methods has been developed to synthesize functionalized nanoparticles for biomedical applications such as drug delivery, cancer therapy, diagnostics, tissue engineering and molecular biology, and the structure-function relationship of these functionalized nanoparticles has been extensively examined.[95] Nanoparticles are particles between 1 and 100 nanometres in size. In nanotechnology, a particle is defined as a small object that behaves as a whole unit with respect to its transport and properties. Particles are classified according to their composition and diameter. Their properties allow the functionalization with diverse biomolecules, including DNA, by different chemical means. In particular, the controlled assembly and disassembly of gold nanoparticles (AuNPs) has been a subject of great interest over the past decade due to the potential applications of these particles in nanobiotechnology.[96] Their unique physical properties,[97] particularly their localized surface plasmon resonance (LSPR)[98] and their efficient interaction with molecules with a free thiol group, make AuNPs attractive building blocks for nanoscale electronic and photonic devices.[99] Due to the strong interaction between gold and thiols (-SH), a single monolayer of DNA around the gold particle can be obtained. The negative charge repulsion of the phosphate backbone of DNA orients the DNA strands out into solution with a unique footprint that is dependent on gold nanoparticle size and packing density. Since the first DNA sensor was designed by Mirkin and co-workers,[100] the development of AuNP-based colorimetric biosensors has been increasingly applied for the detection of a large variety of targets, including nucleic acids, proteins, saccharides, small molecules, metal ions, and even cells. This technique takes advantage of the colour change that arises from the interparticle plasmon coupling during AuNP aggregation (red-to-purple or blue) or redispersion of an AuNP aggregate (purple-to-red) (figure 15).[96a, 96b, 96g] It is quickly becoming an important alternative to conventional detection techniques, as fluorescence-based assays, and holds great potential in clinical diagnostics, drug discovery, and environmental contaminant analysis, among others. 
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Figure 15. Schematic representation of the colorimetric change suffered by gold colloid upon aggregation and its UV spectra displacement. Adapted from ref [103].[101]   In contrast, super paramagnetic iron oxide nanoparticles possess different interesting features for nanomedicine. SPION are one of the most promising agents in diagnostics, due to their advantages as MRI contrast agents.[102] Under an applied magnetic field, SPION shorten the spin-spin relaxation time (T2) of the proton, which results in darkening of MR images. A schematic representation of this process is shown in figure 16.[103] 
 
Figure 16. Super paramagnetic iron oxide nanoparticles as negative contrast agents. Under an applied magnetic field, SPION shorten the spin-spin relaxation time (T2) of the proton, which results in darkening of MR images. Adapted from ref. [103] In comparison with the traditional gadolinium-based contrast agents, SPION produce lower toxicity, stronger enhancement of proton relaxation and have a lower detection limit.[104] Furthermore, SPION have several other applications in biomedicine, especially for delivery purposes and biosensing, due to their reduced size and ability to be transported in biological systems.[105] Their functionalization with DNA is not straightforward, as iron oxide interacts poorly with biomolecules. For this reason, organic compounds are used for their coating, focusing in two major objectives: preserve the magnetic properties of magnetic iron oxides and enhance their biocompatibility.[106] 
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Gold and iron-based magnetic nanoparticles seem to be one of the most promising nanoparticles for biomedical applications for their unique properties. The combination of them through a gold coating over the magnetic core provides the benefits from both nanoparticles, adding the magnetic properties to the robust chemistry provided by the thiol functionalization of the gold coating (figure 17).[107] As a result, an increasing number of laboratories is working on the synthesis and applications of this type of gold-coated nanoparticles.[105c, 105d, 108] 
 
Figure 17. Steps in the synthesis and functionalization of gold-coated magnetic nanoparticles. Adapted from ref [107].  As mentioned before, DNA functionalized nanoparticles are suitable for several applications, as drug delivery or the development of sensors for the detection of biomolecules. Nanoparticles provide the benefits from controlled drug delivery and cell-specific targeting, compared to the traditional forms of drug administration. A drug is transported to the place of action, hence, its influence on vital tissues and undesirable side effects can be minimized. Accumulation of therapeutic compounds in the target site increases and, consequently, the required doses of drugs are lower.[109] However, for nanoformulations used in drug delivery the focus in most researches is mainly on the reduction of toxicity of the incorporated drug, whereas the possible toxicity of the carrier used is not considered. Their toxicity due to bioaccumulation still needs to be studied and minimized, as the kind of hazards they may cause are beyond that produced by the chemicals or biomolecules with which they are functionalized. The detection potency of nanoparticles is multidisciplinary, as the combination of their features permits the use of different techniques. SPIONs’ and AuSPIONs’ magnetic properties allow the detection of biomolecules by means of Magnetic Resonance Imagining, because they are contrast agents for image enhancement and the change in contrast (T2) caused by biological reactions resulting in nanoparticles aggregation can be easily detected.[105e] AuSPIONs and AuNPs have a surface plasmon maximum at 520 nm that shifts to higher wavelengths when precipitation occurs, allowing the use of UV-
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spectroscopy as a detection method. And finally, aggregation of the three types of nanoparticles can be detected by Dynamic Light Scattering, measuring the differences in diameter upon several changes caused by biological reactions. Due to all their features, nanoparticles can provide promising and multidisciplinar detection systems for biomedical applications. 
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OBJECTIVES: 
 The long term objective of this thesis is the search for inhibitors of hAGT repair activity to be used as adjuvants in chemotherapy treatment. In order to achieve this goal, in this thesis we have evaluated potential inhibitors of hAGT and we have developed several analytical methods to find a robust technique for the in vitro evaluation of hAGT activity that will help us to characterize hAGT inhibitors. The specific objectives of this thesis are:  A. Primary screening of the compounds with potential capacity to inhibit hAGT. 1. Evaluation of the complex formed by hAGT and its potential inhibitors by ESI-MS. 2. Evaluation of the toxicity and efficacy of the candidate compounds in cell culture.  B. Development of methods for the detection of hAGT repair activity in vitro: 1. Methods based on the conformational change of a G-quadruplex: 1.1. Fluorescence assay based on the conformational change of a G-quadruplex oligonucleotide. 1.2. Design of a supramolecular platform that allows the detection of hAGT activity through the direct monitoring of the conformational change of a pair of G-quadruplexes using Atomic Force Microscopy. 2. New method to detect hAGT activity by transfer of fluorescence from the substrate oligonucleotide to the active site of the protein.  C. Comparative study of the properties of different type of nanoparticles to detect a single methylation that implies a conformational change in a G-quadruplex, to set the bases for a new detection platform for hAGT activity over a nanoparticle system. 
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Chapter 1 
Potential inhibitors of hAGT’s DNA repair activity: study 
of the hAGT-compound complex formation by ESI-MS and 
toxicity in cell culture. 
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In this first chapter, we evaluate the potency of small molecules which can be 
inhibitors of the DNA repair activity of the protein hAGT. A virtual screening was realized 
in collaboration with the Bioinformatics Unit of the CMBSO. A library of 4 million 
compounds was screened for shape complementarity to the active site of the protein, 
assuming that the best candidates could be good hits for hAGT inhibition due to their 
ability to enter the active site and occupy the space where the alkylated guanine of the 
DNA needs to enter in order to be repaired, as well as for their interaction with the amino 
acids implied in the repair. A set of 15 compounds with potential inhibitory activity 
against hAGT was selected. From these 15 compounds, only 10 were commercially 
available. These 10 compounds were studied by ESI-MS to pre-establish their ability to 
form a complex with hAGT in vitro, and subsequently, their toxicity was assessed in cell 
culture by MTT and colony formation assays.  
In this chapter, we include as an annex a work we realized related to the search of 
inhibitors for another DNA repair protein, Ape1, involved in the base excision repair 
pathway. This paper reports the identification of new compounds as potential Ape1 
inhibitors selected by a docking-based virtual screening and characterized following 
similar techniques as the ones described in chapter 1 for hAGT. 
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1. Introduction: inhibition of hAGT. The human O6-alkylguanine-DNA-alkyltransferase (hAGT)[1] is a DNA repair protein that removes alkyl mutations from the O6 position of guanines, restoring the DNA which has been damaged by alkylating agents. This group of chemotherapeutic anticancer drugs, alkylating agents, produce their cytotoxic effects by introducing alkyl groups which generate adducts and crosslinks at multiple sites in DNA.[2] For this reason, hAGT represents a relevant pharmacological target in the fight against chemotherapy resistance and patients’ survival.[3] Chemotherapy based on alkylating agents, together with the inhibition of hAGT, may result in a higher efficiency of the treatment, due to the blocking in the repair of the alkylated-DNA by hAGT that leads to apoptosis of cancer cells.[3]  hAGT is a suicidal enzyme which repairs alkyl damage from the O6 position of guanines, and in minor rate, from the O4 position of thymidines. It has 207 amino acids, a molecular weight of 21645.9 Da and a theoretical isoelectric point of 8.28. Its crystallographic structure was solved by Daniels and coworkers in 2000.[1b] hAGT is a monomer and has 2 domains, the N- and the C-terminal, where the active site cysteine is found (Figure 1). 
 
Figure 1. hAGT structure, described by Daniels et. al. The two domains are clearly seen. The violet sphere corresponds to a zinc atom present in the N-terminal domain. PBD code 1EH8. Later on, the same group solved the structure of hAGT together with DNA, enlightening the mechanism of action and the amino acids involved in the repair reaction.[1c] Arginine 128 plays an important role in the dealkylation process, entering the DNA double strand and pulling out the damaged guanine. In this way, the damaged guanine can accommodate in the active site close to cysteine 145 to be repaired (figure 2). 
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Figure 2. hAGT (green) bound to DNA (red), with Arginine 128 (yellow, left) entering the double helix and 
pushing outside the alkylated guanine (blue), which interacts with the active site, Cysteine 145 (yellow, right). 
PDB code 1T39. 
The first objective of this thesis is to evaluate the potency of small molecules which 
can be inhibitors of the repair activity of hAGT. Previously, a virtual screening was realized 
in collaboration with the Bioinformatics Unit of the CMBSO. A library of 4 million 
compounds was screened for shape complementarity to the active site of the protein, 
assuming that the best candidates could be good hits for hAGT inhibition due to their 
ability to enter the active site and occupy the space where the alkylated guanine of the 
DNA needs to enter in order to be repaired, as well as for their interaction with the amino 
acids implied in the repair. A set of 15 compounds with the best free energy of binding 
with hAGT was selected. We did an exhaustive search for companies that chemically 
synthesize and sell these compounds and finally, from these 15 compounds, only 10 were 
commercially available. Table 1 shows the chemical structure and properties of these 10 
compounds, which were numbered from 1 to 10. 
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Compound Chemical structure xlogP HBD HBA Charge Molecular 
Weight 
1 
 
1.78 3 13 0 453.492 
2 
 
3.68 3 11 0 471.572 
3 
 
2.93 3 13 0 467.519 
4 
 
1.91 4 14 0 483.518 
5 
 
 
2.93 3 12 -1 463.459 
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Compound Chemical structure xlogP HBD* HBA** Charge Molecular 
Weight 
6 
 
2.05 3 13 0 467.519 
7 
 
1.15 3 14 -1 478.430 
8 
 
1.79 3 15 -1 516.454 
9 
 
1.96 3 12 -1 383.348 
10 
 
1.90 1 2 0 148.205 
Table 1. Chemical structure and properties of the compounds tested in this thesis as potential hits of hAGT 
activity, found by a virtual screening. *HBD: hydrogen bond donors. **HBA: hydrogen bond acceptors. 
In order to confirm the results obtained by the virtual screening about the possible 
interaction of this set of compounds with hAGT, we undertook a first evaluation of their 
ability to form a complex with the protein by mass spectrometry, and their toxicity and 
effectiveness as potential inhibitors was tested in cell culture assays. 
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2. hAGT: structure, overexpression and purification 
Recombinant hAGT full length (FL) (Scheme 1A) was used for the MS study of the 
complex formation with the potential inhibitors, but here we also describe in full detail the 
overexpression and purification of a mutant version of hAGT which will be used in the 
following chapters of this thesis. This inactive mutant of hAGT (hAGT C145S) had a shorter 
sequence, where 30 amino acids were removed from its C-terminal end without affecting 
its folding, as represented in scheme 1B. Its active site cysteine was replaced by a serine, 
causing the loss of its repair activity but maintaining its capacity to recognize and bind 
alkylguanine-DNA.[4] This hAGT mutant was designed in order to use it as a negative 
control for the different in vitro assays.  
 
Scheme 1. Amino acid sequence of the hAGT proteins. 1A. hAGT FL with the active site, cysteine 145, in red. 
1B. hAGT ΔC177 C145S, the shorter version of hAGT FL with a mutation at the active site (serine 145) in red. 
The two types of hAGT were overexpressed and purified following the protocol 
described by Ruiz et al.[5] This protocol implied the introduction of a hystidine tag with 
affinity for nickel at the N terminal end of the sequence of the protein, to enable its 
purification by a nickel HiTrap chelating column figure 3A. After that, the resulting sample 
was loaded into a Size exclusion column to further purify the protein and to exchange the 
buffer used in the chelating column to a more convenient buffer for storing the protein 
(figure 3B). hAGT FL was obtained in high yield and purity, as shown by polyacrylamide 
gel electrophoresis (PAGE) which was performed to follow all the purification process 
(figure 3C). 
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Figure 3. Purification of hAGT full length with Hys-tag. 3A. Chromatogram of the nickel HiTrap-column purification. 3B. Chromatogram of the size exclusion column, where a single pure peak can be observed. 3C. PAGE of the purification process. In the case of the hAGT C145S, a dyalisis at 4ºC with prescission protease (PrePro) was carried out after the nickel HiTrap column. PrePro is a protease which cuts a specific sequence introduced between the hystidine tag and the N-terminal of hAGT, removing the Hys tag. Finally, a Size exclusion column was used to further purify the protein and to slowly exchange the buffer to the storing buffer. 
 
Figure 4. Purification of hAGT C145S with Hys-tag. 4A. Nickel HiTrap purification chromatogram. 4B. Size exclusion purification chromatogram. In this case, two peaks are observed: the first and smaller one corresponds to a portion of hAGT which is aggregated and the second one corresponds to the well folded hAGT C145S. 4C. PAGE of the purification process. The top gel shows the sample preparation prior to the nickel column, the nickel column and the GST column. The bottom gel corresponds to the analysis of the fractions collected from the size exclusion column, showing the pure hAGT C145S. Both proteins were concentrated in storing buffer and stored in 40% glycerol at -20ºC until further use. All buffers and conditions are detailed in the experimental section of this chapter. 
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3. Mass Spectrometry analysis of the non-covalent complex between hAGT and the 
lead compounds. 
In order to study the ability of the preselected compounds to form a complex with 
hAGT and pre-establish that they are molecules with potential capacity to inhibit hAGT, we 
performed a Mass Spectrometry analysis of their interaction. Mass spectrometry 
experiments were done using electrospray ionisation, a travelling wave ion mobility cell 
and a time-of-flight mass analyzer. 
This technique allows the detection of an increase in the mass of hAGT when the 
compound shows a strong interaction with the protein, which may indicate that the active 
site of hAGT is occupied with the compound. It does not permit to calculate a constant of 
dissociation nor an inhibitory activity, but is useful to predetermine the disposition of 
these molecules to be better or worse candidates for hAGT inhibition, based on their 
chemical structures. The modification of the mass spectra indicates a complexation 
between hAGT and the studied compounds, but not the nature of this interaction nor the 
degree of interaction. The presence of several new peaks with a delay corresponding to 
the addition of the m/z of the compound may indicate that the complex is not specific and 
more than one molecule can enter the active site of hAGT or interact with its surface 
instead of entering the active site. 
The hAGT buffer was exchanged to 100 mM ammonium acetate pH=7 using BioSpin 
columns P-6, to prevent buffer interferences in the mass spectrometry experiments. All 
the compounds are only soluble in DMSO at high concentrations. For this reason, we first 
realized the mass analysis of hAGT in the presence or absence of DMSO, in order to see 
how DMSO affects the Mass Spectrometry analysis (figure 5). We observed that a volume 
of DMSO higher than 1.5% v/v caused the loss of hAGT spectrum and thus determined the 
maximum concentration of inhibitor which can be used in these experiments, being it 150 
µM. This concentration is optimal for our experiments, because it is within a ratio of 1:5 of 
protein/inhibitor, given that the ideal concentration of hAGT to perform mass 
experiments was found to be around 30 µM. For inhibitors which require higher 
concentrations to be active, this technique cannot be used if they are not soluble in 
aqueous buffer. 
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Figure 5. Mass spectra of hAGT 30 µM in absence (green) or presence of DMSO 1.5% v/v (violet). The mass analysis of hAGT also allowed us also to select the m/z area were the complex formation was observed with clarity, which is from 1800 to 3000. Then, hAGT was mixed with each inhibitor in DMSO on a 1:5 ratio. Figure 6 shows all the results of the mass analysis. Five main peaks of m/z can be observed at 1749.69, 1893.29, 2065.33, 2271.60 and 2530.79. Changes in the chromatogram of hAGT, as the appearance or displacement of the peaks a number of units corresponding to the m/z of the inhibitors, represent an interaction. Our results show that in the case of compounds 1, 2 and 3, no changes in the chromatogram were observed compared with native hAGT, meaning that these compounds are not able to form a complex with hAGT in these conditions. Compound 4 does not seem to interact with the active site of hAGT, neither, however in this case a variation in the peaks’ form is seen in comparison with native hAGT. This replacement of the peaks by a softened curve indicates denaturation of the protein, and we can presume that compound 4 is interacting in some way with hAGT in vitro, but it is impossible to determine by these means if the interaction is due to a binding with the active site or with some other amino acids producing its denaturation or unfolding. The chromatogram of hAGT in the presence of compound 10 was not obtained, probably due to a high rate of denaturation of hAGT, which indicates some kind of interaction between compound 10 and hAGT. Smaller concentrations of inhibitor 10 were tested without achieving a stable signal. In contrast, the rest of the compounds (5, 6, 7, 8 and 9) were able to form a complex with hAGT, some of them in a specific way and some others in a non-specific. Compound 9 forms a clearly non-specific complex with hAGT, as various shifts for each peak of the hAGT chromatogram appear. In the case of compounds 5, 6 and 7, it is very difficult to see if the formed complex is specific or non-specific, as two shifts appear for the fourth peak but only one for the rest of the peaks. This probably means that we would be able to see a 
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non-specific complex formation upon increase of the inhibitor concentration, which is 
currently impossible to perform due to the constraints in DMSO concentration tolerated. 
Finally, compound 8 forms a clearly specific complex with hAGT at 150 µM concentration. 
 
Figure 6. Mass spectra of hAGT and its interaction with the different compounds. hAGT was mixed with each 
inhibitor in DMSO on a 1:5 ration, being hAGT concentration 30 µM. 
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4. Cell culture assays: effect of cytotoxicity and enhancement of BCNU on human 
cancer cells. 
All cell culture assays were performed in colon cancer cells (HT-29), described as a 
cellular line which overexpress hAGT. Carmustine (or BCNU) is a chemotherapeutic drug 
which alkylates and cross-links DNA during all phases of the cell cycle, resulting in 
disruption of DNA function, cell cycle arrest, and apoptosis.[6] This agent also 
carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic 
effect.[7] Carmustine is highly lipophilic and crosses the blood-brain barrier readily.[8] 
Inhibition of hAGT in cell culture has been shown to increase sensitivity of human cells to 
BCNU, and to enhance its efficiency.[9] 
These experiments were conducted to establish an IC50 value (inhibitory 
concentration 50%) for all the compounds, which allows to compare its efficiency in 
enhancing BCNU. According to the FDA, IC50 represents the concentration of a drug that is 
required for 50% inhibition in vitro.[10] This quantitative measure indicates how much of a 
particular drug or other substance (inhibitor) is needed to inhibit a given biological 
process. In the same line, we have calculated the LD50 (lethal dose 50%) for all the 
compounds, which is the required dose to produce a 50% of cell death.[11] This value was 
estimated to establish the toxicity of the compounds by themselves. 
4.1. MTT assays. 
The MTT cytotoxicity assays were performed to evaluate the toxicity of the 
compounds per se or in combination with carmustine. MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) is a bright yellow compound which is reduced to purple 
formazan in living cells (figure 7). This reduction and change of color allows the detection 
by UV absorption of the remaining living cells after a certain treatment and is widely used 
for the toxicity evaluation of new drugs.[12] 
 
Figure 7. Reduction of MTT (yellow) to formazan (purple blue) by the mitochondrial reductase in living cells. 
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We first tested the toxicity of carmustine per se, observing that BCNU produced 
around 30% of cell death at 160 μM in 2 hours. This concentration was found to be 
optimal for our MTT assays, as smaller concentrations of carmustine did not kill the cells 
and higher concentrations of carmustine did not show a significant increase in cell death. 
Figure 8 shows the cell survival at different concentrations of BCNU and the optimal 
concentration of BCNU required for this assay. 
 
Figure 8. Increasing concentrations of BCNU treatment on cells seeded at 6000 cells/well (2 hours of 
exposure). 
Cells were incubated with the 10 compounds described before, during and after 
BCNU treatment, to ensure that inhibitors were present during the entire period of time 
needed for DNA damage to be formed and repaired. As negative controls we evaluated  the 
effect of DMSO and the solvent used as vehicle for BCNU (EtOH:PBS 1:1), which were 
found to be negligible. Scheme 2 explains the protocol followed for these experiments. 
Cells incubated with compound alone were used to evaluate its toxicity per se.  
 
Scheme 2. Schematic representation of the MTT assay for the study of the toxicity of each compound per se 
(compound + vehicle) or in combination with BCNU (compound + BCNU). Light and dark colours refer to the 
colour coding of figures 8 and 9. 
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From the 10 potential inhibitors, compounds 5 and 8 were non-toxic by themselves, 
as the survival of the cells was not effected in the range of 0 to 100 μM concentrations. The 
rest of them were toxic, but at different ranges of concentrations (figure 9 and table 2). 
Compounds 1, 3 and 10 were found to be slightly toxic from 0,1-1 μM concentrations, 
producing over 20, 30 and 10% of cell death respectively and their LD50 was found to be > 
100 µM. However, they maintained the level of toxicity constant upon concentration. 
Compound 2 was slightly toxic at 0.1-1 μM, causing less than 20% of the cell death, but at 
more than 50 μM it was found to be very toxic, producing a 60% of cell death per se. Its 
LD50 was estimated to be around 5 µM. Instead, compound 4 was progressively toxic while 
increasing its concentrations, reaching a level of 80% of cell death (LD50 ~ 2.5 μM), and 
compounds 6 and 7 were toxic from 1 μM but their LD50 differed, as compound 6 requires 
higher concentrations than 100 μM and in contrast the LD50 found for compound 7 was 
around 10 μM. Compound 9 was toxic from 0.1 μM (40% of cell death) but its toxicity was 
not significantly affected by increasing concentrations. These results suggest that 
compounds 2, 4 and 7 are clearly toxic by themselves and compounds 1, 3, 6, 9 and 10 
were slightly toxic, too. Only compounds 5 and 8 were found to be non-toxic per se. 
 
Figure 9. MTT toxicity assays of the different compounds (1-10). Light colours represent the toxicity of the 
compounds by themselves, while dark colours indicate the toxicity of the different compounds in the presence 
of 160 µM of Carmustine. The dashed lines indicate the 50% of the cell survival. The p values were calculated 
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using the Student’s t test comparing cells treated with inhibitor in the absence and presence of BCNU. * p ≤ 0.1, 
** p ≤ 0.05 and *** p ≤ 0.005. 
 Regarding their enhancement of BCNU toxicity, compounds 5 and 8, which were 
non-toxic per se, were found to enhance significantly the effect of carmustine, with IC50s of 
around 10 and 50, respectively. Compounds 2, 4, 6 and 7 enhanced the effect of 
carmustine with IC50s around 1 µM, even if they were toxic per se. The behaviour of 
compound 2 at low micromolar concentrations is not toxic while the others presented 
toxicity by themselves. Compound 1 exhibited a relative capacity to stimulate cell death 
caused by carmustine, without reaching an IC50 at this range of concentrations. Compound 
9 showed an increased effect in carmustine toxicity, but this effect is due to its increasing 
toxicity upon concentrations. In contrast, compounds 3 and 10 were unable to change the 
effect of carmustine significantly, remaining stable upon increasing concentrations. IC50 
values were estimated from these results and are shown in table 2. Student’s t test was 
performed for all the compounds. The p values demonstrate that the enhancement of 
carmustine toxicity produced by the compounds 5 and 8 were significant.  
Compound LD50 (toxicity per se) IC50 (enhancement of BCNU) 
1 >100 µM >100 µM 
2 5 µM 1.5 µM 
3 >100 µM >100 µM 
4 2.5 µM 1 µM 
5 NT ~10 µM 
6 >100 µM <1 µM 
7 ~10 µM <1 µM 
8 NT ~50 µM 
9 >100 µM >1 µM 
10 >100 µM >100 µM 
Table 2. Estimated LD50 and IC50 of the 10 compounds studied by MTT assay. NT = non-toxic. 
 
From these results, we can conclude that compounds 5 and 8 are good candidates to 
enhance the effect of BCNU in cell culture, as both were non-toxic at 100 μM and they were 
able to improve the rate of cell death significantly when incubated with carmustine.  
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4.2. Colony formation assays. 
The colony formation assay was used in order to study in more detail the capability 
of compounds 5, 6, 7 and 8 to enhance BCNU cytotoxicity in colorectal cells. These 
compounds were selected due to their previous good performance in the MS analysis and 
MTT toxicity assays. The mass spectrometry analysis points to compounds 5, 6, 7, 8 and 9 
as capable of forming a non-covalent complex with hAGT. From this five, compounds 5, 6, 
7 and 8 were found to enhance BCNU’s toxicity in the MTT assays, and 5 and 8 were non-
toxic for the cells by themselves. Compounds 6 and 7 were found to be very toxic for the 
cells, and will allow us to compare the results obtained. 
Cells were incubated with the 4 compounds mentioned above, before, during and 
after BCNU treatment, to ensure that inhibitors were present during the entire period of 
time needed for DNA damage to be formed and repaired by hAGT. Then, cells were 
replated and left to grow for a week with periodic replacement of media. We analysed the 
colony formation efficiency of HT-29 colorectal cells exposed to inhibitor alone, and in 
combination with BCNU. In this case, we added 240 μM of carmustine, enough to produce 
a 50% of cell death (see figure 8). Figure 10 shows the remaining cells stained with crystal 
violet after treatment with the compounds in absence or presence of carmustine. 
 
Figure 10. Pictures of a colony formation assay, with the remaining cells after treatment and a week of growth 
stained with crystal violet. 
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Figure 11. Colony formation assay of compounds 5, 6, 7 and 8. Light colours represent the cell viability of the 
cells incubated with the compounds alone, while dark colours indicate the survible of the cells in presence of 
the different compounds and 240 µM of carmustine. The dashed lines indicate the 50% of the cell survival. The 
p values were calculated using the Student’s t test comparing cells treated with inhibitor in the absence and 
presence of BCNU. * p ≤ 0.1, ** p ≤ 0.05 and *** p ≤ 0.005. 
As shown in Figure 11, all compounds except compound 6 enhanced BCNU 
cytotoxicity. However, compound 5 reduced cell viability by itself in this case, showing a 
LD50 of around 0.5 µM and enhancing carmustine. The other 3 compounds were found to 
be non-toxic by these means. Compound 6 seemed not toxic but had little effect in 
enhancing carmustine. Even though, this results cannot be considered final as the effect of 
carmustine in this assay was very limited. In contrast, compound 7 is not toxic per se but 
enhances carmustine, showing an IC50 around 0.1 µM even if higher concentrations do not 
seem to potentiate this effect. Compound 8 is slightly more toxic than compound 7 per se 
but strongly enhances BCNU toxicity. IC50 values were estimated from these graphical 
results and are shown in table 3. 
Compound LD50 (toxicity per se) IC50 (enhancement of BCNU) 
5 >0.5 µM <0.05 µM 
6 NT >100 µM 
7 NT ~0.1 µM 
8 NT ~7.5 µM 
Table 3. Estimated LD50 and IC50 of the 4 compounds studied by colony formation assays. NT = non-toxic. 
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5. Conclusions 
 This set of 10 compounds were selected as candidates for the inhibition of hAGT in 
a virtual screening. We have tested their complex formation with hAGT by mass 
spectrometry, and their toxicity to tumoral cells, as well as their capacity to enhance the 
effect of an alkylating agent, carmustine. Table 1 summarizes the results obtained for the 
three experiments: 
 ESI-MS MTT assays: 
 
Colony formation assays: 
Toxicity 
per se 
(LD50) 
Enhancement 
of BCNU 
(IC50) 
Toxicity 
per se 
(LD50) 
Enhancement 
of BCNU 
(IC50) 
Cpd 1 Non observed Slightly toxic 
(>100 µM) 
 
Low 
(>100 µM) 
 
- - 
Cpd 2 Non observed Toxic 
(5 µM) 
 
Low 
(1.5 µM) 
 
- - 
Cpd 3 Non observed Slightly toxic 
(>100 µM) 
 
Low 
(>100 µM) 
 
- - 
Cpd 4 Denaturation of 
hAGT 
Toxic 
(2.5 µM) 
 
Significant 
(1 µM) 
- - 
Cpd 5 Complex  
(Non specific) 
Non Toxic 
(>>100 µM) 
 
Significant 
(~10 µM) 
 
Toxic 
(0.5 µM) 
 
Significant 
(<0.05 µM) 
Cpd 6 Complex  
(Non specific) 
Slightly toxic 
(>100 µM) 
 
Significant 
(<1 µM) 
 
Non toxic 
(>>100 µM) 
 
Low 
(>100 µM) 
 
Cpd 7 Complex  
(Non specific) 
Toxic 
(10 µM) 
 
Significant 
(<1 µM) 
 
Non toxic 
(>>100 µM) 
 
Significant 
(~0.05 µM) 
 
Cpd 8 Complex  
(Specific) 
 
Non toxic 
(>>100 µM) 
 
Significant 
(>50 µM) 
 
Non toxic 
(>>100 µM) 
 
Significant 
(~7.5 µM) 
 
Cpd 9 Complex  
(Non specific) 
 
Slightly toxic 
(>100 µM) 
 
None 
(>100 µM) 
 
- - 
Cpd 10 Precipitation of 
the sample 
Slightly toxic 
(>100 µM) 
 
None 
(>100 µM) 
 
- - 
Table 1. Summary and comparison of the results obtained for the mass spectrometry and the cell culture 
studies. 
Combining the results obtained by ESI-MS and by cell culture assays, we can 
conclude that 2 compounds out of our first ten are able to form a specific (8) or non-
specific (5) complex with hAGT and are non-toxic per se in MTT toxicity assays. In 
addition, they seem to enhance the effect of carmustine, both in MTT and in colony 
formation assays. However, compound 5 showed toxicity per se in the colony formation 
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assays. The differences in toxicity found by MTT and colony formation assays may be due 
to the fact that the latter studies the cell viability during 10 days, while MTT is applied 24h 
after the treatment with compounds and BCNU. Even though, the colony formation assays 
are preliminary and should be reproduced before considering these results conclusive. 
Compound 8 represents the best candidate for the study of hAGT inhibition for 
chemotherapy enhancement, as it formed a specific complex with hAGT, was not found to 
be toxic per se neither by MTT nor by colony formation assays and showed a clear 
enhancement of carmustine at high concentrations. Following the line of this thesis, these 
potential inhibitors should be tested by the methods described subsequently to reveal 
their active concentrations and their suitability to continue preclinical studies in animal 
models. 
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6. Experimental details: 
1. hAGT overexpression and purification. 
hAGT-FL protein cloned in the pet-21a(+) (Novagen) vector was expressed in the 
E. coli strain Rosetta. Once the culture reached an OD600 value of 0.98, hAGT was induced 
by adding 1 mM IPTG (Sigma) and left to grow for 4 h at 30 °C. The pellet from a 1-L 
culture was disrupted by sonication and centrifuged. The supernatant was filtered, loaded 
into a HiTrapTM FF column (GE Healthcare) with buffer 350 mM NaCl, 20 mM Tris pH 8, 20 
mM imidazole, and 1 mM BME, and then eluted with an imidazole (Fluka) gradient up to 
500 mM in the same buffer. Finally, the protein was loaded into a Superdex 75 16/60 
column (GE Healthcare) with the following buffer: 200 mM NaCl (Merck), 20 mM Tris pH 
8.0 (Merck), 10 mM DTT (Sigma) and 0.1 mM EDTA (Sigma). The protein was 
concentrated to 2 mg/ml in this buffer and kept at -20 °C in the presence of 40 % glycerol. 
A similar protocol was used for the purification of the inactive mutant hAGT-C145S, cloned 
in the pet-28a (+) vector (Novagen) and expressed in the E. coli strain BL21. However, in 
this case the hystidine tag was cut using PrePro during a 4h dyalisis at 4ºC. 
2. Compounds. 
10 mg of the compounds 1 to 9 were purchase from IBScreen. Compound 10 (2’-
aminoquinoline) was obtained from TCI Europe. Their reference numbers are shown in 
this list. 
Compound 1: STOCK5S-10931 
Compound 2: STOCK4S-24457 
Compound 3: STOCK4S-98799 
Compound 4: STOCK4S-90334 
Compound 5: STOCK4S-14286 
Compound 6: STOCK4S-97010 
Compound 7: STOCK4S-94755 
Compound 8: STOCK4S-96314 
Compound 9: STOCK4S-99868 
Compound 10: A0417 
All of them were dissolved in DMSO (Sigma) at a final stock concentration of 1 mM and 
kept at -20°C until used. 
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3. Mass spectra of the complex with hAGT. 
Mass spectrometry experiments were performed on a Waters (Manchester, UK) 
instrument equipped with electrospray ionisation, a travelling wave ion mobility cell and a 
time-of-flight mass analyser. Synapt G1 was interfaced to a chip-based nanoESI device, 
(Advion, Triversa Nanomate). This device contains a 384-well-sample plate, 384 
disposable spraying tips and an ESI chip with 100 nozzles in front of the inlet of the mass 
spectrometer. The instrument was operated in the automatic mode using a contact closure 
signal. A spraying voltage of +1.76 kV and a sample pressure of 5.80 psi were applied. Each 
well was loaded with 10µl of sample, from which a total of 4 µl was infused during 10 min. 
Operating conditions for the Synap G1 mass spectrometer were: cone voltage = 20V; 
extraction cone = 5.5 V; source temperature = 20 ºC; trap and transfer voltages = 6 V and 
4V, respectively. The ion mobility cell was filled with N2 and an electric field was applied to 
the cell in the form of waves (wave height = 9.5 V) that passed thought the cell at 300 m/s. 
The bias voltage for ion introduction into the IMS cell was 15V. 
The hAGT buffer was exchanged to 100 mM ammonium acetate pH=7 using BioSpin 
columns P-6, to prevent buffer interferences in the mass spectrometry experiments. hAGT 
in the presence of DMSO was used as Mass spectrum control. Different concentrations of 
DMSO were studied to find the optimal conditions. Once the mass spectrum for the native 
form of hAGT was confirmed, the non-covalent inhibitor-protein complexes were 
analyzed. hAGT (30 µM) was mixed with (150 µM of) each inhibitor in ammonium acetate 
buffer at a final volume of DMSO of 1.5% v/v (1, 2, 3, 4, 5, 6, 7, 8, , 9 and 10) separately and 
left to equilibrate at rt for one hour. Each study was performed in triplicates. 
4. Cell culture assays. 
HT-29 colon cancer cells were purchased from ATCC (catalog No. HTB-38) and 
cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum 
(Gibco) at 37ºC and 5% CO2. BCNU (1,3-bis-(2-chloroethyl)- 1-nitrosourea) was obtained 
from Sigma and dissolved in 50% phosphate-buffered saline buffer (PBS)-50% ethanol at 
4 mM (10 mg/ml) stock solution. 
4.1. MTT toxicity assays. 
The optimal concentration of BCNU was explored using MTT assays. 6000 cells per 
well (in 100 μL RPMI medium) were seeded in a 96-well plate and left to grow for 24 
hours. Then, cells were incubated during 2 h with concentrations of carmustine ranging 
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from 40 to 240 μM and after that, cells were rinsed with PBS and media was replaced. The 
day after, 20 μL of MTT (2mg/ml in PBS) were added and left to react for 4 hours. At the 
end of the reaction blue crystals inside the living cells could be observed at the 
microscope. The medium + MTT was removed and the crystals resuspended in 200 μL of 
DMSO and agitated until reaching homogeneity. Absorbance was read at 560 nm using a 
ELx 800 Universal Microplate Reader (Bio-Tek Instruments INC). 
The cytotoxic effects of compounds 1 to 10 in HT-29 human colorectal tumoral cells 
were analyzed by means of MTT toxicity assay. 6000 cells per well (in 100 μL RPMI 
medium) were seeded in a 96-well plate and left to grow for 24 hours. The day after, the 
cells were incubated for 6 hours with different concentrations of compounds 1 to 10 (0, 
0.01, 0.1, 1, 10, 50 and 100 μM). Then, enough quantity of BCNU to reach a concentration 
of 160 μM (or the equivalent volume of the vehicle as negative control) was added and left 
to react during 2 hours. Afterwards, the medium was replaced by compound-containing 
RPMI (using the same concentrations as before the treatment) and left overnight. The next 
morning, the medium was replaced by fresh RPMI and cells were left to grow for 24 hours. 
Then, 20 μL of MTT (2mg/ml in PBS) were added and left to react for 4 hours. The medium 
+ MTT was absorbed and the crystals resuspended in 200 μL of DMSO and shaked until 
reaching homogeneity. Absorbance was read at 570 nm using a ELx 800 Universal 
Microplate Reader (Bio-Tek Instruments INC) and toxicity of the compounds per se or in 
combination with BCNU was determined relative to untreated cells. All these experiments 
were performed in triplicates and repeated three times. IC50 values were estimated from 
the graphical results. The p values were calculated using the Student’s t test (2 tails, equal 
variance) comparing cells treated with inhibitor in the absence and presence of BCNU. 
4.2. Colony formation assays. 
The effect of compounds 6 to 9 on the sensitivity of human colorectal (HT-29) cells 
to BCNU was determined using colony formation assays as it has been previously 
described.[5] HT-29 cells were seeded at 10 x 103 cells per well density in 24-well, flat-
bottomed plates and incubated in a humidified, 5% CO2 incubator at 37ºC for 48 h. 
Compound solutions were diluted in the culture medium RPMI at final concentrations of 
100, 50, 10, 5, 1, 0.5, 0.1, and 0.05 µM, and were immediately used to treat the cells. Cells 
were incubated with these compounds’ solutions for 6 h and then BCNU (or the equivalent 
volume of the vehicle as negative controls) was added to a final concentration of 160 µM. 
After 2 hours of incubation, the medium was replaced with fresh medium containing the 
same compound concentration, and cells were left to grow for an additional 16 hours. The 
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cells were then replated at densities of 2000 cells per well in 24-well plates and grown for 
1 week until discrete colonies were formed. Colonies were washed twice with PBS and 
stained with a 0.5% crystal violet - 20% ethanol solution. Cells were rinsed with deionized 
water and air dried. Stained colonies were counted in a ELx 800 Universal Microplate 
Reader (Bio-Tek Instruments INC) and clonogenic survival was determined relative to 
untreated cells. Samples were assayed in triplicates and experiments repeated three times. 
IC50 values were estimated from the graphical results. The p values were calculated using 
the Student’s t test (2 tails and equal variance), comparing cells treated with inhibitor in 
the absence and presence of BCNU. 
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Introduction
Chemo- and radiotherapy are the two main currently available
treatments to improve the outcome in cancer patients. The cy-
totoxicity of many of these agents is directly related to their
propensity to induce genomic DNA damage.[1] The persistence
of unrepaired DNA damage results in accumulation of muta-
tions, cell cycle arrest, and apoptosis.[2] However, the ability of
cancer cells to recognize this damage and initiate DNA repair
is an important mechanism that impacts negatively upon ther-
apeutic efficacy.[3]
The base excision repair (BER) pathway is the major mecha-
nism for dealing with a variety of lesions in DNA produced by
alkylating agents. This pathway is initiated by specific DNA gly-
cosylases, which recognize and excise the damaged base to
generate an apurinic/apyrimidinic (AP) site. AP endonuclease 1
(Ape1) cleaves the phosphodiester backbone adjacent to the
5’ site of the AP site, generating a 3’-hydroxy and 5’-deoxyri-
bose phosphate termini.[4] Polymerase b removes the 5’-deoxy-
ribose phosphate, fills in the single-nucleotide gap, and the
consequent nick is ligated by DNA ligase I or by DNA ligase III/
XRCC1.[5] Ape1 is a fundamental protein in this essential repair
pathway and it is thought to be responsible for 95% of total
AP endonuclease activity in human cell lines.[6] Ape1 also pos-
sesses 3’-phosphodiesterase, 3’-phosphatase, RNase H, and
3’!5’ exonuclease functions.[7] In addition to its DNA repair ac-
tivities, Ape1 acts as a redox factor for a variety of important
transcription factors such as NF-kB, p53, c-Fos, and c-Jun.[8] The
DNA repair and the redox activities of Ape1 are distinct, both
structurally and functionally.
Ape1 protein levels and intracellular distribution have been
related to the pathogenesis of several human tumors[5a,9] and
its expression pattern appears to have a prognostic signifi-
cance in cancer cells, including breast,[9b] lung,[10] ovarian,[9e]
gastro-esophageal[11] and pancreatic–biliary,[11] and bone[12]
tumors. For this reason, several preclinical and clinical studies
have suggested that Ape1 may be an attractive target for anti-
cancer drug development. Using either antisense oligonucleo-
tides or RNA interference approaches, different groups have re-
ported that depletion of intracellular Ape1 sensitizes mammali-
an cells to a variety of DNA-damaging agents.[5a,13] In pancreat-
ic cancer cell lines for example, down-regulation of Ape1 po-
tentiated the cytotoxicity of gemcitabine[14] and
The endonucleolytic activity of human apurinic/apyrimidinic
endonuclease (AP endo, Ape1) is a major factor in maintaining
the integrity of the genome. Conversely, as an undesired
effect, Ape1 overexpression has been linked to resistance to
radio- and chemotherapeutic treatments in several human
tumors. Inhibition of Ape1 using siRNA or the expression of
a dominant negative form of the protein has been shown to
sensitize cells to DNA-damaging agents, including various che-
motherapeutic agents. Therefore, inhibition of the enzymatic
activity of Ape1 might result in a potent antitumor therapy. A
number of small molecules have been described as Ape1 in-
hibitors ; however, those compounds are in the early stages of
development. Herein we report the identification of new com-
pounds as potential Ape1 inhibitors through a docking-based
virtual screening technique. Some of the compounds identified
have in vitro activities in the low-to-medium micromolar range.
Interaction of these compounds with the Ape1 protein was ob-
served by mass spectrometry. These molecules also potentiate
the cytotoxicity of the chemotherapeutic agent methyl metha-
nesulfonate in fibrosarcoma cells. This study demonstrates the
power of docking and virtual screening techniques as initial
steps in the design of new drugs, and opens the door to the
development of a new generation of Ape1 inhibitors.
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troxacitabine.[15] Ape1 down-regulation has also been shown
to block ovarian cancer cell-growth.[16] In melanoma and colon
cell lines, Ape1 down-regulation alone or in combination with
bleomycin led to an increase in apoptosis,[2a,17] whereas its
overexpression conferred protection from cisplatin- or H2O2-in-
duced apoptosis.[17a] Attempts to create Ape1 knockout mice
were embryonically lethal, suggesting that Ape1 is crucial for
embryonic development.[18] Heterozygous Ape1 mice were
viable but abnormally sensitive to oxidative stress and prone
to cancer progression.[19]
Recently, there has been a significant effort toward identify-
ing inhibitors of DNA repair proteins in keeping with the
emerging concept that sensitizing cancer tissue to core che-
motherapeutic regimens by simultaneous targeting DNA repair
may result in enhanced treatment outcomes.[20] As a result of
the promising therapeutic potential of the inhibition of Ape1
DNA repair activity, several reports have described the identifi-
cation and characterization of small molecules that inhibit its
repair endonuclease activity,[21] including methoxyamine (MX),
lucanthone and 7-nitroindole-2-carboxilic acid (NCA). All three
compounds were able to enhance the effects of methyl metha-
nesulfonate (MMS) or temozolamida (TMZ) in ovarian,[22]
breast,[22b,23] colon,[24] and HT1080 fibrosarcoma cancer cells.[25]
In addition, Lucanthone was able to potentiate the effects of
radiation therapy in patients with brain metastasis.[26] However,
the evidence of lucanthone topoisomerase inhibitory activity
raised concerns regarding an off-target effect[27] and the syner-
gistic cell killing effects observed by NCA with TMZ or MMS
were unclear, as recent data showed that its specificity for
Ape1 is controversial.[22b,28] By using a fluorescence-based high-
throughput assay, Kelley and co-workers described the identifi-
cation of 2,4,9-trimethylbenzo[b][1,8]napthyridin-5-amine
(AR03), which was found to be active in the low micromolar
range in vitro against purified Ape1 and inhibited AP site inci-
sion activity and its repair in SF67 glioblastoma cells.[29]
Other research groups using high-throughput screening
(HTS) approaches reported Ape1 inhibitors including com-
pounds containing arylstibonic[30] or bis-carboxylic acid,[31] Re-
active blue 2, 6-hydroxy-d,l-DOPA, and myricetin.[32] The bis-
carboxylic acid derivatives were not tested in cell-based
assays,[31] and no information about its in vivo activity can be
inferred. The arylstibonic acid compounds effectively inhibited
Ape1 in vitro, but were ineffective in vivo due to poor cellular
uptake.[30] Moreover, antimony-containing compounds are gen-
erally considered from a probe development standpoint due
to their possible promiscuity akin to the effect of heavy metal
ions and their occasional high toxicity.[33] Reactive blue 2, 6-hy-
droxy-d,l-DOPA, and myricetin were found to have numerous
other targets besides Ape1 in cells ; therefore, they lack the se-
lectivity and specificity required for promising Ape1 inhibi-
tors.[32]
We recently developed a flexible, fully automated virtual
screening computational platform (VSDMIP)[34] to identify in-
hibitors of protein targets from libraries of millions of com-
pounds. This computational platform has been successfully ap-
plied to the discovery of new inhibitors of the DNA repair pro-
tein O6-alkylguanine DNA alkyltransferase[35] and in the devel-
opment of small molecules that compete with ubiquitin E2
variant for its interactions with ubiquitin-conjugating enzyme
UBC13, inhibiting its enzymatic activity,[36] among others.
Herein we report the identification of new Ape1 inhibitors
by using a docking-based virtual screening technique. The ac-
tivity of these compounds has been experimentally proved
both in vitro and in vivo. These molecules are promising lead
candidates to establish quantitative structure–activity relation-
ship models for further development of clinically relevant Ape1
inhibitors as co-adjuvants in cancer chemotherapy.
Results and Discussion
Virtual screening (VS)
The virtual screening protocol employed here is summarized in
Scheme 1 and briefly described in the Experimental Section.
An essential part of the procedure is to characterize the shape
of the active site. For this purpose we used GAGA algorithm
(see Experimental Section) to obtain a sort of a negative image
of the binding site (Figure 1). Overall, the shape of the active
site does not undergo significant conformational changes even
after binding to the DNA, as very low RMSD values were ob-
tained after superimposing the different Ape1 structures de-
posited in the PDB (IDs: 1BIX,[37] 1DE9,[38] 1DEW,[38] 1DE8,[38]
1E9N,[39] 2ISI, and 1HD7[39]). This fact is reassuring taking into
account that the protein flexibility is not explicitly considered
during the docking process. The active site is a well-defined
deep V-shaped cleft, with an Mg2+ cation located in its
“elbow”.
Upon characterizing the binding site, the free database of
commercially available compounds ZINC[40] was first screened
Scheme 1. Flowchart of the virtual screening procedure applied in this
study.
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using DOCK[41] and the negative image of the binding site. We
applied a ZScore (see Experimental Section) cutoff value of 4
on the DOCK-ranked list, and a set of 2288 molecules were
taken through to the next step. These molecules were then re-
docked with CDOCK[42] and scored with its molecular mechan-
ics energy function, which specifically includes solvent and H-
bonding terms. The 100 highest-scoring compounds were sub-
mitted to MD simulation in explicit solvent and their binding
energies estimated and pairwise decomposed by MM-GBSA[43]
calculation over a large collection of snapshots homogenously
sampled along the trajectories.
Finally, from the top-scoring compounds, and upon visual
examination, a total of 15 candidates were selected, pur-
chased, and tested experimentally. For those showing in vitro
activity against Ape1, the MM-GBSA[43] method was used to es-
timate the binding free-energies from molecular dynamics
(MD) trajectories. The physicochemical properties of the mole-
cules as stored in the ZINC database[40] are listed in Table 1.
Ape1 endonuclease in vitro assays
Fifteen top-ranked compounds selected from the VS computa-
tions were first dissolved in DMSO. The ability of those 15 can-
didates to inhibit the recombinant Ape1 activity in vitro was
determined by a fluorescence-based assay described by differ-
ent groups.[25,30] In brief, a double-stranded DNA (dsDNA) sub-
strate was used containing, in one of the strands, an internal ri-
bitol (THF) AP site mimic,[44] and a 5’-6-carboxyfluorescein
(FAM) label, whereas the complementary strand was labeled
with a 3’-Dabsyl fluorescence-quencher moiety. The close prox-
imity of the fluorophore and the quencher results in a damp-
ened signal upon light excitation. Following DNA-backbone
cleavage by Ape1, a short single-stranded DNA fragment 5’-
tagged with the FAM group is released from the duplex DNA
substrate, resulting in an increase in the fluorescence. Because
assay variability is to be expected, as a comparative control we
included a compound that was previously described as Ape1
inhibitor (data not shown).[30] Ape1 (at 590 pm concentration)
was incubated with the dsDNA at 37 8C for 30 min in the pres-
ence of each of the 15 compounds selected during the VS at
concentrations of 100 and 200 mm. The results of this first
assay showed that compounds 11 to 15 did not exhibit any in-
hibitory action against Ape1 at these concentrations (Table 1).
Compounds 7–10 showed an inhibitory effect versus Ape1 at
concentration between 150 and 200 mm and therefore they
were not evaluated further.
On the other hand, compounds 1–6 showed inhibitor activi-
ty at concentrations below 100 mm and were further analyzed
to determine the concentration dependence for the inhibition
of Ape1 endonuclease activity. All of them inhibited Ape1 with
IC50 values in the low-to-medium micromolar range. Com-
pounds 1 and 2 were identified
as the most potent inhibitors of
Ape1 with an IC50 of 1.8 and
6.8 mm, respectively. These two
lead compounds had compara-
tive or slightly higher effects in
blocking Ape1 activity than thi-
olactomycin, methyl 3, 4-de-
phostatin and better than other
compounds found by Simeonov
and colleagues.[32] Compounds
3 and 4 had an intermediate
effect (IC50 : 17–39.5 mm), where-
as compounds 5 and 6 were
weakly active (IC50>50 mm). The
resultant IC50 values obtained
for all active compounds are
listed in Table 1 and in Figure 2.
The chemical structures of
these compounds are shown in
Figure 3, prioritized by low mi-
cromolar IC50 values.
Figure 1. Inside view of the Ape1 active site with the ligand negative
spheres image computed with GAGA.
Table 1. The 15 top-ranked compounds obtained in the virtual screen.[a]
ZINC ID logP HBD[b] HBA[c] Charge Mr [Da] IC50 [mm]
[d,f] EC50 [mm]
[e,f]
1 ZINC08790444 1.57 3 10 0 497.89 1.80.5 >100
2 ZINC09086704 1.82 0 9 0 497.54 6.80.5 7.3
3 ZINC00708759 6.37 0 9 1 543.58 17.30.6 >50
4 ZINC00870176 6.39 0 9 1 543.58 39.20.8 >100
5 ZINC00730105 4.79 1 8 1 487.56 52.80.9 28.5
6 ZINC02118845 1.97 2 8 1 473.51 55.70.8 >100
7 ZINC04059809 5.19 0 8 1 427.48 >130 ND
8 ZINC08854784 2.61 0 12 0 477.50 >150 ND
9 ZINC08877288 2.12 3 9 1 493.58 >150 ND
10 ZINC04060698 4.63 0 8 1 413.45 >150 ND
11 ZINC03583501 3.69 0 9 0 523.95 >200 ND
12 ZINC08932744 3.48 2 6 0 440.52 >200 ND
13 ZINC09042551 1.91 3 9 1 423.45 >200 ND
14 ZINC04202254 3.97 0 8 1 456.53 >200 ND
15 ZINC00706278 2.61 0 8 1 421.41 >200 ND
[a] The computed chemical properties (as found in the ZINC database) and the in vitro and in vivo activities of
the active compounds are listed. [b] H-bond donors. [c] H-bond acceptors. [d] in vitro IC50 value: compound
concentration required to decrease Ape1 activity by 50%. [e] in vivo EC50 value: compound concentration re-
quired to kill 50% of cells in the presence of 300 mm MMS; ND: not determined. [f] Values represent the aver-
age standard error of the mean (SEM) of three separate experiments.
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DNA intercalation binding
To test if these compounds inhibit Ape1 activity through non-
specific DNA binding rather than by direct inhibition of the en-
zymatic activity, we employed a fluorescent-dye displacement
assay.[32,45] Briefly, if a compound acts nonspecifically by associ-
ation with DNA, it would displace a DNA-bound fluorophore
such as thiazole orange (ThO) or ethidium bromide. As these
molecules emitted fluorescence upon intercalation to DNA, its
displacement should produce a decrease in the fluorescence
of the complex dye-DNA when increasing amounts of the
compounds were added. We selected ThO, which binds nonco-
valently to DNA with high affinity instead of ethidium bromide,
due to the fact that its fluorescence excitation and emission
are red-shifted, which ensures a decreased susceptibility to
compound autofluorescence.[32] As shown in Figure 4, com-
pounds 1–6 did not displace bound ThO at any range of con-
centrations starting from
100 pm to 100 mm. This result
suggests that these molecules
do not inhibit the Ape1 DNA
repair activity by a noncompeti-
tive effect such as DNA binding.
In contrast, mitoxantrone, de-
scribed in Simeonov et al.[32] as
a DNA binding compound, was
able to displace ThO producing
a 100% decrease in fluores-
cence in the same concentra-
tion range.
Complex formation detected
by MS
Electrospray ionization mass
spectrometry (ESIMS) has
become an established tool for
the investigation of macromo-
lecular complexes.[46] ESI is
a gentle ionization method that
enables the analysis of proteins
without causing internal frag-
mentation of the molecule.
Their typical multiply charged
ions result in low mass-to-
charge values that allow an ac-
curate mass determination.[47]
The noncovalent complex for-
mation of Ape1 with com-
pounds 1–6 was analyzed by
this means. The mass spectrum
of Ape1 alone exhibited a char-
acteristic series of multiply
charged positive ions (Fig-
ure 5a). A narrow range of
charge state is a good indica-
tion that Ape1 has retained its
folded or native conformation.
Moreover, the ion mobility measurements further confirmed
that the protein was folded during the nano-ESIMS experi-
ments.
The direct observation of the protein–ligand complex ion
can be easily achieved for tight-binding complexes. However,
weakly bound complexes, particularly those dependent on hy-
drophobic effects, are fragile and may dissociate during desol-
vation,[48] as observed with compounds 2–4 (data not shown).
The mass spectra of Ape1 in complex with compound 5 (Fig-
ure 5a) showed that although the peaks are too complex to
be observed in detail, the free-protein peaks shifted to
a higher mass-to-charge value and this fact may indicate an in-
hibitor–protein interaction. In the mass spectrum of Ape1 in
presence of compounds 1 and 6, a clear signal of complex for-
mation was observed. The upper part of Figure 5a shows the
ESIMS peaks corresponding to free protein (P) and protein in
Figure 2. Concentration curves showing the inactivation of human Ape1 by compounds 1–6 [panels a)–f), respec-
tively] . Remaining Ape1 activity as a function of compound concentration is plotted relative to untreated control
samples. Compounds 1–3 show inhibitory effects on Ape1 activity in the low micromolar range, whereas com-
pounds 4–6 show inhibitory effects in the mid-micromolar range. Data are the averageSEM of three separate
experiments performed in triplicate.
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complex with inhibitor (PI). The complex peaks are shown in
greater detail in Figure 5b. The estimated stoichiometry of the
complex between Ape1 and the three studied compounds (1,
5 and 6) respectively was equimolar (1:1).
Docking binding modes
For those compounds showing in vitro activity against Ape1,
the binding mode was refined by MD simulations. The binding
mode of compound 2 with Ape1 highlights the interaction
with the metallic cation, which energetically is the most impor-
tant. The H-bonding pattern is represented in Figure 6. These
interactions were established between: 1) the nitro group of
compound 2 and the backbone NH group of residue Asn174;
and 2) an oxygen atom from
the sulfonyl moiety and the
amino group from the side
chain of residue Asn212 on the
one hand, and the NHe group
of residue His309, on the other
hand. This binding mode also
presented a network of hydro-
phobic contacts surrounding
the quinoxaline core of com-
pound 2 with Phe266, Trp280,
and Leu282, and an additional
stacking interaction with Tyr269,
which stabilizes the benzylpyri-
dinium moiety.
The other five active com-
pounds all have a carboxylic
moiety in common, which also
presented their main interaction
with Ape1 through the Mg2+
cation. However, compared with
compound 2, this interaction is
somehow skewed. This fact allows a gradual contribution to
the stability of the complex from a salt bridge that is formed
between the carboxylic moiety and the side chain of residue
Lys98, which in turns depends on the position of the Mg2+
cation. Nevertheless, rather similar interaction energies were
obtained for the contacts of the ligands with the hydrophobic
residues Phe266 and Trp280 and polar Asn174 and Asn212. Fi-
nally, an important interaction was established between the
central core of the ligands and the side chain of residue Lys98,
which is mainly hydrophobic except for compound 1 in which
a hydrogen bond is formed with one of the oxygen atoms in
the succinimide-like central moiety.
Effects of cytotoxicity and enhancement of MMS on human
cells
The presented data suggested that the six compounds can po-
tently and selectively inhibit Ape1 in vitro. However, to have
a general utility as BER inhibitors, it is important to confirm
that they can block Ape1 function in living cells. A colony-
forming assay was used to study the capability of compounds
1–6 to enhance MMS cytotoxicity in HOS cells.[12,22b,23, 25,49] MMS
creates base damage by methylation, which is either lost spon-
taneously or excised by the alkylpurine DNA glycosylase, re-
sulting in a high number of cytotoxic abasic sites.[50] Inhibition
of Ape1 in cell culture or the expression of a dominant nega-
tive form of the protein has been shown to increase sensitivity
of human cells to MMS.[12,22b,23,25,49]
Cells were incubated with the six compounds before,
during, and after MMS treatment to ensure that inhibitors
were present during the entire period of time required for
DNA damage to occur. We analyzed the colony formation effi-
ciency of HOS cells exposed to MMS alone, each inhibitor
alone, or the combination of MMS plus inhibitor, relative to an
unexposed control. MMS alone decreased the number of colo-
Figure 3. Structures of the six compounds that show Ape1 inhibition in the micromolar range.
Figure 4. ThO inhibitor displacement assays were used to evaluate the DNA
binding ability of all compounds (1–6) that were active in the Ape1 in vitro
assay. No decrease in ThO fluorescence was observed upon addition of the
compounds, indicating that they do not bind DNA. Mitoxantrone, a clear
DNA binding molecule, was used as positive control (&). The fluorescence
signal was normalized against DNA.
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nies by 15%, and, as shown in Figure 7, all six compounds en-
hance MMS cytotoxicity. However, no significant effect of the
compounds alone was observed, indicating that none of them
is toxic by itself in the concentrations used. Compounds 1 and
3 are less effective in sensitizing the tumor cell to MMS than
the rest, requiring a concentration above 100 mm to obtain
a 50% increase in cell death. The lower-sensitizing effect of
compound 3 is consistent with its slightly smaller in vitro affini-
ty for Ape1. However, the inefficiency of compound 1 was un-
expected on the basis of its high ability to inhibit Ape1 activity
in vitro. This observation suggested that it may not be able to
cross cell membranes or it could be degraded before reaching
its final target. Compound 4 had almost no effect on the cyto-
toxicity produced by MMS; only a small decrease in cell surviv-
al was observed at 50 mm, which was not incremented when
cells were incubated with higher concentrations of 4. Com-
pound 5 exhibited an increasing capability to enhance the kill-
ing effect of MMS with an EC50 value ~50 mm, which is close to
the IC50 value obtained in the in vitro experiments. Compound
6 showed a progressive lethal effect (until 50 mm), even if at
Figure 5. Complex formation identified by mass spectrometry: Ape1 (28 mm)
was mixed with each inhibitor (140 mm) in ammonium acetate buffer
(100 mm) and allowed to equilibrate at 4 8C for 1 h as described in the Exper-
imental Section. a) ESIMS spectra of Ape1 alone (bottom) or with test com-
pounds as indicated; b) zoom-in of the complex regions for Ape1 with com-
pounds 6 and 1.
Figure 6. Average minimized structure of the Ape1–compound 2 complex
after MD simulations. The protein is represented by the ribbon and loop
structure in cyan; side chains of main interacting residues are colored by
atom type: C cyan, N blue, and O red. For compound 2, C atoms are in
orange, N in blue, O in red, and S in yellow. Hydrogen atoms have been
omitted for clarity. The grey sphere represents the Mg2+ cation. Dashed
lines correspond to H-bond interactions.
higher concentrations it was unable to further increase the tox-
icity of MMS in the cells.
The combination of MMS and compound 2 presented the
best result in vivo. Its lethality was found to be in the lower
micromolar range (7.25 mm), being consistent with its affinity
for Ape1 in vitro. The results observed for this lead compound
opens the door for its further optimization as Ape1 inhibitor.
Conclusions
Several classes of inhibitors of Ape1 have been described pre-
viously. However, the specificity of some of these compounds
for Ape1 remain unclear[27] or slightly controversial.[22b,28] Here,
we have applied a docking-based virtual screening technique
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to select a concrete number of molecules (15 compounds) as
hit compounds from a 4 million library, to become new and
more potent Ape1 inhibitors. Six of these molecules selected
from the ZINC database were found to be active. In particular,
two of them are single-digit micromolar inhibitors against puri-
fied Ape1 (similar or even more potent than prior reported in-
hibitors), with the capacity to potentiate the cytotoxicity of
a relevant DNA-damaging agent like MMS. The predicted bind-
ing modes highlighted the interaction with the metallic cation,
which is energetically the most important, the hydrogen bond-
ing with residues Asn174 and Asn212, and a network of hydro-
phobic contacts of the ligands with the Phe266 and Trp280. In
the case of compound 2, the most important interactions with
Ape1 are mainly established through the quinoxaline core.
In summary, new compounds have been identified as
potent leads of Ape1 DNA repair inhibition. The binding prop-
erties, cellular uptake, and solubility of these compounds can
be further optimized to produce a subfamily of candidates
with improved pharmacological properties. This new genera-
tion of compounds could lead to innovative drugs that may
act as co-adjuvants in cancer chemotherapy.
Experimental Section
Materials : The Ape1 gene (Homo sapiens) inserted into the pOTB7
vector was obtained from the Genomics Unit (Clone ID: IMAGE
2823545) at the Centro Nacional de Investigaciones Oncologicas
(CNIO). The pet28a plasmid and the competent E. coli strains
(DH5a, BL21(DE3), Rosetta) were purchased from Novagen. The en-
Figure 7. Effect of compounds 1–6 [panels a)–f), respectively] on HOS cell survival relative to untreated cells. Dark-grey bars show samples in the presence of
various compound concentrations as indicated with no MMS added; light-grey bars show the same experiment in the presence of MMS (300 mm). MMS alone
decreased the cell number to an average of 15%. Data represent the averageSEM of three separate experiments performed in duplicate. Significance was
determined by Student’s t test, comparing cells treated with inhibitor in the absence and presence of MMS: *p0.1, **p0.05, ***p0.01, ****p0.001.
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zymes and their corresponding buffers for cloning were purchased
from Fermentas or New England Biolabs. The chemical reagents
used for the expression and purification steps were purchased
from Sigma, Merck, Bio-Rad or Fluka, and the SDS-PAGE standards,
gels and buffers, from Invitrogen. HiTrap FF and size-exclusion
(HiLoad Superdex 75 16/60) columns were purchased from GE
Healthcare.
The oligonucleotides 5’-FAM-GAGAA[X]ATAGTCGCG-3’ and 3’-Q-
CTCTTGTATCAGCGC-5’ (in which FAM is fluorescein, Q is Dabsyl,
and X is ribitol,[51] an abasic (AP) site analogue) were custom-made
by Sigma. Candidate compounds were purchased from various
sources; in particular, compounds 1, 5, and 6 were obtained from
IBScreen, compound 2 was obtained from Enamine, and com-
pounds 3 and 4 were obtained from Specs. Stock solutions were
prepared by dissolving them in DMSO at a final concentration of
1 mm and kept at 20 8C until further use. The fluorescence assay
was carried out on a spectrofluorimeter multi-detection microplate
reader BioTek FLx800 and a Jasco FP6200, in optical 96-well reac-
tion plates. Human osteosarcoma cells, (ATCC Number HOS) were
cultured in RPMI 1640 medium (Gibco) supplemented with 10%
fetal bovine serum (Invitrogen). Methyl methanesulfonate (MMS)
was obtained from Sigma.
Virtual screening (VS): All VS calculations were performed within
the automated platform VSDMIP[34] (virtual screening data manage-
ment on an integrated platform), see Figure 1. For clarity, we brief-
ly describe below the main steps of the protocol (Scheme 1).
Receptor preparation : The crystal structure of PDB ID 1HD7[39] was
selected as a receptor because no substantial differences were
found in the active site amongst the available Ape1 structures and
it presented the highest resolution structure (1.95 ). All atoms
other than the receptor were deleted except for the divalent metal
(Pb2+) in the active site, which, to resemble in vivo conditions, was
replaced by magnesium, the preferred metal cofactor of the
human Ape1 enzyme.[52] The AMBER8 ff99[53] force field was then
used to assign atom types and charges for each atom in the recep-
tor. Hydrogen atoms were added assuming standard protonation
states of titratable groups, except for the key interacting residues,
in which the hydrogen atoms were assigned based on the informa-
tion given from the H+ + web server.[54]
For this purpose, the receptor was submitted to the server and
a Generalized Born (GB) model was used for the pKa calculation at
pH 6.5 with 0.15m salt concentration and internal and external die-
lectric constants of 4 and 80, respectively. The histidine residue
His309, present in the binding site, was found to be protonated,
which is consistent with an NMR study done by Lowry et al.[55]
Binding site definition and characterization : To delimit the bind-
ing site PDB codes 1HD7[39] (Ape1 apo form) and 1DEW[38] (Ape1
bound to DNA, subunit A) were superimposed, (RMSD among Ca
atoms 0.28 ) selecting a DNA fragment as the core around
which to build the docking box by adding a 5.0  cushion to its
maximum dimensions. This DNA fragment consists of an abasic
sugar connected to a cytosine nucleotide residue to its 5’ end and
including the following 5’ phosphate. An equally spaced grid of
0.375  was then built, and CGRID[42] was used to calculate recep-
tor interaction fields, a 12–6 Lennard–Jones term. The electrostatic
term was modeled with a sigmoidal dielectric screening function
using typical atom probes (C, H, N, O, S, P, F, Cl, Br, and I) at each
grid point. Next benzene, water, and methanol probes were
docked with CDOCK[42] to generate intermolecular interaction
energy maps aimed to capture the most favorable hydrophobic,
hydrophilic, and H-bond interaction areas, respectively. These areas
were further compressed into Gaussian functions using GAGA algo-
rithm,[56] producing a sort of a negative image of the interaction
site. The putative active ligands in the library must conform to this
approximate shape.
Chemical library preparation : Ligands for VS consisted of a library
with more than 4 million (4039777) non-redundant molecules, ob-
tained from the publicly available ZINC database[40] in SMILES
format.[57] Multiple protonation states and tautomeric forms were
considered as implemented by default in ZINC database. The mole-
cules were then processed within VSDMIP[34] as follows: a) conver-
sion from SMILE to 3D MOL2 using CORINA,[58] b) atomic charges
calculations with MOPAC[59] (MNDO ESP method) on every single
structure provided by CORINA, and c) atom types assignment ac-
cording to the AMBER ff99[53] force field and conformational analy-
sis with ALFA.[60]
Filter 1: An initial filter was performed with the docking program
DOCK[41] to quickly discard those molecules that do not geometri-
cally fit within the binding site. The spheres needed by DOCK were
generated previously with GAGA. We used DOCK contact as scor-
ing function, normalizing the score values (scorei) by converted
them into ZScore using mean (average score) and standard devia-
tion (s) values (ZScorei= (scoreiaverage score)/s). Only molecules
with a ZScore beyond a cutoff value of 4 were selected and 2500
passed onto the next step.
Filter 2 : Selected molecules from filter 1 were studied with the
more accurate docking algorithm CDOCK.[42] CDOCK exhaustively
docks each molecule within the binding site of the receptor using
the interaction energy grids previously calculated with CGRID. This
was achieved by an exhaustive exploration of the location and ori-
entation of each molecule by positioning its centers of mass on
grid points, where discrete rotations of 278 arc on each axe are
performed. Finally, the energy for each pose was evaluated by the
molecular mechanism force-field scoring function implemented in
CDOCK, which besides including a 12–6 Lennard–Jones term and
an electrostatic term modeled with a sigmoidal dielectric screening
function, also accounts for ligand and receptor desolvations as
well as for H-bonding interactions.[61]
Molecular dynamics simulations : The top ranked 100 molecules
(according to the scoring function of CDOCK) were subjected to
a more exhaustive binding free-energy estimation by a combination
of MD trajectories and MM-GBSA[43] calculation on these trajecto-
ries. The 100 complexes were hydrated by using boxes containing
explicit water molecules, energy minimized, heated (20 ps), and
equilibrated (100 ps). Then, when the equilibration was reached,
MD trajectories were continued for 2 ns. Structures were homoge-
nously sampled at each ps and stored for post-processing. All the
simulations were performed at constant pressure and temperature
(1 atm and 300 K) with an integration time step of 2 fs. SHAKE[62]
was used to constrain all the bonds involving H atoms at their
equilibrium distances. Periodic boundary conditions and the Parti-
cle Mesh Ewald methods were applied to treat long-range electro-
static effects.[63] AMBER ff99[53] and TIP3P[64] force-fields were used
in all cases. Finally, the effective binding free energies were qualita-
tively estimated with the MM-GBSA[43] approach, which calculates
the free energy of binding as a sum of a molecular mechanics
(MM) interaction term, a solvation contribution thorough a General-
ized Born (GB) model and a Surface Area (SA) contribution to ac-
count for the nonpolar part of desolvation. A 12–6 Lennard–Jones
term was used to model the MM contribution. For GB, the solute
dielectric constant was set to 4, whereas that of the solvent was
set to 80, and the dielectric boundary was calculated using a sol-
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vent probe radius of 1.4 . The SA contribution was approximated
as a linear relationship to the change in solvent accessible surface
area (SASA):
DGnp ¼ aþ bDSASA
in which a is 0.092 kcalmol1, b is 0.00542 kcalmol12, DGnp is
the SA contribution, and the change in SASA refers to the complex
SASA minus the sum of that of the receptor and the ligand alone.
In addition, an interaction energy analysis between the ligands and
the more relevant residues in the binding site were computed
(with MM-GBSA) and are contained in Table 2. All the trajectories
and analysis were performed using the AMBER 8 computer pro-
gram and associated modules.[65]
Selection of candidates : Among the 100 molecules with highest
scoring values, a total of 15 were selected upon visual examina-
tion. All visualizations were done within the molecular graphics
program PyMOL.[66] Averaged structures along the MD trajectories
were obtained and minimized in vacuum with the ff99 force field,
without periodic boundary conditions and during 1000 steps (the
first 500 with the steepest descent method and the rest with the
conjugated gradient) solely to alleviate the possible clashes that
may be originated by averaging the coordinates. These structures
were used for graphical representation and comparison of the
binding modes. Finally, those 15 selected compounds were pur-
chased and tested experimentally.
Inhibition of Ape1 activity
Protein production and purification : The in vitro assays were carried
out using recombinant Ape1. The cDNA of full-length Ape1
(IMAGE:2823545) was amplified by PCR using primers 5’-CCC GGG
CAT ATG CCG AAG CGT GGG AAA AAG-3’ and 5’-GCC CTC GAG
TCA CAG TGC TAG GTA TAG GGT-3’, which incorporated the NdeI
and XhoI restriction enzymes sites, respectively. The PCR product
was cloned into the pet-28a(+) (Novagen) vector. The resulting
construct, Ape1-pet28a, was verified by nucleic acid sequencing.
The protein was expressed in the E. coli strain BL21 and once the
culture reached an OD600 value of 0.6 it was induced by adding
1 mm IPTG during 3 h at 30 8C. The pellet from a 2 L culture was
disrupted by sonication and centrifuged. The supernatant was fil-
tered, loaded into a HiTrap FF column (GE Healthcare), and eluted
with an imidazole gradient. Finally, the protein was loaded into
a Superdex 75 16/60 column (GE Healthcare), with buffer NaCl
(300 mm), Tris pH 8.0 (20 mm), DTT (1 mm), and glycerol (5% v/v).
Ape1 activity assay : The in vitro AP site cleavage assay was carried
out by using a modified version of the protocol that had been de-
scribed previously.[25,30] Briefly, the Ape1 enzyme (590 pm) was incu-
bated with or without compounds (at 100 and 200 mm) in a buffer
containing Tris·HCl (50 mm, pH 8.0), MgCl2 (1 mm), NaCl (5 mm)
and dithiothreitol (DTT; 2 mm) at room temperature for 30 min.
The sequence 5’-FAM-GAGAA[X]ATAGTCGCG-3’ and its complemen-
tary oligonucleotide 3’-Q-CTCTTGTATCAGCGC-5’ were annealed to
form a double-stranded DNA, and the reaction was initiated by ad-
dition of the annealed substrate at 50 nm, considering that this
concentration was found to be below the KM value of Ape1 in the
reaction buffer and conditions (data not shown). Fluorescence
readings were taken continuously after 30 min incubation at 20 8C,
at excitation and emission wavelengths of 485 and 535 nm, respec-
tively. Hits from the initial screen were analyzed further for inhibi-
tory potency using decreasing dilutions of inhibitor. Each com-
pound concentration was assayed in triplicate and experiments re-
peated three times. The percent of inhibition was calculated rela-
tive to DMSO-control samples. Bovine serum albumin (BSA) was
used as a negative control (data not shown). The IC50 values were
determined using OriginPro8 data analysis and graphic software,
using the four-parameter equation as follows:
y ¼ A2 þ
A1  A2
1þ exp xx0dx
 
Each value is an average of three independent experiments with
their corresponding standard errors.
DNA intercalation assay : A modified version of the ethidium bro-
mide-based DNA binding assay was carried out essentially as de-
scribed previously.[32,45] In brief, a mixture of labeled double-strand-
ed DNA (500 nm) and ThO (2.5 mm) in Ape1 reaction buffer was
prepared to a total volume of 400 mL. Compounds (at concentra-
tions in the range of 100 pm to 100 mm) were added, and the fluo-
rescence signal (excitation 501 nm and emission 530 nm) was mea-
sured after 10 min of incubation at room temperature in Tris·HCl
(pH 7.5, 50 mm), NaCl (50 mm), MgCl2 (10 mm) and EDTA (1 mm).
Each compound concentration was assayed in triplicates. The per-
centage fluorescence was calculated relative to the total fluores-
cence acquired with double-stranded DNA and ThO (2.5 mm).
Mass analysis of the noncovalent complex between Ape1 and lead
compounds : Mass spectrometry experiments were performed on
Waters (Manchester, UK) instrument equipped with electrospray
ionization, a travelling wave ion mobility cell and a time-of-flight
mass analyzer. The Synapt G1 instrument was interfaced with
a chip-based nano-ESI device, (Advion, Triversa Nanomate). This
device contains a 96-well sample plate, 96 disposable spraying tips
and an ESI chip with 100 nozzles in front of the inlet of the mass
spectrometer. The instrument was operated in the automatic
mode by using a contact closure signal. A spraying voltage of
+1.76 kV and a sample pressure of 5.80 psi were applied. Each
well was loaded with 10 mL of sample, from which a total of 4 mL
was infused during 10 min. Operating conditions for the Synapt G1
mass spectrometer were as follows: cone voltage=20 V; extraction
cone=5.5 V; source temperature=20 8C; trap and transfer voltag-
es=6 V and 4 V, respectively. The ion mobility cell was filled with
N2, and an electric field was applied to the cell in the form of
Table 2. Interaction energies for compounds 1–6 as computed from MD
simulations by the MM-GBSA approach.
Residue Eint [kcalmol
1]
1 2 3 4 5 6
Lys98 1.75 0.3 5.97 1.93 4.85 1.94
Tyr128 0.23 0.13 0.16 0.87 1.99 0.53
Asn174 0.3 2.45 2.56 1.98 3.23 0.34
Arg177 3.91 0.3 2.81 7.47 4.25 5.42
Asn212 0.34 6.27 1.85 0.17 1.49 0.23
Phe266 1.94 3.04 3.55 1.51 2.94 1.09
Thr268 1.2 0.56 1.92 2.51 1.38 0.84
Tyr269 3.38 3.31 0.38 1.44 0.03 1.22
Trp280 2.1 1.31 2.2 1.43 3.65 0.04
Leu282 0.68 1.4 1.02 0.14 0.78 0.09
Asp308 0.04 6.07 2.33 0.54 0.08 3.46
His309 0.31 7.83 0.66 0.42 0.47 0.5
Mg2+ 59.51 37.66 41.01 56.41 60.33 70.59
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waves (wave height=9.5 V) that passed through the cell at
300 ms1. The bias voltage for ion introduction into the IMS cell
was 15 V.
The Ape1 buffer was exchanged to 100 mm ammonium acetate
pH 7 to prevent buffer interferences in the mass spectrometry ex-
periments. Once we confirmed the mass spectrum for the native
form of Ape1, we proceeded to analyze the noncovalent inhibitor–
protein complexes. Ape1 (28 mm) was mixed with each inhibitor (1
to 6 ; 140 mm) separately and let to equilibrate at 4 8C for 1 h. Ape1
in the presence of DMSO or an inactive molecule (16) were used
as Mass spectrum controls.
Cell culture cytotoxic assay : The effect of compounds 1–6 on the
sensitivity of human osteosarcoma cells (HOS) to methyl methane-
sulfonate (MMS) was determined using colony formation assays as
it has been previously described in Ape1 inhibition studies.[30] HOS
cells were seeded at 10103 cells per well density in 24-well, flat-
bottomed plates and incubated in a humidified, 5% CO2 incubator
at 37 8C for 36 h. Compound solutions were diluted in the culture
medium at final concentrations of 100, 50, 30, 20, 5, 2.5, and 1 mm,
and were immediately used to treat the cells. Cells were incubated
with the drug solutions for 6 h and then MMS (or the equivalent
volume of the vehicle as negative controls) was added to a final
concentration of 300 mm. After 2 h of incubation, the medium was
replaced with fresh medium containing the same compound con-
centration, and cells were left to grow for an additional 16 h. The
cells were then re-plated at densities of 2000 cells per well in 24-
well plates and grown for 1 week until discrete colonies were
formed. Colonies were washed twice with PBS and stained with
a solution of 0.5% crystal violet and 20% ethanol. Cells were
rinsed with deionized water and air dried. Stained colonies were
counted in a ELx 800 Universal Microplate Reader (BioTek Instru-
ments Inc.) and clonogenic survival was determined relative to un-
treated cells. Samples were assayed in duplicates and experiments
repeated three times.
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 
       
     
      
 
   
   
 
 
    
    
   
     
      
    
    
    
     
      
     
       
       74
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In order to find inhibitors of the repair activity of hAGT to be used as adjuvants in 
chemotherapy, we developed a real-time fluorescence hAGT activity assay for the in vitro 
evaluation of hAGT activity. This method is based on the detection of the conformational 
changes of the α-thrombin-binding aptamer (TBA). The quadruplex structure of TBA is 
disrupted when a central guanine of one of its two tetrads is replaced by an O6-methyl-
guanine. The TBA sequence contains a fluorophore and a quencher attached to the 
opposite ends. In the unfolded structure, the fluorophore and the quencher are separated. 
When hAGT removes the methyl group from the alkylated guanine, TBA folds back 
immediately into its quadruplex structure. Consequently, the fluorophore and the 
quencher come into close proximity, thereby resulting in a decrease in fluorescence 
intensity. In this chapter we developed a new method to quantify the hAGT activity 
without using radioactivity. This new fluorescence resonance energy transfer assay has 
been designed to detect the conformational change of TBA that is induced by the removal 
of the O6-methyl group. 
In addition, we include as annex of this chapter a review on the chemical 
modifications that affect the structure of TBA and its biomedical applications, written by 
our group. 
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Human O6-alkylguanine-DNA alkyltransferase (hAGT) is a DNA repair protein that reverses the eﬀects of alkylating agents by
removing DNA adducts from the O6 position of guanine. Here, we developed a real-time fluorescence hAGT activity assay that
is based on the detection of conformational changes of the thrombin-binding aptamer (TBA). The quadruplex structure of TBA
is disrupted when a central guanine is replaced by an O6-methyl-guanine. The sequence also contains a fluorophore (fluorescein)
and a quencher (dabsyl) attached to the opposite ends. In the unfolded structure, the fluorophore and the quencher are separated.
When hAGT removes the methyl group from the central guanine of TBA, it folds back immediately into its quadruplex structure.
Consequently, the fluorophore and the quencher come into close proximity, thereby resulting in decreased fluorescence intensity.
Here, we developed a new method to quantify the hAGT without using radioactivity. This new fluorescence resonance energy
transfer assay has been designed to detect the conformational change of TBA that is induced by the removal of the O6-methyl
group.
1. Introduction
Alkylating agents are chemotherapeutic anticancer drugs
that produce their cytotoxic eﬀect by generating adducts at
multiple sites in DNA [1]. A subset of alkylating agents,
which includes nitrosoureas and temozolamide, have a
preference for alkylating guanine at the O6 position, which is
the most relevant in terms of mutagenesis and carcinogenesis
[2–9]. In particular, 1,3-bis-(2-chloroethyl)-1-nitrosourea
(BCNU) attacks initially at the O6 guanine position, causing
its rearrangement in a cyclic intermediate thus giving rise
to N1,O6-ethanoguanine [10]. Finally, a cross-link with
the opposite cytosine is formed, and, as a consequence,
DNA replication is blocked, producing G2/M arrest [11].
In addition to the well-known side eﬀects and limitations
of chemotherapeutic agents, these substances also present
problems of acquired tumor resistance. In particular, the
DNA-repair human O6-alkylguanine DNA alkyltransferase
(hAGT or MGMT) is responsible for removing alkyl adducts
from the O6 position of guanines, thereby blocking the
cytotoxic eﬀects of the alkylating agents and making a crucial
contribution to the resistance mechanism [12–14]. It is well
established that tumor cells show greater expression of this
protein than healthy cells. Thus, this increased expression
appears to be predictive of a poor response to chemother-
apeutic drugs. This eﬀect has been observed in a large
number of cancers, ranging from colon cancer, lung tumors,
breast cancer, pancreatic tumors, non-Hodgkin’s lymphoma,
myeloma, and glioblastoma multiforme, among others [15–
17]. In addition methylation of the hAGT promoter and
consequently the complete depletion of hAGT, it has been
associated with longer survival in patients with gliomas
undergoing combined radiation-chemotherapy treatment
[18, 19]. Therefore, pharmacological inhibition of hAGT has
the potential to enhance the cytotoxicity of a diverse range of
anticancer agents [20]. 79
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hAGT is a 22-kDa (207 AA) DNA-binding protein that
contains a highly conserved internal cysteine, which acts as
the acceptor site for alkyl groups. The S-alkyl-Cys formed
is not regenerated and the protein, which behaves as a
suicidal enzyme, inactivates itself in the dealkylation process
[21, 22]. This single turnover of hAGT renders it vulnerable
to inactivation. On the basis of this observation, intense
research eﬀort has been devoted to the identification of
small molecules capable of inhibiting hAGT activity and
significantly enhancing the cytotoxic eﬀect of BCNU in
prostate, breast, colon, and lung tumor cells [20].
Several methods are available to characterize the mech-
anism of action of hAGT and its activity. Moreover, they
also have the capacity to evaluate the capacity of small
molecules to inhibit hAGT. Most of these methods are based
on radioactivity assays while others are based on multiple-
step enzymatic reactions [23–26].
G-quadruplexes are a family of four-stranded DNA
structures stabilized by the stacking of guanine tetrads, in
which four planar guanines form a cyclic array of hydrogen
bonds [27]. These G-rich regions are connected by lateral,
central, or diagonal loops of diverse sizes and composition
that form base-pairing alignments, which in turn stack
with the terminal G-tetrads, thus further stabilizing G-
quadruplex structures [28]. Another key element in G-
quadruplex formation is the presence of monovalent cations,
which stabilize the negative electrostatic potential created by
the guanine O6 oxygen atoms within the quadruplex core
[29, 30]. However, most divalent cations have the capacity
to induce the dissociation of G-quadruplex structures [31].
Finally, modifications in the base composition of the tetrads
are poorly tolerated by these structures. As an example,
inosine [32] and O6-methylguanine [33], both nonnatural
bases can form a smaller number of hydrogen bonds and thus
destabilize the G-quadruplex.
Given the potential relevance of hAGT as a prognostic
marker of cancer and as a therapeutic target, and that
its substrate O6-methylguanine disrupts the formation of
G-quadruplex structures [33], here, we developed a new
fluorescence activity assay for hAGT. For this purpose, we
selected the thrombin-binding aptamer (TBA) as our G-
quadruplex model. TBA is a well-known 15 mer that adopts
a chair-like structure consisting of two G-tetrads connected
by two lateral TT loops and a central TGT loop [34]. The
modification of its sequence in positions 5 or 6 by replacing
a guanine of the tetrad for an O6-methylguanine disrupts
folding, leaving it in an extended conformation. Giving that
the two conformations bring the two ends of TBA together
take them further apart, our working hypothesis was that the
incorporation of fluorescence probes results in a measurable
change in intensity. The final aim of this fluorescence assay
was to measure the DNA repair activity of hAGT and thus
facilitate the search for new and more potent inhibitors
which enhance chemotherapeutic drugs. Although several
methods have been described to quantify hAGT activity [23–
26], none of them use the conformational change of G-
quadruplex for this purpose. Here, we describe the devel-
opment of a straightforward, rapid, one-step fluorescence
resonance energy transfer (FRET) assay.
2. Materials and Methods
2.1. Chemicals. 5′-Fluorescein CE phosphoramidite (6-
FAM), 3′-Dabsyl CPG, O6-methylguanine (O6-MeG) and
Gdmf phosphoramidites were purchased from Link tech-
nologies (UK) and Glen Research (USA). O6-methylguanine
was protected with the isobutyryl group [35]. Standard
phosphoramidites and ancillary reagents were purchased
from Applied Biosystems (Europe).
Thematrices forMALDI-TOF experiments were 2′,4′,6′-
trihydroxiacetophenone monohydrate (THAP) and ammo-
nium citrate dibasic.
Solvents for chromatographic analysis were prepared
using triethylamine, acetic acid, and acetonitrile as mobile
phase. All other chemicals were of analytical reagent grade
and were used as supplied. Ultrapure water (Millipore, USA)
was used in all experiments.
2.2. Instrumentation. Semipreparative reverse phase (RP)
HPLC was performed on a Waters chromatography system
using Nucleosil semipreparative 120 C18 (250 × 8mm)
columns. Analytical RP-HPLC was performed using an
XBridge OST C18 2.5 μm column and a Nucleosil Analytical
column 120 C18 (250 × 4mm). Oligonucleotides were
detected by UV absorption at 260 nm. Mass spectra were
recorded on a MALDI Voyager DETM RP time-of-flight
(TOF) spectrometer (Applied Biosystems, USA) with a
nitrogen laser at 337 nm using a 3-ns pulse. Fluorometric
measurements were performed on a spectrofluorometer
multidetection microplate reader Biotek FL × 800 and a
Jasco FP6200.Molecular absorption spectra between 220 and
550 nm were recorded with a Jasco V650 spectrophotometer.
The temperature was controlled with a Jasco ETC 272T
Peltier device. Hellma quartz cuvettes (0.5 and 1.0 cm path
length, 500 or 1000 μL volume) were used.
2.3. Oligonucleotide Synthesis. Oligonucleotide sequences
(shown in Table 1) were synthesized on an ABI 3400
DNA Synthesizer (Applied Biosystems, USA) using a 200-
nmol scale synthesis and following the standard proto-
cols. We used dimethylformamidino-protected guanine Gdmf
phosphoramidite for all the syntheses. 5′-Fluorescein CE
phosphoramidite (6-FAM), O6-methylguanine (O6-MeG)
and Gdmf phosphoramidites were from commercial sources.
The isobutyryl group was used to protect the amino group
of O6-MeG [35]. The quencher group was introduced at
the 3′ end using the controlled pore glass functional-
ized with a 3′-Dabsyl derivative CPG. O6-MeG-containing
oligonucleotides were deblocked using concentrated aqueous
ammonia overnight at room temperature following theman-
ufacturer’s instructions. The resulting products were desalted
by Sephadex G-25 (NAP-10, GE Healtcare, USA) and puri-
fied by reversed-phase HPLC using Nucleosil columns. The
yields and purities obtained for the products were around
85% for 5-O6-MeG-TBA and 6-O6-MeG-TBA, and >98%
for the rest of the sequences. The length and homogene-
ity of the oligonucleotides were checked by MALDI-TOF.80
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Table 1: Sequences of TBA oligonucleotide derivatives used in the development of the hAGT fluorescence assay. MeG represents O6-
methylguanine. MB represents the fluorophore group (FAM), labelled in the 5′ end, and the quencher group (Dabsyl), labelled in the 3′
end of the sequence.
Abbreviation Sequence
TBA 5′-GGT TGG TGT GGT TGG-3′
5-O6-MeG-TBA 5′-GGT T MeGG TGT GGT TGG-3′
6-O6-MeG-TBA 5′-GGT TG MeGTGT GGT TGG-3′
C-TBA 5′-CCA ACC ACA CCA ACC-3′
MB-TBA 5′-FAM-GGT TGG TGT GGT TGG-Dabsyl-3′
MB-5-O6-MeG-TBA 5′-FAM-GGT T MeGG TGT GGT TGG- Dabsyl-3′
MB-6-O6-MeG-TBA 5′-FAM-GGT TG MeG TGT GGT TGG- Dabsyl-3′
3-HP-TBA 5′-A CCT TTT GGT TGG TGT GGT TGG-3′
6-HP-TBA 5′-C CAA CCT TTT GGT TGG TGT GGT TGG-3′
9-HP-TBA 5′-A CAC CAA CCT TTT GGT TGG TGT GGT TGG-3′
5-O6-MeG-TBA [M] = 4731.7 (expected 4737.8), 6-O6-
MeG-TBA [M] = 4729.9 (expected 4737.8), MB-5-O6-MeG-
TBA [M] = 5828.49 (expected 5826.0), MB-6-O6-MeG-TBA
[M] = 5826.80 (expected 5826.0).
The DNA-strand concentration was determined by
absorbance measurements (260 nm) by calculating extinc-
tion coeﬃcients. Oligonucleotide samples were kept at
4◦C until further use. Double-stranded O6-MeG-TBA was
formed by annealing equimolar concentrations of comple-
mentary oligonucleotide strands at 72◦C for 5 min and then
allowed to slowly cool to room temperature.
2.4. Melting Temperature Studies. Melting curves were mea-
sured by monitoring the absorbance hyperchromicity at 295
and 495 nm in a JASCO V650 spectrophotometer equipped
with a Peltier temperature-controlling unit. UV/Vis absorp-
tion spectra were recorded at 1◦C/min intervals, with a 1-
min equilibration time at each temperature; the sample was
heated over the range 20–80◦C. The buﬀer solutions used
were 10mM sodium cacodylate pH 7.0 and 100mM KCl.
Sample concentration was around 4 μM. Each sample was
allowed to equilibrate at the initial temperature without any
external control of temperature for 5 min before the melting
experiment began. The melting temperatures (Tm) are the
average value of at least one pair of Tm experiments.
2.5. CD Spectra. Samples were prepared as described for
the melting experiments by UV spectroscopy. Measurements
were conducted in 10mM sodium cacodylate pH 7.0 and
100mM KCl. Sample concentration was between 1–4 μM.
The CD spectra were recorded on a Jasco J-810 spectropo-
larimeter attached to a Julabo F/25HD circulating water bath
in 1 cm path-length quartz cylindrical cells. Spectra were
recorded at room temperature using a 100 nm/min scan rate,
a spectral band width of 1 nm and a time constant of 4 s. All
the spectra were corrected with the buﬀer blank and plotted
using Origin software.
2.6. Human Recombinant hAGT Protein. Full-length hAGT
was overexpressed and purified as previously described [36].
Briefly, hAGT protein cloned in the pet-21a (+) (Novagen)
vector was expressed in the E. coli strain Rosetta. Once the
culture reached an OD600 value of 0.98, hAGT was induced
by adding 1mM IPTG (Sigma) and left for 4 h at 30◦C.
The pellet from a 1-L culture was disrupted by sonication
and centrifuged. The supernatant was filtered, loaded into
a HiTrap FF column (GE Healthcare) with buﬀer 350mM
NaCl, 20mM Tris pH 8, 20mM imidazole, and 1mM BME,
and then eluted with an imidazole (Fluka) gradient up to
500mM in the same buﬀer. Finally, the protein was loaded
into a Superdex 75 16/60 column (GE Healthcare) with the
following buﬀer: 200mM NaCl (Merck), 20mM Tris pH 8.0
(Merck), 10mM DTT (Sigma) and 0.1mM EDTA (Sigma).
The protein was concentrated to 2mg/mL in this buﬀer and
kept at −20◦C in the presence of 40 % glycerol. The same
protocol was used for the purification of the inactive mutant
hAGT-C145S, cloned in the pet-28a (+) vector (Novagen),
and expressed in the E. coli strain BL21.
2.7. HPLC hAGT Assay. Assays were conducted using
double-stranded 5-O6-MeG and 6-O6-MeG TBA paired with
TBA complementary sequence or using single-stranded 5-
O6-MeG and 6-O6-MeG TBA.
In order tomeasure the dealkylation of O6-MeG, 50 pmol
of the O6-MeG-TBA substrates were incubated with a range
of concentration of hAGT (16 nM to 1.6 μM) to a final
volume of 120 μL in a reaction buﬀer (200mM NaCl,
50mM Tris pH 8.0, 1mM DTT, and 5mM EDTA). Several
incubation times were tested (30, 60, 90, 120, 360, and 1440
min) at 37◦C and the reaction was stopped by heating the
samples at 72◦C for 5 min. The reaction products were
analyzed by HPLC on a Nucleosil analytical column at 60◦C
or room temperature, depending on the substrates used
in the experiment (double- or single-stranded TBA). The
HPLC flow rate was 1mL/min, and a gradient of 10%–40%
acetonitrile for 20 min was used.
2.8. Fluorescence Assay for hAGT Activity. The fluorescence
assay was performed in a multidetection microplate reader
biotek FLx800 in optical 96-well Optical btm reaction plates81
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Figure 1: Scheme of fluorescence-based hAGT assay. The sub-
strate is the thrombin-binding aptamer modified by an O6-
methylguanine (Me) in extended conformation, with a fluorophore
and quencher in the opposite ends of the sequence. The refold of the
G-quadruplex structure of TBA is dependent on the removal of the
methyl adduct by alkyl-guanine-DNA-O6-alkyltransferase (hAGT).
This repair moves the quencher and the fluorophore molecules in
close proximity and blocks fluorescence.
(Nunc, USA). Full-length hAGT recombinant protein (207
amino acids) was used for the assay and the hAGT-C145S
inactive mutant was used as a negative control. The reaction
was performed in a total volume of 50 μL in each well,
incubating increasing concentrations of hAGT (5, 10, 20,
40, 60, and 80 nM) enzyme in reaction buﬀer (200mM
NaCl, 50mM Tris pH 8.0, 1mM DTT, 5mM EDTA, and
20mM KCl). The assay of hAGT was then initiated by the
addition of 5 μL of diﬀerent concentrations (5, 10, 25, and
50 nM) of fluorescently labelled MB-O6-MeG-TBA substrate
and this solution was then placed in a microplate reader
system. Fluorescence was measured every minute for 20 min
or 40 min at excitation and emission wavelengths of 485 and
535 nm, respectively. Averages over three readings were taken
for each condition tested. Each experiment was performed in
triplicate.
3. Results and Discussion
The aim of this study was to develop a real-time hAGT
activity assay based on the detection of diﬀerences between
extended and folded conformations of TBA. Our working
hypothesis was that the quadruplex structure of TBA is
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Figure 2: CD spectra of MB-TBA and MB-5-O6-MeG-TBA at
25◦C. Buﬀer conditions: 10mM sodium cacodylate pH 7.0 and
100mM KCl, sample concentration 1 μM.
disrupted when a central guanine is replaced by an O6-
methylguanine. The TBA sequence also contains a fluo-
rophore and a quencher group attached to 5′ or 3′ end,
respectively. In the presence of O6-methylguanine, methy-
lated TBA unfolds and the fluorophore and the quencher
become physically separated beyond the Fo¨rster distance.
When the repair protein hAGT is added to the methylated
aptamer, the enzyme removes the methyl group from the
mutated guanine, thus allowing TBA to fold back into its
chair-like conformation. As a result, the quencher comes
closer to the fluorophore and blocks its fluorescence, as
illustrated in Figure 1. This loss of fluorescence is quantified
as a direct measurement of hAGT activity.
3.1. Synthesis of Modified G-Quadruplex Sequences. The G-
quadruplex sequences used in this study are shown in
Table 1. Oligonucleotide synthesis was performed by the
solid-phase 2′-cyanoethyl-phosphoramidite method [37].
Ammonia treatment was performed at room temperature
overnight to minimize decomposition of O6-methylguanine.
For the same reason, the dimethylformamidino group was
selected for the protection of 2′-deoxyguanosine [38]. The
sequences were characterized by HPLC and mass spectrom-
etry, which provided the expected molecular weights. The
yields of the isolated molecular beacon oligonucleotides after
HPLC purification and desalting were in the range of those
obtained for unmodified oligonucleotides.
3.2. Thermal Stability of Methylguanine-Modified TBA. In
order to induce the unfolding of the quadruplex structure
of TBA, we introduced an O6-methyl-guanine at position
5 or 6 of TBA. Melting curves of the modified sequences
were performed by UV spectroscopy and compared with
the unmodified sequence. These experiments were carried82
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Figure 3: Schematic representation of the structure of several derivatives of thrombin-binding aptamers (TBAs) prepared in this study.
TBA sequence is shown in black, and T4 loop with diﬀerent sizes of the complementary sequences are shown in red. (a) Native TBA;
(b) TBA-hairpin containing three overhanging complementary nucleotides (3-HP-TBA); (c) TBA-hairpin containing six overhanging
complementary nucleotides (6-HP-TBA); (d) TBA-hairpin containing nine overhanging complementary nucleotides (9-HP-TBA). Between
3–6 complementary nucleotides are required to disrupt the intramolecular quadruplex to form an intramolecular duplex.
out at pH 7 in buﬀer containing 10mM sodium cacody-
late and 100mM KCl, which is predicted to stabilize G-
quadruplexes structures. We did not observe a melting
temperature at 295 nm for 5-O6-MeG-TBA or 6-O6-MeG-
TBA and the corresponding molecular beacons (see Figures
S1–S4 in Supplementary Data Material available online at
doi: 10.4061/2010/632041). The absence of this transition is
consistent with the disruption of the quadruplex structure.
These results contrast with the melting temperature of native
TBA (Tm 48◦C) andMB-TBA (Tm 46◦C).Moreover, circular
dicroism of methylated-TBA derivatives did not show the
presence of the maximum at 295 nm, which is characteristic
of the antiparallel quadruplex of TBA (Figure 2 and Figure
S5). These results confirmed that methylation of guanine in
either of the two positions of the TBA sequence prevents the
formation of the chair structure. This observation confirms
our working hypothesis.
Given that the DNA repair activity exerted by hAGT
is higher in double-stranded DNA than single-stranded
DNA [39], we studied the stability and the quadruplex
formation of elongated self-complementary TBA derivatives
(see Table 1). We designed several TBA oligonucleotides
elongated in their 3′ end with a subset of self-complementary
sequences of diverse sizes. The purpose of these elongations
was to check whether the extended sequences have the
capacity to form a double strand helix of diﬀerent lengths
and strengths with themselves without disrupting the chair-
like structure. For 6-HP-TBA and 9-HP-TBA, we found that
the corresponding Tm at 260 nm were 63oC and 71.8◦C,
respectively. This observation confirms our hypothesis of
a double helix structure that increases in strength as the
sequence length increases. However, we did not detect a
melting temperature of these two sequences at 295 nm.
The absence of a transition at 295 nm is consistent with
the absence of an antiparallel quadruplex structure. In
contrast, 3-HP-TBA, corresponding to an overhang of only
3 nucleotides, gave a melting temperature of 46◦C at 295 nm,
which is slightly but similar to that obtained for natural TBA.
This result indicates that 3-HP-TBA forms an antiparallel
quadruplex instead of a duplex because the overhang is too
short to break the chair-like structure. Circular dichroism
confirms the quadruplex structure of 3-HP-TBA and the
absence of quadruplex structure in 6-HP-TBA and 9-HP-
TBA (Figure S6). Models of all these structures are shown
in Figure 3.
3.3. HPLC Analysis of DNA Repair Activity of hAGT. In order
to observe the eﬃciency of hAGT to remove alkyl groups
from single-stranded oligonucleotides, we performed several
assays to determine the optimal conditions of the reaction.
For this purpose, the full-length hAGT was first over-
expressed and purified as described previously [36]. Increas-
ing concentrations of the protein were incubated with
double-stranded 5-O6-MeG and 6-O6-MeG TBA, annealed
with its complementary sequence. Figure 4(a) shows the
HPLC profile of the final product of the reaction with
double-stranded 5-O6-MeG-TBA. In order to separate the
two strands of the TBA substrate (Figure 4(a) top right
panel), HPLC analyses were done at 60◦C. After incubation
with hAGT, we detected a peak with a shorter retention time,
which corresponds to the restored TBA sequence caused by83
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Figure 4: HPLC analysis of hAGT activity over double- and single-stranded TBA before and after incubation with hAGT. (a) Repair of
double-stranded 5-O6-MeG-TBA by hAGT. The peak labelled as cTBA corresponds to the complementary sequence of 5-O6-MeG-TBA.
The top right panel shows HPLC chromatogram in absence of hAGT. The gradient was from 10%–40% acetonitrile for 20 min at 60◦C. (b)
Repair of single- stranded 5-O6-MeG-TBA by hAGT. The inserted panel shows HPLC chromatogram in the absence of hAGT. Gradient used:
10%–40% acetonitrile, 20 min at room temperature.
0
20
40
60
80
100
Fl
u
or
es
ce
n
ce
(%
)
1 2 3 4
(a)
0
20
40
60
80
100
Fl
u
or
es
ce
n
ce
(%
)
0 20 40 60
(nM)
(b)
Figure 5: Fluorescence intensity of the real-time hAGT assay, measured at excitation and emission wavelengths of 485 nm and 535,
respectively. (a) Illustration of the diﬀerent controls with 5 nM MB-5-O6-MeG-TBA: (1) Positive control of MB-5-O6-MeG-TBA in the
absence of hAGT; (2) Intensity in presence of the inactive mutant hAGT-C145S; (3) Decrease in fluorescence when adding 40 nM active
hAGT; and (4) basal fluorescence of 5 nM of MB-TBA. (b) Decrease in intensity caused by the activity of hAGT at a range of concentrations
(0, 20, 40, and 60 nM), in all of them the basal fluorescence of MB-TBA was subtracted.
the removal of the methyl group. We obtained the same
results when we used double-stranded 6-O6-MeG-TBA as a
substrate (data not shown). As expected, hAGT activity was
not aﬀected by the position of the alkyl group within the
sequence. We then tested hAGT activity over single-stranded
methylated TBA in the previously optimized conditions
and obtained similar results to those shown in Figure 4(b).
The top right panel shows the HPLC chromatogram in the
absence of hAGT. In this case, the HPLC analyses were
performed at room temperature because the substrate was
single-stranded TBA. Our results confirmed that hAGT has
the capacity to removemethyl groups from single- or double-
stranded TBA with the same eﬃcacy. Therefore, we selected
single-stranded TBA as substrate for the development of our
fluorescence assay.
3.4. Fluorescence hAGT Activity Assay. On the basis of the
results obtained in the melting temperature and the HPLC
experiments, we tested the eﬀectiveness of our proposed
model to the DNA repair activity of hAGT by means of
fluorescence. First of all, we determined the minimum
amount of TBA required to achieve a detectable and reliable84
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diﬀerence in intensity compared to the background. As
expected, the negative control natural TBA quadruplex gave
low background fluorescence, because of the proximity of
the fluorophore and the quencher groups in the chair-like
structure (Figure 5(a)). Although the fluorescence of MB-
TBA was low, this fluorescence was subtracted from the
fluorescence value in each experiment. The concentration
of 5 nM of fluorescently labelled MB-O6-MeG-TBA was
considered the optimal concentration as the fluorescence
signal was intense and only a small amount of hAGT protein
was required to achieve a substantial decrease in fluorescence
in 20–40 min. In the optimal conditions, the presence
of hAGT produced a remarkable decrease in fluorescence
intensity, caused by the demethylation of the O6 position
of guanines, thereby allowing the TBA to form its typical
quadruplex structure, which brings together the fluorophore
and the quencher groups, as occurred in the negative control.
The rate of decrease in fluorescence intensity correlated
directly with the amount of hAGT in the reaction mixture
(Figure 5(b)). Moreover, the inactive mutant hAGT-C145S
did not exhibit any decrease in fluorescence (Figure 5(a)).
This result was expected because of the inability of this
mutated protein to repair the modified TBA. Figure 5(b)
shows the fluorescence intensities for the real time hAGT
assay. All these observations are consistent with the hypothe-
sis and design of our FRET method.
4. Conclusion
Although radioactivity has been widely used in the search
of potential inhibitors of hAGT [23, 24], this technique
does not allow real-time data acquisition and, in addition,
requires radioactive materials. Here, we developed a sensitive
fluorescence method that allows the quantification of hAGT
activity in a single step and in a straightforward manner.
Although another fluorescence method has already been
developed for this purpose [25], it requires the addition
of a restriction enzyme, followed by the addition of an
exonuclease after the hAGT activity reaction. Consequently,
although it is a real-time assay, a three-step reaction is
required before observing an increase in fluorescence. In
contrast, in our assay, a change in fluorescence is detected
in a single step (homogeneous), and this method does not
depend on the activity of two additional enzymes.
Our assay is based on the detection of conforma-
tional changes of TBA in the presence or absence of O6-
methylguanines in its structure. The quadruplex structure
of TBA is disrupted when a central guanine is replaced by
an O6-methylguanine. Fluorophore groups can be added to
the modified sequence in order to detect the conformational
changes by fluorescence. The variation in fluorescence can
be quantified as a direct measurement of hAGT activity. In
addition, this technique requires lower amounts of substrate
and does not call for the use of radioactive materials.
Furthermore, this method can be easily transferred to a high
throughput experiment for the evaluation of small molecules
as potential hAGT inhibitors [36]. Research in this direction
is currently underway in the laboratory.
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 Figure S1. UV spectra of MB-TBA (5’-FAM-GGT TGG TGT GGT TGG-Dabsyl-3’) at 
20 and 80 ºC. 
 
 
 
 
 
 
 
 
 
Figure S2. UV spectra of MB-5-O6-MeG-TBA (5’-FAM-GGT TMeGG TGT GGT TGG-
Dabsyl-3’) at 20 and 80 ºC. 
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Figure S3. Melting curves of MB-TBA  and MB-5-O6-MeG-TBA recorded at 295 nm. A 
quadruplex-to-random-coil transition is observed for the MB-TBA (Tm = 46 ºC). No 
transition was observed for MB-5-O6-MeG-TBA. 
 
 
 
 
 
 
 
 
 
Figure S4. Melting curves of MB-TBA and MB-5-O6-MeG-TBA recorded at 495 nm. A 
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transition was observed for MB-5-O6-MeG-TBA. 
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Figure S5. CD spectra of TBA, 5-O6-MeG-TBA and 5-O6-MeG-TBA recorded at 25 ºC. 
Conditions 10 mM sodium cacodylate pH 7.0 and 100 mM KCl., sample concentration 4 
M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. CD spectra of TBA, 3HP-TBA, 6HP-TBA and 9HP-TBA recorded at 25 ºC. 
Conditions 10 mM sodium cacodylate pH 7.0 and 100 mM KCl., sample concentration 4 
M. 
 
 
 
 
 
220 240 260 280 300 320
-20
-10
0
10
20
30
40


d
eg
 c
m
2 d
m
ol
-1
)
nm)
 TBA
 5-O6-MeG-TBA
 6-O6-MeG-TBA
220 240 260 280 300 320
-20
-10
0
10
20
30
40


d
eg
 c
m
2 d
m
ol
-1
)
nm)
 TBA
 3-HP-TBA
 6-HP-TBA
 9-HP-TBA
92
  
 
 
 
 
 
 
 
Appendix 2 
Thrombin binding aptamer, more than a simple aptamer: 
chemically modified derivatives and biomedical 
applications. 
  
93
   
94
 Thrombin binding aptamer, more than a simple aptamer: 
chemically modified derivatives and biomedical 
applications. 
Anna Aviñó,1 Carme Fàbrega,1 Maria Tintoré,1 and Ramon Eritja1 
 
Current Pharmaceutical Design (2012) Volume 18, Issue 14, pages 2036-2047.  
DOI: 10.2174/138161212799958387. Impact factor: 3.288 
 
 
 
  
                                                          
1 Institute for Research in Biomedicine of Barcelona, IQAC-CSIC, CIBER-BBN Networking, 
Centre on Bioengineering Biomaterials and Nanomedicine. Cluster Building, Baldiri i 
Reixach 10, E-08028 Barcelona 
 
95
 96
 Current Pharmaceutical Design, 2012, 18, 000-000 1 
 1381-6128/12 $58.00+.00  © 2012 Bentham Science Publishers 
Thrombin Binding Aptamer, More than a Simple Aptamer: Chemically Modified De-
rivatives and Biomedical Applications 
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Abstract: The thrombin binding aptamer (TBA) is a well characterized chair-like, antiparallel quadruplex structure that binds specifically 
to thrombin at nanomolar concentrations and therefore it has interesting anticoagulant properties. In this article we review the research 
involved in the development of new TBA derivatives with improved anticoagulant properties as well as the use of the TBA as a model 
compound for the study of quadruplex structures. Specifically, we describe the impact of modified nucleosides and non-natural back-
bones in the guanine tetrads or in the loops and the introduction of pendant groups at the 3’ or 5’-ends. The modified oligonucleotides are 
shown to be excellent tools for the understanding of the molecular structure of the TBA and its folding properties. Finally, we review the 
use of the TBA-Thrombin recognition system for the development of analytical tools based on the TBA folding. 
Keywords: Thrombin binding aptamer, TBA, G-quadruplex, thrombin, anticoagulant, oligonucleotide synthesis, DNA, aptamer. 
INTRODUCTION  
 Aptamers are oligonucleotides that were originally derived 
from an in vitro selection and polymerase chain reaction process 
known as SELEX (systematic evolution of ligands by exponential 
enrichment) [1-4] which selects them on the basis of their specific 
and tight binding affinity to a target of choice from a library of 
sequences including proteins. Through this approach, a large num-
ber of aptamers with very high affinity have been developed for 
diagnostics, therapeutics and other technical applications [5], but 
there is still room for improvement in terms of increasing their 
binding properties and their pharmacokinetic properties [6]. 
 The thrombin binding aptamer (TBA) is the first example of a 
potential nucleic acid therapeutic agent, targeted to a protein that 
does not physiologically bind nucleic acids with the following con-
sensus sequence: 5’-G1G2T3T4G5G6T7G8T9G10G11T12T13G14G15-3’ 
[7]. This 15-base-long oligonucleotide binds specifically to throm-
bin at 10 nM concentrations and therefore, it has interesting antico-
agulant properties. It inhibits specifically clot-bound thrombin and 
reduces arterial thrombus formation. In addition, it does not com-
pete with other known active site inhibitors of thrombin [7-10]. 
Nevertheless, TBA binding to other serum proteins or proteolytic 
enzymes is essentially undetectable. 
 In an effort to identify the region of thrombin with which the 
TBA aptamer interacts, the inhibition of fibrinogen-clotting activity 
was studied using recombinant mutagenesis of anion-binding 
exosite of thrombin (exosite I) [10]. The results suggested that the 
single-stranded DNA binding site is located in the thrombin exosite 
I and overlaps the thrombin platelet receptor and thrombomodulin 
binding sites. The TBA binding site on thrombin was also examined 
by solid-phase plate binding assays [11] and by chemical modifica-
tions studies [12]. These studies showed that the TBA aptamer 
binds specifically to ?-thrombin but not to ?-thrombin, which is a 
proteolytic cleavage product of ?-thrombin in the fibrinogen-
binding exosite. Both results suggest again that the thrombin 
exosite I is important for the aptamer-thrombin interaction.  
 The awareness of the folded structure of this aptamer, both free 
in solution or bound to thrombin, is essential to understand its  
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biological activity and useful in the future development of oligonu-
cleotide-based therapeutics or drug design. The TBA has been 
characterized by NMR spectroscopy [12-15] and X-ray crystallog-
raphy [16-18]. These studies have led to the description of its com-
pact and symmetrical chair-like, unimolecular antiparallel quadru-
plex structure. This structure consists of two G-tetrads connected by 
three edge-wise loops: two TT loops (T3T4 and T12T13) at one end 
and a single T7G8T9 loop in the other end Fig. (1A). The conforma-
tional distribution of the four co-planar 2’-deoxyguanosines in the 
G-quartets of the TBA aptamer is well defined and they are stabi-
lized by cyclic Hoogsteen hydrogen bounding Fig. (1B). All sugar 
puckers are predominantly South (S) while the guanines on the 
same G-quartet plane display alternating 5’-syn-anti-syn-anti-3’ 
conformations with respect to the glycosyl torsion angle (syn-G at 
positions G1, G5, G10 and G14; anti-G at positions G2, G6, G11 and 
G15, Fig. (1)), except for the G8 and the thymines in the loops which 
are all anti. The two TT loops, both at one end of the quadruplex, 
span a narrow groove, while the TGT loop, placed at the other end, 
spans a wide groove.  
 It has been known for several years that not only the primary 
nucleotide sequence, but also environmental conditions and in par-
ticular cations, play an important role in the formation, topology 
and stability of G-quadruplexes [19-25]. In the case of the thrombin 
binding aptamer, it was believed that the presence of K+ in the me-
dium was necessary to shift the equilibrium toward the quadruplex 
conformation, subsequently favouring thrombin binding, its ionic 
size fitting into the free space existing in the center of each quartet. 
Preliminary studies with Mn2+ suggested that it can bind strongly in 
two sites with one in the each narrow groove [26]. Both Mn2+ ions 
are released when the aptamer is complexed with thrombin, indicat-
ing that both narrow grooves are involved in the TBA-thrombin 
interactions. Some authors have used a combination of temperature-
dependent UV spectroscopy, calorimetry, NMR and electrospray 
ionization mass spectrometry techniques to evaluate the effect in 
the stability, hydration and thermodynamics of the monovalent and 
divalent metal ions in the formation of 3D structures of the TBA 
complexes [26-34]. Divalent ions (Pb2+, Ba2+ and Sr2+) and NH4+ 
bind and stabilize the quadruplex structure with even higher effi-
ciency than K+ while Li+, Na+, Cs+, Mg2+ and Ca2+ form weaker 
complexes only at very low temperatures. These results have been 
rationalized in terms of their radii; cations with an ionic radius in 
the range 1.3-1.5 ? fit well within the two G-quartets of the com-
plex while the other cations do not. The divalent cations like Pb2+, 
Ba2+ and Sr2+ efficiently occupy the region between the two quar-
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tets in the TBA-ion complex in a 1:1 stoichiometry [27, 29, 33]. 
The aptamer complex with monovalent and divalent ions unfolds in 
a monophasic transition [30].  
 Hong et al. have determined the alkali metal binding site and 
constant by electrospray ionization (ESI) and infrared multiphoton 
dissociation (IRMPD) respectively [35]. The binding constant of 
potassium is 5-8 times greater than those for other alkali metal ions 
and the K+ binding site is different from other metal binding sites. 
In a 1:1 TBA-metal complex, potassium coordinated between the 
bottom G-quartet and the two adjacent TT loops of the TBA. In a 
1:2 ratio TBA-metal complex, the second potassium ion binds at the 
distant TGT loop. In the other hand, Na+, Rb+ and Cs+ bind at the 
lateral TGT loop in both 1:1 and 1:2 complexes, presumably due to 
the formation of ion-pair adducts. 
By contrast, some published works provide evidence that the TBA 
is able to bind thrombin in the absence of divalent and monovalent 
ions [24, 25, 36-37], which suggests that the binding to thrombin 
promotes the TBA folding to its 3D structure, even in the absence 
of salts. 
 Several groups have studied and suggested that molecular 
crowding causes a structural transition from an antiparallel to a 
parallel DNA G-quadruplex and they are an important factor to 
control the formation of G-quadruplex [38-39]. Miyoshi et al. have 
shown that different molecular crowding promotes and stabilizes 
the G-quadruplex structure of the TBA by a favourable enthalpic 
contribution that exceeds an unfavourable entropic contribution. 
Moreover, the thermodynamic effect correlates with the number of 
hydroxyl groups of the molecular crowding cosolute [39]. 
 It is worth noting that despite the robust stability of the in-
tramolecular quadruplex structure, alternative intermolecular quad-
ruplexes are possible at high aptamer concentration, as detected by 
CD and electrophoresis migration experiments [40]. The crystal 
structure of the TBA-thrombin complex solved by Padmanabhan et 
al. [16] at 2.9 ? resolution differs in the aptamer quadruplex topol-
ogy with the NMR structure. Indeed, the core of the two G-tetrads 
is the same in the two models, although structural differences exist 
in the way the central bases are connected. A difference concerning 
the disposition of the two TT and the TGT loops with respect to the 
grooves. In an effort to resolve this ambiguity, the structure of the 
TBA-thrombin complex has been determined at 2.8 ?, built on the  
 
basis of the NMR structure of the aptamer [17]. The results con-
firmed that both structures fit the crystallographic data equally well, 
thus leaving the doubt on which binding model is the correct one. In 
both models, the TBA is sandwiched between two symmetry-
related thrombin molecules and interacts with the exosite I of a 
thrombin molecule and exosite II of the second one. In particular, 
the two TT loops in the NMR structure interact with the fibrinogen-
recognition site (exosite I) of the thrombin molecule and the TGT 
loop interacts with the heparin-binding site (exosite II) of the 
neighbouring thrombin, whereas in the X-ray structure the opposite 
occurs [16-17]. The structure of the complex between thrombin and 
TBA is shown in Fig. (2). 
 The uncertainty between the two models was caused by the 
absence or poor electron density in the region of the TT loops and 
in the G10 for the X-ray structure and in the G14 and in the TGT 
loop for the NMR structure. In a more systematic analysis [18], 
eight orientations of the NMR aptamer were evaluated in an effort 
to reconcile the NMR and X-ray data [16-17]. The resulting crystal-
lographic R-factors and the analysis of the aptamer-protein com-
plexes clearly distinguished between the two possible oligonucleo-
tides backbone directionalities. However, due to the missing density 
in the connecting loops of the aptamer, the details of the ligand 
protein interactions could not be properly addressed. Moreover, 
even recent papers still discuss modified aptamer-thrombin interac-
tions on the bases of both models [39]. 
 The recent solved high resolution structure of the complex of 
thrombin with a modified TBA (mTBA), which contains a 5’-5’ 
inversion between T3 and T4, clarifies several questions regarding 
thrombin-aptamer interaction [41]. The aptamer tightly binds to 
thrombin exosite I by its TT loops, through a mix of hydrophobic 
and polar interactions in agreement with the results obtained in the 
systematic analysis [18]. However, the interaction details are differ-
ent for the two aptamers due to the chain inversion of the mTBA. 
This chain inversion allows the formation of a great number of 
contacts with the enzyme and lead to an increase in shape comple-
mentarity. In addition, the quadruplex structure is efficiently stabi-
lized by a potassium ion, which is sandwiched between the two 
quartets. 
 The antiparallel quadruplex structure of the TBA has a distinc-
tive denaturation-renaturation profile that is reversible and observ- 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A) Folding topology of the intramolecular quadruplex adopted by the d(G1G2T3T4G5G6T7G8T9G10G11T12T13G14G15) thrombin-binding DNA aptamer 
containing three edge-wise loops. B) Structure of the G-quartet with cyclic array of four guanines formed by Hoogsteen-type H-bonds, M indicates a metal 
ion.  
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Fig. (2). Structure of the complex formed by thrombin and the thrombin 
binding aptamer (TBA). Thrombin is coloured in green with the amino acid 
residues that contact the TBA in red (cartoon representation). The TBA is 
coloured in blue except the residues involved in the TT and TGT loops that 
are highlighted in yellow (stick representation).  
 
able by different techniques, particularly by NMR experiments, 
which suggest that the denaturation of the quadruplex occurs by the 
opening of the G-G base pairs that are not protected by a loop, fol-
lowed by the opening of the TGT loop [42]. 
1. CLINICAL TRIALS WITH THE THROMBIN-BINDING 
APTAMER 
 The anticoagulant properties of TBA were first evaluated on 
cynomolgus monkeys, and sheeps [8]. The rapid onset and the short 
half-life of TBA (t1/2: 2 min) in vivo lead to an interest for the use of 
TBA for certain acute clinical settings such as surgical interventions 
where regional anticoagulation is required. TBA was able to inhibit 
clot-bound thrombin and platelet thrombus formation in an ex vivo 
whole-artery angioplasty model [9]. Moreover, when TBA was 
administered by infusion in a short-term canine cardiopulmonary 
bypass model it was shown that TBA could be used as anticoagu-
lant safely and as efficiently as heparine [43]. Clinical trials evalu-
ating TBA (ARC-183, HD1, Archemix Corporation) as anticoagu-
lant during coronary artery bypass graft surgery were halted after 
phase I due to suboptimal dosing profiles, primarily caused by the 
restricted binding affinity of the aptamer [44]. A more potent sec-
ond-generation DNA aptamer (NU172, Archemix Coorp., Nuvelo 
Inc.) was developed showing clear inhibition of clot formation [45].  
2. MODIFICATIONS ON THE THROMBIN-BINDING AP-
TAMER 
 In recent years, several attempts to improve pharmacological 
properties of the TBA have been described, such as stability, higher 
thrombin affinity, longer life time in vivo etc. These modifications 
have included substitutions in the nucleosides [46], LNA [47-48], 
UNA [49], RNA [50-51] or 2’-O-methyl-RNA [50, 52], methyl-
phosphonate or phosphorothioate internucleoside linkages [50, 52], 
partial inversion of the TBA polarity with and 5’-5’ internucleoside 
linkage or change in the loop size and sequence [28]. In some cases, 
the modifications introduced are evaluated in different positions of 
the aptamer in order to increase the knowledge of the interactions 
between thrombin and the TBA which are critical for the biological 
activity. Besides these modifications, thrombin binding aptamer has 
been functionalized with different derivatives such as fluorescein, 
biotin or thiol groups to be incorporated in biosensors for the detec-
tion of thrombin. These derivatives will be described in section 7. 
Herein, we have classified the modifications of the TBA depending 
on the location: G-tetrads, loops or changes of the overall quadru-
plex structure. 
2.1. Modifications of the Guanine Tetrad  
 Several modifications have been introduced in the G-tetrads, 
some of which are analogues of the guanine base. Other modifica-
tions are related with the sugar structure or with the internucleotide 
phosphate bonds in the guanine tetrad. The guanine analogues that 
have been introduced in the TBA are summarized in Fig. (3). Hy-
poxanthine, 7-deazaguanine and C8-methylguanine were the first 
guanine analogues to be introduced into the TBA to understand its 
structure by NMR. These guanine derivatives are unable to form the 
hydrogen bond required for the formation of the G-tetrad and con-
sequently cause significant disruption to the chair-like structure 
[12]. He and co-workers studied the N2 and C8-alkyl substituted of 
the G residues forming G-tetrads [53]. These positions are not 
forming the H-bonding of the tetrads and are available for attaching 
one or more groups pointing away from the chair-like structure. 
This is the main reason why these substitutions caused relatively 
small perturbation on the quadruplex structure. However, they can 
produce different effects on the thrombin activity. The increased 
activities for the substitutions on C8 positions may be explained by 
the stabilization of syn conformation of the G residues, while the 
increased activities for the substitutions on N2 positions may be due 
to the interaction with thrombin. 
 6-Thioguanine reduced the quadruplex formation due to the 
increased radius and decreased electronegativity of the sulphur [54]. 
This modification caused a destabilization of the Hoogsteen hydro-
gen bonding of guanine tetrads. Moreover, the thiol group at posi-
tion 6 disrupted the interactions with water molecules and with 
cations, becoming a weaker hydrogen bond acceptor than the oxo 
group. 8-Aminoguanine did not significantly alter the structure of 
the TBA quadruplex but it has a small destabilization effect on the 
TBA quadruplex. A detailed study of this modification in the G2 
position was carried out by molecular dynamics simulations, NMR, 
UV spectroscopy and circular dichroism. The presence of 8-
aminoguanine did not affect hydrogen bonding or purine-ion inter-
action, but clearly reduced the strength of stacking interactions [55]. 
Nallagatla et al. prepared a library of all possible substitutions of 
guanine by isoguanine in the TBA by split and mix synthesis [56]. 
The library was screened for binding to human thrombin and se-
lected sequences were individually resynthesized and their affinities 
were assayed by isothermal titration calorimetry. Three modified 
aptamers carrying one single isoguanine were found to have higher 
binding affinity for thrombin than the unmodified TBA. The ther-
mal stability of these modified TBAs was not analysed although it 
is presumed that the effect of the modification will depend on the 
position of the aptamer.  
 Finally, the effect of adding a third tetrad on the TBA aptamer 
has also been explored [28]. This modified thrombin binding ap-
tamer is more stable than the native TBA due to the enthalpic con-
tribution of the extra guanine tetrad. 
2.2. Modification of the 2’-deoxyribose of the Guanine Tetrad  
 Several modifications in the TBA have been applied to the 
sugar moiety of the guanine tetrad. The structures of the modified 
2’-deoxyribose incorporated in the TBA are summarized in Fig. (4). 
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In some of them, the 2’-deoxyribose moiety was replaced by a non 
carbohydrate structure. On the contrary, other modifications are 
based on the addition of different groups in the 2’-position. These 
groups may influence sugar puckering and glycosidic bond confor-
mation of the G-tetrad. 
 In a very interesting work, Shafer’s group [51] examined the 
influence of individual nucleoside conformation on the overall fold-
ing topology by selective replacement of deoxyG by riboG. The 
unimolecular antiparallel TBA is reversed to bimolecular parallel 
quadruplex by a specific ribonucleotides substitutions. The parallel 
quadruplex conformation implies that all nucleosides are in the anti 
conformation. The strong preference of guanine ribonucleosides for 
the anti conformation is the driving force for the change in topology 
and also impact in quadruplex molecularity. 
 The denaturation behaviour of the TBA derivatives carrying 
ribonucleotides was also described by Mergny’s group [50]. The 
authors prepared a TBA analogue with all the G of the two tetrads 
replaced by riboG. In this case, the modified TBA presented a com-
plex behaviour with a non-superimposable and multi-phasic re-
sponse upon heating and cooling (hysteresis). The same authors 
also described the same TBA analogues with 2’-O-Me guanosine 
substitutions. This analogue, instead, showed reversible transitions 
with concentration independent of the melting temperature (Tm). In 
fact, substitution of the ribose 2’-H with a methoxy group destabi-
lized the quadruplex structure. 
 LNA are 2’-O-4’-C-methylene-linked ribonucleotide nucleic 
acids analogues that bind with increased affinity to DNA and RNA. 
The bicyclic structure of DNA forces the sugar to be in the C3’-
endo conformation, and nucleotides with a C3’-endo conformation 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Chemical structure of the modified guanines in the TBA tetrads.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Chemical structure of the modified carbohydrate moiety in the guanine TBA tetrads. LNA: locked nucleic acid, UNA: unlocked nucleic acid.  
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prefer the glycosidic bond to be in the anti configuration. Three 
different works were addressed to study the effect of LNA in the 
TBA quadruplex [47-48, 57]. Mayol’s group prepared four different 
TBA-based oligonucleotides containing LNA residues [47, 57]. The 
first analogue was fully substituted by LNA residues. This oligonu-
cleotide was unstructured most probably due to the decreased flexi-
bility of the oligomer. Oligonucleotides containing G-LNA in the 
eight positions of the tetrads or in the first G1 position (syn configu-
ration) gave mixtures of several structures. On the other hand, the 
oligonucleotide containing G-LNA in the last guanine G15 (anti 
configuration) folded in the same TBA chair-like quadruplex. Boni-
facio et al. also studied the effect of single LNA substitutions on 
different positions of the TBA [48]. The LNA substitutions had 
either a moderate stabilizing or destabilizing effect on the folded 
structure, depending on the position of the LNA in the TBA. The 
thermal stability of the substituted aptamers did not correlate to 
thrombin inhibition. 
 Damha and co-workers studied the impact of 2’-deoxy-2-
fluoroarabinonucleoside residues (2’-F-araN) on the thrombin bind-
ing aptamer [58]. 2’-Deoxy-2’-fluoro-D-arabinonucleic acids (2’F-
araN) confer DNA-like (South/East) conformation to oligonucleo-
tides while rendering them more nuclease resistant. It was found 
that incorporation of 2’-F-araN G or T residues into the TBA stabi-
lizes the complex (?Tm + 3ºC /2’-F-araN modification). Oligonu-
cleotides with all nucleotides replaced by 2’-F-araN in the G-syn 
positions or in the G-tetrads showed a moderated increase of the 
melting temperature compared to the unmodified TBA. The CD 
spectrum and the hysteresis observed in the heating and cooling 
processes of these analogues supported a parallel structure with all 
anti-dG and the existence of multimeric G-quadruplex structures. 
On the contrary, when the 2’-F-araN are replaced in the G-anti 
positions, in the loops or in both the resulted quadruplex structures 
correspond to antiparallel quadruplex with alternating syn-anti Gs. 
The lack of concentration dependence in the Tm data and the lack 
of hysteresis in the heating/cooling processes support a unimolecu-
lar G-quadruplex structure. Moreover, nuclease resistance of this 
modified TBA was increased up to 48-fold in 10 % fetal bovine 
serum (FBS).  
 Carbacyclic bicyclo [3.1.0] hexane locked nucleoside analogues 
are a different “locked” nucleoside from the previously presented 
LNA [52]. An advantage of this methanocarba nucleoside system 
over LNAs is that both North (N)- and South (S)-locked platforms 
can be prepared by shifting the position of the fused cyclopropane 
ring. It has been described the effects of replacing a single 2’-
deoxyguanosine residue at the 3’-end of the TBA (positions dG14 
and dG15) with methanocarba nucleosides locked in either the N- or 
S-conformation [59]. These positions were selected to explore the 
combined effects of a constrained sugar pucker (N or S) and the 
corresponding biased glycosyl torsion angle (anti or syn) associated 
with a particular pseudosugar conformation. Experimental and 
theoretical results indicated that a N-pseudosugar conformation 
favours the anti glycosyl orientation, whereas the S-pseudosugar 
conformation favours the syn disposition of the base. The introduc-
tion of methanocarba nucleosides at positions G14 and G15 with 
locked-N(anti) and locked-S (syn) conformations fixed the confor-
mational state of these nucleosides and helped to understand the 
impact of conformational restrictions on the antiparallel, G-quartet 
DNA structure of the TBA. These results indicated that the glycosyl 
conformation is more restrictive for the TBA stability than the 
sugar puckering. 
 Wengel’s group examined the influence of unlocked nucleic 
acid (UNA) on the thermodynamic stability, binding affinity and 
biological activity of the quadruplex TBA [49]. UNA is an acyclic 
RNA mimic, which misses the bound between the C2’ and C3’ 
atoms of the ribose ring. The modified variants are aptamers singly 
substituted with a UNA monomer in every possible position. UNA 
modified TBAs in positions U3, U7 and U12 showed an antiparallel 
folding topology. In contrast, modifications of any of the guanine 
monomers forming G-tetrads resulted in significant destabilization 
of the quadruplex structure. The modified TBA with UNA in posi-
tion 7 resulted in the highest thrombin binding affinity. Recently, 
the same authors have also evaluated the effects of the modification 
of 2’-C-piperazino-UNA monomer [60]. This monomer is charac-
terized by more efficient stabilization of quadruplexes structures in 
comparison to regular UNA and increases thermodynamic stability 
of TBA by 0.28-0.44 kcal/mol in a position depending manner with 
retained quadruplex topology and molecularity. 
2.3. Modifications in the Internucleotide Phosphates of the 
Guanosine Tetrad 
 The TBA has been modified with three different phosphate 
linkers, phosphorothioate, methylphosphonate and formacetal. The 
structures of these linkages are summarized in Fig. (5). The modi-
fied TBA oligonucleotides containing thiophosphoryl substitutions 
at different internucleotide sites were studied. It was found that 
these linkages do not disrupt the antiparallel ntramolecular quadru-
plex [52]. The substitutions placed between planes of G-quartets led 
to a drop in formation free energy, and the stability decreases line-
arly with the number of these modifications. The TBA containing 
phosphorothioate linkages have more resistance to various nucle-
ases. In this way, the in vivo half-life of the modified TBAs are 
increased. Mergny’s group also studied the introduction of phos-
phorothioate bonds in all of G-forming tetrads [50]. The resulting 
modified TBA was less stable than the unmodified TBA. It also had 
an intramolecular G-quadruplex structure with concentration inde-
pendent melting temperatures showing a reversible quadruplexes to 
random coil transitions. The same group studied the modified TBA 
carrying backbone methylphosphonate in the two G- tetrads [50]. 
The methylphosphonate TBA variant suffered a loss of negative 
charge at the level of the phosphate backbone that led to a strong 
destabilization. Non observable melting transition was detected. 
The negative charge of the oxygen atoms in the phosphate groups 
was found to be involved in a complex pattern of water bridges 
with the sugar group and the edges of the guanine units. A series of 
TBA analogues were synthesized containing one or more phos-
phodiester linkages replaced by a natural formacetal group [61]. 
The formacetal group is achiral and the incorporation of these 
moieties into oligonucleotides decreased the tissue uptake and in-
creased the in vivo half-life. Unfortunately, no structural studies 
were carried out with these TBA analogues. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Chemical structure of the modified internucleotide phosphate 
bonds in the guanine TBA tetrads. 
 
 In summary, several G-tetrad modifications of the TBA have 
been studied. Some of them have destabilized or disrupted the 
quadruplex structure because the introduced modification have 
changed directly the H-bonding tetrad arrangement, sugar pucker-
ing or glycosidic guanine orientation. In addition, some modifica-
tions have destabilized the antiparallel quadruplex to form a more 
undefined multimer quadruplex structures.  
O
CH2
O
O
PS
O
O-
O
PO
O
CH3
Phosphorothioate Methylphosphonate Formacetal
101
6    Current Pharmaceutical Design, 2012, Vol. 18, No. 00 Aviñó et al. 
3. MODIFICATION OF THE LOOPS 
 The TBA is formed by two guanine tetrads connected by three 
edge-wise-loops: a central TGT loop and two TT loops as it is 
shown in the Fig. (1A). The loops are important in the folding of 
the aptamer and in the interactions with the thrombin. Most of the 
modifications are based in changes of the composition or in the 
length of the loops. Thymine bases in the loop region exclusively 
prefer the anti orientation. The literature reports that G8 shows base 
stacking interactions with the first tetrad, but the conformation of 
the nucleoside is not mentioned. 
3.1. Modifications of the Loop Composition by Natural Nucleo-
sides 
 Shafer’s group has undertaken a systematic examination of the 
thermodynamic stability of thrombin aptamer analogues containing 
sequence modifications in one or more loops [28]. The results indi-
cated that changes in loop sequences had a significant impact on the 
aptamer stability. Most of the changes in the central loop led to a 
decrease in thermodynamic stability, indicating that, at least among 
the sequences explored, the TGT loop sequence is optimal for sta-
bility. These effects may involve changes in both stacking interac-
tions and cation binding. The impact of replacing single Ts in the 
external loops with Cs provide evidence for hydrogen bond forma-
tion between these loops, as observed in the NMR structures. The 
stability of aptamers containing a C in position 3 or 12 was similar 
or slightly higher than the unmodified TBA. A recent paper has 
examined the stability of the G-quadruplex of TBA in which 
thymine residues were substituted by adenine. The G-quadruplexes 
formed by T4A and T13A were more stable and T3A, T7A, T9A and 
T12A were more unstable than that of the wild-type [62]. 
3.2. Modifications of the Loop Composition by Non-natural 
Nucleosides 
 Replacement of anti thymines in the loops with anti conforma-
tionally biased 2’-F-araT increased the thermal stability to different 
degrees depending on the number and position of the modification. 
In addition, the modification of G8 with 2’-F-araG resulted in an 
increase of the stability. Overall, 2’-F-araN modifications in the 
loops stabilizes the formation of a unimolecular G-quadruplex [58]. 
LNA substitutions in the loops demonstrate a position dependent 
effect on the stability of the TBA. The substitution of G8 for G-
LNA increased the stability, but the substitution of T7 decreased the 
stability. Nevertheless, substitution of T4 disrupted the aptamer 
[48]. On the other hand, single UNA modification of the TBA in 
U3, U7 and U12 positions did not affect the stability of the uni-
molecular antiparallel structure. However, these same modifications 
in positions U4, G8, U9 and U13 resulted in significant destabiliza-
tion of the quadruplex structure [49]. 
 Borbone’s group modified the different positions of the TBA 
with flexible acyclic thymidines [63]. They obtained the same pat-
tern of thermodynamic stabilities than UNA modifications. These 
analogues were able to fold into a bimolecular or monomolecular 
quadruplex structure depending on the nature of the monovalent 
cations (sodium or potassium) coordinated in the quadruplex core. 
Thermal stability was in agreement with the structural model in 
which T9, T4 and T13 are stacked on the adjacent G-quartet. These 
interactions were totally or partially disrupted by the introduction of 
the acyclic nucleotide at these positions. The TBA analogues con-
taining an acyclic residue at positions T3, T7 or T12 resulted in a 
similar stability than the observed for the unmodified TBA, thus 
suggesting a marginal role of these positions on the structural sta-
bility [63].  
 Modifications of the TBA loops by thiophosphoryl internucleo-
tide bonds were evaluated [52]. No destabilization was observed in 
each of the loop regions, although the stability against nuclease was 
increased in comparison to that of the native TBA. Finally, a new 
TBA aptamer modified with 4-thio-2’-deoxyuridines replacing 
some Ts in the loops was described [64]. This substitution was 
based on previous experiments showing that oligonucleotides with 
4-thio-2’-deoxyuridines showed high-affinity binding to HIV-1 
reverse transcriptase [65]. No thermodynamic data were performed 
but TBA modified with 4-thio-2’-deoxyuridines has an increased 
anticoagulant and antithrombotic properties [64].  
3.3. Modification of the Loop Length 
 Loop length plays an important role in intramolecular quadru-
plex formation. When the central loop was replaced by four nucleo-
tides, the resulting aptamer had a lower stability compared to un-
modified TBA [28]. The thermodynamic analysis indicated that the 
central loop sequence in the parent aptamer is optimal for stability. 
Reduction of the two external TT loops to a single T led to a com-
plete disruption of the quadruplex structure. This was expected due 
to the difficulty of forming a single base loop. On the contrary, 
extension to TTT loops had the same stability as the unmodified 
TBA. Addition of a single G at the 5’-end decreased the stability of 
the aptamer while addition of a G at the 3’-end increased the stabil-
ity [28].  
4. SYNTHESIS OF DIFFERENT CONSTRUCTS BASED ON 
THE TBA 
 In an effort to select more potent and selective DNA ligands to 
thrombin, several authors have synthesized different constructs. 
Most of them have modified the TBA structure itself or others have 
incorporated additional structures or molecules to the TBA. The 
first approach was comprised of an unimolecular quadruplex motif 
and complementary flanking sequences capable of forming an addi-
tional Watson-Crick duplex motif [66]. After that, following the 
same approach, a new 29 nucleotide single stranded oligonucleotide 
based on a quadruplex/duplex structure was described to bind the 
heparin-binding exosite of thrombin [67]. Seela’s group proposed a 
new construct arising by replacement of the TGT loop of the TBA 
by a mini-hairpin 5’-GCGAAGC-3’. This fused oligonucleotide 
exhibited a two-phase thermal transition indicating the presence of 
the two unaltered moieties [68].  
 A new interesting architecture demonstrated that the combina-
tion of bivalent TBA aptamers, which simultaneously targeted and 
accordingly inhibited the regulatory exosites I and II of thrombin 
[69]. This approach turned out to be a combination of features of 
the individual aptamers in one molecule: high affinity binding and 
anticoagulant activity. A new quadruplex structure was studied in 
the d(G2T4G2CAG2GT4G2T) sequence, which differs from the TBA 
in having longer first (T4) and third (GT4) loop and a shorter (CA) 
middle loop. This oligonucleotide has different strand directionali-
ties, loop connectivities and syn/anti G-tetrad distribution [70]. 
Circularization is an attractive alternative to chemical modification 
for improving aptamer stability. This new approach was used in the 
design and construction of a TBA aptamer. The new construct has 
increased target binding affinity and much improved stability in 
biological fluids [71]. 
 Mayol and co-workers described a new topology of the TBA 
that consists of a series of oligonucleotides containing 3’-3’ or 5’-5’ 
inversion of polarity sites [72]. The oligonucleotide d(3’-GGT-5’-
5’-TGGTGTGGTTGG-3’) was characterized by an unusual fold-
ing, three strands parallel to each other and only one strand oriented 
in an opposite manner. This led to an anti-anti-anti-syn and syn-
syn-syn-anti arrangement of the Gs in the two tetrads. The thermal 
stability of the modified oligonucleotide was higher than the corre-
sponding for the unmodified TBA. 
 Several intercalating agents have been conjugated to the 3’-end 
of the TBA and they have been found to stabilize the aptamer. 
Moreover, the hydrophobicity and fluorescent properties may be 
used to enhance the bioavailability of these conjugates [73]. Finally, 
the capping of the 3’-end of the TBA with bridged nucleosides was 
described. The bridged nucleosides increased the nuclease resis-
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tance 36-27 fold and the stability in serum 1.5-4 fold without affect-
ing the binding affinities of the aptamers to thrombin [74]. 
5. BINDING ACTIVITY OF MODIFIED THROMBIN BIND-
ING APTAMERS 
 The reported bibliography concerning the modified TBAs 
might give an insight into the variables involved in the mode of 
action of the TBA. Nevertheless, the mode of action of the TBAs 
actually requires a more wide recognition process that involves 
even locally a single residue. Several assays are described to study 
the binding or interaction of the modified TBAs to thrombin such as 
nitrocellulose filter binding assay [58], isothermal tritation calo-
rimetry [53, 56, 62, 75], surface plasmon resonance [49] or by non-
equilibrium capillary electrophoresis of equilibrium mixtures (NE-
CEEM) [74]. Recently, the interaction of the TBA with thrombin 
was evaluated by differential pulse voltammetry at a glassy carbon 
electrode and atomic force microscopy at a highly oriented pyro-
lytic graphite electrode [76]. 
 Thrombin binding affinity of the modified TBAs in the tetrads 
was studied by different researchers. The thrombin binding of a 
TBA containing 2’-deoxyinosine or 7-deaza-2’-deoxyguanosine 
was significantly decreased as the residues were unable to form the 
hydrogen bonds required for the formation of the G-tetrad [77]. On 
the contrary, the TBA containing isoguanine showed an enhanced 
binding activity to human ?-thrombin compared to the unmodified 
TBA determined by isothermal titration calorimetry [56]. The effect 
of 2’-F-araN modifications was conducted using nitrocellulose filter 
binding assay. The binding of 2’-F-araN aptamers to thrombin was 
always adversely affected when the modification was on G tetrads 
themselves. Some loop modifications with 2’-F-araN also reduced 
thrombin binding. However, the two loop modified aptamers in 
positions 7, 9, 12, 13 or 3, 4 , 7, 9 showed a 4-5 fold enhancement 
in thrombin binding affinity [58].  
 On the other hand, real-time measurements of the interaction 
between thrombin and the TBA containing UNA modifications 
were performed by surface plasmon resonance. The modification of 
the G1 position showed similar affinities to the unmodified TBA. 
The rest of the Gs involved in the tetrads showed a higher dissocia-
tion constant or were not measurable, presumably due to a lack of 
significant affinity towards thrombin after the incorporation of 
UNA in these positions. The U7 UNA modification located in the 
central loop was the only UNA modified aptamer that showed small 
but significant improvement in affinity [49]. Similar results were 
obtained with 2’-C-piperazino-UNA-U monomer, but in this case 
the presence of a positively charge decreased the thrombin affinity 
[60]. 
 Another interesting work has focused on the replacement of 
thymine loop residues by adenine. Isothermal titration calorimetry 
(ITC) measurements indicated that the binding constant of the in-
teractions between T13A, T7A, T9A and T12A aptamers and throm-
bin was close to that of the unmodified TBA, whereas T13A was 
significantly lower and T4A did not appear to bind thrombin [62]. 
The binding energy of the modified TBA containing a 5’-5’-site of 
polarity inversion to thrombin was characterized by means of ITC. 
The equilibrium constant for the interaction of the modified TBA 
was about one order of magnitude higher than that for the TBA. 
The binding process was enthalpically driven with a larger favor-
able enthalpy for the modified aptamer [75]. The construct formed 
by a quadruplex core of the TBA and a duplex interacted with a 20 
to 50 –fold higher affinity to the heparin-binding exosite than the 
unmodified TBA by nitrocellulose filter [67]. Finally, thrombin 
binding affinities of capped TBAs with 2’,4’-bridged nucleotides 
were measured using non-equilibrium capillary electrophoresis of 
equilibrium mixtures (NECEEM) [74]. The binding abilities were 
almost the same level than the native TBA.  
 According to the different strategies used to measure the 
thrombin binding, we can conclude that no important binding 
changes are observed when the modification does not disrupt the 
quadruplex structure. In addition, some modifications in the loops 
or in the overall construct structure do not affect or increase the 
binding affinity. 
6. THROMBIN INHIBITION BY MODIFIED THROMBIN 
BINDING APTAMERS 
 Prothrombin Time (PT) is the more used assay to study the 
inhibition of thrombin. PT assay is a routine diagnostic assay that 
evaluates in vitro the activation of extrinsic pathway of the coagula-
tion cascade. This ultimately measures the conversion of fibrinogen 
in fibrin by thrombin, with the consequent formation of a solid gel 
clot. When this assay is performed in presence of the aptamer TBA, 
the binding of fibrinogen to the thrombin is inhibited and a longer 
time is required to form a clot. Moreover, other important assays 
are fibrinopeptide A release assay, platelet aggregation and throm-
bus growth. 
 The effects of the substitutions at N2 and C8 of the G residues 
which form the G-tetrad on the thrombin inhibitory activity meas-
ured by PT were relatively small. The introduction of a benzyl 
group into N2 of G6 and G11 and naphthylmethyl groups into N2 of 
G6 increased the thrombin inhibitory activity, whereas other sub-
stituents in these positions had almost no effect or decreased the 
activity. Particularly, the oligonucleotides carrying a 1–
naphthylmethyl group in the N2 position of G6 showed an increase 
in activity by about 60% in vitro and in vivo. The introduction of a 
relatively small group such as methyl and propynyl, into the C8 
positions of G1, G5, G10 and G14 increased the activity, presumably 
due to the stabilization of the quadruplex, whereas the introduction 
of a large substituent group, decreased the activity, probably due to 
steric hindrance [53]. The 2’-C-piperazino-UNA-U monomer modi-
fication showed an unfavorable impact of the piperazino moiety on 
the inhibition with thrombin [60]. The biological effect of the 
UNA-modified TBAs was tested in a prothrombin time assay. The 
TBA modified with UNA-U7 showed an increased inhibitory effect 
relative to the unmodified TBA, while inhibition of coagulation by 
G1, U3, G8, U9 and U12 was near two fold decreased, and U4, U13 
and G15 showed no influence on fibrin-clot formation [49]. 
 The TBA modified with LNA showed a different thrombin 
inhibition according the position of the modification. Stable aptam-
ers with LNA in positions G5, T7 or G8 showed a decreased throm-
bin inhibition measured by fibrin clotting assay. Nevertheless, a less 
stable aptamer with LNA at G2 was as active as the unmodified 
aptamer [48]. In addition, Mayol’s group described that the TBA 
modified by LNA in the G15 position displayed a prolonged PT 
[47]. The modification of the phosphate linkages by formacetal [61] 
or thiophosphoryl [52] groups exhibited a similar prothrombin time 
to the one found for the unmodified TBA. The effect of the modi-
fied loops on the thrombin inhibitory activity was also studied using 
acyclic nucleosides. In this case, the analysis of PT assays con-
firmed that the highest PT value was obtained for a modified TBA 
containing an acyclic thymidine in position 7 [63]. On the other 
hand, the TBA modified with four 4-thiodeoxyuridine showed a 2-
fold increased inhibition of thrombin catalyzed fibrin clot forma-
tion, fibrinopeptide A release and thrombus formation [46]. 
 The structural changes in the overall structure that have been 
described do not seem to affect too much the thrombin inhibition 
[75]. The TBA containing a 5’-5’ inversion of polarity site affected 
sensibly the biological inhibition. Cook and co-workers presented a 
series of constrained unimolecular quadruplex/duplex molecules 
with increased thrombin inhibition using clot formation assay and 
release of fibrinopeptide A [66]. Moreover, Steiner also described a 
quadruplex/duplex molecule construct that binds the heparin-
binding exosite with 20-50 fold higher affinity measured by clotting 
time [67].  
 Finally, the new construct assembled by two distinct aptamers 
that targets thrombin combines features of the individual aptamer 103
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subdomains with enhanced activities regarding both functionalities; 
these are probably due to an enhanced affinity of the bivalent fusion 
aptamer. This structure displayed enhanced anticoagulant activity 
when compared to the TBA, however, affinities were improved 
only two to three fold compared to those of the individual precur-
sors [69].  
 Similar conclusions could be obtained for the thrombin inhibi-
tion of the modified TBA. It is important to mention that T7 posi-
tion seems very sensitive to different modifications in terms of 
increasing the thrombin inhibition. Moreover, the addition of dif-
ferent constructs with improved pharmacokinetic properties to the 
TBA could be a reasonable idea that probably would not compro-
mise the inhibitory activity. 
7. NOVEL APPLICATIONS USING THROMBIN BINDING 
APTAMER. 
 In addition to the anticoagulant properties, a large number of 
analytical tools based on the folding and refolding of the TBA have 
been developed. In the following section some of these new devel-
opments are reviewed. 
7.1. The TBA as Model for the Analysis of Binding Mode of 
Drugs with Affinity to G-Quadruplex 
 G-quadruplexes have become structures of special interest for 
drug development due to their possible implications in anticancer 
research. The potential role of G-quadruplexes has been highlighted 
with the development of strategies designed to stabilize telomere 
ends as G-quadruplex structures using specific small molecules, 
which can destabilize telomere maintenance in tumour cells [78]. 
G-quadruplexes are also found in transcriptional regulatory se-
quences of critical oncogenes such as c-myc and c-kit [79, 80]. 
Ligands that selectively bind and stabilize these structures were 
studied as potential anticancer drugs of interest [81]. The TBA was 
used as a model for the analysis of the interaction of several drugs 
with G-quadruplex structures. In one of the first studies, Joachimi et 
al. described the potential role of porphyrins in the modulation of 
the anticoagulant properties of the TBA [82]. Later, Del Toro et al. 
confirmed the formation of an interaction complex with a 
stoichiometry 1:1 between the porphyrin (TmPyP4) and the TBA 
[83]. Ultraviolet melting and circular dichroism data reflected that 
the initial G-quadruplex structure of the TBA was stabilized in the 
interaction complex: being slightly disordered by the presence of 
the ligand. The interaction between the porphyrin (TmPyP4) and 
the TBA was also studied by time-resolved fluorescence anisotropy. 
Based on the anisotropic decay curves, a sandwich-type binding 
mode was proposed in which both terminal G-quartet and T-T base 
pairs stack on the porphyrin ring [84]. The interaction between the 
TBA and the bipyridinium salts was studied by cyclic voltammetry. 
A strong interaction between G-quadruplex forming DNA se-
quences and viologens was observed [85]. 
7.2. TBA as Sensing Element for Thrombin and Metal Ions 
 The conformational change of the TBA during the folding 
/unfolding process was exploited for building sensors for metal ions 
and for detection of thrombin. This work together with the use of 
other aptamers as sensors has been summarized in several recent 
reviews [86-90]. One of the most relevant studies is the develop-
ment of probes for the detection of intracellular potassium concen-
tration [91-92]. Oligonucleotides containing the TBA sequence 
functionalized with a fluoresceine derivative as fluorophore and a 
rhodamine dye as quencher at the 3’ and 5’-ends were prepared. 
Upon binding of potassium, the TBA probes folded in the in-
tramolecular quadruplex. The quadruplex folding induced by potas-
sium was observed by a decrease of fluorescence due to fluoro-
phore-quencher interaction [91-92]. The development of quadru-
plex DNA-based FRET probes with special emphasis on the TBA 
quadruplexes were reviewed [93].  
 A similar FRET experiment was adapted recently for the detec-
tion of the activity of human O6-alkylguanine-DNA alkyltransferase 
(hAGT) [94]. The modified TBA probe contained one O6-
methylguanine residue that prevented quadruplex formation. Upon 
removal of the O6-methyl group in the guanine by hAGT, the natu-
ral TBA sequence is formed and it folds into the quadruplex, induc-
ing a decrease of fluorescence due to fluorophore-quencher interac-
tion [94]. A colorimetric assay for the determination of mercury (II) 
using the TBA was also reported [95]. The binding of mercury to 
the TBA induced the folding of the molecule that triggered salt-
induced gold nanoparticle aggregation [95].  
 The folding/unfolding of the TBA can also be regulated by 
light. The incorporation of o-nitrobenzyl thymidine derivatives 
(caged nucleosides) in the TBA sequence did not allow the folding 
of the TBA, preventing thrombin binding. Photoremoval of the 
nitrobenzyl groups on thymidines generated the native aptamer 
which now is capable of binding thrombin, which prevented blood 
clotting [96]. Also, the effect of a photoactive nitrobenzyl group on 
a guanine residue of TBA has been studied using classical molecu-
lar simulations [97]. Theoretical calculations are able to describe 
the change in the structure when the modified residue is incorpo-
rated in the TBA as well as the formation of the quadruplex after 
photolysis [97]. The photodeprotection of the nitrobenzyl groups is 
irreversible and for this reason, Ogazawara et al. [98] developed a 
guanine derivative carrying a fluorenylvinyl group at position 8. 
The fluorenylvinyl guanine derivative may undergo to cis-trans 
photoisomerization that is reversible. The cis-trans isomerization 
affected the formation of the quadruplex structure and subsequently 
the binding of thrombin. In this way, the binding of thrombin to the 
TBA derivatives carrying guanines with the fluorenylvinyl group 
can be reversibly modulated by light [97].  
 The conjugation of several derivatives of the TBA to gold 
nanoparticles was studied [99]. Some of the TBA-gold nanoparti-
cles are highly efficient as anticoagulants [99]. Moreover, the func-
tionalization of iron oxide nanoparticles with TBA has described 
[100]. The TBA magnetic nanoparticles conjugates showed a clear 
magnetic resonance imaging (MRI) signal when binding to throm-
bin [100]. 
 Several electrochemical sensing platforms based on the TBA 
quadruplex were developed for the detection of thrombin. A label-
free electronic detection system for the direct detection of thrombin 
based on electrochemical impedance spectroscopy was developed 
[101]. The TBA carrying an amino group was covalently linked to 
multi walled carbon nanotube disposable screen-printed carbon 
electrodes by amide formation and the resulting electrodes were 
able to sense thrombin at a detection limit of 105 pM [101]. The 
incorporation of ferrocene to the TBA increased the sensitivity of 
the detection reaching a detection limit for thrombin to 0.5 pM 
[102]. Conjugation of the TBA to silver nanoparticles and to gold 
nanoshells allowed the detection of thrombin by surface-enhanced 
Raman spectroscopy [103-106]. The interaction of thrombin with 
the TBA was also studied on quantum dots and in surface plasmon 
resonance [107].  
 The absorption and redox behavior of the TBA and the complex 
thrombin-TBA was evaluated by differential pulse voltammetry at a 
glassy carbon electrodes [76, 108]. The TBA guanine oxidation 
peak was found to be sensitive to G-quadruplex formation and to 
thrombin binding, showing a higher oxidation potential [76, 108]. 
Recently, the excellent binding properties of a 29-base-long throm-
bin-binding aptamer linked to gold nanoparticles were used for the 
development of a sensitive detection of DNA that relied on the 
modulation of the thrombin activity on the surface of the nanoparti-
cles [109].  
7.3. Single-molecule Experiments on the TBA  
 One of the first single-molecule experiments using the TBA-
thrombin interaction was performed by atomic force microscopy 104
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(AFM) [110]. An AFM gold-coated tip was functionalized with the 
thiolated TBA. The thrombin was linked covalently to a gold-
coated glass slide. The rupture force for a single aptamer/thrombin 
complex was determined as 4.45 pN. The analysis of the system 
revealed that the rupture forces corresponded to the melting of the 
G-quadruplex of the aptamer bound to the thrombin and subsequent 
dissociation of the complex [110]. 
 Recently, the TBA folding and unfolding induced by ions was 
studied using nanopores encapsulated with single molecules. The 
TBA quadruplex was formed rapidly in the presence of potassium 
ions and had a slow unfolding reaction. The sodium and lithium 
complex of the TBA were similar but the folding and unfolding of 
the sodium complex was faster than the folding and unfolding of 
the lithium complex [111]. 
 The excellent molecular recognition properties of DNA were 
exploited to incorporate functionalities in molecular constructs and 
for the design of 2-dimensional arrays with well defined structures 
[112-113]. A remarkable development in this field was the use of 
stable DNA Holliday junctions with addressable sticky ends to form 
two-dimensional DNA crystals [113]. The so-called DNA tile sys-
tem was used for the assembly of bidimensional DNA arrays, con-
taining thrombin binding aptamer sequences [114-115]. The DNA 
arrays templated the formation of ordered thrombin arrays that were 
visualized by AFM [114-117]. Origami DNA is a new method for 
the rational organisation of structures that uses a circular viral sin-
gle stranded DNA (M13 DNA) and about two hundred oligonucleo-
tides (staple strands) that are designed to fold the viral DNA into a 
rationally designed shape [118]. The TBA sequences were also 
introduced in DNA origamis, showing a nanometric control of the 
deposition of thrombin molecules on the origami [119-120]. 
CONCLUSIONS  
 Aptamers are a novel class of nucleic acids with affinity to pro-
teins that may be used for therapeutic or diagnostic purposes. The 
thrombin-binding aptamer was one of the first aptamers developed 
by SELEX and probably one of the most studied aptamer. The TBA 
is a relatively short sequence, easy to synthesize with a well-defined 
structure and has a good affinity for thrombin. For all these reasons, 
it can be considered a paradigm of the potential applications of the 
aptamers. During the last 20 years, several authors have defined the 
structural facets of the TBA molecule exploring several potential 
variables such as sugar puckering, glycosidic bond conformation, 
H-bonding groups, backbone modifications, etc… Some of the 
modified TBA derivatives have a good affinity for thrombin, as 
well as a large stability in physiological conditions, which has led 
to the setting of some clinical assays. The lessons learned in this 
process are important not only for the anticoagulant properties of 
the TBA but also to improve the understanding of G-quadruplex 
structures present in telomeres and some promoter regions of onco-
genes.  
 An important development in the last years has been the conju-
gation of the TBA to nanomaterials such as gold and iron oxide 
nanoparticles, which may increase the stability in plasma as well as 
it may open the opportunity of adding receptor-mediated systems 
for efficient in vivo targeting. Moreover, the TBA-thrombin recog-
nition system is already being used for the development of sensors 
based on both electrical and optical methods, and more recently for 
the DNA-templated directed assembly of nanomaterials. As the 
time goes on, the potential applications of this relatively simple 
DNA molecule are increasing exponentially. This intense activity 
will help to further develop the aptamer field and it may also span 
the knowledge about other useful nucleic acids for therapeutic or 
diagnostic purposes. 
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 The self-assembly of DNA molecules provides an attractive route towards the formation of complex structures at the nanoscale. In particular, the DNA origami uses hundreds of nucleotides “staples” to fold a long single-stranded DNA scaffold of 7-kilobase, the M13 phage genome, in a rational and desired shape. It represents a versatile tool for the self-assembly of other molecular species and constitutes an excellent platform to create a variety of new nanoscale devices with great potential and applications. In this chapter, we describe the use of the DNA origami as a nanosensor to analyze the enzymatic DNA repair activity of hAGT via TBA conformational changes that condition α-thrombin interaction with DNA aptamers. As this structural change can be caused by a single methylation in the central guanines of the tetrads of the aptamers, it can be utilised to detect the DNA repair activity of hAGT, given that methylguanine is the substrate of this protein. These findings illustrate the potential use of the DNA origami as a protein recognition biosensor, and open the door to the development of a method for the evaluation of potential inhibitors of hAGT. As a result of the high impact achieved by the publication of this work, we were invited to write a review on the state of the art of DNA nanotechnology, and this work is included as an annex of this chapter. In this review we examine recent progresses towards the potential use of DNA nanostructures for molecular and cellular biology. 
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The development of DNA origami[1] has been one of the most
important advances for structural DNA nanotechnology.[2]
This method uses hundreds of nucleotide staples to fold
a long single-stranded DNA scaffold of 7-kilobase, the M13
phage genome in a rational and desired shape. DNA origami
is a versatile method for the self-assembly of other molecular
species[3] and is an excellent way to create a variety of new
nanoscale devices[4] with great potential and applications.[5]
Yan and co-workers have used the DNA origami as an
addressable support for label-free detection of RNA hybrid-
ization;[6] more recently, Seeman and co-workers have
developed a nanosensor to detect single nucleotide poly-
morphism (SNP).[7] Both strategies are an innovative way to
use the DNA origami method to create a nanosensor for
biomedical applications at the single-molecule level using
atomic force microscopy (AFM).
Advances in the molecular biology of cancer have
identified key mechanisms involved in the DNA repair
pathways induced by chemotherapeutic drugs, as for example
alkylating agents. Adducts formed at the O6 position of
guanine are of major importance in both the initiation of
mutations and in the cytotoxic effects of these agents. Human
O6-alkylguanine-DNA alkyltransferase (hAGT) is a DNA-
binding protein responsible for the repair of the O6-methyl-
guanine, contributing to the resistance to chemotherapeutic
agents. For these reasons, hAGT is considered relevant as
a prognosis marker of cancer and is a potential therapeutic
target.[8] Intense research efforts have been devoted to the
identification of small molecules capable of inhibiting hAGT
activity and enhancing the cytotoxic effect of the alkylating
agents in tumor cells.[9] Several methods are available to
characterize the mechanism of action of hAGT, its activity,
and its inhibition by small molecules. However, most of these
methods are based on radioactivity assays, while others are
based on multiple-step enzymatic reactions.[10] Our research
group developed a new fluorescence method using a DNAG-
quadruplex, the thrombin binding aptamer (TBA), as amolec-
ular beacon for the detection of hAGT activity and the
development of new inhibitor compounds.[11]
G-quadruplexes are a family of four-stranded DNA
structures stabilized by the stacking of guanine tetrads in
which four planar guanines form a cyclic array of hydrogen
bonds stabilized by the presence of monovalent cations.[12]
Modifications in the base composition of the tetrads are
poorly tolerated by these structures. As an example, O6-
methylguanine can form a smaller number of hydrogen bonds
and consequently destabilize the G-quadruplex, provoking
the loss of its conformation (Supporting Information, Fig-
ure S1).[13]
Herein, we exploit the spatial addressability of DNA
origami in combination with the change of conformation of
a DNA G-quadruplex to visually detect by AFM the change
in its binding affinity to a-thrombin. As this structural change
is caused by a single methylation in the central guanines, it can
be utilized to detect the DNA repair activity of hAGT, given
that methylguanine is the substrate of this protein. To attain
this goal, we have used the specific binding properties of the
TBAs (aptamers with anticoagulant properties) to a-throm-
bin, their natural substrate.[14] The two TBA sequences used in
this work (see the Supporting Information, Table S1, for
sequences) are known to bind specifically and cooperatively
to two specific and almost opposite epitopes of a-thrombin.[15]
TBA1 (primarily fibrinogen-recognition exosite binding)[14] is
a 15 mer nucleotide composed of two G-tetrads that are
connected by three edge-wise loops, forming a well-charac-
terized intramolecular chair-like, antiparallel quadruplex. In
contrast, TBA2 (29mer nucleotide, heparin-binding exosite)
forms a combined quadruplex/duplex structure.[15]
Previous studies provide evidence that the TBAs are able
to bind a-thrombin in the absence of monovalent cations
promoting the TBA folding to its 3D structure, following the
typical chaperone-macromolecule system.[16]
Previously, to study the interaction between TBA1 and a-
thrombin, fluorescence quenching experiments and electro-
phoresis mobility shift assays were performed (Supporting
Information, Figures S2 and S3). Both results confirmed that
the introduction of a methylated guanine prevented a-
thrombin interaction, and furthermore that a 10-fold concen-
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tration of a-thrombin can be sufficient to appreciate a differ-
ent pattern of union of this protein to the TBAs and methyl-
TBA-containing origami.
Based on these preliminary studies, we designed a DNA
origami in which some of the staple strands were modified by
the insertion of TBA1 and TBA2 in the middle, protruding
from the DNA origami surface[17] (see the Supporting
Information, Table S1, for sequences). The staple strands
were arranged asymmetrically along the length of the origami
in a way that allowed the differentiation between methylated/
non-methylated, to enable the observation and quantification
of a-thrombin interaction with the aptamers. For this purpose,
we built a dual-aptamer system composed of two lines of five
TBA1 and TBA2 doublets placed at a distance of about
5.8 nm from each other, increasing the recognition probabil-
ities by at least 10-fold as reported by Rinker et al.[17] The
right double line corresponds to the unmodified dual system,
and the left dual-aptamer line consists of 15 mer methylated-
TBAs and non-modified 29 mer TBAs (Supporting Informa-
tion, Scheme S1). The formation of the DNA origami with the
modified TBA staple strands was performed successfully,
confirming that the addition of a methylated sequence does
not affect its assembly (Supporting Information, Figure S4).
Afterwards, the complex formation between a-thrombin
and the non-methylated/methylated TBA modified origami
was studied. In Figure 1, the asymmetric interaction can be
observed. As expected (Scheme 1a), the complex was only
formed with the native TBAs, whereas in the left line no
interaction was reported, confirming that a-thrombin is not
able to bind the disrupted quadruplex. The study of the
profiles and pixel distribution (Figure 3b) confirms that the
height of the dots in the dual-aptamer is in agreement with the
expected size of a-thrombin (ca. 4 nm in diameter) in
comparison with the height of the origami control (Fig-
ure 3a). We observed that more than 95% of the chemically
modified origami tiles faced pointing towards the solution, in
agreement with data reported by Voigt et al.[4c]
This result is a clear confirmation that the complex
between the dual-aptamer system and a-thrombin is only
formed with the non-methylated TBA, and confirms the
ability of our design to discern between the methylated and
non-methylated state.
To explore the efficiency of our design, we performed
a quantitative study of the binding location of a-thrombin.
From the 160 well-formed DNA origami studied, around
20% of them contained all five a-thrombin molecules in
positions coinciding with unmodified TBA and almost none in
the methylated line. In all, more than 93% of the DNA arrays
contained at least 1 a-thrombin attached to the unmodified
TBAs (see the Supporting Information).
We then intended to repair the O6-methylguanine of the
TBA-containing staple strands by hAGT. For this purpose,
the methyl-TBA-staple strands were incubated with hAGT.
hAGT was removed and the resulting strands were used to
assemble the DNA origami (seeMaterials andMethods in the
Supporting Information). The recovery of the chair-like
structure of the now demethylated 15mer was expected,
leading to the binding of a-thrombin to both dual-aptamers,
as the two of them contain the native 15 and 29mer TBAs.
The binding of a-thrombin in both dual-aptamers is shown
in Figure 2, confirming the repair of the alkylated guanine by
hAGT. Upon quantitative exploration of the binding, we can
conclude that a-thrombin binds with equal contingency in
both lines of the origami, with no significant tendency (p<
0.5) for any of the dual systems composed by TBA1 and
TBA2. The study of the height profiles corroborated the
theoretical height of the a-thrombin on both dual-aptamers
(Figure 3c). Furthermore, we titrated hAGT (0 to 10-fold
origami:hAGT; see the Supporting Information) against
methyl-TBA staples and incorporated these staples into the
DNA origami. The results showed that a-thrombin binding to
the methylated/repair side was clearly dependent on hAGT
concentration (Supporting Information, Figures S10 and
S11).
In summary, we have developed a new method to study
the DNA repair activity of hAGT. To the best of our
Figure 1. a),b) AFM images (scale bars 200nm (a), 100 nm (b)) of the
interaction of a-thrombin with the origami. The interaction can be
observed as white aligned dots deposited over the origami surfaces.
The complex was only formed with the native TBAs (right line; see
inserts in (a) for more details), whereas in the left line, in which the
15mer TBA carried an O6-methylguanine, no interaction was observed.
Scheme 1. a) Representation of the asymmetric binding of a-thrombin
to TBA aptamers of methylated DNA origami. b) Methyl-TBA repair by
hAGT, thus allowing G-quadruplex formation. c) Representation of the
symmetric binding of a-thrombin to the repaired DNA origami quad-
ruplexes.
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knowledge, this is the first time the enzymatic activity of
hAGT has been visualized on an origami platform. This study
combines the capabilities of the a-thrombin recognition/
binding to TBA and the single-molecule features of the DNA
origami applied to the detection of DNA repair. The system
appears to be extremely effective and reliable, and the results
are clearly visualized by AFM. Their consistency suggests that
our system could be further evolved to design hAGT activity
assays for the identification of potential inhibitors as chemo-
therapy enhancers and for the study of other DNA repair
enzymes. The application of the DNA origami as a platform
for single-molecule recognition opens the door for the
development of new biosensors for the detection of a variety
of complexes and the activity of other proteins. Finally, it can
also contribute to the study of other DNA lesions that affect
G-quadruplexes. This in turn would increase our knowledge
on the effect of DNA damage in biologically relevant G-
quadruplex structures.[18]
Experimental Section
Standard oligonucleotides were purchased from Sigma. Modified
staple strands were synthesized on a DNA synthesizer following
standard methods. All of the oligonucleotides sequences are detailed
in the Supporting Information. Full-length hAGTwas overexpressed
and purified as previously described.[10e] A mixture of the modified
staple strands containing the methylated 15-mer TBA sequence were
left to react with hAGT. DNA origami tiles
were assembled following the method devel-
oped by Rothemund.[1] A sufficient amount of
a-thrombin was added and left to equilibrate
before imaging. Images were acquired in
tapping mode in liquid environment using
triangular-shaped AFM probes and their anal-
ysis was performed using NanoScope Analysis
Version 1.40. All of the experiments were
performed in triplicate. Statistical compari-
sons of the binding performance were done
according to Students t distribution.
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1. Materials and Methods 
 
1.1. Abbreviations.  
3’-Dabsyl CPG: 1-Dimethoxytrityloxy-3-[O-(N-4'-sulfonyl-4-(dimethylamino)- 
  azobenzene)-3-aminopropyl]-propyl-2-O-succinoyl-long chain alkylamino-CPG 
6’-FAM: 6-[(3’,6’-dipivaloylfluoresceinyl)-carboxamido]-hexyl-1-O-[(2-cyanoethyl)-(N,N-diiso 
  propyl)]-phosphoramidite 
AFM: atomic force microscopy 
BCNU: bis-chloroethylnitrosourea or carmustine 
CPG: controlled pore glass 
dmf: N,N-dimethylamino methylidene 
hAGT: human O6-alkylguanine-DNA alkyltransferase  
MALDI: matrix-assisted laser disorption/ionization 
O6-MeG: O6-methylguanine 
PAGE: Polyacrylamide gel electrophoresis 
RP-HPLC: reverse phase high pressure liquid chromatography 
TEAA: triethylammonium acetate 
THAP: trihydroxyacetophenone monohydrate 
TOF: time of flight 
UV: ultraviolet 
 
118
  
 
1.2. Chemicals 
The standard phosphoramidites and ancillary reagents used during oligonucleotide synthesis 
were obtained from Applied Biosystems and Link Technologies Ltd. 5’-Fluorescein CE 
phosphoamidite (6’-FAM) was acquired from Link Technologies, 3’-Dabsyl CPG, O6-
methylguanine (O6-MeG) and Gdmf phosphoramidites were from Glen Research. Matrix for 
MALDI-TOF experiments were 2’,4’,6’-trihydroxiacetophenone monohydrate (THAP, Aldrich) 
and ammonium citrate dibasic (Fluka). Solvents for HPLC analysis were prepared using 
triethylammonium acetate (TEAA) and acetonitrile (Merck) as mobile phase. The rest of the 
chemicals are analytical reagent grade from commercial sources as specified. Ultrapure water 
(Millipore) was used in all experiments. The 10 % non denaturing PAGE were prepared from 
the stock solution acrylamide/bis-acrylamide solution 40% (Sigma).  
1.3. Instrumentation 
Modified staple strands were synthesized on an ABI 3400 DNA Synthesizer (Applied 
Biosystems). Semipreparative RP-HPLC was performed on a Waters chromatography system 
using Symmetry Nucleosil Semipreparative 120 C18 (250x8mm) column. Analytical RP-HPLC 
was performed using an XBridge OST C18 2.5 μm column. Mass spectra were recorded on a 
MALDI Voyager DE RP time-of-flight (TOF) spectrometer (Applied Biosystems). Molecular 
absorption spectra between 220 and 550 nm were recorded with a Jasco V650 
spectrophotometer. The temperature was controlled with an 89090A Agilent Peltier device. 
Hellma quartz cuvettes (0.5 and 1.0 cm path length, 500 or 1000 μl volume) were used. The CD 
spectra were recorded on a Jasco J-810 spectropolarimeter attached to a Julabo F/25HD 
circulating water bath in 1 cm path-length quartz cylindrical cells. Fluorometric measurements 
were performed on a spectrofluorometer Jasco FP6200 at 25ºC. Set temperature was controlled 
with an 89090A Agilent Peltier device and Hellma quartz cuvettes were used (100 μL volume). 
Non-denaturing PAGE was run on an AA Hoefer SE 600 standard vertical electrophoresis 
device, using an Apelex Electrophoresis Power Supply PS 3002. Gels were imaged with a Gene 
Genius Bioimaging system (Syngene). AFM imagenes were obtained by liquid tapping on a 
Nanoscope 3A Multimode 4 AFM, using Bruker SNL-10 silicon tips. 
1.4. Oligonucleotides Synthesis 
Standard staple strand oligonucleotides were purchased to Sigma. Modified staple strands were 
synthesized on an ABI 3400 DNA Synthesizer (Applied Biosystems), using the 200-nmol scale 
synthesis and the standard protocols. The more labile dmf grup was used for the protection of all 
guanines. For strands containing O6-MeG or FAM, these phosphoramidites were site-
specifically inserted into the oligonucleotide. In the case of the fluorescent probes, the quencher 
group was introduced at the 3’ end using the controlled pore glass functionalized with a 3’-
Dabsyl derivative CPG. O6-MeG-containing oligonucleotides were deblocked according to the 
manufacturer’s instructions (ammonia deprotection was performed overnight at room 
temperature and followed by 1h at 55ºC). The resulting products were desalted by Sephadex G-
25 (NAP-10, Amersham Biosciences) and purified by RP-HPLC using Nucleosil columns. The 
length and homogeneity of the oligonucleotides were checked by MALDI-TOF. The DNA-
strand concentration was determined by absorbance measurements (260 nm) and their extinction 
coefficient. Oligonucleotide samples were kept at 4 ºC until further use. All the oligonucleotides 
sequences are detailed in Table 1. 
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1.5. CD spectra. 
Measurements were conducted in 10 mM sodium cacodylate pH 7.0 and 100 mM KCl. Sample 
concentration was between 1-4 μM. Each sample was allowed to equilibrate at the initial 
temperature without any external control of temperature for 5 min before the melting 
experiment began. Spectra were recorded at room temperature using a 100 nm/min scan rate, a 
spectral band width of 1 nm and a time constant of 4 s. All the spectra were corrected with the 
buffer blank and plotted using Microsoft Office Excel 2007 software. 
1.6. Fluorescence assay 
Binding between human α-thrombin (Haematologic Technologies Inc.) and TBA, 5-O6-MeG-
TBA and 6-O6-MeG-TBA molecular beacons (MB) was monitored by measuring changes in 
fluorescence intensity of the MB solution over time. 150 μL of a 1μM solution of MB-TBA in 
MB buffer (20 mM Tris pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5% 
v/v). Each time, 1.5 μL of α-thrombin were added and after a quick manual mix, the 
fluorescence intensity was measured at excitation wavelength of 485 nm and emission 
wavelength of 520 nm. The measurements were performed until reaching a molar ratio of 3:1 
between α-thrombin and the molecular beacon MB-TBA. This same experiment was repeated 
using the modified MB-5-O6-MeG-TBA and MB-6-O6-MeG-TBA sequences. All the 
experiments were performed in triplicates. 
1.7. EMSA assay 
In these experiments TBA sequences with an overhang of 5 thymines were used, to make the 
DNA longer and easier to manipulate. TBA(T)5 and 5-O
6-MeG-TBA(T)5 (1μM) were incubated 
with specified amounts of α-thrombin for 1 hour at room temperature. The reaction buffer was 
250 mM Tris pH 7.4, 150 mM acetic acid, 15 mM EDTA and 37.5 mM magnesium acetate. The 
reaction was stopped by adding the loading buffer and a non-denaturing 10% PAGE was run at 
constant 160 V for 3 hours at 20 ºC. The gels were stained with SybrGold (Invitrogen, 1× dye in 
100 mL water) or SybrGreen (Invitrogen, 1× dye in 100 mL water).  
1.8. hAGT expression and purification 
Full-length human AGT was overexpressed and purified as previously described.[1] Briefly, 
hAGT protein (pet-21a(+) vector, Novagen) was overexpressed in the E. coli strain Rosetta and 
once the culture reached an OD600 value of 0.8, it was induced by adding 1 mM IPTG during 4 h 
at 30 °C. The pellet from a 1 L culture was disrupted by sonication and centrifuged. The 
supernatant was filtered, loaded into a HiTrapTM FF column (GE Healthcare) and eluted with 
an imidazole gradient. Finally the protein was loaded into a Superdex 75 16/60 column (GE 
Healthcare), being the buffer 200 mM NaCl, 20 mM Tris pH 8.0, 10 mM DTT and 0,1 mM 
EDTA. The protein was concentrated to 2 mg/ml in hAGT reaction buffer (200 mM NaCl, 50 
mM Tris pH 8.0, 1 mM DTT and 5 mM EDTA) and kept at -20 °C in presence of 40 % 
glycerol.  
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1.9. hAGT repair of the methylated TBA strands 
 
1.9.1 Repair of the methylated TBAs in the origami 
hAGT was incubated directly with the methylated origami adsorbed over the mica surface, (for 
origami formation details, see AFM imaging section1.10). Sufficient amount of hAGT to reach 
a concentration 10 fold bigger than the origami was added to the solution and left to react for 
one hour in hAGT reaction buffer. Then, the mica surface was washed three times with 40 μL of 
TAE-Mg+2 buffer (40 mM Tris pH 8.0, 12.5 magnesium acetate, 2.5 mM EDTA and 20 mM 
acetic acid). Afterwards, 10 fold concentration of α-thrombin was added to the solution and left 
to equilibrate for some minutes before imaging. 
1.9.2 Reaction of hAGT with the methylated TBA staple strands 
A mixture of the five modified staple strands containing the methylated 15-mer TBA sequence 
was dried under vacuum and resuspended in hAGT reaction buffer to reach a concentration of 
35 μM. Then, increasing concentrations (0, 70, 175 and 350 μM) of hAGT were added, and the 
resulting mixtures were incubated during one hour at 37 ºC. In order to purify the demethylated 
staple strands, the reaction mixtures were loaded into a Niquel His SpinTrap column (GE 
Healthcare) and washed out with water three times to allow the oligonucleotides to elute. 
Recovered samples were quantified, concentrated to 10 μM and stored until further use. 
1.10.AFM imaging 
Tall rectangle DNA origami tiles were assembled following the method developed by 
Rothemund[2]. Helper strands modified with different TBA sequences and unmodified helper 
strands were mixed with the viral DNA M13 at molar ratio of 10:5:1. In the case of the 
demethylated origami, helper strands modified with TBA sequences, hAGT-demethylated TBA 
staple strands and unmodified helper strands were mixed with the viral DNA M13 at molar ratio 
of 10:50:5:1. The origami was assembled using a Biorad Termocycler starting at 90ºC and 
decreased to 20ºC at -1ºC per minute. Two methodologies were used to bind α-thrombin to the 
origami surface with equal success. Firstly, arrays were mixed with α-thrombin (1:10 ratio 
origami:thrombin) and incubated during 1 hour before imaging. 1 μL of sample was deposited 
on a mica surface and left to adsorb for 1 minute before 40 μL of TAE-Mg+2 buffer was added. 
In the second case, 1 μL of plain origami was deposited on a mica surface and left to adsorb for 
1 minute, and then 60 μL of TAE-Mg+2 buffer (40 mM tris pH 8.0, 12.5 magnesium acetate, 2.5 
mM EDTA and 20 mM acetic acid) were added. Sufficient amount of α-thrombin to reach a 
concentration 10 fold bigger than the origami was added to the solution and left to equilibrate 
for some minutes before imaging. To perform the measurements shown in this study, an 
Extender Multimode AFM attached to a Nanoscope III electronics (Bruker) was used. Images 
were acquired in tapping mode in liquid environment using triangular-shaped AFM probes 
(SNL-10, Bruker) with a nominal spring constant of 0.35nN/nm. 30 minutes were laged before 
acquiring topographic images so as to thermically equilibrate the sample and the probe and to 
ensure a stable environment. The cantilevers are made of silicon nitride, while the tip pyramid is 
made of silicon for maximum sharpness and resolution. In order to maintain the sample integrity 
while scanning, free amplitude was maintained as low as possible (typically between 0.2 and 
0.4V) and amplitude setpoint was maximized for these conditions. Scan rate was set between 
1.5 and 3 Hz depending on the softness of the sample and image resolution was set to 512x512 
pixels. 
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Comparison of averages of the two types of binding (right line and left line) was performed 
using Student’s t model.  
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1. TBA staple strands, helper strands sequences and DNA origami design. 
ODN Sequence (5’ to 3’) 
TBA1* GGTTGGTGTGGTTGG 
5-O6-MeG-TBA1* GGTTGMeGTGTGGTTGG 
6-O6-MeG-TBA1* GGTTGGMeTGTGGTTGG  
TBA2 AGTCCGTGGTAGGGCAGGTTGGGGTGACT 
Fluorescence assays 
MB-TBA1* FAM-GGTTGGTGTGGTTGG-Dabsyl 
MB-5-O6-MeG-TBA1* FAM-GGTTGMeGTGTGGTTGG-Dabsyl 
MB-6-O6-MeG-TBA1* FAM-GGTTGGMeTGTGGTTGG-Dabsyl 
EMSA assays 
TBA1(T)5* GGTTGGTGTGGTTGGTTTTT 
5-O6-MeG-TBA1(T)5* GGTTG
MeGTGTGGTTGGTTTTT 
Origami assembly 
t-5r4e-5-O6-MeG-TBA1* 
AAAGGCCGCTCCAAAATTTTGGTTGMeGTGTGGTTGGTTTT
GGAGCCTTAGCGGAGT 
t-5r8e-5-O6-MeG-TBA1* 
CCAAATCATTACTTAGTTTTGGTTGMeGTGTGGTTGGTTTTC
CGGAACGTACCAAGC 
t-5r12e-5-O6-MeG-TBA1* 
TAAATATTGAGGCATATTTTGGTTGMeGTGTGGTTGGTTTTG
TAAGAGCACAGGTAG 
t-5r16e-5-O6-MeG-TBA1* 
TTTCATTTCTGTAGCTTTTTGGTTGMeGTGTGGTTGGTTTTC
AACATGTTTAGAGAG 
t-5r20e-5-O6-MeG-TBA1* 
CATGTCAAAAATCACCTTTTGGTTGMeGTGTGGTTGGTTTTA
TCAATATAACCCTCA 
t3r4e-TBA1 
GTTTGCCACCTCAGAGTTTTGGTTGGTGTGGTTGGTTTTCC
GCCACCGCCAGAAT 
t3r8e-TBA1 
ATACCCAAACACCACGTTTTGGTTGGTGTGGTTGGTTTTGA
ATAAGTGACGGAAA 
t3r12e-TBA1 
AGGTTTTGGCCAGTTATTTTGGTTGGTGTGGTTGGTTTTCA
AAATAAACAGGGAA 
t3r16e-TBA1 
ACGCTCAACGACAAAATTTTGGTTGGTGTGGTTGGTTTTGG
TAAAGTATCCCATC 
t3r20e-TBA1 
TTGAATTATTGAAAACTTTTGGTTGGTGTGGTTGGTTTTAT
AGCGATTATAACTA 
t5r2f-TBA2 
AATGCCCCATAAATCCTTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTTCATTAAAAGAACCAC 
t5r6f-TBA2 
AGCACCGTAGGGAAGGTTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTTAAATATTTTATTTTG 
t5r10f-TBA2 
GCAATAGCAGAGAATATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTACATAAAAACAGCCAT 
t5r14f-TBA2 
TCATTACCGAACAAGATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTAAAATAATAATTCTGT 
t5r18f-TBA2 
AGGCGTTAGGCTTAGGTTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTTTGGGTTAAGCTTAGA 
t-3r2f-TBA2 
TGTAGCATAACTTTCATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTACAGTTTCTAATTGTA 
t-3r6f-TBA2 
TTTCATGATGACCCCCTTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTAGCGATTAAGGCGCAG 
t-3r10f-TBA2 
TTTCAACTACGGAACATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTACATTATTAACACTAT 
t-3r14f-TBA2 
TCAGAAGCCTCCAACATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTGGTCAGGATTTAAATA 
t-3r18f-TBA2 
CAAAATTAGGATAAAATTTTAGTCCGTGGTAGGGCAGGTT
GGGGTGACTTTTTATTTTTAGGATATTCA 
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Table 1. Modified oligonucleotides used in this work. All the strands used for the G-quadruplex disruption 
studies and for α-thrombin interaction studies were synthesized in the laboratory, as well as the staple 
strands containing methylated-TBA (*). Bold remarks the sequence of TBA1 and TBA2 and red identifies 
the position of the O6-methylguanine. The rest of the staple strands with TBA1 and TBA2 sequences 
inserted were purchased from commercial sources. 
 
Scheme S1. Sketch of the DNA origami design, showing the right and left dual-aptamer system 
formed by TBA1 (blue), TBA2 (green) and 5-O6-Methylguanine-TBA1 (red). The loop 
indicates the direction of the origami. 
 
List of the helper strands used to build the DNA origami. All these oligonucleotides were 
purchased from commercial sources: 
 
t1r0g AGGGTTGATATAAGTATAGCCCGGAATAGGTG 
t1r2e TAAGCGTCGGTAATAAGTTTTAACCCGTCGAG 
t1r2f AGTGTACTATACATGGCTTTTGATCTTTCCAG 
t1r4e AACCAGAGACCCTCAGAACCGCCACGTTCCAG 
t1r4f GAGCCGCCCCACCACCGGAACCGCTGCGCCGA  
t1r6e GACTTACGTAAAGGTCGCAACATACCGTCACC 
t1r6f AATCACCACCATTTGGGAATTAGACCAACCTA 
t1r8e TTATTACGTAAAGGTCGCAACATACCGTCACC 
t1r8f TACATACACAGTATGTTAGCAAACTGTACAGA 
t1r10e TGAACAAAGATAACCCACAAGAATAAGACTCC 
t1r10f ATCAGAGAGTCAGAGGGTAATTGAACCAGTCA 
124
  
t1r12e TATTTTGCACGCTAACGAGCGTCTGAACACCC 
t1r12f TCTTACCAACCCAGCTACAATTTTAAAGAAGT 
t1r14e ATCGGGCTGACCAAGTACCGCACTCTTAGTTGC 
t1r14f GGTATTAATCTTTCCTTATCATTCATATCGCG 
t1r16e CATATTTATTTCGAGCCAGTAATAAATCAATA 
t1r16f AGAGGCATACAACGCCAACATGTATCTGCGAA 
t1r18e ACAAAGAAAATTTCATCTTCTGACAGAATCGC 
t1r18f TTTTAGTTCGCGAGAAAACTTTTTTTATGACC 
t1r20e AAATCAATCGTCGCTATTAATTAAATCGCAAG 
t1r20f CTGTAAATATATGTGAGTGAATAAAAAGGCTA 
t1r22e TTTAACGTTCGGGAGAAACAATAACAGTACAT 
t1r22f CTTTTACACAGATGAATATACAGTGCCATCAA 
t1r24e TTATTAATGAACAAAGAAACCACCTTTTCAGG 
t1r24f ATTTTGCGTTTAAAAGTTTGAGTACCGGCACC 
t1r26e CTAAAGCAAATCAATATCTGGTCACCCGAACG 
t1r26f AAACCCTCTCACCTTGCTGAACCTAGAGGATC 
t1r28e CTAAAAGCAAATCAATATCTGGTCACCCGAACG 
t1r28f GCGTAAGAAGATAGAACCCTTCTGAACGCGCG 
t1r30e GTTGTAGCCCTGAGTAGAAGAACTACTTCTG 
t1r30f ATCACTTGAATACTTCTTTGATTAGTTGTTCC 
t1r32h TACAGGGCGCGTACTATGGTTGCTAATTAACC 
  
t3r0g TGCTCAGTACCAGGCGGATAAGTGGGGGTCAG 
t3r2e GGAAAGCGGTAACAGTGCCCGTATCGGGGTTT 
t3r2f TGCCTTGACAGTCTCTGAATTTACCCCTCAGA 
t3r4f GCCACCACTCTTTTCATAATCAAATAGCAAGG 
t3r6e TTATTCATGTCACCAATGAAACCATTATTAGC 
t3r6f CCGGAAACTAAAGGTGAATTATCATAAAAGAA 
t3r8f ACGCAAAGAAGAACTGGCATGATTTGAGTTAA 
t3r10e GCGCATTAATAAGAGCAAGAAACAATAACGGA 
t3r10f GCCCAATAGACGGGAGAATTAACTTTCCAGAG 
t3r12f CCTAATTTAAGCCTTAAATCAAGAATCGAGAA 
t3r14e CTAATTTACCGTTTTTATTTTCATCTTGCGGG 
t3r14f CAAGCAAGCGAGCATGTAGAAACCAGAGAATA 
t3r16f TAAAGTACCAGTAGGGCTTAATTGCTAAATTT 
t3r18e TATGTAAAGAAATACCGACCGTGTTAAAGCCA 
t3r18f AATGGTTTTGCTGATGCAAATCCATTTTCCCT 
t3r20f TAGAATCCCCTTTTTTAATGGAAACGGATTCG 
t3r22e ACAGAAATCTTTGAATACCAAGTTAATTTCAT 
t3r22f CCTGATTGAAAGAAATTGCGTAGAAGAAGGAG 
t3r24e CGACAACTTCATCATATTCCTGATCACGTAAA 
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t3r24f CGGAATTACGTATTAAATCCTTTGGTTGGCAA 
t3r26e GCCACGCTTTGAAAGGAATTGAGGAAACAATT 
t3r26f ATCAACAGGAGAGCCAGCAGCAAAATATTTTT 
t3r28e GTCACACGATTAGTCTTTAATGCGGCAACAGT 
t3r28f GAATGGCTACCAGTAATAAAAGGGCAAACTAT 
t3r30e GTAAAAGACTGGTAATATCCAGAAATTCACCA 
t3r30f CGGCCTTGGTCTGTCCATCACGCATTGACGAG 
t3r32h CACGTATAACGTGCTTTCCTCGTTGCCACCGA 
  
t5r0g CCTCAAGAGAAGGATTAGGATTAGAAACAGTT 
t5r2e ACAAACAACTGCCTATTTCGGAACCTGAGACT 
t5r4e TCGGCATTCCGCCGCCAGCATTGATGATATTC 
t5r4f CACCAGAGTTCGGTCATAGCCCCCTCGATAGC 
t5r6e ATTGAGGGAATCAGTAGCGACAGACGTTTTCA 
t5r8e GAAGGAAAAATAGAAAATTCATATTTCAACCG 
t5r8f TCACA ATCCC GAGGA AACGC AATAA TGAAATA 
t5r10e CTTTACAGTATCTTACCGAAGCCCAGTTACCA 
t5r12e GAGGCGTTTCCCAATCCAAATAAGATAGCAGC 
t5r12f ATTATTTATTAGCGAACCTCCCGACGTAGGAA 
t5r14e TAAGTCCTGCGCCCAATAGCAAGCAAGAACGC 
t5r16e GCGTTATACGACAATAAACAACATACAATAGA 
t5r16f CCAGACGACAAATTCTTACCAGTAGATAAATA 
t5r18e TAACCTCCAATAAGAATAAACACCTATCATAT 
t5r20e AAAACAAACTGAGAAGAGTCAATATACCTTTT 
t5r20f TTAAGACGATTAATTACATTTAACACAAAATC 
t5r22e AACCTACCGCGAATTATTCATTTCACATCAAG 
t5r22f GCGCAGAGATATCAAAATTATTTGTATCAGAT 
t5r24e GGATTTAGTTCATCAATATAATCCAGGGTTAG 
t5r24f GATGGCAAAAGTATTAGACTTTACAAGGTTAT 
t5r26e AGGCGGTCTCTTTAGGAGCACTAAACATTTGA 
t5r26f CTAAAATAAGTATTAACACCGCCTCGAACTGA 
t5r28e GAAATGGAAAACATCGCCATTAAACAGAGGTG 
t5r28f TAGCCCTATTATTTACATTGGCAGCAATATTA 
t5r30e AGAAGTGTCATTGCAACAGGAAAAAATCGTCT 
t5r30f CCGCCAGCTTTTATAATCAGTGAGAGAATCAG 
t5r32h AGCGGGAGCTAAACAGGAGGCCGAGAATCCTG 
  
t-1r0g TATCACCGTACTCAGGAGGTTTAGATAGTTAG 
t-1r2e ACGTTAGTTCTAAAGTTTTGTCGTGATACAGG 
t-1r2f CGTAACGAAAATGAATTTTCTGTAGTGAATTT 
t-1r4e CAATGACAGCTTGATACCGATAGTCTCCCTCA 
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t-1r4f CTTAAACAACAACCATCGCCCACGCGGGTAAA 
t-1r6e AAACGAAATGCCACTACGAAGGCAGCCAGCAA 
t-1r6f ATACGTAAGAGGCAAAAGAATACACTGACCAA 
t-1r8e CCAGGCGCGAGGACAGATGAACGGGTAGAAAA 
t-1r8f CTTTGAAAATAGGCTGGCTGACCTACCTTATG 
t-1r10e GGACGTTGAGAACTGGCTCATTATGCGCTAAT 
t-1r10f CGATTTTAGGAAGAAAAATCTACGGATAAAAA 
t-1r12e TTTGCCAGGCGAGAGGCTTTTGCAATCCTGAA 
t-1r12f CCAAAATAAGGGGGTAATAGTAAAAAAAGATT 
t-1r14e TTTTAATTGCCCGAAAGACTTCAACAAGAACG 
t-1r14f AAGAGGAACGAGCTTCAAAGCGAAAGTTTCAT 
t-1r16e CGAGTAGAACAGTTGATTCCCAATATTTAGGC 
t-1r16f TCCATATATTTAGTTTGACCATTAAGCATAAA 
t-1r18e CTGTAATAGGTTGTACCAAAAACACAAATATA 
t-1r18f GCTAAATCCTTTTGCGGGAGAAGCCCGGAGAG 
t-1r20e TCAGGTCATTTTTGAGAGATCTACCCTTGCTT 
t-1r20f GGTAGCTATTGCCTGAGAGTCTGGTTAAATCA 
t-1r22e AAATAATTTTTAACCAATAGGAACAACAGTAC 
t-1r22f GCTCATTTCGCGTCTGGCCTTCCTGGCCTCAG 
t-1r24e GCTTCTGGCACTCCAGCCAGCTTTACATTATC 
t-1r24f GAAGATCGTGCCGGAAACCAGGCAGTGCCAAG 
t-1r26e CCCGGGTACCTGCAGGTCGACTCTCAAATATC 
t-1r26f CTTGCATGCCGAGCTCGAATTCGTCCTGTCGT 
t-1r28e GGGAGAGGCATTAATGAATCGGCCACCTGAAA 
t-1r28f GCCAGCTGCGGTTTGCGTATTGGGAATCAAAA 
t-1r30e AGTTTGGACGAGATAGGGTTGAGTGTAATAAC 
t-1r30f GAATAGCCACAAGAGTCCACTATTAAGCCGGC 
t-1r32h GAACGTGGCGAGAAAGGAAGGGAATGCGCCGC 
  
t-3r0g CCCTCAGAACCGCCACCCTCAGAAACAACGCC 
t-3r2e TGCTAAACTCCACAGACAGCCCTCTACCGCCA 
t-3r4e ATATATTCTCAGCTTGCTTTCGAGTGGGATTT 
t-3r4f TCGGTTTAGGTCGCTGAGGCTTGCAAAGACTT 
t-3r6e CTCATCTTGGAAGTTTCCATTAAACATAACCG 
t-3r8e AGTAATCTTCATAAGGGAACCGAACTAAAACA 
t-3r8f ACGGTCAATGACAAGAACCGGATATGGTTTAA 
t-3r10e ACGAACTATTAATCATTGTGAATTTCATCAAG 
t-3r12e ACTGGATATCGTTTACCAGACGACTTAATAAA 
t-3r12f CATAACCCGCGTCCAATACTGCGGTATTATAG 
t-3r14e GAAGCAAAAAAGCGGATTGCATCAATGTTTAG 
t-3r16e TCGCAAATAAGTACGGTGTCTGGACCAGACCG 
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t-3r16f TGCAACTAGGTCAATAACCTGTTTAGAATTAG 
t-3r18e CAACGCAAAGCAATAAAGCCTCAGGATACATT 
t-3r20e AGAGAATCAGCTGATAAATTAATGCTTTATTT 
t-3r20f ACCGTTCTGATGAACGGTAATCGTAATATTTT 
t-3r22e CTTTCATCTCGCATTAAATTTTTGAGCAAACA 
t-3r22f GTTAAAATAACATTAAATGTGAGCATCTGCCA 
t-3r24e TTCGCCATGGACGACGACAGTATCGTAGCCAG 
t-3r24f GTTTGAGGTCAGGCTGCGCAACTGTTCCCAGT 
t-3r26e TCATAGCTTGTAAAACGACGGCCAAAGCGCCA 
t-3r26f CACGACGTGTTTCCTGTGTGAAATTTGCGCTC 
t-3r28e TGGTTTTTCTTTCCAGTCGGGAAAAATCATGG 
t-3r28f ACTGCCCGCTTTTCACCAGTGAGATGGTGGTT 
t-3r30e TGGACTCCGGCAAAATCCCTTATACGCCAGGG 
t-3r30f CCGAAATCAACGTCAAAGGGCGAAAAGGGAGC 
t-3r32h CCCCGATTTAGAGCTTGACGGGGAAAAGAACG 
  
t-5r0g CTCAGAGCCACCACCCTCATTTTCCGTAACAC 
t-5r2e GAGAATAGGTCACCAGTACAAACTCCGCCACC 
t-5r2f TGAGTTTCAAAGGAACAACTAAAGATCTCCAA 
t-5r4f AAAAAAGGCTTTTGCGGGATCGTCGGGTAGCA 
t-5r6e GCGAAACAAGAGGCTTTGAGGACTAGGGAGTT 
t-5r6f ACGGCTACAAGTACAACGGAGATTCGCGACCT 
t-5r8f GCTCCATGACGTAACAAAGCTGCTACACCAGA 
t-5r10e AAAGATTCTAAATTGGGCTTGAGATTCATTAC 
t-5r10f ACGAGTAGATCAGTTGAGATTTAGCGCCAAAA 
t-5r12f GGAATTACCATTGAATCCCCCTCACCATAAAT 
t-5r14e TACCTTTAAGGTCTTTACCCTGACAATCGTCA 
t-5r14f CAAAAATCATTGCTCCTTTTGATAATTGCTGA 
t-5r16f ATATAATGGGGGCGCGAGCTGAAATTAACATC 
t-5r18e TATATTTTCATACAGGCAAGGCAAAGCTATAT 
t-5r18f CAATAAATAAATGCAATGCCTGAGAAGGCCGG 
t-5r20f AGACAGTCTCATATGTACCCCGGTTTGTATAA 
t-5r22e ACCCGTCGTTAAATTGTAAACGTTAAAACTAG 
t-5r22f GCAAATATGATTCTCCGTGGGAACCGTTGGTG 
t-5r24e GGCGATCGCGCATCGTAACCGTGCGAGTAACA 
t-5r24f TAGATGGGGTGCGGGCCTCTTCGCGCAAGGCG 
t-5r26e GCTCACAAGGGTAACGCCAGGGTTTTGGGAAG 
t-5r26f ATTAAGTTTTCCACACAACATACGCCTAATGA 
t-5r28e AGCTGATTACTCACATTAATTGCGTGTTATCC 
t-5r28f GTGAGCTAGCCCTTCACCGCCTGGGGTTTGCC 
t-5r30e TATCAGGGCGAAAATCCTGTTTGACGGGCAAC 
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t-5r30f CCAGCAGGCGATGGCCCACTACGTGAGGTGCC 
t-5r32h GTAAAGCACTAAATCGGAACCCTAAAACCGTC 
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3. Disruption of the G-quadruplex 
G-quadruplexes are a family of four-stranded DNA structures stabilized by the stacking of 
guanine tetrads, in which four planar guanines form a cyclic array of hydrogen bonds.[3] 
Modifications in the base composition of the tetrads are poorly tolerated by these structures. As 
an example, O6-methylguanine[4], a non-natural base, can form a smaller number of hydrogen 
bonds and consequently destabilize the G-quadruplex. 
 
Scheme S2. a) Schematic representation of a G-tetrad and a G-quadruplex. b) Chemical structure of 
guanine and it variant, O6-methylguanine. 
To determine the disruption of the quadruplex structure, its circular dichroism spectrum was 
recorded. As shown in Figure S1, the circular dichroism spectra of methylated derivatives of 
TBA1 did not show the presence of the maximum at 295 nm, characteristic of antiparallel 
quadruplexes as TBA. 
 
Figure S1. Circular dichroism of the methylated derivatives of TBA1 (in pink and green), contrasted with 
the profile of the unmodified TBA1 (in blue). 
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4. Fluorescence assays to study α-thrombin-TBA binding. 
A fluorescence quenching assay was intended to evaluate the variation in the binding between 
α-thrombin and native or modified TBA. This experiment was designed on the basis of our 
previous work in the development of a fluorescent TBA probe to detect the activity of the DNA 
repair protein hAGT.[5] There, we demonstrated that the introduction of a methylated guanine in 
the tetrads of the TBA prevents its folding, leaving it in an extended conformation. Given that 
the two conformations bring the two ends of TBA together or take them further apart, we 
incorporated fluorescence probes at each ends, to be able to measure the changes in intensity. 
 A TBA1 sequence and its equivalents with the 5th and 6th guanine replaced by O6-
methylguanine were synthesized, containing a fluorophore (6’-FAM) and a quencher group 
(Dabsyl) attached to their 5’ or 3’ ends respectively. A conformational change in the MB-TBA 
occurs when α-thrombin binds the aptamer, due to its capability of folding the random coiled 
oligonucleotide into its chair-like quadruplex structure. This rearrangement brings close the 
fluorophore and the quencher group attached to the ends, and thus reduces the intensity of its 
emitted fluorescence. It is expected that O6-methylguanine-modified MB-TBAs will not be 
recognized nor folded by α-thrombin and the fluorophore and the quencher will remain 
physically separated beyond the Förster distance, not allowing a significant decrease in the 
fluorescence intensity.  
 
Scheme S3. Schematic representation of the bases of the fluorescence assay. A. Fluorescence is blocked 
when TBA1 is incubated with thrombin, which is able to fold it into a quadruplex and thus reduce its 
emission. B. By contrast, methylated TBA1 cannot be folded and therefore it is not able to adopt its 
quadruplex structure and the fluorescence emitted remains almost unchanged. 
 Titration of the modified MB-TBAs was carried out in physiological buffer at 25 ºC. 
Figure S2 shows the titration curves for the unmodified molecular beacon TBA and the two 
modified TBAs, either in position 5 or 6. As predicted, the fluorescence of the MB-TBA was 
decreased almost in a continuous way when an excess of α-thrombin was added, until reaching 
stabilization, indicating that α-thrombin was folding the MB-TBA back into its quadruplex 
structure. The stoichiometric binding ratio obtained from the titration curve was 1:1-1:1.5, as 
described previously[6]. 
By contrast, the interaction between α-thrombin and the methylated MB-TBAs was 
clearly smaller. Although the fluorescence intensity decreased smoothly at the beginning, it 
reached rapidly a plateau without reducing fluorescence’s intensity significantly. These 
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observations indicated that α-thrombin is almost unable to fold the TBA typical structure. The 
variation in the slope of the schuss proved that the interaction of α-thrombin with TBA depends 
on the capability of the aptamer in adopting its quadruplex structure. In addition, this difference 
seemed to apply for both methylated TBAs, indicating that modifications in both tetrads are 
evenly efficient in disrupting the chair-like structure[5] and hence, making it impossible for α-
thrombin to interact.  
 
Figure S2. Titration of MB-TBAs in physiological buffer at 25ºC. The diamond red graph represents the 
titration of the unmodified MB-TBA, triangle green plot shows the interaction of α-thrombin with the 5-O6-
methylated derivative of MB-TBA and the squared blue one the interaction with 6-O6-MeG-TBA molecular 
beacon. In the three cases, the concentration of MB is 1μM. The experiments were performed in 
triplicates. 
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5. EMSA assay to explore α-thrombin-TBA binding. 
To confirm the fluorescence results, gel-mobility shift assays were performed to analyze the 
interaction between α-thrombin and the modified TBAs. Increasing concentrations of human α-
thrombin were incubated with a constant TBA concentration, as shown in figure S3.  
When non-modified TBA(T)5 sequence was incubated with α-thrombin, a clear 
migration of the bands could be appreciated from 10 μM concentration, representing that a 
population of the DNA was binding α-thrombin at 1:10 ratio. However, when increasing 
concentrations of α-thrombin were incubated with 5-O6-MeG-TBA(T)5, no complex formation 
could be observed, even at a molar ratio of 1:15 and 1:20. These results confirmed that the 
methylation of the aptamer prevents its quadruplex structure formation and thus makes it 
impossible for α-thrombin to recognize and bind to it, at least at these concentration ratios. From 
this EMSA assay, the apparent KD value for TBA: α-thrombin is estimated to be 15 nM and for 
5-O6-MeG-TBA, >120 nM. 
Considering that 6-O6-MeG-TBA and 5-O6-MeG-TBA behaved similarly in the 
fluorescence assays, EMSA experiments were decided to be done only for 5-O6-MeG-TBA, as 
only one of the sequences will be required to design the origami modified staple strands. 
From these results, we could presume that a concentration of 10 fold of α-thrombin can 
be sufficient to appreciate a different pattern of union of this protein to the TBA and O6-MeG-
TBA-containing origami. 
 
Figure S3. Gel-mobility shift assays. Non-denaturing (10% polyacrylamide) PAGE image of the titration 
experiment for TBA(T)5 (lanes 1 to 5) and 5-O6-MeG-TBA(T)5 (lines 6 to 9). Lane M corresponds to a 10 bp 
double stranded DNA ladder. TBA(T)5 (1) and 5-O6-MeG-TBA(T)5 (6) served as controls, and were loaded 
at 1 μM concentration, which was the same for all the samples. Lanes 1, 2, 3, 4 and 5 correspond to TBA 
with increasing concentrations of α-thrombin. TBA: α-thrombin ratios were the following:  1:0, 1:5, 1:10, 
1:15 and 1:20. Lanes 6, 7, 8 and 9 correspond to the same increasing concentration of α-thrombin 
incubated with the methylated TBA (1:0, 1:10, 1:15 and 1:20).  
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6. Origami formation control 
The formation of the tall rectangle origami where several staple strands were modified by the 
insertion of TBA1, 5-O6-MeG-TBA1 and TBA2 was performed successfully, as it is shown in 
figure S4. The protruding TBAs can be clearly seen by means of AFM as two parallel lines as it 
was intended in the design of the array. 
 
Figure S4. AFM image of the DNA origami carrying the modified TBA staple strands. The origami was 
formed correctly, showing that the introduction of the modified tiles did not affect to its assembly. The 
protruding TBA sequences can be observed as white lines of up to 3 nm height above mica, while the 
plannar unmodified origami protrudes 1.5 nm from mica.[2] Image height: -2.0 nm to 2.7 nm. 
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7. Additional AFM images of α-thrombin-DNA origami interaction 
 
Figure S5. AFM images of the origami containing methylated TBA staple strands in the left line, incubated 
with α-thrombin. Image size: 3 μm x 3 μm. In this case, the height represents an increase up to 3-4 nm, 
due to the α-thrombin molecules attached to the origami surface. Image height: -2.0 nm to 2.7 nm. 
 
Figure S6. AFM images of the origami containing methylated TBA staple strands in the left line, incubated 
with α-thrombin. Image size: 1 μm x 1 μm. Image height: -2.0 nm to 2.7 nm. 
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Figure S7. AFM images of the origami containing demethylated TBA staple strands, incubated with α-
thrombin. Images size: 3 μm x 3 μm. Image height: -2.0 nm to 2.7 nm. 
  
Figure S8. AFM images of the origami containing demethylated TBA staple strands, incubated with α-
thrombin. Images size: 1 μm x 1 μm. Images height: -2.0 nm to 2.7 nm. 
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8. Section analysis of the AFM images. 
 
 
Figure S9. Line section of the methylated origami: a) AFM images of the methylated origami binding 
thrombin. b) Horizontal section of the origami, in yellow, origami surface; in green, protruding 
methylated TBAs; in blue five thrombin molecules interacting with the natives TBAs. C) Cross-section of 
the origami. 
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9. Titration of the hAGT repair activity. 
 
 
Figure S10. Titration of hAGT activity in the origami. Repair of the methylTBAs with increasing 
concentrations of hAGT (0x, 2x, 5x and 10x).  
 
Figure S11. AFM images of the demethylated origami binding thrombin, showing improving occupation 
due to the increase in TBA repair by hAGT. 
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10. Quantitative and statistic studies of α-thrombin-TBA binding on DNA origami 
 
10.1. Quantitative studies of TBA- α-thrombin binding on the methylated origami. 
To explore the binding reactions quantitatively, all α-thrombin molecules on the well-shaped 
two-dimensional origami templates were counted according to their position, and of the 160 
well-formed DNA origami structures investigated, around 20% of them contained all five α-
thrombin molecules in positions coinciding with the unmodified TBAs. If we consider those 
origamis that were found to contain more than 4 α-thrombin molecules attached to the TBA 
overhangs, more than the 40% are to fit in this group. Accordingly, the counting reveals that 
almost the 60% of the well-shaped origamis contained more than 3 out of 5 possible positions 
occupied, and almost 80% considering more than 2 occupied positions. In all, more than 93% of 
the DNA arrays contained almost 1 α-thrombin attached to the unmodified TBAs. 
10.2. Statistic studies to validate the α-thrombin binding models 
Comparison of averages of the two types of binding (right line and left line) was performed 
using Student’s t distribution. Right line corresponded to the TBA2 and TBA1 staple strands, 
the later methylated and subsequently repaired by hAGT, and the left one consisted of TBA1 
and TBA2 staple strands, both unmodified. Binding of α-thrombin was supposed to happen 
similarly in both lines after hAGT demethylation. Comparison of averages resulted in an 
insignificant difference between them (p < 0.5), which confirmed that binding was occurring 
equally, without any preference for any line. 
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Introduction
Last year saw the sixtieth anniversary of the DNA double-helix
model of Watson and Crick.[1] The advances in the field since
then have been prodigious and far beyond expectations in
areas as diverse as medicine, basic biology, genetics, forensics,
and archeology, and culminated in the sequencing of the
human genome.[2]
Deoxyribonucleic acid is a self-assembling biopolymer that
forms double helices directed by canonical Watson–Crick base
pairing and is stabilized by hydrogen bonds, p–p stacking, and
hydrophobic interactions. The B-form of these double-helical
molecules have well-defined structures, which are repeated
along the strands: the helical turn measures ~3.4 nm, the di-
ameter is ~2.0 nm, and the twist angle between base pairs in
solution is ~34.38.[1] The remarkable specificity of the molecular
recognition between complementary nucleotides has made
DNA an attractive molecule for scientists and engineers inter-
ested in micro- and nanofabrication. Its predictability, rigidity,
and precise structural control, as well as the creation of algo-
rithms for de novo design of new self-assembled structures,[3]
make it a useful building material to develop different kinds of
nanotechnological platforms. Compared to other self-assem-
bling molecules, DNA nanostructures offer programmable in-
teractions and surface features for the precise positioning of
other nanoparticles and biomolecules.[4]
The field of DNA nanotechnology was pioneered by Ned
Seeman, who set the basis for the use of DNA as a scaffold for
nanoscale building.[5] Seeman’s original goal was the creation
of regular 3D lattices of DNA that could be used as scaffolding
for the rapid, orderly binding of biological macromolecules, in
order to speed the formation of suitable crystals for 3D pro-
tein–structure elucidation in X-ray diffraction studies.[5] This
gave rise to the tile-based assembly method, which has been
used to synthesize two-dimensional periodic lattices[6] and
three-dimensional architectures (e.g. , a cube in solution,[7] and
a solid-phase truncated octahedron).[8] In both cases a strategy
that relies on repeated enzymatic treatment and purification
was used.
Another important breakthrough in the field of structural
DNA nanotechnology has been the development of DNA “ori-
gami” by Paul Rothemund,[9] where a long scaffold strand is
folded with the help of hundreds of short “staples” to create
the desired 2D shape. Since then, various 2D and 3D DNA
motifs have been designed, and extensive studies are currently
ongoing to apply these nanostructures to a large range of bio-
medical, computational, and molecular motor purposes.
In this review, we outline the evolution of DNA nanotechnol-
ogy from simple to sophisticated, complex systems, with the
aim of providing insights into the applications of the DNA-
based nanostructures for the study of biological systems.
1. Basic Considerations in DNA Nano-
technology
The design and construction of DNA-based nanoarchitectures
involves several major considerations. The design of the con-
struct and its potential applications should be identified, and
concerns, such as flexibility or rigidity of the scaffold, and
static or dynamic devices, should be defined. It must be con-
sidered whether symmetric or non-symmetric patterns of the
array are required, and whether the growth is to be limited or
infinite. The periodicity and growth dimensions of the scaffold
are also important. All these requirements of the scaffold archi-
tecture determine the DNA motif, as well as the building
blocks design, which can comprise junctions, loops, crossovers,
and single-strand binding sites. These motifs can be chemically
modified to enable the attachment of non-nucleic-acids, such
as proteins and nanoparticles. In addition, particular properties,
such as length, specific hybridization of complementary
strands, minimization of undesired hybridization, different
binding sites for proteins, and restriction sites for characteriza-
tion, need to be studied to achieve the final nanostructure
with the best yield.
Seeman developed the first program, SEQUIN, to facilitate
the design of oligonucleotides for the preparation of arrays.[10]
Since then, several automated software packages have been
described.[11] An overview of the concepts and algorithmic ap-
proaches of some programs was presented by Brenneman and
Codon.[12]
Finally, the designed DNA oligonucleotides have to be as-
sembled in vitro, and it can be as easy as following a typical
self-assembly process by simple mixing components. However,
sometimes more complex protocols are needed, such as the
DNA’s remarkable molecular recognition properties, flexibility,
and structural features make it one of the most promising scaf-
folds to design a variety of nanostructures. During recent de-
cades, two major methods have been developed for the con-
struction of DNA nanomaterials in a programmable way; both
generate nanostructures in one, two, and three dimensions.
The tile-based assembly process is a useful tool to construct
large and simple structures ; the DNA origami method is suita-
ble for the production of smaller, more sophisticated and well-
defined structures. Proteins, nanoparticles and other functional
elements have been specifically positioned into designed pat-
terns on these structures. They can also act as templates to
study chemical reactions, help in the structural determination
of proteins, and be used as platform for genomic and drug
delivery applications. In this review we examine recent pro-
gresses towards the potential use of DNA nanostructures in
molecular and cellular biology.
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assembly of single building blocks, different kinds of purifica-
tion, structural integrity characterization by biochemical meth-
ods like electrophoresis,[13] digestion and/or fragmentation
analysis,[14] and visualization techniques such as atomic force
microscopy (AFM),[6] transmission electron microscopy (TEM),
and cryo-electron microscopy.[15]
Major DNA motifs
In the early 1980s, Seeman conducted pioneering work on the
construction of artificial nucleic acid architectures by using
branched DNA junctions containing three or four arms of
double-stranded DNA helices with sticky ends (Figure 1A).[5]
Variants with five and six arms were less stable.[16] Sticky ends
at the junction arms enabled self-assembly into 2D lattices (by
enzymatic or chemical coupling).[5] Three-dimensional “dendrit-
ic” structures labeled with different fluorescent dyes[17] have
been generated with these junctions motifs, but they are con-
sidered inappropriate for the assembly of regular architectures
because of their high flexibility.[18] A study by Malo and co-
workers demonstrated that the presence of a DNA-binding
protein in the process of assembling a four-armed junction
resulted in a grid of squares rather than hexagon–triangle latti-
ces (Kagome-lattices).[19a] One-dimension “railroad track” and
two-dimensional lattices have been assembled with four arm
junctions despite the high flexibility of these building
blocks.[19b]
The generation of “44 tile” motifs (containing four-armed
junctions with T4 loops at their arms) facilitated assembly as
linear ribbons and two-dimensional arrays. He et al. assembled
larger two-dimensional arrays from this motif by applying two
new concepts (Figure 1B).[20] First, the motif was designed to
be symmetric, and second, it followed a “corrugation strategy”,
consisting of two adjacent building blocks facing opposite di-
rections in such a way that the small curvatures of the individ-
ual motifs are canceled (by each other) instead of accumulat-
ing throughout the structure. This system has been used to
template streptavidin (STV) into periodic protein arrays, by in-
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Figure 1. Major motifs in DNA nanotechnology. Arrows indicate the 3’-ends
of DNA strands. A) Branched DNA junctions containing three or four arms/
strands. Double-helix arms form between strand pairs. B) A 44 DNA tile of
nine unique strands. C) A DNA triangle contains three DNA duplexes, shown
as rods (left) or as thin lines for single DNA strands (“st” right). D) A DX mole-
cule results from double exchange between double helices. A TX molecule
results from two successive double reciprocal exchanges. Both molecules
contain exchanges between strands of opposite polarity. A PX molecule is
formed when two double helices exchange strands at every point where
helices come into contact. A JX2 molecule differs from PX in that it lacks the
two central crossovers. The exchanges in PX and JX2 are between strands of
the same polarity.
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serting a biotin group into the T4 loops at the tile center.[21] A
step toward versatile, size-controlled, and programmable DNA-
based nanoarrays was reported with cross-shaped tiles, by
using a stepwise hierarchical assembly technique.[22]
DNA triangles are promising candidates for the fabrication
of “tensegrity” structures. These are constructs of rigid rods
connected by short “tendons” (here, branch points of DNA
junction motifs) that are connected by short tensegrity seg-
ments (Figure 1C).[23] As mentioned above, DNA junctions are
rather flexible, and assembly does not often yield a regular
structure. Seeman and co-workers solved this problem by cre-
ating the most fundamental motif in DNA nanotechnology:
the double crossover (DX) motif (Figure 1D). This consists of
two double-stranded helices that interchange single strands at
two crossover points.[24] DX motifs with sticky ends allow the
constructions of 2D arrays.[6] Rinker demonstrated that it is
possible to replace DNA strands in a DX motif with locked nu-
cleic acid (LNA) strands in the formation of 2D arrays.[25] After
the success of the DX motif, triple-crossover (TX) tiles were de-
signed; these consist of three helices lying in a plane, connect-
ed at crossover points (Figure 1D),[26] as found in linear lattices,
2D arrays,[26] and DNA tubes.[27] Various other tiles (other than
square and rectangular) have been prototyped. At least three
versions of triangular tiles have been described: in one the
plane is tiled entirely with triangles,[23] and in the other two
hexagonal patterns are formed.[28] Three-point[29] and six-point
star[30] motifs have also been self-assembled into two dimen-
sional arrays.
Another important class of DNA motif is the paranemic
crossover (PX) motif,[31] which is composed of two parallel heli-
ces with crossovers at every possible site (Figure 1D). This
motif can be topoisomerased to form the JX2 motif, where the
relative positions of the two ends of the motif are rotated 1808
relative to PX (Figure 1D).[32] Extensive information about DNA
major motifs, self-assembled DNA nanostructures and mechan-
ical devices is found in several reviews.[33]
1.2. Polyhedra
One of the major goals in DNA nanotechnology is the con-
struction of three-dimensional DNA structures. However, 3D
constructs have proved to be more difficult to build than 2D
constructs.[34] The first 3D structures to be assembled were a
cube[7] and a truncated octahedron[35] (Figure 2A and B), but
these were obtained with low yield and were not suitable for
biological applications. Seeman successfully engineered crys-
tals with altered lattice dimensions in 2004,[36] thus pursuing
his initial idea to generate 3D crystals for X-ray crystallographic
study of “guest” molecules, such as proteins.[37] A remarkable
achievement was the design and synthesis of an octahedron
with DX-like edges and PX motifs :[38] a 1.7-kb, ssDNA molecule
amplified by polymerase and folded with five 40-mer synthetic
oligodeoxynucleotides (Figure 2D).[15] Later, a chiral tetrahedral
unit with short double helix edges was constructed in higher
yield (Figure 2C).[39] By this approach, it was found that adding
programmable linkers confers structural stability and resistance
to deformation. The robustness of the structure was studied
by AFM.[40] One of the edges of the tetrahedron was examined
for mechanical movement by exchanging the DNA strands,
thereby producing a reconfiguration of the DNA tetrahedral
shape in a precise and reversible manner.[41] Covalently closed
octahedral DNA cages were reported to be resistant to thermal
and chemical denaturation, and could thus represent a step to-
wards to the use of these devices as delivery systems.[42] More
Figure 2. A) Cube formed from twelve equal-length double-helical edges ar-
ranged around eight vertices. B) Double-helical representation of an ideal
truncated octahedron. Reprinted with permission from ref. [35] . Copyright
1994, American Chemistry Society. C) DNA tetrahedron. Reprinted with per-
mission from ref. [40] . Copyright 2005, American Association for the Ad-
vancement of Science. D) 3D model of an octahedron. Secondary structures
consist of five DX and seven PX motifs; hybridization of PX motifs for 3D for-
mation. Reprinted with permission from ref. [15] . Copyright 2004, Nature
Publishing Group. E) Polyhedral structures: tetrahedron, dodecahedron and
buckyball, assembled from three-point star building blocks. Adapted with
permission from ref. [45] . Copyright 2008, Nature publishing Group.
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complex and modified polyhedra were also created in a single
step.[43]
Sleiman reported a new method to increase the range of 3D
structures to include a prism, a cube, pentameric and hexame-
ric prisms, a heteroprism, and a biprism.[44] Mao took advant-
age of the “sequence symmetry”[20] to generate three-point
star motifs or tiles. By controlling the flexibility and the con-
centration of the tiles and adapting the length of central
single-stranded loop, his group synthesized a tetrahedron, a
dodecahedron, and a buckyball from a minimal set of building
blocks (Figure 2E).[45] By the same strategy, a five point start
motif was designed and self-assembled into icosahedra.[46]
Strategies to restrict polyhedral faces to those with an even
number of vertices were used to assemble DNA cubes.[47] Triso-
ligonucleotides with an organic vertex (C3h linker) were em-
ployed to assemble a DNA dodecahedron, thus demonstrating
the usability of this construct for multimodular machines by
the introduction of extension arms that allow overhanging
with other sequence.[48]
Chirality is an essential feature in nature.[49] Enzymes and cell
receptors have the ability to distinguish different substrates
stereoisomers, thus leading to highly efficient and stereoselec-
tive reactions and binding. Understanding and control of chir-
ality is crucial for drug design,[50] encapsulation,[51] and other
processes.[52] The chirality of DNA duplexes is indisputable;
however, its extension to building stereoisomeric pure DNA
nanostructures has been a challenge. Mitchell et al. described
the self-assembly of chiral nanotubes,[53] and subsequently, He
et al. reported a well-defined chiral octahedron.[54] The assem-
bly of both structures was relatively straightforward, and their
chiral features might enable the use of this type of structures
for all the applications mentioned above.
Another important tool in 3D DNA nanotechnology is “ten-
segrity”: the balance between components that are in pure
compression and those in pure tension for stability. The Shih
group reported nanoscale prestressed 3D tensegrity structures
in which rigid bundles of DNA resist compressive forces exert-
ed by single-stranded DNA segments that act as tension-bear-
ing cables.[55] These tensile structural elements could be used
to study molecular forces, cellular mechanotransduction and
other fundamental processes.
1.3. DNA origami
The implementation of DNA computing by Winfree’s group in
2004[3] formed the basis for the development of what would
be one of the most important breakthroughs in the field: DNA
origami, as reported by Rothemund in 2006.[9] This involves the
folding of a long, circular, single-stranded DNA scaffold into ar-
bitrary 2D shapes, directed by a collection of various (hundreds
of) shorter single-stranded oligonucleotides that are comple-
mentary to different regions of the scaffold (Figure 3A). The
specific matching of the scaffold and “staple” strands leads to
well-shaped nanostructures, with high yield and reproducibility
(Figure 3B). In addition, it avoids stoichiometric dependence,
thus eliminating the need for purification and exact determina-
tion of the concentration of the oligonucleotides, and thereby
reducing the time and effort required for its assembly. One of
the most attractive features of this technique is the addressa-
bility of the surface, thus permitting the attachment of differ-
ent biomolecules or nanoscale objects by the modification of
specific staple strands at desired positions.[4]
The origami approach was further developed for the con-
struction of 3D nanostructures. Gothelf’s group assembled a
box with a controllable lid from a combination of six origami
sheets;[56] at the same time, Kuyuza and Komiyana designed
another box-shaped origami by selective closing of a pre-
formed motif.[57] A scaffold DNA origami of a closed DNA tetra-
hedron was designed by Ke et al. ; this resembled the icosahe-
dral structure of many viral particles.[58] Shih and co-workers in-
troduced a strategy to generate 3D nanostructures by honey-
combing (or square packing) scaffolded DNA[59] (Figure 3D).
This group also described the insertion of twists and curves
into 3D nanoconstructs, through addition or deletion of base
pairs at specific positions within the helical layers.[60] The Yan
group developed a method based on the organization of con-
centric DNA rings of different radii to build DNA shapes with
complex curvatures (Figure 3E).[61] They also reported the
design of quasi-2D origami tiles with a Mobius topology, which
implies a certain degree of twist and curvature, as well as flexi-
bility and strength.[62] These novel 3D structures further dem-
onstrate the robustness and potential of the origami technique
in different kinds of application.
An important limitation of this technique is that it results in
a relatively small area, limited by the length of the standard
scaffold. In many cases, the origami surface might not be suffi-
cient for the precise positioning of functional molecules or for
other applications. For this reason, other efforts in the field are
focused on assembling larger structures, including approaches
such as algorithmic assembly from origami seeds,[63] origami
oligomerization[64] and polymerization,[65] the use of eight-helix
bundles as staples,[66] long single-stranded PCR amplification
products,[67] and double-stranded viral genomes[68] as scaffolds.
An example of this oligomerization is given in Figure 3C.[64b] A
more detailed description of these methodologies can be
found in a review by Tørring et al.[69]
A novel approach by Sugiyama’s group was to design RNA-
templated DNA origami structures that were folded to form
seven-helix, bundled rectangular shapes. These nanoconstructs
were composed of an RNA transcript (as scaffold) with DNA
staple strands, and have been exploited for specific applica-
tions such as catalysis and RNA interference.[70]
Recently, DNA origami technology is becoming more acces-
sible to researchers from different fields because of the devel-
opment of several computational tools for the design of di-
verse structures, for example SARSE-DNA,[71] caDNAno,[72] and
CanDo.[73] These software tools facilitate the sketching and pat-
terning of the nanoconstructs and broaden the scope in terms
of time, cost and need for researcher experience. Today, a few
hours and basic computation fluency is sufficient to design ori-
gami tiles for a wide variety of applications.
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2. Biochemical Applications
The advent of nanotechnology and the expansion of computa-
tional algorithms has led to an explosion in the number of
DNA scaffolds that can be created, and for a wide variety of
applications, including nanomaterial assembly, biosensors,[41]
molecular computation,[33d,74] biomolecular actuation, drug de-
livery, and nanodevices.[33d]
2.1. Tiles and Polyhedra
One great challenge in engineering functional materials and
devices has been how to integrate and assemble them into hi-
erarchical arrays with minimal defects. However, innovative
methods by Mirkin[75] and Alivisatos[76] demonstrated that gold
particles and surfaces are generally easily modified with oligo-
nucleotides, and assembled into different packing densities
and arrangements for a variety of applications. The design and
generation of more-complex DNA tile motifs have been used
for the assembly of lattices, particularity for allowing the incor-
poration of components that protrude from the plane,[26] such
as gold nanoparticles[77] of different size[78] (Figure 4A), and
combinations of streptavidin and gold nanoparticles.[79] All
these developments open the door to extensive work for the
creation of nanoelectronic, nanophotonic, and optoelectronic
devices, which are beyond the scope of this review.
Mirkin[80] and Gang[81] demonstrated that DNA can be used
to control the crystallization of nanoparticle–oligonucleotide
conjugates; different DNA sequences guide the assembly of
the same type of inorganic nanoparticles into different crystal-
line states, thereby controlling distance and packing dynamics.
Nanostructures for the sensitive detection of biomolecules
have been reported by Niemeyer and co-workers by using
DNA–streptavidin conjugates. Such DNA–protein conjugates
could be versatile molecular tools in immunoassays, nanoscale
biosensor elements, microstructural biochips, and supramolec-
ular devices.[82] The streptavidin–biotin interaction has been
the most explored method in the creation of molecular net-
works.[21,22, 83] Efficient assembly into 2D DNA arrays of other
ligands such as DNA aptamers[84] with target proteins such as
thrombin or antibodies has been accomplished (Figure 4B).[85]
In a similar approach, Krishnan and co-workers designed the I-
switch, a DNA nanosensor that maps spatial and temporal pH
changes inside living cells by FRET.[86] Organic and inorganic
linkage connecting multiple DNA strands has been extended
to include dendrimers,[84a, 87] macrocycles,[88] multibranched
Figure 3. A) Formation of DNA origami. B) Example DNA origami nanostructures and their AFM images described by Paul Rothemund. Reprinted with permis-
sion from ref. [9] . Copyright 2006, Nature Publishing Group. C) Example strategy for enlargement of DNA origami dimensions, by the union of “jigsaw” pieces.
Adapted with permission from ref. [64b]. Copyright 2011, American Chemistry Society. D) Strategy to generate 3D nanostructures by honeycomb or square
packing of the scaffolded DNA. Reprinted with permission from ref. [59a] . Copyright 2009, Nature Publishing Group. E) Method to build DNA shapes with
complex curvatures, based on the organization of concentric DNA rings of different radii. Adapted with permission from ref. [61]. Copyright 2011, American
Association for the Advancement of Science.
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structures,[89] and linear arrays containing functional mole-
cules.[90]
Many biochemical systems in biology require more than just
one catalytic reaction by a single enzyme; for instance, with
multienzyme reaction complexes,[91] the substrate is passed di-
rectly from one catalytic site to the next. A benefit of special
arrangements of enzymes is concerted action of several com-
plementary enzymes to cooperatively perform a complex task.
Artificial co-localization of enzymes (to improve reaction flux)
has been attempted by a variety of approaches, such as with
solid matrices, by chemical connections, by recombinant engi-
neering, or by using protein–protein interaction domains.[92]
In recent decades, there have been several attempts to
apply DNA scaffolding for the creation of artificial multi-
enzyme systems. Niemeyer and co-workers[93] demonstrated
for the first time that DNA-directed assembly of two proteins
could be the initial step for the efficient generation of artificial
multienzyme complexes (Figure 4C). Later, they also reported
the covalently linkage of enzymes like glucose oxidase (GOX)
or horseradish peroxidase (HRP) to DNA to generate supra-
molecular complexes.[94] In both cases, improved performance
was observed when the proximity of the cooperative enzymes
was constrained.[93,94] The first example of enzyme systems ar-
ranged on a larger supramolecular DNA scaffold was demon-
strated by Wilner et al.[95] Again with the GOX/HRP system,
they reported a significant increase in overall activity when the
two enzymes were held in close proximity by a hexagon-type
DNA scaffold. In addition, they immobilized glucose dehydro-
genase and its tethered cofactor NAD+ on the scaffold, and
observed different activities for different tether lengths and
distances. More recently, the same multienzyme system was in-
corporated into a switchable DNA scaffold to dynamically con-
trol a diffusion distance of intermediate products.[85c] In this
way, the system reversibly regulated the reaction in situ.[96] An-
other impressive achievement was the control of spatial organ-
ization of a multienzymatic complex by using RNA molecules
that are sequence-programmed to be isothermally assembled
into predefined discrete, 1D and 2D structures in vivo. The re-
action was optimized as a function of scaffold architecture.[97]
Further studies could be useful for the development of novel
catalysts for enzymatic processes or to perform multistep
Figure 4. A) DNA scaffold deposited on mica combined with DNA-encoded nanocomponents of two sizes, and AFM and TEM images. Adapted with permis-
sion from ref. [78a] . Copyright 2005, American Chemical Society. B) Aptamer-directed self-assembly of thrombin protein (green spheres) on a 2D DNA tile gen-
erates a linear protein arrays. AFM images prior to and after thrombin binding. Adapted with permission from ref. [84a] . Copyright 2005, Wiley. C) DNA-direct-
ed organization. Biotinylated recombinant enzymes are coupled to covalent DNA-streptavidin conjugates. D) Dynamic structural changes upon hybridization
of a specific complementary strand in a prism structure. E) Tetrahedral delivery system for siRNA conjugated to cancer-targeting ligands. AFM image shows
tetrahedron nanoparticles on mica. AFM image show the three upper edges of the tetrahedral. Adapted with permission from ref. [99c] . Copyright 2012
Nature Publishing Group. F) Tetrahedron containing a molecule of cytochrome c. Adapted with permission from ref. [100a]. Copyright 2006, Wiley.
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chemical transformations of cheap precursors into drugs and
fine chemicals.
DNA nanostructures are also promising candidates for drug
delivery, as they possess a combination of features. Firstly, they
have a great flexibility in size and shape, thus offering a variety
of parameters for optimization in order to improve cellular in-
ternalization.[84b,98] Sleiman has reported a new method for the
construction of the first dynamic 3D DNA capsules whose size
is able to switch between three different lengths. These 3D
switchable capsules can be used for drug delivery and dynamic
DNA structures (Figure 4D).[44] In addition, DNA can be func-
tionalized with different molecules as cargos, by covalent mod-
ification,[98a] self-assembly of DNA polyhedral nanoparticles
with a well-defined size which can deliver small molecules,
siRNAs and antisense oligodeoxynucleotides into cells and si-
lence target genes in tumors,[99] and encapsulation (Figure 4E
and F).[100] Recently, Wollman et al. created a DNA molecular
motor that performs a wide range of tasks, including self-or-
ganization, capture, and concentration of cargoes transport
signals for release and track or follow disassembly.[101] More-
over, these structures are stable under physiological condi-
tions[102] and, as natural material in living creatures, possess
excellent biocompatibility.[98a]
2.2. DNA origami
Since Rothemund’s original report,[9] a large number of re-
search groups have adopted the DNA origami technique in
several novel applications, from all type of chemical or enzy-
matic single-molecule reactions to applications in photon-
ics,[103] nanorobotics,[104] and nanomechanics.[105] Here we pro-
vide a brief list of these applications. Gold nanoparticles have
been selectively positioned and patterned on origami structur-
es.[103b,106] Yan and co-workers connected gold nanoparticles to
DNA origami nanotubes, a development which represents
progress towards the goal of combining origami self-assembly
and lithographic methods to design patterns on surfaces.[107]
Precise DNA sequences with sugar moieties covalently at-
tached were used for the site-specific immobilization of fluo-
rescent silver nanoclusters at predefined positions on the
nanoscaffold;[108] the resulting high density array of emissive
nanoclusters could have potential applications in the nano-
fabrication of semiconductor nanostructures. A methodology
combining gold and silver nanoparticles using a predetermined
pattern was developed by Pal et al.[103c] A general method for
arranging single-walled carbon nanotubes (SWNT) in two di-
mensions by using DNA origami was reported by the Winfree
group; it has potential use in the synthesis of multi-SWNT
logic gates or memory circuits.[109] As a final example, Stein
et al.[110] achieved a combination of multistep energy transfer
in a photonic wire-like origami structure using fluorophores
that undergo an energy-transfer cascade. This work demon-
strates the wide and multidisciplinary potential of DNA origami
nanotechnology for the above-mentioned applications. Given
that the field is so extensive, here we focus on the biological
and biochemical applications of DNA origami and their pros
and cons for specific uses; we do not review the more me-
chanical and computational approaches, which have been cov-
ered in many excellent reviews.[4,111]
2.2.1. Material organization: There is almost no limitation in
attaching functional biomolecules to DNA origami, as chemi-
cally modified sequences can be incorporated to staple
strands, or specifically modified DNA can be readily attached
by hybridization to staples strands.[112]
Several research groups have demonstrated the possibility
of displaying nucleic acids on the origami surface: when mRNA
probes are attached to DNA origami structures, they can be
used for the detection of gene expression at the single-mole-
cule level.[113] These findings open the door for using the origa-
mi technique for a great variety of diagnostic applications. By
using the same basic concept, the complete sequence of a syn-
thetic oligonucleotide can also be tracked down over an origa-
mi surface by using complementary probes, with broad appli-
cations for the recognition of unknown DNA sequences.[114]
In addition, a huge number of proteins have been pro-
grammed over DNA nanoconstructs. Niemeyer and co-workers
decorated DNA origami with three types of proteins by using
coupling systems orthogonal to the biotin–streptavidin interac-
tion (Figure 5A).[115] This study raised the question over prefer-
ence for face-down or face-up orientation of the origami struc-
tures when deposited over mica; this was found to depend
principally on the method used for the binding of the proteins
to the origami tile.
A possible application of the origami technique is the study
and control of the binding distances between DNA and the
protein partners. For example, Rinker et al. studied the multiva-
lent interactions of a-thrombin and its two a-thrombin bind-
ing aptamers (TBA), and the distance dependence for simulta-
neous binding (Figure 5B).[116] By taking advantage of the spa-
tial accuracy of this platform, it was found that a-thrombin
binds the dual system with a tenfold better recognition than
with a single aptamer, and it was shown for the first time that
5.3 nm between the two aptamers is optimal for bivalent bind-
ing. This group used a similar strategy to study the distance-
dependent kinetic processes associated with the GOX/HRP
enzyme pair. The distance between enzymes was systematical-
ly increased from 10 to 65 nm, thereby revealing strongly
enhanced activities for these enzymes when closely spaced,
whereas the activity dropped dramatically when as little as
20 nm apart. They also observed that strong activity enhance-
ment was not simply achieved by reducing the inter-enzyme
distance but also by restricting the diffusion of intermediates
to the 2D surface connecting the enzymes.[117] These results
further demonstrate the high resolution and spatial accuracy
of the technique, and the possibility of using it for the visuali-
zation and characterization of single-molecule events.
A new method was reported to direct protein nanopattern-
ing over origami nanoconstructs, by using nitrilotriacetic acid
and histidine-tag metal-linked interactions. This report de-
scribes a new way of selectively binding a staple strand to the
target protein—highly relevant in protein immobilization on
DNA origami.[118] Although it provided a novel way of attaching
proteins to the DNA origami surface, this method needs to be
extended to other tags, as the histidine tag is not well tolerat-
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ed by all proteins, and can prevent folding and/or activity. The
chemical functionalization of the target molecules could be
also be a drawback, so will need further development to
extend this method to a broader range of proteins.
Streptavidin nanoarrays were created by using periodical
nanometer-scale wells embedded in DNA origami in which
single streptavidin molecules could be held (Figure 5C).[119]
This represents an innovation because all in previous attach-
ments nanomaterials were anchored to DNA origami at the
surface of the array. In this design, gold nanoparticles were
nanopatterned, by selectively capturing a single nanoparticle
in each well of the punched DNA origami. Subsequently, they
combined alternating organic (streptavidin) and inorganic
(gold nanoparticle) materials in a defined pattern.[120]
Recently, zinc-finger proteins (ZFP) were assembled on an
origami scaffold (Figure 5D).[121] Orthogonal targeting of the
specific locations in the structures was demonstrated by using
two adaptors, and Escherichia coli lysate containing the adap-
tor-fused proteins successfully afforded the expected protein–
DNA assembly. The diversity of target DNA sequences and the
semi-programmable design of ZFPs offers orthogonal adaptors,
thus enabling the placement of multiple engineered proteins
at different locations on DNA-origami structures. Nature uses
multiple enzymes in close proximity to efficiently carry out
chemical reactions and signal transduction. Such assemblies of
multiple proteins could be realized in vitro by using DNA ori-
gami structures that have predefined binding sites and various
kinds of ZFP adaptor-fused proteins.
2.2.2. Single-molecule reaction: Single-molecule studies are
crucial to understand the trajectories of molecules as they un-
dergo reactions. For this reason, considerable effort has been
made in this area, and the application of the origami tech-
nique has given the opportunity to solve many spatial and iso-
lation problems because of its nanometric resolution and ad-
dressability. In addition, any functionality that can be conjugat-
ed with DNA can be placed on the origami surface, thereby
serving as a molecular recognition probe. Some of the applica-
tions described in the above could be also considered single-
molecule reactions, for example RNA hybridization assays or
the distance-dependent thrombin-aptamers binding.
One of the first reports to show the possibility of detecting
single molecule reactions in real time at positions of an origa-
Figure 5. Examples of precise material organization on DNA origami surfaces. A) Orthogonal decoration of DNA origami, raising the controversy of face-up or
face-down disposition of the nanostructures over mica surfaces for visualization. Reprinted with permission from ref. [115] . Copyright 2010, Wiley. B) Distance-
dependence study of multivalent interactions of a-thrombin with two binding aptamers (TBA) on an origami platform. Adapted with permission from
ref. [116] . Copyright 2008 Nature Publishing Group. C) Construction of a streptavidin nanoarray on a DNA origami, by size-selective capture of one streptavi-
din tetramer in each well. Adapted with permission from ref. [119] . Copyright 2009, Wiley. D) Assembly of zinc-finger proteins (ZFP) on DNA origami struc-
tures, to enable placement of multiple engineered proteins at different locations. Reprinted with permission from ref. [121a] . Copyright 2012, Wiley.
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mi platform was conducted by Voigt et al.[122] They performed
three successive cleavage and bond-forming reactions with
high yield and chemoselectivity, and they demonstrated the
feasibility of post-assembly chemical modification of DNA
nanostructures, as well as their potential use as locally address-
able solid supports. Furthermore, they gave a different per-
spective to the face-up/face-down discussion by finding that in
their case almost all of the constructs had the chemical modifi-
cations pointing towards the solution, thus keeping the ques-
tion raised by Niemeyer and co-workers[115] open to debate.
Several methods exist for the detection of single-nucleotide
polymorphism (SNPs),[123] as these differences are the major
basis for phenotypic individuality and genetic variation. The
ability of DNA nanotechnology to detect SNP unimolecularly is
straightforward, as probes for the polymorphism can be
placed over the origami sequence with full control of the loca-
tion of each probe. Seeman and co-workers employed the ef-
fectiveness of kinetic methods based on branch migration[124]
to detect single molecule polymorphisms by AFM over an ori-
gami surface (Figure 6A).[113b] However, these methodologies
are still far from feasible as diagnostics, as they require AFM,
which is neither quick to use nor affordable for many labs. In
addition, DNA microarrays are extensively used for the same
purpose, with good efficiency and simpler manipulation. The
application of the DNA origami platform for detecting SNPs
needs to be simplified and cost-reduced to be implemented as
a diagnostic system.
An interesting application of DNA nanotechnology involves
extension of the study of kinetics and conformational changes
to different types of molecules. The kinetics of the formation
Figure 6. Study of different single-molecule reactions by the DNA origami approach. A) Detection of single nucleotide polymorphisms “SNPs”; by AFM over
an origami surface. Adapted with permission from ref. [113b]. Copyright 2011, American Chemistry Society. B) Detection of the formation of G-quadruplexes
in G-rich DNA sequences on a frame-like DNA origami. Adapted with permission from ref. [126]. Copyright 2010 American Chemistry Society. C) Methyl trans-
fer reaction of EcoRI methyltransferase and analysis of the structural effect of this methylation by using a frame-like DNA origami. Adapted with permission
from ref. [130]. Copyright 2010, American Chemistry Society. D) Nanosensor to analyze DNA repair activity of hAGT by a-thrombin interaction with methylated
DNA aptamers, substrates of the protein. Reprinted with permission from ref. [133]. Copyright 2013, Wiley.
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of a duplex DNA structure can be monitored on an origami
tile—studying in real time the binding and unbinding events
and estimating association/dissociation rates. As well as static
analysis, dynamic processes in the sub-second range can be in-
vestigated on an origami platform in real time, and the results
are comparable with those obtained by traditional methods to
detect ensemble events.[125] In addition, conformational
changes of biomolecules can also be analyzed with this plat-
form. A novel method to detect the formation of G-quadru-
plexes in G-rich DNA sequences was developed by Sugiyama’s
group.[126] G-quadruplexes are four-stranded structures formed
by the square arrangement of a tetrad of guanines, stabilized
by the formation of Hoogsteen bonds.[127] They are promising
anticancer agents, as they inhibit telomerase.[128] A DNA origa-
mi frame structure was designed: two sets of connection sites
were introduced for the hybridization of duplex DNA. Each
duplex contained a single strand rich in guanines in the upper
and lower region in the presence of K+ it changed its confor-
mation to a G-quadruplex. This event was visualized by AFM in
real time (Figure 6B).
The secondary DNA binding site of human topoisomerase I
was identified by using an origami construct designed by
Knudsen and co-workers.[129] A bait DNA protrusion was at-
tached to the rectangular DNA nanoarray, by a 21-nucleotide
extension of one of the staple strands. The secondary interac-
tion of topoisomerase was discovered by adding either
TopoIB–DNA complex (T1 mode) or by stepwise addition of the
TopoIB and cleavage complex (T2 mode), and by monitoring
the process by AFM. These results led to the conclusion that
topoisomerase can bind positively and negatively supercoiled
DNA. However, this should be confirmed by other methods, as
this was the first time that a second binding site for topoiso-
merase was identified.
The study of the mechanism of enzymatic reactions in real
time is crucial for understanding their biological functions, and
great advances in DNA nanotechnology could help. Numerous
publications have described the detection of enzymatic activity
by DNA origami, and most of the studied enzymes have bio-
medical implications. Regulation of DNA methylation by using
different tensions of double strands was studied and moni-
tored by AFM by Sugiyama and co-workers.[130] They intro-
duced two different double-helical tensions (tense and relaxed)
into an origami frame, to control the methyl transfer reaction
of EcoRI methyltransferase and examine the structural effect of
this methylation (Figure 6C).[130] A further development was
a versatile nanochip for direct analysis of DNA base-excision
repair by 8-oxoguanine glycosylase and T4 pyrimidine dimer
glycosylase.[131] The exact positioning and displacement of the
enzymes in the reaction were monitored and analyzed. By
using the same origami model, Suzuki et al.[132] developed
a method for the visualization of Cre-mediated site-specific re-
combination events. Controlling the orientation and topology
of the loxP substrate in a DNA frame nanoscaffold the process
was regulated, thus influencing the synapsis and the outcome
of the reaction. These systems could be extended to the direct
observation of various enzymatic phenomena in designed
nanoscale spaces, even though currently the methodology is
only useful for DNA-related mechanisms.
Another study of DNA methylation was conducted in our
lab:[133] the use of the DNA origami as a nanosensor to analyze
the DNA repair activity of human O6-methylguanine alkyltrans-
ferase (hAGT) by a-thrombin interaction with methylated DNA
aptamers, substrates of the hAGT. This DNA repair enzyme is
a cancer prognosis indicator. Inhibition of hAGT can enhance
the efficiency of chemotherapeutic treatment. Previously, we
demonstrated that introduction of a methyl group into any of
the guanine tetrads of TBA destabilizes the G-quadruplex
formed by this G-rich sequence, thus preventing thrombin
from recognizing/binding to it.[134] The introduction of several
methylated TBAs at specific positions of the origami allowed
us to observe the loss of thrombin binding. When the O6-
methylguanine of the modified TBA was repaired by hAGT, a-
thrombin was able to bind to the aptamers, as they could
form the quadruplex structure required for the interaction (Fig-
ure 6D). This detection of the DNA repair activity of hAGT in
an origami could be further developed to design hAGT activity
assays for the identification of potential inhibitors as chemo-
therapy enhancers.
Accurate quantitative determination of microRNA was per-
formed on a DNA origami motif. Zhu et al. developed
a method for detecting single-strand displacement based on
the interaction of streptavidin and quantum dots, measured by
AFM in a linear and direct way.[135] This methodology has ad-
vantages over fluorescence signal detection: it is simple, time-
and material-saving, potentially multitarget in one unique
motif, and accurate enough for certain impure samples, as the
signals are directly counted by AFM.
All these studies assumed that immobilization of biomole-
cules on a 2D platform does not affect their activity. By using
fluorescence-based assays, Tinnefeld demonstrated that DNA
origami does not influence the function of biomolecules (by
comparison with data obtained in solution), and confirmed
that DNA origami is a biocompatible surface.[136]
2.2.3. Carriers for delivery: In previous sections, we mostly re-
viewed applications of 2D DNA origami, as one of the most rel-
evant features is precise positioning control on the planar sur-
face. In contrast, many origami platforms developed as carriers
for drug delivery have employed 3D nanostructures.
Many reports have described preliminary results pointing to
the use of DNA origami as nanocarriers for cellular delivery. An
important consideration is stability of these nanostructures
under physiological conditions (maintenance of folding): DNA
double helical domains and the connecting cross-overs should
remain intact for the correct performance. Dietz’s group re-
ported that DNA origami objects built with a average staple
length and cross-over density can be safely incubated at 37 8C
(typical for cell-culture application).[73] They also proved that
these nanoconstructs are stable in cell-culture medium
(DMEM), and in Tris buffer with BSA or salted dextran (crowd-
ing agents), and at low pH. Furthermore, they tested stability
in the presence of different nucleases, and found that their
scaffolds were stable against T7 exonuclease, E. coli exonu-
clease, Lambda nuclease, and Micrococcus MseI restriction exo-
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nuclease. However, they were degraded by DNAseI and T7 en-
donuclease, although they were more stable to DNAseI than
double stranded DNA (degraded after 1 hour instead of 5 min
at 37 8C). In addition, Mei et al. demonstrated that DNA origami
are stable in cell lysate; this allows them to be easily separated
from lysate mixtures, unlike natural single- and double-strand-
ed DNA.[137] These findings illustrate the potential of DNA ori-
gami in cellular applications, and overcome some of the main
problems that other delivery systems suffer.
Visualization of the intracellular location and stability of DNA
origami with a label-free fluorescent probe was performed suc-
cessfully by Shen et al.[138] They reported a strategy to study
the distribution and stability of DNA origami nanostructures in
living cellular systems, by using carbazole-based biscyanine as
a probe. After 12 h incubation, most DNA origami nanostruc-
tures were localized in lysosome. After 60 h, most were disas-
sembled or unfolded. Their results provide important informa-
tion for the development of DNA origami as a biocompatible
drug delivery vehicle, with the potential to accomplish con-
trolled release.
Kjem, Gothelf and co-workers designed an origami box with
a controllable lid; opening and closing was demonstrated by
FRET experiments (Figure 7A).[56] Programmable access to the
interior of the box could yield several interesting applications,
for example the controlled release of nanocargos. A further de-
velopment of this is the logic-gated DNA nanopill that was de-
signed by Douglas et al. for the selective delivery of molecular
payloads to the cell.[139] These nanopills are capable of induc-
ing a great variety of responses in cell behavior. The biological-
ly active payloads can be bound indirectly by antibody frag-
ments, thus enabling applications in which the nanorobot is
able to stimulate signals for activation and inhibition tasks
before target delivery (Figure 7B).
Another cutting-edge cellular application of DNA origami
was the design of DNA-based channel that can introduce
pores into the cell’s lipid membrane (Figure 7C). Single-mole-
Figure 7. 3D origami structures (and AFM or TEM images) for cellular delivery. A) DNA box with a controllable lid (potential drug carrier). Reprinted with per-
mission from ref. [56] . Copyright 2009 Nature Publishing Group. B) Logic-gated DNA nanopill for selective delivery of molecular payloads. Reprinted with per-
mission from ref. [139]. Copyright 2012, American Association for the Advancement of Science. C) DNA-origami based channel to punch pores into the cell
membrane, with ability to discriminate single DNA molecules. Reprinted with permission from ref. [141]. Copyright 2012, American Association for the Ad-
vancement of Science. D) DNA origami as a carrier for circumvention of doxorubicin resistance. Adapted with permission from ref. [142]. Copyright 2012
American Chemistry Society. E) Incorporation of CpG oligonucleotides into a DNA origami for the induction of strong immune responses. Adapted with per-
mission from ref. [143]. Copyright 2011, American Chemistry Society.
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cule translocation experiments showed that the synthetic DNA
channels can be used to discriminate single DNA molecules.[140]
DNA origami has also been used as a carrier to circumvent
drug resistance.[141] Doxorubicin (a well-known anticancer drug)
was attached to a DNA origami by intercalation, thereby ach-
ieving high efficiency of drug loading when the nanostructures
were administered. As a result, the cellular internalization of
doxorubicin was increased, thus contributing significantly to
enhance the cell-killing effect in doxorubicin-resistant MCF-7
cells (Figure 7D). In addition, Hçgberg developed two DNA ori-
gami structures with precise degrees of global twist to deliver
doxorubicin in three different breast cancer cell lines.[142] They
were able to regulate encapsulation efficiency and the drug
release kinetics by tuning the nanostructure. With the aid of
these DNA tiles, the cytotoxicity of doxorubicin was increased
as the intracellular elimination rate was decreased, as com-
pared to free drug. These results suggest that DNA origami
has immense potential as an efficient and biocompatible drug
delivery vehicle, although how exactly the origami nanostruc-
tures deliver the anticancer drugs remains unclear.
As mentioned above, many functional nucleic acids (includ-
ing aptamers, antisense oligonucleotides, short interference
RNA, and microRNA) have high diagnostic and therapeutic po-
tential. As the carrier and the cargo are essentially the same
type of molecule, the loading process can be simplified: nucle-
ic acid hybridization or integration of the required sequence
into the carrier. However, it is necessary to take architectural
issues into account when designing the nanostructure, to
avoid undesired interactions (between the cargo and the carri-
er) that could reduce the efficacy of the delivery process. The
incorporation of cytosine-phosphate-guanosine (CpG) oligonu-
cleotides to a DNA origami tube represents a good examina-
tion of this. Schller et al.[143] tested the immune responses
induced by hollow 30-helix DNA origami tubes covered with
up to 62 CpG sequences in freshly isolated spleen cells (Fig-
ure 7E). The DNA constructs showed no detectable toxicity (in
contrast to lipofectamine) and did not affect the viability of
the splenocytes, but triggered a strong immune response,
characterized by cytokine production and immune cell activa-
tion. Given that DNA oligonucleotides can be easily modified
to incorporate a wide variety of biomolecules, this approach
could be extended to combinations with viral moieties to gen-
erate vaccines and enhancers designed with nanometer preci-
sion and high biocompatibility.
2.2.4. DNA nanomachines and nanodevices: In addition to
the static DNA origami structures, continuous advances in DNA
nanotechnology have made possible the construction dynamic
nanosystems that combine walkers, cargo, tracks and drive
mechanisms to achieve complex motion on 2D or 3D surfaces.
These DNA nanomachines and nanodevices are promising for
biological applications.
Several nanomachines have been reported, such as a system
that integrates a spider-like molecular walker with ability to
move along a 2D substrate track assembled on a DNA origami
array.[104b] DNA transporters that moved along a designed track
were constructed on a DNA origami device, and the multistep
motion of the motor strand was traced by AFM and
TEM.[104a,144] Reck-Peterson and co-workers built a programma-
ble synthetic cargo by using 3D DNA origami to which differ-
ent DNA oligonucleotide-linked motors were attached, thereby
allowing control of motor type, number, spacing, and orienta-
tion.[145] This cargo system was useful to determine and charac-
terize the motile behavior of microtubule-based motor ensem-
bles, depending on polarity of orientation. The behavior was
found to be similar to that observed in vivo. Further develop-
ment of these nanoconstructs might result in bidirectional
powerful transport nanodevices to investigate the motile prop-
erties of motors and the mechanisms of motor regulation.
A DNA origami nanomachine with the potential for in vivo
biosensing and intelligent delivery of biological activators was
produced by Firrao’s group.[146] This 3D DNA nanodevice per-
formed its function in response to an external signal : in the
presence of a small amount (picomols) of its target DNA, the
robot moved a flap, thereby exposing its cargo DNA and self-
assembly of the latter into a stable DNAzyme.
A versatile sensing system for the detection of a variety of
chemical and biological targets at molecular resolution was
designed by Kuyuza et al.[147] Their sensing methodology was
based on a nanomechanical device formed by two DNA origa-
mi levers connected by a fulcrum, and was used to visually
detect (by AFM) the biomolecule and its shape. All of the
described mechanical detection mechanisms are suitable for
targets of interest and can be used orthogonally with different-
ly shaped origami devices in the same mixture on a single plat-
form.
A development of previous work concerning material organ-
ization and single-molecule reactions[94,95,117] was conducted by
Fan and co-workers.[148] They designed DNA nanostructures
with unprecedented properties as nanoscale bioreactors, to
study enzyme activities and cascades in highly organized and
crowded cell-mimicking environments. These artificial systems
were developed in a reliable and single-step strategy with high
speed and cooperativity.
A different type of biological application was addressed by
Lin et al.[149] They designed sub-micrometre nanorods that act
as fluorescent barcodes and produce up to 216 barcodes that
can be decoded unambiguously by using epifluorescence or
total internal reflection fluorescence microscopy. The potential
applications of this novel approach are of great variety: they
could be used to improve tagging techniques, to develop
a set of versatile imaging tools for single-molecule biological
reactions and for biomedical diagnostics. They could also be
modified with diverse biomolecules, such as monoclonal anti-
bodies for immunophenotyping applications, or they could be
used for in situ labeling of multiple cell types. By following the
same approach, Yin and co-workers developed a multiplexed
3D cellular super-resolution technique for imaging, by using
DNA origami to obtain multiplexed images for studying com-
plex biomolecular systems in cell cultures.[150]
Upon refinement of their features and performance, these
dynamic nanodevices could be further developed for many dif-
ferent biological and biomedical applications because of their
predictable biophysical and biomechanical behavior and inter-
action with the cellular environment.
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Outlook and Prospects
The biological applications reviewed here are just a starting
point to show the potential of DNA nanotechnology for bio-
medical applications. Since the establishment of structural
DNA nanotechnology as a field of research, scientists from dif-
ferent disciplines have been working together to develop nu-
merous innovations over more than three decades. It has ad-
vanced from static scaffolds to dynamic functional devices that
include other synthetic and natural materials. It has been ap-
plied for a variety of purposes from nanoelectronics, nanopho-
tonics, and nanorobotics to more biological implementations,
which could evolve into diagnostic and therapeutic tools.
However, some current difficulties must be addressed for
the application of nanotechnology for biomedical purposes.
Yield and scale-up of complex constructs remain a challenge;
apparently, both are inversely related to the complexity and
density of the desired structures. Deeper investigation into the
kinetics and thermodynamics of annealing and assembly
might come up with solutions to increase the stability and
yield of the nanodevices and thus enable better prospects for
in vivo application. Methods to expand the dimensions of the
constructs should be addressed, as well as to increase the rate
of encapsulation of biomolecules and inorganic material for
delivery, and to broaden the diagnostic and therapeutic possi-
bilities. The performance of single-molecule analytical tech-
niques requires improvement of spatial resolution and time-
scale, and additional methodologies will be required for a
better understanding of unimolecular processes, and the appli-
cation to diagnostics.
A number of previously unfulfilled goals have been ach-
ieved, thus leading to successful progress of DNA nanotechnol-
ogy. On this basis, we believe that further development of
these techniques holds great potential for biological applica-
tions, hopefully with highly programmable and controllable ca-
pabilities in the very near future.
Acknowledgements
The Communities FUNMOL, “Fondo de Investigaciones Sanitarias”
(grant PI06/1250) and by “Ministerio Ciencia e Innovacin” (grant
CTQ-2010-20541-C03-03) are acknowledged for financial support.
C.F is grateful to Generalitat de Catalunya and Instituto de Salud
Carlos III for a SNS Miguel Servet contract. M.T. was supported by
a pre-doctoral fellowships from MINECO.
Keywords: biosensors · DNA nanotechnology · DNA origami ·
DNA structures · DNA tiles · nanostructures
[1] J. D. Watson, F. H. Crick, Nature 1953, 171, 737–738.
[2] a) F. Sanger, G. M. Air, B. G. Barrell, N. L. Brown, A. R. Coulson, C. A.
Fiddes, C. A. Hutchison, P. M. Slocombe, M. Smith, Nature 1977, 265,
687–695; b) K. B. Mullis, F. A. Faloona, Methods Enzymol. 1987, 155,
335–350; c) F. W. Studier, Proc. Natl. Acad. Sci. USA 1989, 86, 6917–
6921; d) A. Martin-Gallardo, W. R. McCombie, J. D. Gocayne, M. G. Fitz-
Gerald, S. Wallace, B. M. B. Lee, J. Lamerdin, S. Trapp, J. M. Kelley, L.-I.
Liu, M. Dubnick, L. A. Johnston-Dow, A. R. Kerlavage, P. de Jong, A. Car-
rano, C. Fields, J. C. Venter, Nat. Genet. 1992, 1, 34–39; e) X. C. Huang,
M. A. Quesada, R. A. Mathies, Anal. Chem. 1992, 64, 2149–2154.
[3] L. M. Demers, C. A. Mirkin, R. C. Mucic, R. A. Reynolds III, R. L. Letsinger,
R. Elghanian, G. Viswanadham, Anal. Chem. 2000, 72, 5535–5541.
[4] J. Fu, M. Liu, Y. Liu, H. Yan, Acc. Chem. Res. 2012, 45, 1215–1226.
[5] N. C. Seeman, J. Theor. Biol. 1982, 99, 237–247.
[6] E. Winfree, F. Liu, L. A. Wenzler, N. C. Seeman, Nature 1998, 394, 539–
544.
[7] J. H. Chen, N. C. Seeman, Nature 1991, 350, 631–633.
[8] Y. Zhang, N. C. Seeman, J. Am. Chem. Soc. 1994, 116, 1661–1669.
[9] P. W. K. Rothemund, Nature 2006, 440, 297–302.
[10] N. C. Seeman, J. Biomol. Struct. Dyn. 1990, 8, 573–581.
[11] a) U. Feldkamp, R. Wacker, H. Schroeder, W. Banzhaf, C. M. Niemeyer,
ChemPhysChem 2004, 5, 367–372; b) U. Feldkamp, H. Rauhe, W. Banz-
haf, Genet. Program. Evolvable Machines 2003, 4, 153–171.
[12] A. Brenneman, A. Condon, Theor. Comput. Sci. 2002, 287, 39–58.
[13] N. C. Seeman, H. Wang, X. Yang, F. Liu, C. Mao, W. Sun, L. Wenzler, Z.
Shen, R. Sha, H. Yan, M. H. Wong, P. Sa-Ardyen, B. Liu, H. Qiu, X. Li, J.
Qi, S. M. Du, Y. Zhang, J. E. Mueller, T.-J. Fu, Y. Wang, J. Chen, Nanotech-
nology 1998, 9, 257.
[14] N. C. Seeman, Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 225–248.
[15] W. M. Shih, J. D. Quispe, G. F. Joyce, Nature 2004, 427, 618–621.
[16] Y. Wang, J. E. Mueller, B. Kemper, N. C. Seeman, Biochemistry 1991, 30,
5667–5674.
[17] a) Y. Li, Y. D. Tseng, S. Y. Kwon, L. d’Espaux, J. S. Bunch, P. L. McEuen, D.
Luo, Nat. Mater. 2004, 3, 38–42; b) Y. Li, Y. T. H. Cu, D. Luo, Nat. Bio-
technol. 2005, 23, 885–889.
[18] N. C. Seeman, Y. Zhang, J. Chen, J. Vac. Sci. Technol. A 1994, 12, 1895.
[19] a) J. Malo, J. C. Mitchell, C. Vnien-Bryan, J. R. Harris, H. Wille, D. J. Sher-
ratt, A. J. Turberfield, Angew. Chem. Int. Ed. 2005, 44, 3057–3061;
Angew. Chem. 2005, 117, 3117–3121; b) C. Mao, W. Sun, N. C. Seeman,
J. Am. Chem. Soc. 1999, 121, 5437–5443.
[20] Y. He, Y. Tian, Y. Chen, Z. Deng, A. E. Ribbe, C. Mao, Angew. Chem. Int.
Ed. 2005, 44, 6694–6696; Angew. Chem. 2005, 117, 6852–6854.
[21] a) H. Yan, S. H. Park, G. Finkelstein, J. H. Reif, T. H. LaBean, Science 2003,
301, 1882–1884; b) S. H. Park, P. Yin, Y. Liu, J. H. Reif, T. H. LaBean, H.
Yan, Nano Lett. 2005, 5, 729–733.
[22] S. H. Park, C. Pistol, S. J. Ahn, J. H. Reif, A. R. Lebeck, C. Dwyer, T. H.
LaBean, Angew. Chem. 2006, 118, 749–753; Angew. Chem. Int. Ed.
2006, 45, 735–739.
[23] D. Liu, M. Wang, Z. Deng, R. Walulu, C. Mao, J. Am. Chem. Soc. 2004,
126, 2324–2325.
[24] T. J. Fu, N. C. Seeman, Biochemistry 1993, 32, 3211–3220.
[25] S. Rinker, Y. Liu, H. Yan, Chem. Commun. 2006, 2675–2677.
[26] T. H. LaBean, H. Yan, J. Kopatsch, F. Liu, E. Winfree, J. H. Reif, N. C.
Seeman, J. Am. Chem. Soc. 2000, 122, 1848–1860.
[27] D. Liu, S. H. Park, J. H. Reif, T. H. LaBean, Proc. Natl. Acad. Sci. USA 2004,
101, 717–722.
[28] a) B. Ding, R. Sha, N. C. Seeman, J. Am. Chem. Soc. 2004, 126, 10230–
10231; b) N. Chelyapov, Y. Brun, M. Gopalkrishnan, D. Reishus, B. Shaw,
L. Adleman, J. Am. Chem. Soc. 2004, 126, 13924–13925.
[29] Y. He, Y. Chen, H. Liu, A. E. Ribbe, C. Mao, J. Am. Chem. Soc. 2005, 127,
12202–12203.
[30] Y. He, Y. Tian, A. E. Ribbe, C. Mao, J. Am. Chem. Soc. 2006, 128, 15978–
15979.
[31] Z. Shen, H. Yan, T. Wang, N. C. Seeman, J. Am. Chem. Soc. 2004, 126,
1666–1674.
[32] H. Yan, X. Zhang, Z. Shen, N. C. Seeman, Nature 2002, 415, 62–65.
[33] a) K. V. Gothelf, T. H. LaBean, Org. Biomol. Chem. 2005, 3, 4023–4037;
b) N. C. Seeman, Methods Mol. Biol. 2005, 303, 143–166; c) N. C.
Seeman, Trends Biochem. Sci. 2005, 30, 119–125; d) U. Feldkamp, C. M.
Niemeyer, Angew. Chem. Int. Ed. 2006, 45, 1856–1876; Angew. Chem.
2006, 118, 1888–1910; e) C. Lin, Y. Liu, S. Rinker, H. Yan, ChemPhys-
Chem 2006, 7, 1641–1647.
[34] N. C. Seeman, Curr. Opin. Struct. Biol. 1996, 6, 519–526.
[35] Y. Zhang, N. C. Seeman, J. Am. Chem. Soc. 1994, 116, 1661–1669.
[36] P. J. Paukstelis, J. Nowakowski, J. J. Birktoft, N. C. Seeman, Chem. Biol.
2004, 11, 1119–1126.
[37] N. C. Seeman, DNA Cell Biol. 1991, 10, 475–486.
[38] X. Zhang, H. Yan, Z. Shen, N. C. Seeman, J. Am. Chem. Soc. 2002, 124,
12940–12941.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1374 – 1390 1387
CHEMBIOCHEM
REVIEWS www.chembiochem.org
158
[39] R. P. Goodman, R. M. Berry, A. J. Turberfield, Chem. Commun. 2004,
1372–1373.
[40] R. P. Goodman, I. A. T. Schaap, C. F. Tardin, C. M. Erben, R. M. Berry, C. F.
Schmidt, A. J. Turberfield, Science 2005, 310, 1661–1665.
[41] R. P. Goodman, M. Heilemann, S. Doose, C. M. Erben, A. N. Kapanidis,
A. J. Turberfield, Nat. Nanotechnol. 2008, 3, 93–96.
[42] F. F. Andersen, B. Knudsen, C. L. P. Oliveira, R. F. Frøhlich, D. Krger, J.
Bungert, M. Agbandje-McKenna, R. McKenna, S. Juul, C. Veigaard, J.
Koch, J. L. Rubinstein, B. Guldbrandtsen, M. S. Hede, G. Karlsson, A. H.
Andersen, J. S. Pedersen, B. R. Knudsen, Nucleic Acids Res. 2008, 36,
1113–1119.
[43] a) C. M. Erben, R. P. Goodman, A. J. Turberfield, J. Am. Chem. Soc. 2007,
129, 6992–6993; b) C. Zhang, M. Su, Y. He, Y. Leng, A. E. Ribbe, G.
Wang, W. Jiang, C. Mao, Chem. Commun. 2010, 46, 6792–6794.
[44] F. A. Aldaye, H. F. Sleiman, J. Am. Chem. Soc. 2007, 129, 13376–13377.
[45] Y. He, T. Ye, M. Su, C. Zhang, A. E. Ribbe, W. Jiang, C. Mao, Nature 2008,
452, 198–201.
[46] C. Zhang, M. Su, Y. He, X. Zhao, P.-a. Fang, A. E. Ribbe, W. Jiang, C.
Mao, Proc. Natl. Acad. Sci. USA 2008, 105, 10665–10669.
[47] C. Zhang, S. H. Ko, M. Su, Y. Leng, A. E. Ribbe, W. Jiang, C. Mao, J. Am.
Chem. Soc. 2009, 131, 1413–1415.
[48] J. Zimmermann, M. P. J. Cebulla, S. Mçnninghoff, G. von Kiedrowski,
Angew. Chem. Int. Ed. 2008, 47, 3626–3630; Angew. Chem. 2008, 120,
3682–3686.
[49] J. W. Lough, W. I. Wainer, Chirality in Natural and Applied Science, CRC,
Oxford, 2002.
[50] Chiral Drugs (Ed. : C. A. Challener), Willey, Hampshire, 2001.
[51] J. Rebek, Jr. , Angew. Chem. Int. Ed. 2005, 44, 2068–2078; Angew. Chem.
2005, 117, 2104–2115.
[52] Methods in Molecular Biology: Vol. 243: Chiral Separations : Methods and
Protocols (Eds. : G. Gbitz, M. G. Schmid), Human, Totowa, 2004.
[53] J. C. Mitchell, J. R. Harris, J. Malo, J. Bath, A. J. Turberfield, J. Am. Chem.
Soc. 2004, 126, 16342–16343.
[54] Y. He, M. Su, P.-a. Fang, C. Zhang, A. E. Ribbe, W. Jiang, C. Mao, Angew.
Chem. Int. Ed. 2010, 49, 748–751; Angew. Chem. 2010, 122, 760–763.
[55] T. Liedl, B. Hçgberg, J. Tytell, D. E. Ingber, W. M. Shih, Nat. Nanotechnol.
2010, 5, 520–524.
[56] E. S. Andersen, M. Dong, M. M. Nielsen, K. Jahn, R. Subramani, W. Mam-
douh, M. M. Golas, B. Sander, H. Stark, C. L. P. Oliveira, J. S. Pedersen, V.
Birkedal, F. Besenbacher, K. V. Gothelf, J. Kjems, Nature 2009, 459, 73–
76.
[57] A. Kuzuya, M. Komiyama, Chem. Commun. 2009, 4182–4184.
[58] Y. Ke, J. Sharma, M. Liu, K. Jahn, Y. Liu, H. Yan, Nano Lett. 2009, 9,
2445–2447.
[59] a) S. M. Douglas, H. Dietz, T. Liedl, B. Hogberg, F. Graf, W. M. Shih,
Nature 2009, 459, 414–418; b) Y. Ke, S. M. Douglas, M. Liu, J. Sharma,
A. Cheng, A. Leung, Y. Liu, W. M. Shih, H. Yan, J. Am. Chem. Soc. 2009,
131, 15903–15908; c) Y. Ke, N. V. Voigt, K. V. Gothelf, W. M. Shih, J. Am.
Chem. Soc. 2012, 134, 1770–1774.
[60] H. Dietz, S. M. Douglas, W. M. Shih, Science 2009, 325, 725–730.
[61] D. Han, S. Pal, J. Nangreave, Z. Deng, Y. Liu, H. Yan, Science 2011, 332,
342–346.
[62] D. Han, S. Pal, Y. Liu, H. Yan, Nat. Nanotechnol. 2010, 5, 712–717.
[63] a) K. Fujibayashi, R. Hariadi, S. H. Park, E. Winfree, S. Murata, Nano Lett.
2008, 8, 1791–1797; b) R. D. Barish, R. Schulman, P. W. K. Rothemund,
E. Winfree, Proc. Natl. Acad. Sci. USA 2009, 106, 6054–6059.
[64] a) Z. Li, M. Liu, L. Wang, J. Nangreave, H. Yan, Y. Liu, J. Am. Chem. Soc.
2010, 132, 13545–13552; b) A. Rajendran, M. Endo, Y. Katsuda, K.
Hidaka, H. Sugiyama, ACS Nano 2011, 5, 665–671.
[65] W. Liu, H. Zhong, R. Wang, N. C. Seeman, Angew. Chem. Int. Ed. 2011,
50, 264–267; Angew. Chem. 2011, 123, 278–281.
[66] Z. Zhao, H. Yan, Y. Liu, Angew. Chem. Int. Ed. 2010, 49, 1414–1417;
Angew. Chem. 2010, 122, 1456–1459.
[67] E. Pound, J. R. Ashton, H. A. Becerril, A. T. Woolley, Nano Lett. 2009, 9,
4302–4305.
[68] B. Hçgberg, T. Liedl, W. M. Shih, J. Am. Chem. Soc. 2009, 131, 9154–
9155.
[69] T. Tørring, N. V. Voigt, J. Nangreave, H. Yan, K. V. Gothelf, Chem. Soc.
Rev. 2011, 40, 5636–5646.
[70] M. Endo, S. Yamamoto, K. Tatsumi, T. Emura, K. Hidaka, H. Sugiyama,
Chem. Commun. 2013, 49, 2879–2881.
[71] a) E. S. Andersen, A. Lind-Thomsen, B. Knudsen, S. E. Kristensen, J. H.
Havgaard, E. Torarinsson, N. Larsen, C. Zwieb, P. Sestoft, J. Kjems, J.
Gorodkin, RNA 2007, 13, 1850–1859; b) E. S. Andersen, M. Dong, M. M.
Nielsen, K. Jahn, A. Lind-Thomsen, W. Mamdouh, K. V. Gothelf, F.
Besenbacher, J. Kjems, ACS Nano 2008, 2, 1213–1218.
[72] S. M. Douglas, A. H. Marblestone, S. Teerapittayanon, A. Vazquez, G. M.
Church, W. M. Shih, Nucleic Acids Res. 2009, 37, 5001–5006.
[73] C. E. Castro, F. Kilchherr, D.-N. Kim, E. L. Shiao, T. Wauer, P. Wortmann,
M. Bathe, H. Dietz, Nat. Methods 2011, 8, 221–229.
[74] a) C. Mao, T. H. LaBean, J. H. Relf, N. C. Seeman, Nature 2000, 407, 493–
496; b) G. Seelig, D. Soloveichik, D. Y. Zhang, E. Winfree, Science 2006,
314, 1585–1588; c) L. Qian, E. Winfree, Science 2011, 332, 1196–1201.
[75] C. A. Mirkin, R. L. Letsinger, R. C. Mucic, J. J. Storhoff, Nature 1996, 382,
607–609.
[76] A. P. Alivisatos, K. P. Johnsson, X. Peng, T. E. Wilson, C. J. Loweth, M. P.
Bruchez, Jr. , P. G. Schultz, Nature 1996, 382, 609–611.
[77] a) S. Xiao, F. Liu, A. E. Rosen, J. F. Hainfeld, N. C. Seeman, K. Musier-For-
syth, R. A. Kiehl, J. Nanopart. Res. 2002, 4, 313–317; b) J. D. Le, Y. Pinto,
N. C. Seeman, K. Musier-Forsyth, T. A. Taton, R. A. Kiehl, Nano Lett.
2004, 4, 2343–2347; c) Z. Deng, Y. Tian, S.-H. Lee, A. E. Ribbe, C. Mao,
Angew. Chem. Int. Ed. 2005, 44, 3582–3585; Angew. Chem. 2005, 117,
3648–3651; d) J. Sharma, R. Chhabra, Y. Liu, Y. Ke, H. Yan, Angew.
Chem. Int. Ed. 2006, 45, 730–735; Angew. Chem. 2006, 118, 744–749;
e) F. A. Aldaye, H. F. Sleiman, J. Am. Chem. Soc. 2007, 129, 4130–4131;
f) A. J. Mastroianni, S. A. Claridge, A. P. Alivisatos, J. Am. Chem. Soc.
2009, 131, 8455–8459.
[78] a) Y. Y. Pinto, J. D. Le, N. C. Seeman, K. Musier-Forsyth, T. A. Taton, R. A.
Kiehl, Nano Lett. 2005, 5, 2399–2402; b) J. Zheng, P. E. Constantinou,
C. Micheel, A. P. Alivisatos, R. A. Kiehl, N. C. Seeman, Nano Lett. 2006, 6,
1502–1504.
[79] H. Li, S. H. Park, J. H. Reif, T. H. LaBean, H. Yan, J. Am. Chem. Soc. 2004,
126, 418–419.
[80] S. Y. Park, A. K. R. Lytton-Jean, B. Lee, S. Weigand, G. C. Schatz, C. A.
Mirkin, Nature 2008, 451, 553–556.
[81] D. Nykypanchuk, M. M. Maye, D. van der Lelie, O. Gang, Nature 2008,
451, 549–552.
[82] C. M. Niemeyer, Trends Biotechnol. 2002, 20, 395–401.
[83] C. M. Niemeyer, M. Adler, S. Gao, L. Chi, Bioconjugate Chem. 2001, 12,
364–371.
[84] a) Y. Liu, C. Lin, H. Li, H. Yan, Angew. Chem. Int. Ed. 2005, 44, 4333–
4338; Angew. Chem. 2005, 117, 4407–4412; b) A. S. Walsh, H. Yin, C. M.
Erben, M. J. A. Wood, A. J. Turberfield, ACS Nano 2011, 5, 5427–5432.
[85] a) C. Lin, E. Katilius, Y. Liu, J. Zhang, H. Yan, Angew. Chem. Int. Ed. 2006,
45, 5296–5301; Angew. Chem. 2006, 118, 5422–5427; b) B. A. R. Wil-
liams, K. Lund, Y. Liu, H. Yan, J. C. Chaput, Angew. Chem. Int. Ed. 2007,
46, 3051–3054; Angew. Chem. 2007, 119, 3111–3114; c) C. Zhou, Z.
Yang, D. Liu, J. Am. Chem. Soc. 2012, 134, 1416–1418.
[86] S. Modi, M. G. Swetha, D. Goswami, G. D. Gupta, S. Mayor, Y. Krishnan,
Nat. Nanotechnol. 2009, 4, 325–330.
[87] M. S. Shchepinov, I. A. Udalova, A. J. Bridgman, E. M. Southern, Nucleic
Acids Res. 1997, 25, 4447–4454.
[88] a) M. Scheffler, A. Dorenbeck, S. Jordan, M. Wstefeld, G. von Kiedrow-
ski, Angew. Chem. Int. Ed. 1999, 38, 3311–3315; Angew. Chem. 1999,
111, 3513–3518; b) J. S. Choi, C. W. Kang, K. Jung, J. W. Yang, Y.-G. Kim,
H. Han, J. Am. Chem. Soc. 2004, 126, 8606–8607.
[89] a) K. M. Stewart, L. W. McLaughlin, J. Am. Chem. Soc. 2004, 126, 2050–
2057; b) K. M. Stewart, J. Rojo, L. W. McLaughlin, Angew. Chem. Int. Ed.
2004, 43, 5808–5811; Angew. Chem. 2004, 116, 5932–5935.
[90] a) S. M. Waybright, C. P. Singleton, K. Wachter, C. J. Murphy, U. H. F.
Bunz, J. Am. Chem. Soc. 2001, 123, 1828–1833; b) K. M. Stewart, L. W.
McLaughlin, Chem. Commun. 2003, 2934–2935; c) J. Sharma, Y. Ke, C.
Lin, R. Chhabra, Q. Wang, J. Nangreave, Y. Liu, H. Yan, Angew. Chem.
Int. Ed. 2008, 47, 5157–5159; Angew. Chem. 2008, 120, 5235–5237.
[91] a) T. Maier, S. Jenni, N. Ban, Science 2006, 311, 1258–1262; b) D. N.
Dhanasekaran, K. Kashef, C. M. Lee, H. Xu, E. P. Reddy, Oncogene 2007,
26, 3185–3202; c) S. Raboni, S. Bettati, A. Mozzarelli, Cell. Mol. Life Sci.
2009, 66, 2391–2403.
[92] F. C. Simmel, Curr. Opin. Biotechnol. 2012, 23, 516–521.
[93] C. M. Niemeyer, J. Koehler, C. Wuerdemann, ChemBioChem 2002, 3,
242–245.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1374 – 1390 1388
CHEMBIOCHEM
REVIEWS www.chembiochem.org
159
[94] J. Mller, C. M. Niemeyer, Biochem. Biophys. Res. Commun. 2008, 377,
62–67.
[95] O. I. Wilner, Y. Weizmann, R. Gill, O. Lioubashevski, R. Freeman, I. Will-
ner, Nat. Nanotechnol. 2009, 4, 249–254.
[96] L. Xin, C. Zhou, Z. Yang, D. Liu, Small 2013, 9, 3088–3091.
[97] C. J. Delebecque, A. B. Lindner, P. A. Silver, F. A. Aldaye, Science 2011,
333, 470–474.
[98] a) S. Ko, H. Liu, Y. Chen, C. Mao, Biomacromolecules 2008, 9, 3039–
3043; b) J. Li, H. Pei, B. Zhu, L. Liang, M. Wei, Y. He, N. Chen, D. Li, Q.
Huang, C. Fan, ACS Nano 2011, 5, 8783–8789; c) G. D. Hamblin,
K. M. M Carneiro, J. F. Fakhoury, K. E. Bujold, H. F. Sleiman, J. Am. Chem.
Soc. 2012, 134, 2888–2891.
[99] a) J.-W. Keum, J.-H. Ahn, H. Bermudez, Small 2011, 7, 3529–3535; b) M.
Chang, C.-S. Yang, D.-M. Huang, ACS Nano 2011, 5, 6156–6163; c) H.
Lee, A. K. R. Lytton-Jean, Y. Chen, K. T. Love, A. I. Park, E. D. Karagiannis,
A. Sehgal, W. Querbes, C. S. Zurenko, M. Jayaraman, C. G. Peng, K.
Charisse, A. Borodovsky, M. Manoharan, J. S. Donahoe, J. Truelove, M.
Nahrendorf, R. Langer, D. G. Anderson, Nat. Nanotechnol. 2012, 7,
389–393.
[100] a) C. M. Erben, R. P. Goodman, A. J. Turberfield, Angew. Chem. Int. Ed.
2006, 45, 7414–7417; Angew. Chem. 2006, 118, 7574–7577; b) D.
Bhatia, S. Mehtab, R. Krishnan, S. S. Indi, A. Basu, Y. Krishnan, Angew.
Chem. Int. Ed. 2009, 48, 4134–4137; Angew. Chem. 2009, 121, 4198–
4201.
[101] A. J. M. Wollman, C. Sanchez-Cano, H. M. J. Carstairs, R. A. Cross, A. J.
Turberfield, Nat. Nanotechnol. 2014, 9, 44–47.
[102] J.-W. Keum, H. Bermudez, Chem. Commun. 2009, 7036–7038.
[103] a) S. Helmig, A. Rotaru, D. Arian, L. Kovbasyuk, J. Arnbjerg, P. R. Ogilby,
J. Kjems, A. Mokhir, F. Besenbacher, K. V. Gothelf, ACS Nano 2010, 4,
7475–7480; b) B. Ding, Z. Deng, H. Yan, S. Cabrini, R. N. Zuckermann,
J. Bokor, J. Am. Chem. Soc. 2010, 132, 3248–3249; c) S. Pal, Z. Deng, B.
Ding, H. Yan, Y. Liu, Angew. Chem. Int. Ed. 2010, 49, 2700–2704;
Angew. Chem. 2010, 122, 2760–2764; d) P. K. Dutta, R. Varghese, J.
Nangreave, S. Lin, H. Yan, Y. Liu, J. Am. Chem. Soc. 2011, 133, 11985–
11993; e) R. Schreiber, J. Do, E.-M. Roller, T. Zhang, V. J. Schller, P. C.
Nickels, J. Feldmann, T. Liedl, Nat. Nanotechnol. 2014, 9, 74–78.
[104] a) H. Gu, J. Chao, S. J. Xiao, N. C. Seeman, Nature 2010, 465, 202–205;
b) K. Lund, A. J. Manzo, N. Dabby, N. Michelotti, A. Johnson-Buck, J.
Nangreave, S. Taylor, R. Pei, M. N. Stojanovic, N. G. Walter, E. Winfree,
H. Yan, Nature 2010, 465, 206–210.
[105] a) J. Liu, Y. Geng, E. Pound, S. Gyawali, J. R. Ashton, J. Hickey, A. T.
Woolley, J. N. Harb, ACS Nano 2011, 5, 2240–2247; b) R. J. Kershner,
L. D. Bozano, C. M. Micheel, A. M. Hung, A. R. Fornof, J. N. Cha, C. T.
Rettner, M. Bersani, J. Frommer, P. W. K. Rothemund, G. M. Wallraff, Nat.
Nanotechnol. 2009, 4, 557–561.
[106] J. Sharma, R. Chhabra, C. S. Andersen, K. V. Gothelf, H. Yan, Y. Liu, J.
Am. Chem. Soc. 2008, 130, 7820–7821.
[107] B. Ding, H. Wu, W. Xu, Z. Zhao, Y. Liu, H. Yu, H. Yan, Nano Lett. 2010,
10, 5065–5069.
[108] S. Pal, R. Varghese, Z. Deng, Z. Zhao, A. Kumar, H. Yan, Y. Liu, Angew.
Chem. Int. Ed. 2011, 50, 4176–4179; Angew. Chem. 2011, 123, 4262–
4265.
[109] H. T. Maune, S.-p. Han, R. D. Barish, M. Bockrath, W. A. Goddard III,
P. W. K. Rothemund, E. Winfree, Nat. Nanotechnol. 2010, 5, 61–66.
[110] I. H. Stein, C. Steinhauer, P. Tinnefeld, J. Am. Chem. Soc. 2011, 133,
4193–4195.
[111] a) J. Nangreave, D. Han, Y. Liu, H. Yan, Curr. Opin. Chem. Biol. 2010, 14,
608–615; b) A. Rajendran, M. Endo, H. Sugiyama, Angew. Chem. Int. Ed.
2012, 51, 874–890; Angew. Chem. 2012, 124, 898–915; c) N. Michelotti,
A. Johnson -Buck, A. J. Manzo, N. G. Walter, Wiley Interdiscip. Rev.
Nanomed. Nanobiotechnol. 2012, 4, 139–152; d) G. Zhang, S. P. Sur-
wade, F. Zhou, H. Liu, Chem. Soc. Rev. 2013, 42, 2488–2496.
[112] A. Kuzuya, M. Komiyama, Nanoscale 2010, 2, 310–322.
[113] a) Y. Ke, S. Lindsay, Y. Chang, Y. Liu, H. Yan, Science 2008, 319, 180–
183; b) H. K. K. Subramanian, B. Chakraborty, R. Sha, N. C. Seeman,
Nano Lett. 2011, 11, 910–913.
[114] Z. Zhang, Y. Wang, C. Fan, C. Li, Y. Li, L. Qian, Y. Fu, Y. Shi, J. Hu, L. He,
Adv. Mater. 2010, 22, 2672–2675.
[115] B. Sacc, R. Meyer, M. Erkelenz, K. Kiko, A. Arndt, H. Schroeder, K. S.
Rabe, C. M. Niemeyer, Angew. Chem. Int. Ed. 2010, 49, 9378–9383;
Angew. Chem. 2010, 122, 9568–9573.
[116] S. Rinker, Y. Ke, Y. Liu, R. Chhabra, H. Yan, Nat. Nanotechnol. 2008, 3,
418–422.
[117] J. Fu, M. Liu, Y. Liu, N. W. Woodbury, H. Yan, J. Am. Chem. Soc. 2012,
134, 5516–5519.
[118] a) W. Shen, H. Zhong, D. Neff, M. L. Norton, J. Am. Chem. Soc. 2009,
131, 6660–6661; b) R. P. Goodman, C. M. Erben, J. Malo, W. M. Ho, M. L.
McKee, A. N. Kapanidis, A. J. Turberfield, ChemBioChem 2009, 10,
1551–1557.
[119] A. Kuzuya, M. Kimura, K. Numajiri, N. Koshi, T. Ohnishi, F. Okada, M.
Komiyama, ChemBioChem 2009, 10, 1811–1815.
[120] A. Kuzuya, N. Koshi, M. Kimura, K. Numajiri, T. Yamazaki, T. Ohnishi, F.
Okada, M. Komiyama, Small 2010, 6, 2664–2667.
[121] a) E. Nakata, F. F. Liew, C. Uwatoko, S. Kiyonaka, Y. Mori, Y. Katsuda, M.
Endo, H. Sugiyama, T. Morii, Angew. Chem. Int. Ed. 2012, 51, 2421–
2424; Angew. Chem. 2012, 124, 2471–2474; b) T. A. Ngo, E. Nakata, M.
Saimura, T. Kodaki, T. Morii, Methods 2014, 67, 142–150.
[122] N. V. Voigt, T. Tørring, A. Rotaru, M. F. Jacobsen, J. B. Ravnsbæk, R. Sub-
ramani, W. Mamdouh, J. Kjems, A. Mokhir, F. Besenbacher, K. V. Gothelf,
Nat. Nanotechnol. 2010, 5, 200–203.
[123] I. C. Gray, D. A. Campbell, N. K. Spurr, Hum. Mol. Genet. 2000, 9, 2403–
2408.
[124] I. G. Panyutin, P. Hsieh, Proc. Natl. Acad. Sci. USA 1994, 91, 2021–2025.
[125] R. Jungmann, C. Steinhauer, M. Scheible, A. Kuzyk, P. Tinnefeld, F. C.
Simmel, Nano Lett. 2010, 10, 4756–4761.
[126] Y. Sannohe, M. Endo, Y. Katsuda, K. Hidaka, H. Sugiyama, J. Am. Chem.
Soc. 2010, 132, 16311–16313.
[127] a) I. Smirnov, R. H. Shafer, Biochemistry 2000, 39, 1462–1468; b) B. I.
Kankia, L. A. Marky, J. Am. Chem. Soc. 2001, 123, 10799–10804; c) A.
Avino, C. Fabrega, M. Tintore, R. Eritja, Curr. Pharm. Des. 2012, 18,
2036–2047.
[128] a) J.-L. Mergny, C. Hlne, Nat. Med. 1998, 4, 1366–1367; b) S. Neidle,
G. Parkinson, Nat. Rev. Drug Discovery 2002, 1, 383–393; c) L. H.
Hurley, Nat. Rev. Cancer 2002, 2, 188–200.
[129] R. Subramani, S. Juul, A. Rotaru, F. F. Andersen, K. V. Gothelf, W. Mam-
douh, F. Besenbacher, M. Dong, B. R. Knudsen, ACS Nano 2010, 4,
5969–5977.
[130] M. Endo, Y. Katsuda, K. Hidaka, H. Sugiyama, J. Am. Chem. Soc. 2010,
132, 1592–1597.
[131] M. Endo, Y. Katsuda, K. Hidaka, H. Sugiyama, Angew. Chem. Int. Ed.
2010, 49, 9412–9416; Angew. Chem. 2010, 122, 9602–9606.
[132] Y. Suzuki, M. Endo, Y. Katsuda, K. Ou, K. Hidaka, H. Sugiyama, J. Am.
Chem. Soc. 2014, 136, 211–218.
[133] M. Tintor, I. Gllego, B. Manning, R. Eritja, C. Fbrega, Angew. Chem.
2013, 125, 7901–7904; Angew. Chem. Int. Ed. 2013, 52, 7747–7750.
[134] M. Tintore, A. AviÇ	, F. M. Ruiz, R. Eritja, C. Fbrega, J. Nucleic Acids
2010, 2010, 632041.
[135] J. Zhu, X. Feng, J. Lou, W. Li, S. Li, H. Zhu, L. Yang, A. Zhang, L. He, C.
Li, PloS One 2013, 8, e69856.
[136] A. Gietl, P. Holzmeister, D. Grohmann, P. Tinnefeld, Nucleic Acids Res.
2012, 40, e110.
[137] Q. Mei, X. Wei, F. Su, Y. Liu, C. Youngbull, R. Johnson, S. Lindsay, H. Yan,
D. Meldrum, Nano Lett. 2011, 11, 1477–1482.
[138] X. Shen, Q. Jiang, J. Wang, L. Dai, G. Zou, Z.-G. Wang, W.-Q. Chen, W.
Jiang, B. Ding, Chem. Commun. 2012, 48, 11301–11303.
[139] S. M. Douglas, I. Bachelet, G. M. Church, Science 2012, 335, 831–834.
[140] M. Langecker, V. Arnaut, T. G. Martin, J. List, S. Renner, M. Mayer, H.
Dietz, F. C. Simmel, Science 2012, 338, 932–936.
[141] Q. Jiang, C. Song, J. Nangreave, X. Liu, L. Lin, D. Qiu, Z.-G. Wang, G.
Zou, X. Liang, H. Yan, B. Ding, J. Am. Chem. Soc. 2012, 134, 13396–
13403.
[142] Y.-X. Zhao, A. Shaw, X. Zeng, E. Benson, A. M. Nystrçm, B. Hçgberg,
ACS Nano 2012, 6, 8684–8691.
[143] V. J. Schller, S. Heidegger, N. Sandholzer, P. C. Nickels, N. A. Suhartha,
S. Endres, C. Bourquin, T. Liedl, ACS Nano 2011, 5, 9696–9702.
[144] S. F. J. Wickham, M. Endo, Y. Katsuda, K. Hidaka, J. Bath, H. Sugiyama,
A. J. Turberfield, Nat. Nanotechnol. 2011, 6, 166–169.
[145] N. D. Derr, B. S. Goodman, R. Jungmann, A. E. Leschziner, W. M. Shih,
S. L. Reck-Peterson, Science 2012, 338, 662–665.
[146] E. Torelli, M. Marini, S. Palmano, L. Piantanida, C. Polano, A. Scarpellini,
M. Lazzarino, G. Firrao, Small 2014 ; DOI: 10.1002/smll.201400245.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1374 – 1390 1389
CHEMBIOCHEM
REVIEWS www.chembiochem.org
160
[147] A. Kuzuya, Y. Sakai, T. Yamazaki, Y. Xu, M. Komiyama, Nat. Commun.
2011, 2, 449.
[148] Y. Fu, D. Zeng, J. Chao, Y. Jin, Z. Zhang, H. Liu, D. Li, H. Ma, Q. Huang,
K. V. Gothelf, C. Fan, J. Am. Chem. Soc. 2013, 135, 696–702.
[149] C. Lin, R. Jungmann, A. M. Leifer, C. Li, D. Levner, G. M. Church, W. M.
Shih, P. Yin, Nat. Chem. 2012, 4, 832–839.
[150] R. Jungmann, M. S. Avendano, J. B. Woehrstein, M. Dai, W. M. Shih, P.
Yin, Nat. Methods 2014, 11, 313–318.
Received: February 6, 2014
Published online on June 20, 2014
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1374 – 1390 1390
CHEMBIOCHEM
REVIEWS www.chembiochem.org
161
 162
 
 
 
 
 
 
 
 
 
 
Chapter 4 
A fluorescence biosensor for hAGT activity. 
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 O6-alkylguanine-DNA alkyltransferase (hAGT) activity provides resistance to cancer chemotherapeutic agents and its inhibition enhances chemotherapy. In chapter 4, we present the development of a novel fluorescence assay based on the fluorescence transfer from a duplex oligonucleotide containing a fluorophore-quencher pair to the active site of hAGT, for the detection of its DNA repair activity. For this purpose, we designed a double-stranded DNA sequence containing a fluorophore-quencher pair, where the fluorophore was attached to a synthetic 06-benzylguanine. This precursor was synthetized through a novel route which comprises the use of the Mitsunobu reaction for the introduction of the benzyl group into the O6 position of the guanine. We performed HPLC studies of the repair of this benzylguanine by hAGT, to ensure that this bulky substituent can enter the active site of the protein. The repair activity of hAGT was detected by fluorescence transfer, producing an increase in intensity upon repair of the alkylguanine. This assay can be used for the evaluation of potential inhibitors of hAGT in a straightforward manner and avoiding radioactivity. The compounds described in chapter 1 as possible candidates to inhibid hAGT activity were tested by this methodology and the preliminary results obtained are included as Appendix 4. 
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Abstract: 
 
O6-alkylguanine-DNA alkyltransferase (hAGT) activity provides resistance to cancer 
chemotherapeutic agents and its inhibition enhances chemotherapy. We herein 
present the development of a novel fluorescence assay based on a duplex 
oligonucleotide containing a fluorophore-quencher pair for the detection of the DNA 
repair activity of hAGT. This assay can be used for the evaluation of potential 
inhibitors of hAGT in a straightforward manner and avoiding radioactivity. 
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 1. Introduction 
Alkylating agents are chemotherapeutic anticancer drugs that produce their cytotoxic 
effect by generating adducts at multiple sites in DNA.[1] The most relevant adduct in 
terms of mutagenesis and carcinogenesis is the alkylation of the O6 position of 
guanines.[2] In particular, the alkylating agent 1,3-bis-(2-chloroethyl)-1-nitrosourea 
(BCNU) initially attacks at the O6 guanine position, causing its cross-link with the 
opposite cytosine, blocking DNA replication and producing G2/M arrest.[3] In addition to 
the well-known side effects and limitations of chemotherapeutic agents, these 
substances also show acquired tumour resistance problems. The DNA-repair protein 
human O6-alkylguanine DNA alkyltransferase(hAGT or MGMT) is responsible for 
removing alkyl adducts from the O6 position of guanines, thereby blocking the cytotoxic 
effects of the alkylating agents and making a crucial contribution to the resistance 
mechanism.[4] It is well established that tumoral cells show greater expression of this 
protein, which explains their low sensitivity to chemotherapeutic drugs in a large number 
of cancers.[5] On the contrary, the promoter methylation of hAGT has been associated 
with patients’ longer survival.[6] Therefore, pharmacological inhibition of hAGT has the 
potential to enhance the cytotoxicity of a diverse range of anticancer agents.[7] 
hAGT is a DNA-binding protein that contains a highly conserved internal 
cysteine, which acts as the acceptor site for alkyl groups. It behaves like a suicidal 
non-enzyme, inactivating itself since the S-alkylcysteine formed is not regenerated.[8] 
For this reason, intense research effort has been devoted to the identification of small 
molecules capable of inhibiting hAGT activity and significantly enhancing the cytotoxic 
effect of BCNU in prostate, breast, colon and lung tumour cells.[7] 
Given the potential relevance of hAGT as a prognostic marker of cancer and 
as a therapeutic target, several methods are available to characterize its activity. 
Moreover, they are also able to evaluate the capacity of small molecules for inhibiting 
hAGT. Most of these methods involve radioactivity assays, while others are based on 
multiple-step enzymatic reactions.[9] However, the first methods require the use of 
rigorous safety procedures and the others are discontinuous and time-consuming due 
to the necessity of multiple steps. Recently, two methods based on the conformational 
change of an intramolecular G-quadruplex were developed by our group.[10] 
In this paper we describe the development of a one-step FRET assay which 
improves the efficiency of our previous methods because it increases the repair rate 
of hAGT by using double-stranded DNA, the natural substrate of the protein. In 
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addition, the detection of a fluorescence increase that is proportional to the repair rate 
of hAGT represents a low-cost, straightforward and rapid method. 
For this purpose, we designed a double-stranded DNA sequence containing a 
fluorophore-quencher pair (Scheme 1). The fluorophore was post-synthetically and 
covalently attached to a modified O6-benzylguanine (FdG) and the quencher was 
introduced in a very close position of the complementary strand of the duplex (QdT-
complementary or QdT-missmatch), blocking the fluorescence. The fluorophore was 
transferred together with the benzyl group to hAGT’s active site when the protein 
repaired the DNA, restoring the guanine. The removal of the fluorophore brought it 
apart from the quencher, producing a significant increase in fluorescence which 
allowed to measure the repair reaction of hAGT. 
 
 
Scheme 1. A. Chemical structure of the O6-benzylguanine with the fluorophore covalently 
attached to the alkyl group. B. Chemical structure of the quencher group (Dabcyl), covalently 
attached to a thymidine. C. Schematic representation of the fluorescence assay. 1). Annealing 
of the two strands containing a fluorophore and a quencher group, with the correspondent 
extinction of fluorescence. 2). hAGT repair activity over the benzylguanine, dragging the 
fluorescein group and significantly increasing fluorescence. 
 
 
2. Results and Discussion 
The AdG oligonucleotide was prepared using the appropriate modified guanosine 
phosphoramidite (7) in the automated DNA synthesizer using standard protocols[11].  
Derivative 7 was prepared from 2’-deoxyguanosine and the protected 4- trifluoroacetyl-
aminomethylbenzyl alcohol (1) (Scheme 2A). Its incorporation at the O6 position of the 
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guanine was performed through a Mitsunobu reaction. The guanine amino function was 
protected with dimethylaminomethyliden protecting group. Finally, the protection and 
functionalization of the two hydroxyl groups were carried out under standard conditions. 
 
Scheme 2. A) Chemical synthesis of the O6-benzyl-2’-deoxyguanosine phosphoramidite. a) TEA, 
EtTFA in DCM, 0ºC to r.t. o/n b) Ac2O, DMAP, TEA in DMF, r.t. 4h; c) Compound 1, PPh3, DEAD 
in Dioxane, r.t. o/n: d) MeOH:NH3 (1:1), 55ºC 4h; e) (CH3O)2CH-N(CH3)2 in DMF; f) DMT-Cl, 
DIEA in Pyr, r.t. o/n; g) DIEA, CNEOP(Cl)N(iPr)2 in DCM, r.t.  
 
The benzylguanine-containing oligonucleotide and its complementary strands 
with a quencher group (dabcyl, Q) either at the complementary position or at one 
nucleotide shift were synthesized, purified by HPLC and characterised by MALDI-TOF 
(see Supplementary Data). Subsequently, the fluorescein label (F) was attached to the 
O6- benzylguanosine amino group through a fluorescein isothiocyanate (FITC) 
reaction.[12] The DNA duplexes, one complementary and the other containing a 
mismatch due to the positioning of the T-quencher fosforamidite pairing with the 
modified FG, were prepared from the fluorophore-quencher pair of oligonucleotides 
under proper annealing conditions (Table 1). We explored to different positions of the 
quencher group in the complementary sequences to ensure the maximal quenching of 
fluorescence and to minimize steric effects and complementary discrepancies. In the first 
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duplex, the placement of the quencher in the complementary base of the modified 
guanosine provokes a mismatch in the sequence (G:T) instead of a (G:C) pair due to the 
fact that there is no commercially available cytidine covalently modified with the dabcyl 
group and the use of a thymidine was required. The second duplex contains the 
quencher group at one nucleotide shift with respect to the benzylguanine in the 
complementary sequence avoiding the introduction of a mismatch and expecting that the 
fluorescence extinction would remain efficient. 
 
Name Sequence 
Oligo-FdG: Complementary-QT 5’-ATC TTC TC FGATT CA-3’ 
3’-TAG AAG AGCQTAA GT-5’ 
Oligo-FdG:Mismatch-QT 5’-ATC TTC TC FGATT CA-3’  
3’-TAG AAC AGQTTAA GT-5’ 
Table 1. Sequences of the two different duplexes used in this work. 
First, to see the possible effect of this two bulky groups in the duplex formation, 
their thermal stability was studied at 260 and 485 nm and compared to each other (see 
Table S2 at Supplementary Data, SD). In general, we observed destabilization of the 
duplex at 260 nm in the presence of the bulky substituent in the O6 position of the central 
guanine, compared to the controls. However, both duplexes are stable at 30ºC. CD 
spectra of the two duplexes were recorded, showing that both structures formed a 
duplex at 25ºC (See Figure S1, SD). In order to be able to use these two duplexes in a 
fluorescence-quenching assay, we studied how the stability of the duplexes affects the 
emission of fluorescence by monitoring the emitted fluorescence at excitation 
wavelength of 485 nm (See Figure S2, SD). Significant differences in the melting 
temperature were observed due to the release effect of the quencher and a great 
increase in the fluorescent signal was detected. In the case of the mismatched 
sequence, this increase in fluorescence is produced at 26 ºC while in the fully 
complementary duplex, the quencher effect persisted until 53 ºC, allowing us to use it at 
the enzymatic temperature range for hAGT activity. 
Efficient reaction with hAGT requires the FG modification to correctly 
accommodate in the active site. This brings the CH2 which is attached at the O6 position 
in closer proximity to the thyolated ion Cys145, making the reaction possible. For this 
reason, we performed a study on the hAGT dealkylation activity over the F-benzyl 
modified double-stranded substrates. The reaction was followed by HPLC. This study 
171
was performed in the absence and presence of the quencher in the complementary 
strand. 
Figure 1. HPLC profile of the repair reaction of the FdG double stranded sequence in the absence 
of the quencher group in the complementary strand. The HPLC analysis was performed 37 ºC. 
 
For this purpose, the full-length hAGT was over-expressed and purified as 
previously described.[10a, 13] Increasing concentrations of the protein were incubated with 
the double-stranded FdG sequence for 90 min at 30ºC and analyzed using HPLC. Figure 
1 shows one of the HPLC profiles of the reaction’s final products of hAGT at 37ºC. The 
appearance of a peak with a shorter retention time corresponds to the repaired 
sequence, formed by the removal of the F-benzyl group. Our results confirmed that 
hAGT has the capacity to accommodate bulky groups, including a fluorophore, in the 
active site without upsetting its repair activity. 
We then tested the effectiveness of our proposed fluorescence method to 
evaluate the repair activity of hAGT. We performed the hAGT reaction using a 10 nM 
concentration of the fluorescently-dabcyl labelled duplex for 20 min, using different 
hAGT concentrations. We determined 10 nM to be the minimum amount of double-
stranded DNA required to achieve a detectable and reliable difference in intensity 
compared to the background. As expected, the fluorophore-quencher pair gave low 
background fluorescence, because of the quenching effect produced by the proximity of 
these two groups in the base paired sequence. The presence of hAGT produced a 
remarkable increase in fluorescence intensity caused by the transfer of the F-benzyl 
group to its active site, throwing it apart from the quencher. The increase rate in 
fluorescence intensity correlated directly with the amount of hAGT in the reaction mixture 
(Figure 2). Moreover, the inactive mutant hAGT-C145S did not exhibit any decrease in 
fluorescence due to its inability to repair the alkylated DNA (see SD).  
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 Figure 2. hAGT activity assay. A) Increase of fluorescence with respect to the background 
fluorescence of the oligonucleotide during 20 minutes. B) Total increase of fluorescence after 20 
minutes of reaction with different concentrations of hAGT.  
 
In view of all these observations, we corroborated that our initial hypothesis and 
design of the new FRET methodology is consistent. 
 
3. Conclusions 
In summary, we have described a novel route for the synthesis of a O6-benzyl-2’-
deoxyguanosine precursor which incorporated to an oligonucleotide sequence, can 
become a fluorescently labelled substrate for measuring hAGT repair activity. Annealing 
with a complementary quencher strand produces a duplex with low basal fluorescence.  
Using this labelled oligonucleotide, we have developed a new assay for 
quantifying the DNA repair protein hAGT activity and identifying potential inhibitors as 
chemotherapy enhancers. The novelty of this method compared to existing ones is the 
single-step and real-time measurement of the reaction, representing a rapid and 
straightforward method that reduces cost, time and effort. In contrast with our previous 
developed methods to quantify hAGT activity,[10] this system uses a double-stranded 
oligonucleotide, which is the natural substrate for the hAGT activity, improving efficiency 
and reliability due to its easy quantification of the fluorescence increase upon activity. 
We believe that this new method will facilitate the search for new and more potent 
inhibitors which enhance the effect of chemotherapeutic drugs. 
This methodology could be implemented for the study of hAGT dealkylation in 
cell culture and in animal models, through the transfection of fluorescent 
oligonucleotides and visualization of the increase in fluorescence using confocal 
microscopy. However, the thermal stability of the oligonucleotides should be improved to 
ensure their stability at physiological temperature. Work in this direction is currently 
underway. 
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Experimental data: 
Derivative 7 was prepared from 5´,3´-diaceyl-2’-deoxyguanosine and 4-
aminomethylbenzyl alcohol (1.2 eq), previously protected with a trifluoroacetyl group via 
a Mitsunobu reaction in the presence of diethyl azodicarboxylate (3 eq.) and 
triphenylphosphine (3 eq.). Then, the guanine amino function was protected with the 
dimethylaminomethyliden protecting group. Finally, the protection and functionalization 
of the two hydroxyl groups for the DNA synthesis were carried out under standard 
conditions. See SD for further information. 
The oligonucleotide sequences were synthesized using standard protocols and 
purified by reversed-phase HPLC. The incorporation of the O6-(N-4-
((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-deoxyguanosinephosphoramidite (AdG) 
in the sequence was carried out manually with a coupling time of 15 min, obtaining a 
yield of 75%. The length and homogeneity of the oligonucleotide were verified by 
MALDI-TOF (Table 1, SD). The 5’-ATCTTCTCAGATTCA-3’ oligonucleotide was left to 
react post-synthetically with fluorescein isothiocyanate (FITC) through its free amino 
group. The coupling efficiency was determined by HPLC analysis. See SD for further 
details. 
Melting curves of all the possible pairs of complementary oligonucleotides were 
measured by monitoring the absorbance hyperchromicity at 260 nm, heating the sample 
over the range 10-80 ºC. 4 µM of the duplexs in 10 mM sodium phosphate pH 7.0 and 
100 mM NaCl. The CD spectra of all the possible pairs of complementary 
oligonucleotides were registered at 25ºC over a range of 220–320 nm using the same 
concentrations and buffer as for the melting temperature experiments. See SD for more 
detailed information. 
HPLC proof of concept of the dealkylation ofAdG was performed by incubating the 
duplexes with FL hAGT 90 minutes at 30ºC and analyzing by HPLCon a Nucleosil 
analytical column at 37ºCwith a gradient of 10–40% acetonitrile in 20 min. See SD for 
more detailed information. 
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The fluorescence assay was performed incubating increasing concentrations of 
hAGT (50, 100 and 200 nM) with the fluorophore-quencher duplex substrate (10 nM). 
Fluorescence was measured during 20 min at excitation and emission wavelengths of 
485 and 535 nm, respectively. Averages over three readings were taken for each 
condition tested. Each experiment was performed in triplicates. 
All the experimental procedures are further detailedin the Supplementary Data. 
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1. Material and methods 
1.1 Abbreviations: 
Ac: acetyl, Ac2O: acetic anhydride, ACN: acetonitrile, AcOEt: ethyl acetate, anh: 
anhydrous, Ar: aromatic, BCNU: bis-chloroethylnitrosourea, Bz: benzyl, Bzl: benzoyl, 
CPG: controlled pore glass, Dabcyl: dimethylamino-azobenzoic acid, DCM: 
dichloromethane, DEAD: diethyl azodicarboxylate, DIEA: N,N-diisopropylethylamine, 
DMAP: N,N-dimethylaminopyridine, DMF: N,N-dimethylformamide, dmf: 
dimethylaminomethylidene, DMT: 4,4’-dimethoxytrityl, DMT-Cl: 4,4’-dimethoxytrityl 
chloride, DMSO: dimethylsulfoxide, DTT: dithiothreitol, EtTFA: ethyl trifluoroacetate, F: 
fluorescein, FG: fluorescein-benzylguanosine, FITC: Fluorescein isothiocyanate, FRET: 
fluorescence resonance energy transfer, hAGT: human O6-alkylguanine-DNA 
alkyltransferase, LCAA: long chain amino alkyl, MALDI: matrix-assisted laser 
disorption/ionization, MeOH: methanol, PPh3: triphenylphosphine, Pyr: pyridine, QT: (N-
4'-carboxy-4-(dimethylamino)-azobenzene)-aminohexyl-3-acrylamido]-2'-deoxyuridine, 
RP-HPLC: reverse phase high pressure liquid chromatography, TCA: trichloroacetic 
acid, TEA: triethylamine, TEAA: triethylammonium acetate, THAP: 
trihydroxyacetophenone monohydrate, THF: tetrahydrofurane, TLC: thin-layer 
chromatography, TOF: time of flight, UV: ultraviolet. 
1.2 Chemicals 
Reagents for oligonucleotide synthesis including phosphoramidite monomers of dABzl, 
dCBzl, dGdmf and T, the 5’-deblocking solution (3% TCA in DCM), activator solution (0.4 
M 1H-tetrazole in ACN), CAP A solution (Ac2O /Pyr/THF), oxidizing solution (0.02 M 
iodine in THF/Pyr/water (7:2:1), supports and LCAA-CPG were purchased from Applied 
Biosystems (PEBiosystems Hispania S.A., Spain) and Link Technologies 
Ltd.(Scotland) and used as received. Sephadex G-25 (NAP-10) columns were 
purchased from GE Healtcare, USA. The 96-well Optical reaction plates were 
purchased to Nunc, USA. HiTrapTM FF column were purchased at GE Healthcare. 
FITC (isomer I) and the rest of chemicals were purchased from Aldrich, Sigma, or 
Fluka (Sigma-Aldrich Quimica S.A., Spain), and used without further purification. 
Anhydrous solvents and deuterated solvents (CDCl3, CD3OD and DMSO-d6) were 
obtained from reputable sources and used as received. Thin-layer chromatography 
(TLC) was carried out on aluminium-backed Silica-Gel 60 F254 plates. Column 
chromatography was performed using Silica Gel (60 Å, 230 x 400 mesh).  
1.3 Instrumentation 
Oligonucleotide sequences were synthesized on an Applied Biosystems 3400 DNA 
Synthesizer (Applied Biosystems, USA). RP-HPLC purifications were performed on a 
Waters chromatography system using Nucleosil semi-preparative 120 C18 (250x4 mm) 
columns. Analytical RP-HPLC was performed using a XBridge OST C18 2.5 μm 
column and a Nucleosil Analytical column 120 C18 (250x4mm). Oligonucleotides were 
quantified by UV absorption at 260 nm with a Jasco V650 spectrophotometer. Mass 
spectra were recorded on a MALDI Perseptive Voyager DETM RP time-of-flight (TOF) 
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spectrometer (Applied Biosystems, USA) equipped with nitrogen laser at 337 nm using 
a 3ns pulse. The matrix used contained 2,4,6-trihydroxyacetophenone (THAP, 10 
mg/mL in ACN/ water 1:1) and ammonium citrate (50 mg/mL in water). NMR spectra 
were measured on Varian Mercury-400. Chemical shifts are given in parts per million 
(ppm); J values are given in hertzs (Hz). All spectra were internally referenced to the 
appropriate residual undeuterated solvent. 
UV analyses were performed using a Jasco V-650 instrument equipped with a 
thermoregulated cell holder. Set temperature was controlled with an 89090A Agilent 
Peltier device and Hellma quartz cuvettes were used (1000 μL volume). CD spectra 
were recorded on a CD on a JASCO spectropolarimeter J-810. Fluorometric 
measurements were performed on a spectrofluorometer Jasco FP6200 at 25ºC and 
with a Multi-Detection Microplate Reader SpectraMax M5 (Molecular devices BioNova 
cientifica, Sunnyvale, USA).  
2. Chemical synthesis of the 6-benzyl-2’-deoxiguanosine phosphoramidite 
precursor 
2.1. Preparation of N-(4-(hydroxymethyl)benzyl)-trifluoroacetamide (1) 
4-aminomethylbenzylalcohol (500 mg, 2.89 mmol) was dissolved in 3 ml DCM. TEA 
(3.0 eq, 1.169 µl, 8.4 mmol) was added dropwise and kept under argon atmosphere. 
Afterwards, 400 µl (1.2 eq, 3.36 mmol) of EtTFA were added dropwise and the mixture 
was stirred in argon atmosphere at room temperature for 4 hr. The reaction was 
followed up by TLC (DCM:MeOH 5%). The reaction mixture dissolved in DCM and was 
washed with brine and the organic phase dried with MgSO4. The organic phase was 
filtered and evaporated. The crude of the reaction was purified by chromatography 
(silica gel), eluted with a gradient of 0-5% MeOH in DCM. Yield (1, 500 mg, 76%). TLC 
Rf=0.36 (DCM:MeOH 95:5), MS (EI 70 eV) m/z calcd for C10H14F3N2O2 (M+ + NH4+) 
251.1002 found 251.1002. 
1H-NMR (400 MHz, CDCl3) δ [ppm] 4.52 (d, 2H J=5.8 Hz, Bz-CH2NH), 4.70 (s, 2H, Bz-
CH2O), 6.5 (s, 1H, OH), 7.25 (d, 2H J = 8 Hz, Bz-Harom), 7.37 (d, 2H J = 8 Hz, Bz-Harom). 
13C NMR (100 MHz, CDCl3) δ [ppm] 43.64 (Bz-CH2NH), 64.79 (Bz-CH2O), 115.70 (q, 
J = 287.9 Hz, CF3), 127.55 (2Carom), 128.18 (2Carom), 135.16 (Cq-arom), 141.0 (Cq-arom), 
157.09 (q, J = 157.19 Hz, COCF3). 
19F NMR (376 MHz, CDCl3) δ [ppm] -75.84 (COCF3).  
2.2. Preparation of 3’,5’-O-diacetyl-2’-deoxyguanosine (2) 
2’-Deoxyguanosine (1 g, 3.78 mmols, 1 eq.) was dried by coevaporation with 
anhydrous DMF and dissolved in 20 ml of anhydrous DMF. Then, 90 mg of DMAP 
(0.74 mmols, 0.2 eq.) were dissolved in 2 ml of anhydrous DMF and added dropwise. 
Next, 2.6 mL of TEA (18.5 mmols, 5.0 eq.) and 1.05 ml of Ac2O (11.1 mmols, 3.0 eq.) 
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were added and the mixture dissolved completely. The solution was left to react for 4 
hours at r.t. Afterwards cold DCM was added to precipitate the desired compound. The 
mixture was vacuum-filtered and the desired compound dried. Yield (2, 1.1 g, 91.6%). 
MS (EI 70 eV) m/z calcd for C14H18N5O6 (M+ + H+) 352.12 found 352.12 
1H-NMR (400 MHz, MeOD) δ [ppm] 1.93 (s, 3H, CH3O), 2.01 (s, 3H, CH3O), 2.47 (m, 1 
H, 2’), 2.91 (m, 1H, 2’’), 4.2 (m, 1 H, 4’), 4.26 (m, 2H, 5’, 5’’), 5.34 (m, 1H, 3’), 6.15 (m, 
1H, 1’), 7.76 (s, 1H, 8). 
2.3. Preparation of O6-(N-4-((hydroxymethyl)benzyl)-trifluoroacetylmide)-3’,5’-O-
diacetyl-2’-deoxyguanosine (3) 
3’,5’-O-diacetyl-deoxyguanosine (2, 620 mg, 1.79 mmol) was dried 3 times by 
evaporation of DMF. PPh3 (1.42 g; 5.4 mmol, 3 eq) and the protected phenol (1, 500 
mg, 2.15 mmol, 1,2 eq) was added and left under vacuum for 2 h. Then, the mixture 
was dissolved in anhydrous dioxane (10.0 ml) and maintained under an argon 
atmosphere. Finally, DEAD (860 µl; 5.4 mmol 3 eq) was added dropwise. The reaction 
mixture was stirred for 4 hours at room temperature and the progress of the reaction 
was monitored by TLC (DCM:MeOH 9:1). The orange reaction was concentrated in 
vacuum to obtain a viscous oil. The oil was purified by flash chromatography using a 
gradient of MeOH in DCM to yield a white product (750 mg, 75%). TLC R f=0.42 
(DCM:MeOH 9:1), MS (EI 70 eV) m/z calcd for C24H26F3N6O7 (M+ + H+) 567.18 found 
567.181 [M+]. 
1H-NMR (400 MHz, CDCl3) δ [ppm] 2.08 (s, 3H, CH3CO), 2.12 (s, 3H, CH3CO), 2.52 
(m, 1H, 2’), 2.98 (m, 1H, 2’’), 4.33 (m, 2H, 5’,5’’), 4.52 (m, 1H, 4’), 4.90 (s, 2H, Bz-
CH2NH), 5.43 (m, 1H, 3’), 5.55 (s, 2H, Bz-CH2O), 6.28 (dd, 1H, J = 8 Hz, 1’), 7.27 (d, 
2H, J = 8 Hz, Bz-Harom), 7.49 (d, 2H, J = 8 Hz, Bz-Harom), 7.74 (s, 1H, 8). 
13C NMR (100 MHz, CDCl3) δ [ppm] 20.76 (CH3CO), 20.93(CH3CO), 36.69 (C-2’), 
43.60 (Bz-CH2NH), 63.79 (C-5’), 67.51 (Bz-CH2O), 74.61 (C-3’), 82.30 (C-1’), 84.44 (C-
4’), 115.85 (q, J = 287 Hz, CF3), 116.11 (C-5), 128.06 (2Carom), 128.77 (2Carom), 135.74 
(C-8), 136.49 (Cq-arom), 137.56 (Cq-arom), 153.53 (C-4), 156.63-157.74 (q, J = 37 Hz 
COCF3), 159.15 (C-2), 160.87 (C-6), 170.27 (CO), 170.61 (CO). 
19F NMR (376 MHz, CDCl3) δ [ppm] -75.76 (COCF3). 
2.4. Preparation of the deprotected O6-(N-4-((hydroxymethyl)benzyl)-trifluoro-
acetylmide)-2’-deoxyguanosine (4) 
Compound (3) was dissolved in 3 ml of MeOH and transferred to a polypropylene 
conical tube (50 ml) with a stirring bar. Ammonium hydroxide (20%) 3 mL was added 
and the mixture was stirred during 2 hours. The reaction was followed up by TLC. The 
solvent was evaporated and the crude was purified by flash chromatography 
(DCM:MeOH 95:5 to 90:10), yielding the expected compound 5 (112 mg, 46 %). TLC 
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Rf=0.18 (DCM:MeOH 95:5), MS (EI 70 eV) m/z calcd for C20H22F3N6O5 (M+ + H+) 
483.1598 found 483.1599 [M+]. 
1H-NMR (400 MHz, MeOD) δ [ppm] 2.31 (m, 1H, 2’), 2.75 (m, 1H, 2’’), 3.73 (dd J = 12 
Hz, J = 3, 1H, 5’), 3.83 (dd J = 12 Hz, J = 3, 1H 5’’), 4.03 (m, 1H, 4’), 4. 43 (s, 2H, Bz-
CH2NH2), 4.54 (m, 1H, 3’), 5.48 (s, 2H, Bz-CH2O), 6.28 (dd, 1H J = 8 Hz, J = 6 Hz, 1’), 
7.27 (d, 2H J = 8 Hz, Bz-Harom), 7.45 (d, 2H J = 8 Hz, Bz-Harom), 8.01 (s, 1H, 8). 
13C NMR (100 MHz, MeOD) δ [ppm] 39.73 (C-2’), 42.58 (Bz-CH2NH), 62.32 (C-5’), 
67.25 (Bz-CH2O), 71.73 (C-3’), 85.39 (C-1’), 88.24 (C-4’), 114.55 (C-5), 116.049 (q J = 
286.7 Hz, CF3), 127.4 (2Carom), 128.31 (2Carom), 135.91 (C-8), 137.01 (Cq-arom), 138.65 
(Cq-arom), 152.87 (C-4), 157.54 (q, J = 37 Hz COCF3), 159.9 (C-2), 160.66 (C-6). 
19F-NMR (376 MHz, MeOD): δ [ppm] -77.20 (CF3) 
2.5. Preparation of the N2-(N’,N’-dimethylamino)methylen)-O6-(N-4-
((hydroxymethyl)-benzyl)-trifluoroacetylamide)-2’-deoxyguanosine (5) 
The product (4, 0.23 mmol) was dried by evaporation with anhydrous DMF and 
dissolved in 2 ml of DMF under argon. Dmf protecting group 125 μL (4 eq, 0.93 mmol) 
was added and the mixture was stirred during 4 hours. The reaction was followed by 
TLC. The solvent was evaporated and crude was purified by flash chromatography 
over silica gel yielding the expected compound 5 (112 mg, 46 %). TLC Rf=0.28 
(DCM:MeOH 90:10), MS (EI 70 eV) m/z for C23H27F3N7O5 (M+ + H+) 538.202 found 
538.2017 [M+]. 
1H-NMR (400 MHz, MeOD) δ [ppm] 2.39 (m, 1H, 2’), 2.76 (m, 1H, 2’’), 3.08 (s, 3H, 
N(CH3)2), 3.14 (s, 3H, N(CH3)2), 3.73 (dd J = 12 Hz, J = 3, 1H, 5’), 3,79 (dd J = 12 Hz, J 
= 3, 1H 5’’), 4.01 (m, 1H, 4’), 4.43 (s, 2H, Bz-CH2NH), 4.56 (m, 1H, 3’), 5.57 (s, 2H, Bz-
CH2O), 6.41 (dd, 1H J = 8 Hz, J = 6 Hz, 1’), 7.29 (d, 2H J = 8 Hz, Bz-Harom), 7.48 (d, 2H 
J = 8 Hz, Bz-Harom), 8.24 (s, 1H, 8), 8.65 (s, 1H, CH=N). 
13C NMR (100 MHz, MeOD) δ [ppm] 34.58 (C-2’), 40.62, 40.73 (2C, N(CH3)2), 43.14 
(Bz-CH2NH2), 62.54 (C-5’), 68.02 (Bz-CH2O), 71.88 (C-3’), 85.38 (C-1’), 88.63 (C-4’), 
116.77 (q J = 286.7 Hz, CF3), 117.60 (C-5), 128.01 (2Carom), 128.56 (2Carom), 136.77 
(C-8), 137.57 (Cq-arom), 140.62 (Cq-arom), 153.42 (C-4), 158.94 (q, J = 37 Hz COCF3), 
159.6 (C-2), 160.41 (C-6), 162.60 (CH=N). 
19F-NMR (376 MHz, MeOD): δ [ppm] -77.16 (CF3). 
2.6. Preparation of 5’-O-(4,4’-dimetoxytrityl)-[N2-(N,N’-dimethylamino)-O6-(N-4-
((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-deoxyguanosine (6) 
A solution of (90 mg, 167 µmols) of product (5) was dried three times with anhydrous 
pyridine (3  5 mL) and finally dissolved in anh. pyr (4 ml) and placed under argon. 
Then, 125 mg (1.4 eq, 0.32 mmols) of DMT-Cl and 14 mg (0.5 eq, 0.115 mmols) of 
DMAP were added. The reaction was stirred under argon over night at room 
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temperature and protected from the light. The product formation was followed up by 
TLC. Then, the reaction was quenched with 1 ml of MeOH and the solvent was 
evaporated. The crude product was purified by flash chromatography over silica gel 
(DCM 100%, DCM:MeOH 1-10% + 2% Et3N) to give 117 mg (83%) of compound 6. 
TLC Rf=0.68 (DCM:MeOH 95:5). 
1H-NMR (400 MHz, CDCl3) δ [ppm] 2.49 (m, 1H, 2’), 2.65 (m, 1H, 2’’), 2.92 (s, 6H, 
N(CH3)2), 3,41 (m, 2H, 5’ 5’’), 3.66 (s, 6H, DMT-O-CH3), 4.14 (m, 1H, 4’), 4.40 (s, 2H, 
Bz-CH2NH), 4.58 (m, 1H, 3’), 5.44 (s, 2H, Bz-CH2O), 6.33 (t, 1H J = 6 Hz, 1’), 6.66 (d, 
2H J = 8 Hz, DMT-Harom), 6.68 (d, 2H J = 8 Hz, DMT-Harom), 7.06-7.34 (m, 13H DMT-
Harom, Bz-Harom), 7.87 (s, 1H, 8), 9.32 (s, 1H, N=CH). 
19F-NMR (376 MHz, CDCl3): δ [ppm] -75.56 (CF3). 
2.7. Preparation of 5’-O-(4,4’-dimetoxytrityl)-[N2-(N,N’-dimethylamino)-O6-(N-4-
((hydroxymethyl)benzyl)-trifluoroacetylmide)-2’-deoxyguanosine-3’-O-(N,N-
diisopropyl-2-cyanoethyl phosphoramidite (7) 
A solution of product (6) (117 mg, 136 µmols) was dissolved in anhydrous CH2Cl2 
under argon and at 0ºC. Then, DIPEA (95 μL, 540 µmol, 4 eq) and 2-cyanoethyl 
diisopropylphosphoramidochloridite (50 μL, 204 µmol) were added. After 15 min the 
reaction was allowed to reach r.t and stirred for 1 hour. The reaction was quenched 
with brine, extracted with CH2Cl2, dried (MgSO4) and concentrated. The residue was 
used directly without further purification for oligonucleotide synthesis. TLC Rf=0.68 
(hexane/EtOAc 20:70 + + 2% Et3N). 
 
1H-NMR (400 MHz, CDC3) δ [ppm] 1.25 (s, 6H, NCH(CH3)2), 1.26 (s, 6H, NCH(CH3)2), 
2.50 (m, 1H, 2’), 2.65 (m, 3H, 2’’, CH2CN), 2.92 (s, 6H, N(CH3)2), 3.24 (m, 2H, 5’ 5’’), 
3.41 (m, 4H, CH2CH2OP, NCH(CH3)2), 3.66 (s, 6H, DMT-O-CH3), 4.14 (m, 1H, 4’), 4.42 
(s, 2H, Bz-CH2NH), 4.58 (m, 1H, 3’), 5.54 (s, 2H, Bz-CH2O), 6.33 (t, 1H J = 6 Hz, 1’), 
6.65 (dd, 4H J = 7 Hz, DMT-Harom), 7.06-7.34 (m, 13H DMT-Harom, Bz-Harom), 7.87 (s, 
1H, 8), 9.32 (s, 1H, CH=N). 
13C NMR (100 MHz, MeOD) δ [ppm] 20.45 (CH2CN), 24.47, 24.52, 24.54, 24.59 (4C, P-
NCH(CH3)2), 39.28 (C-2’), 43.18 (2C, N(CH3)2), 43.31 (2C, C(CH3)2), 43.55 (Bz-
CH2NH2), 55.16 (2C, DMT-OCH3), 57.94 (CH2CH2OP), 63.48 (C-5’), 68.31 (Bz-CH2O), 
74.38 (C-3’), 84.59 (C-1’), 85.80 (C-4’), 86.43 (DMT-Cq), 113.11 (4C, DMT-C3), 117.46 
(CF3), 117.69 (CN), 119.15 (C-5), 127.28 (2C, Carom), 128.05 (2C, Carom), 128.18, 
128.72, 129.93, 129.95 (9C, DMT-C3-arom), 135.05 (2C, DMT-Cq-arom), 135.56 (Bz-Cq-
arom), 135.97 (C-8), 140.12 (Bz-CqArom), 140.70 (DMT-CqArom), 151.45 (2C, DMT-CqArom), 
152.50 (C-4), 158.47 (2C, COCF3, C-2), 160.57 (C-6), 162.56 (N=CH). 
19F-NMR (376 MHz, CDCl3): δ [ppm] -75.56 (CF3). 
31P-NMR (161 MHz, CDCl3): δ [ppm] 148.83. 
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3. Synthesis and purification of oligonucleotides 
3.1. Oligonucleotide synthesis 
The oligonucleotide sequences were synthesized at 1 µmol scale using the standard 
protocols (Table 1). The incorporation of the O6-(N-4-((hydroxymethyl)benzyl)-
trifluoroacetylmide)-2’-deoxyguanosinephosphoramidite (AdG) in the sequence was 
carried out manually with a coupling time of 15 min, obtaining a yield of 75%. The 
incorporation of the QT-nucleobases to the complementary sequences was 
automatically performed on the synthesizer. In all the syntheses we used 
dimethylformamidino-protected guanine phosphoramidite (7). The syntheses were 
completed using the DMT-OFF protocol, except for the sequence containing AdG, 
which was synthesized in DMT-ON mode to help purification. 
3.2. Oligonucleotides deprotection and purification.  
After oligonucleotide synthesis, the solid supports were transferred to screw-cap vials 
and incubated with a solution of concentrated aqueous ammonia overnight at room 
temperature, and additional 15 min incubation at 55ºC were needed for the sequence 
containing BzG. The solutions were then filtered using sterile cotton and transferred into 
a 2 mL eppendorf tube. The solutions were evaporated using a nitrogen system to 
remove the ammonium. The resulting products were desalted by Sephadex G-25 using 
water as eluent.  
The sequence containing BzG was purified by reversed-phase HPLC using the DMT-
ON protocol in a Nucleosil 120 10-C18 10 µm (250x8 mm) column with a flow rate of 3 
mL/min and an increasing gradient of ACN (15% to 80%) over 0.1 M aqueous TEAA 
pH 6.5, during 20 minutes. The retention time for the oligonucleotide was 10.23 min. 
The pure fractions were combined and evaporated to dryness. The obtained residues 
were detritylated by adding 1 mL of 80% acetic acid solution for 30 min at room 
temperature. The deprotected oligonucleotides were desalted and further purified by a 
second round of chromatography, using the DMT-OFF protocol: 20 minutes of linear 
gradient from 5% to 50% ACN over 0.1 M aqueous TEAA pH 6.5. The yield and purity 
obtained for the products was around 85% in all cases. The length and homogeneity of 
the oligonucleotide were verified by MALDI-TOF (table 1).  
The DNA-strand concentration was determined by absorbance measurements (260 
nm) and its extinction coefficients. Oligonucleotide samples were kept at 4 ºC until 
further use.  
3.3. Preparation of the fluorescent FG oligonucleotide.  
The 5’-ATCTTCTCBzGATTCA-3’ oligonucleotide was left to react with fluorescein 
isothiocyanate (FITC) through its free amino group as follows. 5 O.D. of the 
oligonucleotide were dissolved in 250 μL of an aqueous solution of 0.2 M NaHCO3 (pH 
9) and 10 eq of a solution of FITC solved in 250 μL DMF were added and left to react 
at rt for 8h. Then, 100 μL of an aqueous solution of 0.2 M NaHCO3 (pH 9) and an 
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additional 10 equiv of FITC in 100 μL of DMF were added and the mixture was left to 
react overnight at rt. The mixtures were concentrated to dryness and the residue 
resuspended in 1 mL of water. The solution was purified by Sephadex G-25 and 
analyzed by RP-HPLC using an XBridge OST C18 2.5 μm column. The coupling 
efficiency was determined by HPLC analysis (86 %). The purified oligomers were 
analyzed by MS (MALDI-TOF), see table 1. 
DNA duplexes were obtained by annealing equimolar concentrations of the control, BzG 
and FG sequences with the complementary oligonucleotide strands at 72 ºC for 5 min 
and then allowing them to slowly cool down to room temperature. 
4. hAGT expression and purification 
In vitro assays were carried out using recombinant hAGT, overexpressed and purified 
as previously described.13 Briefly, hAGT protein was expressed in the E. coli strain 
Rosetta, induced by adding 1 mM IPTG and left to express for 4 h at 30 °C. The pellet 
was disrupted by sonication and centrifuged. The supernatant was filtered, loaded into 
a HiTrapTM FF column and eluted with an Imidazole gradient (20-500 mM) in the 
following buffer of 350 mM NaCl, 20 mM Tris pH 8, and 1 mM BME. Finally, the protein 
was loaded into a Superdex 75 16/60 being the buffer 200 mM NaCl, 20 mM Tris pH 
8.0, 10 mM DTT and 0.1 mM EDTA. The protein was concentrated to 2 mg/ml in this 
buffer and kept at -20 °C in the presence of 40 % glycerol. The same protocol was 
used for the purification of the inactive mutant hAGT-C145S expressed in the E. coli 
strain BL21. This mutant was used as negative control in many experiments. 
5. Thermal stability studies. 
Melting curves of all the possible pairs of complementary oligonucleotides were 
measured by monitoring the absorbance hyperchromicity at 260 nm. UV/Vis absorption 
spectra were recorded at 1ºC/min intervals, with a 1-min equilibration time at each 
temperature; the sample was heated over the range 10-80 ºC. The buffer solutions 
used were 10 mM sodium phosphate pH 7.0 and 100 mM NaCl. Sample concentration 
was around 4 μM. Each sample was allowed to equilibrate at the initial temperature 
without any external control of temperature for 5 min before the melting experiment 
began. The melting temperatures (Tm) are the average value of at least one pair of Tm 
experiments. The data were analyzed by the denaturation curve processing program, 
MeltWin v. 3.0. Melting temperatures (Tm) were determined by computer fitting of the 
first derivative of absorbance with respect to 1/T. 
Thermal stability experiments recording the emitted fluorescence at excitation 
wavelength of 485 nm were also performed for the double strands containing a 
fluorophor or a fluorophor-quencher pair. These experiments were realized in the same 
conditions, concentration, range of temperature and buffer described above.  
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6. Circular Dichroism 
The CD spectra of all the possible pairs of complementary oligonucleotides were 
registered at 25ºC over a range of 220–320 nm, with a scanning speed of 50 nm·min−1, 
a response time of 4s, data pitch of 0.5 nm, and a bandwidth of 1nm. The duplexes 
concentration was 2 μM in a buffer solutions of 10 mM sodium phosphate pH 7.0 and 
100 mM NaCl. The samples were annealed before recording of spectra. 
7. HPLC analysis of hAGT dealkylation.  
In order to measure the dealkylation of FG, 142 pmol and 350 pmol of the duplexes 
were incubated with 40 pmol of full-length-hAGT to a final volume of 400 µl in a 
reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 mM EDTA). The 
reaction was incubated for 90 min at 37 ºC and stopped by heating the samples at 72 
ºC for 5 min. The reaction products were analyzed by HPLC on a Nucleosil analytical 
column at 37ºC. The HPLC flow rate was 1 ml/min, and a gradient of 10–40% 
acetonitrile in 20 min was used. 
8. Fluorescence assay for hAGT activity. 
The fluorescence assay was performed with full-length hAGT and the hAGT-C145S 
(inactive mutant) was used as a negative control. The reaction was accomplished in a 
total volume of 50 μl in each well, incubating increasing concentrations of hAGT (50, 
100 and 200 nM) in reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 
mM EDTA, 20 mM KCl). The assay was initiated by the addition of 5 μl of fluorophore-
quencher duplex substrate (10 nM, 0.5 pmol) and this solution was then placed in a 
microplate reader system. Fluorescence was measured every minute for 20 min at 
excitation and emission wavelengths of 485 and 535 nm, respectively. Averages over 
three readings were taken for each condition tested. Each experiment was performed 
in triplicates. 
187
  
Table S1: Sequence of oligonucleotides and its characterization by MALDI-TOF 
Name Sequence Mass found (calculated) 
Oligo-BzG 5’-ATC TTC TCBzG  ATT CA-3’ 4310.9 (expected 4306,94) 
Oligo-FG 5’-ATC TTC TCFG  ATT CA-3’  4702.2 (expected 4695.31) 
Control  5’-ATC TTC TCG ATT CA-3’ 4190.0 (expected 4187.77) 
Complementary 5’-TGA ATC GAG AAG AT-3’ 4333.8 (expected 4332.77) 
Complementary-QT 5’-TGA AQTC GAG AAG AT-3’ 4741.2 (expected 4740.38) 
Mismatch-T 5’-TGA ATT GAG AAG AT-3’ 4348.2 (expected 4347.77) 
Mismatch-QT 5’-TGA ATQT GAG AAG AT-3’ 4757.0 (expected 4755.39) 
Sequences of the different oligonucleotide used in the development of the hAGT 
fluorescence assay. BzG represents O6-benzyl-2’-deoxyguanine. FG corresponds to the 
O6- Fluorescein-benzyl-2’-deoxyguanine, where fluorescein is a fluorophore group. QT 
represents a modified T with the quencher group (Dabcyl). Mass spectrometry analysis 
(MALDI-TOF) and expected mass. 
188
  
Table S2. Melting temperatures of the duplexes. 
5’-ATCTTCTC XA TTCA-3’ 
   3’-TAGAAGA ZW TAAGT-3’ 
 
Name XA ZW Tm (260 nm) Tm (485 nm) 
Control:Complementary GA CT 54.6 Nd 
Control: Mismatch-T GA TT 45.0 Nd 
Oligo-BzG:Complementary BzGA CT 33.3 Nd 
Oligo-BzG:Mismatch-T BzGA TT 36.4 Nd 
Oligo-BzG:Mismatch-QT BzGA QTT 40.2 Nd 
Oligo-BzG: CQT BzGA CQT 41.3 Nd 
Oligo-FG:Complementary FGA CT 33.0 Nd 
Oligo-FG: C QT FGA CQT 30.3 28.0/54.1 
Oligo-FG:Mismatch-T FGA TT 27.9 Nd 
Oligo-FG:Mismatch-QT FGA QTT 34.3 26.1 
nd: not determined. 
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Figure S1: CD spectra of the different duplexes. A) CD spectra of complementary 
duplexes. B) CD of the mismatch duplexes. All de experiments were performed in 10 
mM sodium phosphate pH 7.0 and 100 mM NaCl with a 2 uM of duplexes. 
 
Figure S2: Curves of the melting temperatures of the two fluorescent-quencher 
duplexes at 485nm. 
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Figure S3: HPLC profiles of the control sequences. A) unmodified oligonucleotide 
sequence with its complementary strand. B) fluorescein-benzyl-modified 
oligonucleotide sequence with its complementary strand. The HPLC was performed at 
37 ºC. 
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Figure S4: Control experiments of the fluorescence assay. The background 
fluorescence of the double stranded sequence is observed in the absence of hAGT and 
in the presence of an inactive mutant. An increase of fluorescence is observed in the 
presence of the same concentration of active hAGT (150 nM). 
 
 
 
 
 
 
 
 
 
Figure S5. Kinetic data of figure 2 (main text). The emission of fluorescence 
corresponding to 3 concentrations of hAGT (10, 20 and 30 nM) is measured for 20 
minutes. 
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1H-NMR, 13C-NMR 19F-NMR and 31P-NMR spectra 
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Appendix 4 
In vitro assay to evaluate potential inhibitors of hAGT by a 
new fluorescence method: preliminary results 
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In vitro assay to evaluate potential inhibitors of hAGT by a new fluorescence method In chapter 4 we describe the development of a novel methodology to measure hAGT activity through the fluorescence transfer from a labelled alkyl-guanine to the active site of hAGT. The repair reaction produces the removal of fluorescein, which is withdrawn with the alkyl group and brought apart from the quencher group, which remains in the duplex sequence. Using this methodology, we have performed a first screening of the compounds described in chapter 1. The results obtained are preliminary, but represent a proof of concept of the usability of the assay for the evaluation of potential inhibitors of hAGT.  The assay was performed using the mismatch duplex described in chapter 4. hAGT was incubated with each compound at 30ºC during 30 minutes before adding the fluorescent duplex. Immediately, emission of fluorescence was monitored at 25ºC during 20 minutes. Figure 1 represents the kinetic data obtained for compounds 1 to 9. 
 
Figure 1. Kinetic data of the inhibitory activity of compounds 1 to 9.  This results suggest that compounds 1, 2, 4 and 8 may inhibit hAGT activity in vitro, while compounds 3, 6, 7 9 do not seem to affect hAGT activity. Compound 5 seems to slightly inhibit hAGT during the first minutes of the assay but at minute 20 seems to reach the same fluorescence as hAGT. Inhibition at 20 minutes is represented in figure 2. 
 
Figure 2. Inhibition of hAGT by compounds 1 to 9 at 20 min, calculated from the increase of fluorescence with respect to time 0. The basal increase of fluorescence of the duplex was subtracted from all the measurements. 
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 Compound 8 seems to be the most promising inhibitor in vitro, judging by the results obtained in these experiments. This is in agreement with the results described in chapter 1, where compound 8 was found to form a complex with hAGT by ESI-MS and was observed to be non-toxic per se and a good enhancer of carmustine activity in cellular experiments. However, these experiments are preliminary and should be confirmed by the repetition of the assays at 37ºC.   
206
Experimental details: The fluorescence assay was performed using previously overexpressed and purified full-length hAGT (chapter 1). The reaction was accomplished in a total volume of 50 μl in each well, incubating 150 nM of hAGT with 750 nM of each compound (hAGT:compound 1:5) in reaction buffer (200 mM NaCl, 50 mM Tris pH 8.0, 1 mM DTT, 5 mM EDTA, 20 mM KCl). The compounds were dissolved in 1 mL of DMSO to prepare a stock concentration of 100 µM. Enough volume of each compound was added and left to incubate with hAGT during 30 minutes prior to the repair reaction with DNA. The assay was initiated by the addition of 
5 μl of fluorophore-quencher duplex substrate (15 nM) and this solution was then placed in 96-well plates with black bottom (Nunc). Fluorometric measurements were performed on a spectrofluorometer Jasco FP6200 at 25ºC and with a Multi-Detection Microplate Reader SpectraMax M5 (Molecular devices BioNova cientifica, Sunnyvale, USA). Fluorescence was measured every minute for 20 min at excitation and emission wavelengths of 485 and 535 nm, respectively. Averages over three readings were taken for each condition tested. Each experiment was performed in triplicates.    
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Chapter 5 
Molecular biosensing using gold-coated 
superparamagnetic nanoparticles functionalized with 
DNA aptamers. 
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 Gold and iron-based magnetic nanoparticles seem to be one of the most promising nanoparticles for biomedical applications due to their unique properties. The combination of a gold coating over a magnetic core provides the benefits from both nanoparticles, adding the magnetic properties to the robust chemistry provided by the thiol functionalization of the gold coating. In this chapter, we describe the use of gold-coated magnetic nanoparticles for molecular biosensing. Binding of α-thrombin to two aptamers conjugated to these nanoparticles causes aggregation, given that the aptamers bind cooperatively to opposite sites of the protein, forming a molecular network. This phenomenon can be observed by UV, DLS and MRI. These techniques discriminate even a single methylation in one of the aptamers, which prevents aggregation due to the inability 
of α-thrombin to recognize it when it is not correctly folded. A parallel study with gold and ferromagnetic nanoparticles is also detailed, concluding that the gold coating of Fe3O4 nanoparticle does not affect the performance of the iron-based nanoparticles and that they are suitable for the development of more complex biosensors. These results prove the high detection potency of gold coated superparamagnetic nanoparticles for biomedical applications. This work is the result of a doctoral short stay in the University of Milan and in the CNR. The long-term objective of this detection method is to implement it as a detection method for hAGT repair activity, as it is able to detect a single methylation in guanines, the substrate for hAGT repair activity. 
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Molecular biosensing using gold-coated superparamagnetic 
nanoparticles functionalized with DNA aptamers. 
Maria Tintoré,[a] Stefania Mazzini,[b] Laura Polito,[c] Marcello Marelli,[c] Alfonso Latorre,[d] Álvaro 
Somoza,[d] Anna Aviñó,[a] Carme Fàbrega,[a] and Ramon Eritja*[a] 
 
Abstract: Au- and iron-based magnetic nanoparticles (NPs) are 
promising NPs for biomedical applications due to their unique 
properties. The combination of a gold coating over a magnetic core 
provides the benefits from adding the magnetic properties to the 
robust chemistry provided by the thiol functionalization of gold. Here, 
the use of Au-coated magnetic NPs for molecular biosensing is 
described for the first time. Binding of α-thrombin to two aptamers 
conjugated to these NPs causes aggregation, a phenomenon that 
can be observed by UV, DLS and MRI. These techniques 
discriminate a single methylation in one of the aptamers, preventing 
aggregation due to the inability of α-thrombin to recognize it. A 
parallel study with gold and ferromagnetic NPs is detailed, 
concluding that the Au coating of Fe3O4 NP does not affect their 
performance and that they are suitable for the development of 
complex biosensors. These results prove the high detection potency 
of Au-coated SPIONs for biomedical applications. 
Introduction 
In recent years, a great variety of chemical methods has been 
developed to synthesize functionalized nanoparticles for 
biomedical applications such as drug delivery, cancer therapy, 
diagnostics, tissue engineering and molecular biology, and the 
structure-function relationship of these functionalized 
nanoparticles has been extensively examined. [1] 
In particular, the controlled assembly of gold nanoparticles 
(AuNPs) has been a subject of great interest over the past 
decade due to the potential applications of these particles in 
nanobiotechnology.[2] Their unique physical properties,[3] 
particularly their localized surface plasmon resonance (LSPR) 
and their efficient interaction with molecules with a free thiol 
group make AuNPs attractive building blocks for nanoscale 
electronic and photonic devices.[4] Since the first DNA sensor 
was designed by Mirkin and co-workers,[5] the development of 
AuNPs-based colorimetric biosensors has been increasingly 
applied for the detection of a large variety of targets, including 
nucleic acids, proteins, saccharides, small molecules, metal 
ions, and even cells. This technique takes advantage of the 
color change that arises from the interparticle plasmon coupling 
during AuNP aggregation (red-to-purple or blue) or redispersion 
of an AuNP aggregate (purple-to-red).[2a, 2b, 2g] It is quickly 
becoming an important alternative to conventional detection 
techniques, as fluorescence-based assays, and holds great 
potential in clinical diagnostics, drug discovery and 
environmental contaminant analysis, among others. 
In contrast, super paramagnetic iron oxide nanoparticles 
(SPIONs) possess different interesting features for 
nanomedicine. SPIONs are well known as innovative agents in 
diagnostics, due to their advantages as Magnetic Resonance 
Imaging (MRI) contrast agents.[6] In comparison with the 
traditional gadolinium-based contrast agents, SPIONs produce 
lower toxicity, stronger enhancement of proton relaxation and 
have a lower detection limit.[7] Furthermore, SPIONs have 
several other applications in biomedicine, especially for delivery 
purposes, due to their reduced size, the ability to be transported 
in biological systems[8] and the potential use for therapy by 
magnetic heating.[9] 
Gold and iron-based magnetic nanoparticles (AuSPIONs) 
have a prominent potential in biomedical applications due to 
their unique properties. The combination of a gold coating over 
the magnetic core provides the benefits from both nanoparticles, 
adding the magnetic properties to the robust chemistry provided 
by the thiol functionalization of the gold coating. For this reason, 
there is an increasing interest on the synthesis and applications 
of this type of gold-coated nanoparticles.[8c, 8d, 10] 
In this work, we describe for the first time the use of gold 
coated magnetic nanoparticles as molecular biosensors, 
through their functionalization with DNA aptamers that are 
recognized by the protein α-thrombin. For this purpose, we 
conjugated the α-thrombin binding aptamers 1 and 2 (TBA1 and 
TBA2), and a methylated version of TBA1 (O6-MeG-TBA1) 
(Table 1) to gold-coated iron-oxide nanoparticles, to iron-oxide 
nanoparticles and gold nanoparticles, in order to assess the 
advantages of each type of NPs. The TBA1 and TBA2 
sequences are known to bind cooperatively to two specific and 
almost opposite epitopes of α-thrombin, forming a “molecular 
sandwich” complex.[11] TBA1 (primarily fibrinogen-recognition 
[a] M. Tintoré, Dr. A. Aviñó, Dr. C. Fàbrega, and Prof. R Eritja. 
Department of Chemical and Biomolecular Nanotechnology  
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[b] Dr. S. Mazzini,  
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(DEFENS), Division of Chemistry and Molecular Biology,  
 University of Milan,  
Via Celoria 2, 20133 Milan, Italy. 
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Department Institute of Molecular Science and Technologies 
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Via G. Fantoli 16/15, 20138 Milan, Italy 
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exosite binding)[12] is a 15mer nucleotide composed of two G-
tetrads that are connected by three edge-wise loops, forming a 
well-characterized intramolecular chair-like, antiparallel 
quadruplex. In contrast, TBA2 (29mer nucleotide, heparin-
binding exosite) forms a combined quadruplex/duplex 
structure.[11]  
 
Table 1. Oligonucleotide sequences of the three α-thrombin binding aptamers. 
Name Sequence 
TBA1 5’-HS-T15GGTTGGTGTGGTTGG-3’ 
TBA2 5’-HS-T5AGTCCGTGGTAGGGCAGGTTGGGGTGACT-3’ 
O6-MeG-TBA1 5’-HS-T15GGTTGMeGTGTGGTTGG-3’ 
 
The mixture of TBA1 and TBA2 conjugated nanoparticles 
should form a tridimensional network in presence of α-
thrombin,[8e] as represented in Scheme 1. This interaction can 
be detected in a straightforward manner using three types of 
techniques: UV, Dynamic Light Scattering (DLS) and MRI. 
AuSPIONs and AuNPs have a maximum of absorbance due to 
their surface plasmon resonance at 520 nm that shifts to higher 
wavelengths when aggregation occurs and this change is easily 
detected by UV-spectroscopy. Aggregation of the three types of 
nanoparticles can be detected by DLS, measuring the main 
hydrodynamic diameter (HD) of the nanoparticles resulting in a 
huge increase when α-thrombin is added to the mixture of 
nanoparticles carrying the TBAs. Finally, SPIONs and 
AuSPIONs allow the detection of the complex between α-
thrombin and the nanoparticles by means of MRI, because they 
are contrast agents for image enhancement.  
Scheme 1. Representation of the TBA-conjugated nanoparticles and the 
tridimensional network formation in presence of α-thrombin for the unmodified 
TBAs. TBA1 and TBA2 are represented folded in their chair like structure in 
dark blue and in green respectively α-thrombin is represented in violet. 
 
Furthermore, we also explored the discrimination capacity of 
the AuSPION nanoparticles to detect a single methylation in the 
DNA aptamer, upon destabilizing the quadruplex structure of 
TBA1 by the incorporation of a methylG in one of its tetrads. In 
this case, the mixture does not form a tridimensional network 
because α-thrombin is not able to recognize this modified 
version of the aptamer.[13] Moreover, this inability to form the 
network allowed us to use this set of nanoparticles as a 
detection probe for a single methylation. This system can be 
further developed for the detection of the activity of DNA repair 
proteins which have alkylated guanines as substrate. 
Results and Discussion 
Synthesis of gold superparamagnetic iron oxide 
nanoparticles (AuSPION) 
 
The preparation of the gold coated nanoparticles was performed 
following a process consisting of two main steps, the 
precipitation of the ferromagnetic seeds followed by their 
coating with gold acetate.[10] The precipitation of ferromagnetic 
seeds was obtained in good yield, and the resulting nanoparticle 
cores were characterized by TEM. TEM images (Figure 1A) 
show homogeneity in size and shape of the ferromagnetic core 
which is an indispensable condition to achieve the final 
AuSPION. 
The coating of the ferromagnetic seeds with gold acetate was 
performed subsequently with high yield of coating. The purified 
gold-coated magnetic nanoparticles were analysed by TEM 
(Figure 1B), showing an increase of around 1.6 nm in the core 
diameter, which confirms that the covering was obtained 
successfully. 
Figure 1. TEM images of the gold-coated magnetic nanoparticles, AuSPION. 
A. Images and particle size distribution of the ferromagnetic cores. B. Images 
and particle size distribution of the gold-coated SPION.  
 
Conjugation of the AuNPs, AuSPIONs and SPIONs with 
TBA1, TBA2 and O6-MeG-TBA1 
 
TBA1 and TBA2, that bind to opposite sites of α-thrombin, and 
O6-MeG-TBA1 were conjugated separately and successfully to 
the three types of nanoparticles selected in this work. 
The conjugation of TBAs to AuNPs (commercially available) and 
AuSPIONs was done by incubation of NPs with thiolated-
oligonucleotides followed by slow salt aging as described.[14]  
The superparamagnetic nanoparticles were prepared as 
reported[15] and coated with dimercaptosuccinic acid (DMSA).[16] 
Two type of linkers (maleimide[17] and disulfide,[18] Figure 2) 
were used to functionalize these nanoparticles with TBAs. In 
order to introduce these functionalities, the carboxylate groups 
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of DMSA were activated using EDC/NHS and then reacted with 
the amino groups of the corresponding linkers bearing a 
maleimide or disulfide moiety. Subsequently, the resulting 
SPIONs were reacted with the corresponding thiolated-
oligonucleotides. The degree of functionalization of SPIONs with 
TBAs was independent of the type of linker and they were 
further used indistinguishably. 
 
Figure 2. Schematic representation of the functionalization of SPIONs 
nanoparticles with TBAs (in green) using the two type of linkers maleimide 
(left) and disulfide (right).  
 
The functionalization of all the nanoparticles was confirmed by 
the quantification of the decrease in the concentration of the 
oligonucleotide present in the solution, before and after 
conjugation (data not shown). All nanoparticles were stable after 
centrifugation and resuspension with aqueous buffers. 
 
UV study of the complex formation between α-thrombin and 
AuNPs or AuSPIONs functionalized with TBAs 
 
The behaviour of TBAs functionalized nanoparticles when 
incubated with α-thrombin was monitored by means of UV-
spectroscopy observing the red-shift broadness of the surface 
Plasmon band. [2a, 5] 
Binding interaction of the modified AuNPs-TBAs and 
AuSPIONs-TBAs with α-thrombin was carried out in phosphate 
buffer with additional K+ at 25ºC. As expected, the UV spectrum 
for TBA1 and TBA2 anchored to AuNPs or AuSPIONs showed a 
maximum of absorption at 520 nm before incubation with α-
thrombin (Figure 3). This maximum was displaced to higher 
wavelengths in a continuous way when α-thrombin was added, 
until reaching stabilization (30 nm). These results confirmed that 
α-thrombin was interacting with both TBA1 and TBA2, creating a 
NP network formed by the binding of thrombin to both TBA1 and 
TBA2 sequences. In addition, the formation of this network of 
interactions between α-thrombin and TBAs is not affected by the 
nature of the nanoparticles, as both AuNPs and AuSPIONs 
showed the same response. 
In contrast, the interaction between α-thrombin and the mixture 
of O6-MeG-TBA1 and TBA2 anchored to the two types of 
nanoparticles (AuNPs or AuSPIONs) was evidently smaller. As 
it can be seen in Figure 3B and 3D, at equal concentrations of 
α-thrombin the maximum of absorption was not changed in 
AuNPs (Figure 3B) or slightly displaced in Au SPIONs (Figure 
3D). This small difference in the displacement rate observed in 
Au SPIONs (less than 10 nm), can be explained by the only 
interaction of AuNPs-TBA2 or AuSPIONs-TBA2 with α-thrombin. 
These observations proved that α-thrombin was not able to form 
the network with the same performance as in the case of the 
unmodified TBAs, and that its KD is much higher when one 
guanine in the central tetrad of the TBA sequence is modified 
with a methyl group in the O6 position. This simple modification 
prevents the formation of its quadruplex structure, and for this 
reason, it cannot be recognized by α-thrombin. Moreover, when 
we forced the concentration of α-thrombin versus TBAs (molar 
ratio 4:1), we could observe a small displacement of the 
maximum in the UV spectrum of the mixture containing the 
methylG-TBA1 conjugated with both types of NPs. This effect 
could be due to the formation of small clusters, even if in a 
reduced way if compared to the non-methylated mixture of 
TBAs (10 nm for AuSPIONs and 15 nm for AuNPs). As the 
protein itself is able to recognize the sequence of methylated 
TBA and force it to fold in its quadruplex structure suitable for 
the binding[13a], we presume that the methylated sequence is 
also recognized as a result of the excess of protein in the 
mixture. It is interesting to note that α-thrombin attempts to fold 
it and this may result in some degree of binding.  
Figure 3. UV-Visible spectra of the complex formation between TBAs and α-
thrombin at a molar ratio of (1:1). The curves represent the mixture of NPs-
TBAs in the absence (dashed lines) and in the presence (orange continuous 
lines) of the α-thrombin. Blue represents unmodified TBAs and green, 
methylated TBAs A. and B. display spectra recorded for AuNPs. C. and D. 
display spectra recorded for AuSPIONs. 
 
UV seems a proper and simple way to measure the interaction 
between α-thrombin and the TBAs nanoparticles, as the change 
can be visualized within a direct step and it is not cost nor time 
consuming. This result confirmed that macromolecular 
aggregation processes can be studied indistinguishably by 
these two types of nanoparticles, demonstrating that the gold 
coating maintains the chemical and optical properties of gold 
itself.  
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DLS study of the complex formation between α-thrombin 
and NPs-TBAs. 
 
The study of the complex formation between the three types of 
NPs-TBAs and α-thrombin by dynamic light scattering was 
carried out in phosphate buffer with additional K+ at 25ºC. Figure 
4 and Table 2 show the particle size distribution for the mixture 
of the different types of TBAs nanoparticles with and without α-
thrombin. Particle size analysis was performed after the addition 
of α-thrombin into a mixture of TBA1 and TBA2 anchored to the 
three different types of nanoparticles (AuNPs, SPIONs and 
AuSPIONs). In all three cases the average diameter of the 
nanoparticles immediately increased by 25, 21.5 and 7 fold (see 
Table 2). Even if a small polydispersity is observed in the initial 
state of the mixture with AuSPION, we can clearly detect the 
formation of the α-thrombin-TBAs network. No precipitation was 
observed at these complexes concentration during the 
measurements. Similar results were observed for the SPIONs 
independently of the linker used for the functionalization.  
 
Figure 4. Particle size distribution of NPs-TBAs at 25ºC recorded by DLS. 
The mixtures of TBA1 and TBA2 NPs (left) and O6-MeG-TBA1 and TBA2 NPs 
(right) are displayed in dashed blue, while the same NP mixtures in the 
presence of α-thrombin are represented in orange. In all cases, the molar ratio 
of α-thrombin:TBAs was 0.5:1. From top to bottom: A. AuNP, B. SPIONs and 
C. AuSPION. 
 
In contrast, the interaction between equal concentrations of α-
thrombin with the mixture of each one of the three types of O6-
MeG-TBA1 and TBA2 nanoparticles  was inexistent or clearly 
smaller (see Table 2). These observations indicated that α-
thrombin is not able to form the network with the same efficiency 
when the TBA1 is substituted by methylated TBA1, and thus the 
particle size average remains similar. In these cases, the 
interaction between NPs-TBA2 and α-thrombin was not 
identified. We presume that this may be due to the small 
variation in the size of the nanoparticles, which is too low to be 
observed by DLS.  
 
 
 
 
 
Table 2: Size distribution (HD, nm) by DLS of TBAs nanoparticles in the 
absence and in the presence of α-thrombin. 
Nanoparticles type 
(-) α-thrombin 
HD (nm) 
(+) α-thrombin 
HD (nm) 
AuNPs 
TBA1 & TBA2 38 ± 5 947 ± 283 
O6-MeG-TBA1 & TBA2 38 ± 5 56 ± 7 
SPIONs 
TBA1 & TBA2 36 ± 5 781 ± 185 
O6-MeG-TBA1 & TBA2 39.5 ± 11 39.5 ± 11 
AuSPIONs 
TBA1 & TBA2 91 ± 25 633 ± 225 
O6-MeG-TBA1 & TBA2 91 ± 25 109 ± 34 
 
Magnetic resonance imaging assay to compare the 
complex formation between α-thrombin and NPs-TBAs  
 
The study of the complex formation between α-thrombin and the 
α-thrombin binding aptamers by magnetic resonance imaging 
was already been described by Yigit et al[8e]. In our work we 
went a step forward in the application of the MRI technique 
using gold-coated magnetic nanoparticles as contrast agents, 
studying also the effect produced in the MRI contrast when 
TBA1 is substituted by a methylated TBA1. 
A 1:1 mixture of TBA1 or O6-MeG-TBA1 and TBA2 anchored to 
SPIONs or AuSPIONs was prepared in phosphate-K+ buffer at 
25 ºC. Table 3 summarizes the formation of the molecular 
network due to α-thrombin binding to the nanoparticles, 
monitored by the changes in brightness of the T2-weighted MR 
images of the solution. A 2.4 ug Fe/mL concentration of the 
SPIONs resulted in a T2 of 50 ± 3 ms. After aggregation of the 
mixture by adding α-thrombin, the magnetic relaxation 
properties changed, reducing the T2 relaxation time to 40 ± 3 
ms. Even if the concentration of the AuSPIONs nanoparticles 
was required to be 1000 times higher, due to the fact that the 
gold coating decreases the magnetic response, a similar 
reduction in the T2 was observed. Again, the T2 values for the 
mixture containing methylG-TBA1 did not decrease when α-
thrombin was added, indicating that the network could not be 
formed. These observations are in agreement with our previous 
results obtained by UV and DLS studies, and prove that gold-
coated magnetic nanoparticles can be used as contrast agents 
for MRI detection of biomolecules. 
 
Table 3: T2 relaxation times in the absence or presence of α-thrombin. 
SPIONs were measured at 1/1000 (2.4 µg Fe/mL) and the AuSPIONs 1/1 (2.4 
mg Fe/mL). These results represent the average of at least three independent 
measurements. 
Nanoparticles type 
Concentration of α-thrombin 
0 5 nM 
SPIONs 
TBA1 & TBA2  50 ± 3 ms 40 ± 3 ms 
O6-MeG-TBA1 & TBA2  51 ± 4 ms 51 ± 5 ms 
AuSPIONs. 
TBA1 & TBA2  70 ± 1 ms 62 ± 1 ms 
O6-MeG-TBA1 & TBA2  63 ± 2 ms 62 ± 1 ms 
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Conclusions 
We have obtained in high yield and purity gold-coated magnetic 
nanoparticles. Their functionalization with oligonucleotides is 
comparable with the one obtained for the gold nanoparticles. 
Our results prove the biosensing capacity of AuSPIONs for the 
first time, as they were useful for the detection of a protein by 
three diverse techniques. AuSPIONs were suitable for UV 
experiments with the same performance as AuNP, without 
major changes in the execution nor in the detection. AuSPIONs 
showed similar behaviour in DLS measurements to AuNPs and 
SPIONs, resulting in very similar plots of size distribution. Finally, 
AuSPION were useful for MRI experiments, even if they showed 
a shielding of the magnetic resonance due to the gold coating 
and required higher concentrations to reach the same signal as 
SPIONs.  
Furthermore, this work proves that AuSPION can discriminate 
a normal TBA from a methylated one in the analysis of the 
complex formation between TBAs and α-thrombin by 
biophysical methods. As O6-methylguanine is the substrate for 
DNA repair enzymes, critical for chemotherapy resistance, this 
method can also be used to monitor the activity of these DNA 
repair proteins. Different detection methods for the evaluation of 
the repair activity of one of them, alkylguanine-DNA-transferase 
(hAGT)[19] have been previously described. [13] These methods 
are also based on the conformational change of TBA upon 
methylation of a single guanine. Its repair restores the G-
quadruplex and its recognition by α-thrombin. We envisage that 
AuSPIONs are useful for the development of a new 
methodology to detect hAGT activity in a straightforward 
manner. Work in this direction is currently ongoing in our 
laboratory. We believe that the multidisciplinary detection 
capacity of AuSPIONs can be evolved to design more complex 
biosensors for biomedical applications as well as for drug 
delivery and in vivo imaging.  
Experimental Section 
Abbreviations: AuNPs: gold nanoparticles, AuSPIONs: gold-coated 
superparamagnetic iron oxide nanoparticles, DLS: dynamic light 
scattering, dmf: dimethylformamidino group, DMSA: dimercaptosuccinic 
acid, DTT: dithiothreitol, EDC: 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, Fe3O4: iron oxide, hAGT: human O6-
alkylguanine-DNA alkyltransferase, HD: Hydrodynamic diameter, HPLC: 
high performance liquid chromatography, LSPR: localized surface 
plasmon resonance, MRI: magnetic resonance imaging, NHS: N-
hydroxysuccinimide, NPs: nanoparticles, O6-MeG: O6-methylguanine, 
O6-MeG-TBA1: O6-methylguanine α-thrombin-binding aptamer, SPIONs: 
superparamagnetic iron oxide nanoparticles, T2: spin-spin relaxation 
time, TBA: α-thrombin-binding aptamer, TCEP·HCl: tris(2-
carboxyethyl)phosphine hydrochloride, TEAAc: triethylammonium 
acetate, TEM: transmission electron microscopy, TMAOH: 
tetramethylammonium hydroxide, Tris: Tris(hydroxymethyl) 
aminomethane. 
Chemicals:Human α-thrombin was purchased from Heamatologic 
Technologies Inc. All reagents and dry solvents were purchased from 
Sigma-Aldrich or Fluka and were used without further purification. Other 
chemicals from specific commercial source will be specified as they are 
named. Standard phosphoramidites were purchased from commercial 
sources. Solvents for oligonucleotide synthesis were purchased from 
Applied Biosystems (USA). Gold nanoparticles (10 nm) stabilized in 
aqueous solution of citrate were purchased from Sigma. Low binding 
eppendorf tubes were used in the preparation of the nanoparticles in 
order to avoid adsorption to the tube. Matrix for MALDI-TOF experiments 
were 2’,4’,6’-Trihydroxiacetophenone monohydrate (THAP, Aldrich) and 
Ammonium citrate dibasic (Fluka). Solvents for chromatographic analysis 
were prepared using triethylammonium acetate (TEAA, Merck) and 
acetonitrile (Merck) as mobile phase. Ultrapure water (Millipore, USA) 
was used in all experiments. 
Instrumentation: Analytical RP-HPLC was performed using an XBridge 
OST C18 2.5 μm column and a Nucleosil Analytic column 120 C18 
(250x4mm). Oligonucleotide sequences were detected by UV absorption 
at 260 nm on a JASCO V-650 instrument equipped with a 
thermoregulated cell holder. Mass spectra were recorded on a MALDI 
Voyager DETM RP time of-flight (TOF) spectrometer (Applied Biosystems, 
USA). UV measurements were performed on a spectrofluorometer Jasco 
V-650 at 25ºC. Set temperature was controlled with an 89090A Agilent 
Peltier device and Hellma quartz cuvettes were used (1400 and 500 μL 
volume). Dynamic light scattering studies were performed on a Dynamic 
Light Scattering (DLS) spectrometer (LS Instruments, 3D cross 
correlation multiple-scattering) equipped with a He-Ne laser (632.8 nm) 
with variable intensity. MRI: MRI studies were carried out using a 
standard bore Bruker Avance AV600 spectrometer (Bruker Biospin 
GmbH, Rheinstetten, Germany) equipped with a 10 mm 1H micro-
imaging probe and a variable-temperature control unit. Acquisition and 
data processing were performed with ParaVision v. 4.0 (Bruker BioSpin 
MRI GmbH, Ettlingen, Germany). TEM analysis was performed on a 
Transmission Electron Microscope (TEM) LIBRA® 200FE with an 
electron beam source of 200keV, a ressolution power of 0.24 nm and a 
magnification of 8 x - 1,000,000 x. 
Oligonucleotides synthesis: The three oligonucleotide sequences 
(Table 1) were synthesized on an ABI 3400 DNA Synthesizer (Applied 
Biosystems, USA) using the 200-nmol scale synthesis and following the 
standard protocols. For the introduction of the thiol group at the 5’-end 
we used 5’-thiol modifier C6 S-S phosphoramidite from Link 
Technologies (Scotland, UK). For strands containing O6-MeG, we used 
Gdmf phosphoramidite. O6-MeG-TBA1 was deprotected in ammonia 
solution, overnight at room temperature. The resulting products were 
desalted by Sephadex G-25 (NAP-10, Amersham Biosciences, USA) 
and analyzed by reversed-phase HPLC. The length and homogeneity of 
the oligonucleotides were checked by MALDI-TOF. HO(CH2)6-S-S-
(CH2)6-T15TBA1 [M]= 9617.1 (expected 9612.6), HO(CH2)6-S-S-(CH2)6-
T15-O6-MeG-TBA1 [M]=9621.4 (expected 9626.6), HO(CH2)6-S-S-
(CH2)6-T5-TBA2 [M]=10795.5 (expected 10797.9). The DNA-strand 
concentration was determined by absorbance measurements at 260 nm. 
Oligonucleotide samples were kept dry at -20 ºC until use. 
Synthesis of SPIONs: DMSA coated Fe3O4 nanoparticles were 
obtained in good yield through thermal decomposition, following the 
protocol reported by Salas et. al.[15a] 
Synthesis of maleimide linker[17] :2-(2-aminoethoxy)ethanol (2 mL, 18 
mmol) was protected with (BOC)2O in THF, followed by a standard 
workup. The resulting protected compound was left to react with 
maleimide (2.1 g, 22.5 mmol) in THF, and a freshly solution of PPh3 (3.6 
g, 13.5 mmol) and DIAD (3.6 mL, 18 mmol) following the conditions 
described.[17] The product was precipitated in Et2O, filtered and purified 
by flash chromatography (Hexane/AcOEt 5:2 to 1:1). Then, it was 
deprotected with trifluoroacetic acid and purified to obtain a final yield of 
89%. The resulting product had the same physical and spectroscopical 
properties as the one described by Weber et. al.[20] 
Synthesis of thiopyridinyl linker (PDA*HCl).[18]: The thiopyridinyl linker 
was obtained following reported protocols. Briefly, to a stirred solution of 
aldrithiol (213 mg, 0.96 mmol) in MeOH, 2-mercaptoethylamine 
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hydrochloride (109 mg, 0.96 mmol) was added. After stirring 1h, the 
solvent was evaporated and the residue washed with cold AcOEt three 
times. PDA*HCl was obtained as a white solid in 51% yield. This product 
is the same as the one described in reference 18 and its physical and 
spectroscopical characterization is the same. 
Functionalization of DMSA coated Fe3O4 nanoparticles with 
maleimide or PDA*HCl linker: To 1 mL of SPIONs at 2.4 mg Fe/ mL, 
the maleimide or PDA*HCl linker (50 mmol/g Fe), 1 equivalent of NaOH, 
150 mmol of EDC/g Fe and 75 mmol of NHS/g Fe were added. This 
mixture was stirred at room temperature during 16 h, and was washed 
by iterative centrifugation and redispersion in milliQ water for at least 3 
times. 
Synthesis of AuSPIONs: 
Synthesis of Fe3O4 MNP as seeds[10a]: Iron (III) acetylacetonate (0.355 
g, 1 mmol) was dissolved in phenyl ether (10 mL) with oleic acid (1 mL, 3 
mmol) and oleylamine (1 mL, 2 mmol) in argon atmosphere with 
vigorous stirring. 1,2-hexadecanediol (1.29 g, 5 mmol) was added and 
the solution was heated under reflux at 210 ºC for 2 hours. Then, the 
mixture was left to cool down to room temperature. The final solution 
was used in the following steps without further purification. 
Reduction of Au-acetate (coating)[10b]: 2.5 mL of the Fe3O4 
nanoparticles solution previously prepared (approximately 0.166 mmol 
Fe3O4) were diluted to a final volume of 7.5 mL in phenyl ether and 
mixed up with Au(OOCCH3)3 (0.55 mmol, 0.208 g), oleic acid (0.375 
mmol, 0.125 mL), oleylamine (1.5 mmol, 0.75 mL) and 1,2-
hexadecanediol (3 mmol, 0.775 g), under argon atmosphere with 
vigorous stirring. Temperature was increased following a ramp of 
10ºC/min until reaching 190ºC, and the mixture was refluxed for 1.5 h. 
Then, AuSPIONs were precipitated with ethanol and purified by 
centrifugation. The precipitate was washed twice and redispersed in a 
1M TMAOH solution. Then, trisodium citrate (0.04 g) was added and the 
pH was adjusted to 6.5. Finally, the solution was sonicated for 30 
minutes, and the nanoparticles were collected using a magnet and 
redispersed in pure water. 
Functionalization of the different type of nanoparticles: 
Gold nanoparticles (AuNPs) 2-3 ODs of TBA1, -TBA2 and O6-MeG-
TBA1 were reduced with 300 uL TEAAc 0.1M and TCEP·HCl 34 uL (100 
mM) at 55ºC overnight, to prevent the formation of disulfide bridges and 
to break the already existing ones. Next, 1 OD of the deprotected 
oligonucleotides were diluted in 0.5 ml of MilliQ water and were desalted 
with a NAP-5 column. The resulting oligonucleotide (1 mL) was mixed 
with 1 mL of AuNPs solution and left to conjugate overnight under 
agitation. Then, the solutions were brought to a final concentration of 10 
mM sodium phosphate (pH 7.0). The mixtures were allowed to 
equilibrate before being brought to a concentration of 0.15 M NaCl 
stepwise over a 9 h period. The solutions were sonicated for 10 s before 
each addition to keep the nanoparticles dispersed during the salting 
procedure. The salting processes were followed by an overnight 
incubation at room temperature. Finally, the nanoparticles were purified 
by centrifugation at 13200 rpm (16100 x g) using a buffer containing 
0.15M NaCl, 10 mM sodium phosphate pH 7 and NaN3 0.01%. The 
centrifugation process was performed 4 times for 45 minutes at 15-20ºC. 
The TBAs-conjugated gold nanoparticles were analyzed by UV-visible 
absorption. TBAs conjugated nanoparticles were stored at 4ºC and 
sonicated during 5 minutes before use. 
Superparamagnetic iron oxide nanoparticles (SPION): Aliquots of 
thiolated-aptamers (TBA1, TBA2 and O6-Me-TBA1) for a final 
concentration of 245 µM were mixed with 200 µL of 2.4 mg Fe/mL Fe3O4 
magnetic nanoparticles functionalized with maleimido and 2-thiopyridinyl 
groups[16] and left to react overnight at room temperature. The TBA-
conjugated nanoparticles were purified by iterative centrifugation-
resuspension process. The centrifugation was repeated 3 times for 30 
minutes at maximum speed at room temperature and with the addition of 
small amounts of NaCl to enhance precipitation if required. The 
covalently immobilized TBA was determined by quantification of the 
unbound TBA in the collected supernatants. The TBAs conjugated 
nanoparticles were analysed by UV-visible absorption and stored at 4ºC 
until further use.  
Gold superparamagnetic iron oxide nanoparticles (AuSPION): Equal 
volume of gold coated nanoparticles and thiolated DNA solution (1 OD) 
were mixed and left to conjugate under agitation and at room 
temperature for 48h. The solution followed the same salt aging process 
than AuNPs and the resulting suspension was centrifuged under the 
same conditions used for the AuNPs, resuspended in MilliQ water to 
remove non-conjugated oligonucleotides, and observed for any 
indication of aggregation. Finally, the conjugated oligonucleotides gold 
coated superparamagnetic nanoparticles were analyzed by UV-visible 
absorption. The conjugated nanoparticles were kept at 4ºC in MilliQ 
water until further use, due to precipitation when adding salts to the 
solution. 
Study of the interaction between AuNPs and AuSPIONs and α-
thrombin by UV: Binding between α-thrombin and TBA1, TBA2 and O6-
MeG-TBA1 nanoparticles was monitored by measuring changes in the 
UV spectrum (recorded from 650 to 400 nm) upon increasing 
concentrations of the protein. A mixture of NP-TBA1 and NP-TBA2 were 
diluted in buffer containing 10 mM phosphate pH 7 and 5 mM KCl to 
reach a concentration of 5 nM of nanoparticles in a volume of 500 µL. As 
conjugation was approximated to represent a coating of 100 
oligonucleotides per nanoparticle, the concentration of DNA in the 
sample was considered to be around 500 nM. Each time, enough 
quantity (125 nM) of human α-thrombin was added. After a quick manual 
mix, the UV spectra were recorded. The UV spectra of the mixture and 
increasing concentrations of α-thrombin was recorded until reaching a 
final concentration of 1 uM, which represents a 2:1 molar ratio between 
α-thrombin and DNA. This same experiment was repeated using the 
modified NP-methyl TBA1 and NP-TBA2. All spectra were overlaid 
together to study the displacement of the maximum peak from 520 nm in 
case of AuNPs and 545 nm for AuSPIONs to higher wavelengths, due to 
the formation of a network of TBAs-α-thrombin complexes. Negative 
controls have been carried on by using TBA1, TBA2 and O6-MeG-TBA1 
along with increasing concentrations of hAGT and scrambled DNA along 
with α-thrombin. The protocol used for these studies was the same for 
AuNPs and for AuSPIONs.  
Studies of α-thrombin interaction with TBAs nanoparticles (AuNPS, 
SPIONs and AuSPIONs) by DLS: Binding between α-thrombin and 
TBA1, TBA2 and O6-MeG-TBA1 nanoparticles was studied by analyzing 
the average HD of the particles at room temperature. The molecular 
network originated from this binding was monitored by measuring the 
particles’ radius enlargement upon increasing concentrations of the 
protein. 100 μL of a 5 nM mixture of NP-TBA1 and NP-TBA2 in buffer 
containing 10 mM phosphate pH 7 and 5 mM KCl were measured during 
100 seconds using a 3D cross method with a scattering angle of 90º at 
25ºC. Enough quantity of human α-thrombin was added to reach a 0.5:1 
molar ratio between α-thrombin and DNA. After a quick manual mix, the 
radius length was recorded. The same experiment was repeated using 
the modified NP- O6-MeG-TBA1 and NP-TBA2. The particle radius was 
calculated by fitting of the first cumulant parameter, and the relative 
intensity of the different particle complexes was calculated by fitting the 
contin parameter. All the experiments were performed in triplicates. The 
procedure of the DLS measurements was the same for AuNPs, SPIONs 
and AuSPIONs. 
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Studies of α-thrombin interaction with TBAs nanoparticles (SPIONs 
and AuSPIONs) by MRI: NPs-TBA1 (or NPs-O6-MeG-TBA1) and NPs-
TBA2 were mixed in 1:1 ratio and diluted in 100 mM NaCl, 25 mM KCl 
and 25 mM tris-HCl at pH 7.4, to reach a final concentration of 
nanoparticles of 2.4 µg Fe/mL in the case of the SPIONs and 2.4 mg/mL 
for the AuSPIONs. Then, the samples were incubated with different 
concentrations (0, 5, 10 and 20 nM) of α-thrombin. 100 µL of the mixed 
sample were loaded into a microcapillar and T2 experiments were 
recorded. The magnetic field strength was 14 T, corresponding to a 1 H 
resonance frequency of 600.1 MHz. The images were acquired at room 
temperature, with the following acquisition parameters: MSME (Multi 
Slice Multi Echo) acquisition; number of slices: 1; thickness: 1.50 mm; 
FOV: 0.8 mm; repetition time: 1500 ms; echo time 4.5 ms; number of 
echoes: 10. Two scans were performed, corresponding to a total 
acquisition time of 12 min. T2 values were extracted by a multi-
parametric non-linear fitting y =A+B_e–t/T2 of the intensity decays. All 
measurements were performed three or four times in independent 
experiments. Acquisition and data processing were performed with 
ParaVision v. 4.0. The MRI measurements of the AuSPION were 
performed following the same protocol as the one used for the SPION. 
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Gold coated magnetic nanoparticles combine the magnetic properties of iron and 
the robust chemistry provided by the thiol functionalization of gold. Their good 
performance in the detection of a protein-aptamer complex formation by biophysical 
techniques make them suitable for the development of biosensors for biomedical 
applications. 
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Cellular resistance to alkylating agents is a major drawback for the treatment of 
cancer patients.[1] One of the mechanisms responsible for this resistance is the 
overexpression of DNA repair enzymes, which revert the lesions produced by these 
chemotherapeutic drugs and lead to tumoral cell survival.[2] In particular, the human O6-
alkylguanine-DNA-alkyltransferase[3] is a DNA repair protein that removes alkyl groups 
from the O6 position of guanines, restoring the DNA. For this reason, this protein 
represents a relevant pharmacological target in the fight against chemotherapy resistance 
for patients’ survival.[4] In addition, the level of expression of hAGT has shown to be a 
prognosis biomarker of poor survival in patients who suffer from malignant gliomas.[5] 
Given the relevance of hAGT as a therapeutic target, several methods are available 
to characterise its repair activity. Moreover, they are also able to evaluate the capacity of 
small molecules of inhibiting hAGT.[6] Most of these methods involve radioactivity 
assays,[6b, 6e] while others are based on multiple-step enzymatic reactions.[6a, 6c, 6d] However, 
the first methods are dangerous and require the use of rigorous safety procedures, and the 
others are discontinuous and time-consuming due to the necessity of multiple steps. The 
lack of a straightforward, rapid and costless assay to study hAGT repair activity represents 
a limiting step in the search of potential inhibitors as chemotherapy enhancers. 
Over the last years, different small molecules with hAGT inhibitory capacity have 
been described, although all of them are pseudosubstrates. For example, O6-benzylguanine 
(O6-BG) inactivates hAGT in vitro and in vivo,[7] and has shown to improve the effectiveness 
of chloroethylating agents in clinical trials.[8] However, despite its potential for therapeutic 
inhibition of hAGT, there are considerable limitations in current inhibitors such as O6-BG. 
First, O6-BG has little affinity for hAGT, if compared with the affinity of O6-alkylguanine 
incorporated into double stranded DNA.[9] Second, O6-BG has low bioavailability, very low 
water solubility and a very high plasma clearance. In addition, clinical trials phase I and II 
have shown that it is very likely to produce myelosuppression.[10] A new derivative of 
guanine, lomeguatrib [6-(4-bromo-2-thienyl)methoxy]-purine-2-amino], was proven to be 
more active in vitro than O6-BG.[11] The O6-thienyl analogue was tested in phase I and II 
clinical trials in combination with temozolomide and, as well as O6-BG, did not significantly 
increase the cytotoxic effect associated with the chemotherapeutic agent per se, but also 
caused myelosuppression.[12] 
Later on, many compounds initially thought to be hAGT inhibitors have proven to 
be checkpoint inhibitors instead[13] and only O6-BG is currently on the market. In vitro 
studies of O6-(4-bromo-2-thienyl)-guanine (PaTrin-2 or PAT), a pseudosubstrate 
inactivator of hAGT, showed greater potency than O6-BG. However, it causes dose-limiting 
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toxicities when administered with TMZ.[14] Other novel approaches to hAGT inhibition are 
also being studied with promising results.[13, 15] 
The main objective of this thesis was the finding of new small molecules capable of 
inhibiting hAGT activity, to be used as chemotherapy enhancers. Due to the lack of a 
robust in vitro method to evaluate hAGT activity, we have devoted a substantial part of this 
thesis to the development of such method, trying to avoid radioactivity and complex multi-
step reactions.  
For all the in vitro assays and complex formation experiments described in this 
thesis, recombinant hAGT was used, which was overexpressed and purified following the 
protocols described by Ruiz et al.[6e] Two different constructs of hAGT were used: hAGT-
FL, the human full-length protein and hAGT ΔC177-C145S, a mutant of hAGT where the 
cysteine of the active site was replaced by a serine, making hAGT loose its repair activity 
but maintaining its capacity to recognize and bind alkylguanine-DNA. The sequence of this 
mutant is 30 amino acids shorter than hAGT FL but preserves the folding. This 
modification was done to facilitate its overexpression and manipulation. This hAGT 
mutant was overexpressed and purified in order to use it as a negative control for the 
different in vitro assays. 
Previously, a virtual screening for the selection of potential compounds candidates 
to interact with the active site of hAGT was realized in our group in collaboration with the 
Bioinformatics Unit of the CMBSO. A set of 10 compounds was selected and purchased 
from commercial sources. The standard procedure to evaluate the compounds would be to 
start by an in vitro evaluation of their capacity to inhibit hAGT and subsequently assess 
their toxicity and effectiveness in vivo. However, as detailed before, we do not have an 
adequate in vitro assay available currently and for this reason we started by the cell 
culture experiments and by the study of their ability to form a complex with hAGT by mass 
spectrometry. 
The mass experiments realized allowed us to detect the complex formation between 
hAGT and 5 out of the 10 compounds studied. These results also showed that one of them 
(compound 8) formed a specific complex and the other four (compounds 5, 6, 7 and 9), 
non-specific ones. From the five compounds that showed no interaction with hAGT, one of 
them (compound 10) caused precipitation of hAGT immediately and did not permit the 
study of the complex formation. Another compound (4) showed an alteration in hAGT’s 
mass spectrum, indicating that they interact in such a way that it destabilized in some 
degree its structure. 
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We then tested the toxicity and effectiveness of these potential inhibitors in cell 
culture through MTT assays in human colorectal adenocarcinoma cells. The results 
obtained are discussed extensively in chapter 1. 
The toxicity of the 10 potential inhibitors was studied in cell culture. Two out of the 
ten compounds (5 and 8) were found to be non-toxic, and the other eight compounds were 
toxic at different concentrations. From them, three (2, 4 and 7) were toxic at LD50 values 
lower than 100 µM. Regarding their enhancement of carmustine (BCNU) toxicity, 
compounds 5 and 8, which were non-toxic per se, were found to enhance significantly the 
effect of carmustine, as well as compounds 4, 6 and 7 but these three were toxic. 
Compounds 1, 2 and 3 exhibited a relative capacity to stimulate cell death caused by 
carmustine and in contrast, compounds 9 and 10 were unable to increase the effect of 
carmustine significantly. We performed colony formation assays staining with crystal 
violet with compounds 5 and 8 (non-toxic and enhance BCNU in the MTT assay) and 6 and 
7 (toxic at 1 μM but good enhancement of carmustine). These experiments imply the study 
of the recovery of the cells after treatment with the compounds in presence or absence of 
carmustine, and their capacity to survive and grow during the following 10 days after 
treatment. The results obtained are more difficult to interpret and seem to contradict in 
some ways the experiments of MTT: all the tested compounds except compound 5 were 
found to be non-toxic, allowing the growing of colonies to normal values after 7 days. In 
contrast, compound 5 presented a progressive reduction of colonies over concentration of 
potential inhibitor. These results indicate that cells are able to recover from the treatment 
after some days and redeem their rate of growing, except in the case of compound 5. 
However, their enhancement of Carmustine followed a different pattern: compounds 5, 7 
and 8 improved the rate of cell death and poor survival, while compound 6 did not show a 
stimulating effect on carmustine. Even though, the colony formation assays are 
preliminary and should be reproduced before considering these results conclusive, as for 
example carmustine effect in the compound 6 assay did not seem to be in the same range 
as shown in the other assays. 
From these results, we can pre-establish that compounds 8 seems to be the best 
candidate to enhance the effect of BCNU in cell culture, as it was found to be non-toxic at 
100 μM and improved the rate of cell death when incubated with Carmustine, both in the 
MTT and in the colony formation assay. In addition, compound 5 showed no toxicity and 
good enhancement of carmustine, but it was found to be toxic in colony formation assays. 
Combining the results obtained by ESI-MS and in cell culture, we can conclude that 
2 compounds out of our first ten are able to form a specific (8) or non-specific (5) complex 
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with hAGT and are non-toxic. In addition, they seem to enhance the apoptotic effect of 
Carmustine in MTT and colony formation experiments, even if compound 5 was found to 
be toxic. These compounds represent good candidates for the study of their hAGT 
inhibition effect as potential chemotherapy enhancers. Following the line of this thesis, 
these potential inhibitors should be tested by the methods described subsequently to 
reveal their active concentrations and their suitability to undergo a new optimization cycle 
to obtain a good candidate to start preclinical studies in animal models. 
At the end of this chapter, we include as an annex a work we have realized related 
to the search for inhibitors of another DNA repair protein, Ape1,[16] involved in the base 
excision repair pathway.[17] This paper reports the identification of new compounds as 
potential Ape1 inhibitors through a docking-based virtual screening, following by a 
characterization of them by similar in vitro techniques and cytotoxic evaluating assays as 
the ones described in chapter 1 for hAGT. Interaction of these compounds with the Ape1 
protein was observed by mass spectrometry, and some of the compounds showed in vitro 
activities in the low-to-medium micromolar range. The ability of the candidates to inhibit 
the recombinant Ape1 activity in vitro was determined by a fluorescence-based assay 
described by different groups.[18] These molecules also potentiated the cytotoxicity of the 
chemotherapeutic agent methylmethanesulfonate in fibrosarcoma cells. 
We then intended to evaluate the inhibitory capacity of the candidate molecules in 
vitro. The first intention was to employ the radioactivity assay used by Ruiz et. al.[6e] and 
firstly described by Bresnick and coworkers[19] for the in vitro evaluation of compounds. 
However, the radioactive compound used, 3H-MNU (tritiated methylnitrosourea), was no 
longer commercially available. Other radioactivity-based assays are described, but in 
addition to being multi-enzymatic reactions, they require the use of rigorous safety 
procedures.[6b] Other assays, as ESI-MS-based experiments,[20] electrophoretic mobility 
shift assays[21] or HPLC assays[22] have also been conducted with the aim of studying hAGT 
repair. Mass spectrometry and electrophoretic detection of repaired oligonucleotides 
were most efficient in the case of interstrand cross-linked DNA, due to the fact that the 
repaired oligonucleotide without a cross-link to the complementary strand has a lower 
mass than the two strands covalently cross-linked, after forcing the denaturation of the 
duplex.[20b, 21b] Other assays reported the inhibition of restriction endonuclease followed 
by magnetic bead separation of products.[6a, 6d] Furthermore, a fluorescence assay was 
reported by Moser et al, proving useful and sensible detection of hAGT activity but it 
implied the use of a digestion step for the release of the fluorescent moiety.[6c] All these 
methods are based on multi-step complex reactions and are discontinuous and time-
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consuming and the necessity to find a straightforward and sensible method for the 
detection of hAGT repair activity remains relevant. 
For this reason, we have devoted a great effort and the main part of this thesis to 
the development of new in vitro assays for the detection of hAGT activity which allow to 
evaluate its inhibition by the candidate compounds. We have exploited all the resources 
and techniques of expertise available in our research group, whose field of interest is the 
chemistry and structure of nucleic acids and the application of DNA nanotechnology to 
biomedicine. 
Chapter 2 describes a method to evaluate hAGT activity that takes advantage of the 
conformational change of a single stranded DNA quadruplex,[23] the thrombin binding 
aptamer (TBA),[24] an aptamer that is recognized by α-thrombin when it is folded into its 
quadruplex structure. First, we demonstrated by UV monitoring of the thermal stability of 
the quadruplex and by circular dichroism that the replacement of a single guanine by an 
O6-methylguanine disrupts the G-quadruplex native structure of TBA, because it 
diminishes the amount of chemical groups available for the Hoogsteen hydrogen bonding 
that forms the G-quartets.  
The conformational change of this G-quadruplex was used to develop a 
fluorescence-quencher system that reduces the emission of fluorescence when hAGT 
repairs the methylation introduced previously. The fluorophor and the quencher molecule 
were placed in opposite ends of the sequence, and the distance between them depends on 
its conformation: the native TBA is folded into its quadruplex structure, forcing the 
proximity of the fluorophor and the quencher whilst the methylated TBA, being unable to 
fold the quadruplex, maintains its ends in opposite senses and the fluorophor and the 
quencher are kept apart from each other. The reaction of hAGT represents the key to the 
folding and unfolding of TBA and thus to the emission or suppression of fluorescence.  
Even if the methodology is rapid, simple and avoids the use of radioactivity, it had 
an unexpected drawback: the measurement of the loss of fluorescence was slightly 
delicate, as it is always more difficult to detect and reproduce a particular loss of signal 
than an increase of it from basal conditions. These deliberations led us to consider the 
robustness of this new methodology in terms of being able to implement it for the search 
of more potent inhibitors of hAGT activity. 
For this reason, taking advantage of the expertise of other members of the 
laboratory in DNA Nanotechnology and making use of the conclusion obtained in chapter 2 
about the distortion of the G-quadruplex when a guanine is replaced by a methylguanine, 
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we designed a DNA origami platform[25] as a nanotechnological device to detect hAGT 
activity. The DNA origami had previously been applied as platform to follow single 
molecule reactions,[26] even for the detection of conformational changes of a G-
quadruplexes,[27] for DNA repair proteins’ reaction tracking[28] and for spatial organization 
of proteins[29] or other nanomaterials.[30] All these advances in DNA nanotechnology lead 
us to envisage a new platform for hAGT repair study using DNA origami. This method is 
described in chapter 3. We exploited the spatial addressability of DNA origami in 
combination with the conformational change of a DNA G-quadruplex, TBA, to detect by 
AFM in real-time the complex formation with its substrate α-thrombin. This structural 
change is caused by a single methylation in the central guanines, as reported in chapter 2, 
and it causes that TBA is no longer recognized by α-thrombin. This fact was demonstrated 
by fluorescence and EMSA assays, and both results confirmed that the introduction of a 
methylated guanine prevented α-thrombin interaction, and besides, that a concentration 
of 10 fold of α-thrombin can be sufficient to appreciate a different pattern of union of this 
protein to the TBAs and methyl-TBAs-containing origami. The different behaviour of α-
thrombin towards the TBA and the methylated TBA can be utilised to detect the DNA 
repair activity of hAGT, given that methylguanine is the substrate of this protein. In this 
case, we used two different types of TBA, which bind at opposite exosites of α-thrombin in 
a cooperative way[24] and improved the attachment of the proteins over the DNA origami, 
preventing the sweeping away by the AFM tip. The arrangement of α-thrombin over the 
surface of the DNA origami follows the distance-dependent design described by Rinker et. 
al,[29b] who found that upon placing the two aptamers at a specific distance of 5.8 nm from 
each other, the recognition of the protein increased by 10-fold. The introduction of several 
methylated TBAs in specific positions of the origami allowed to observe the loss of 
thrombin binding. We proved that only one of the aptamers of the pair being methylated 
was enough to disrupt the binding, and no α-thrombin interaction was observed by AFM 
while the control pairs of unmodified aptamers exhibited high rate of binding. When the 
O6-methylguanine of the modified TBA was repaired by hAGT, α-thrombin was able to 
bind again to the repaired aptamers, as they can form the quadruplex structure required 
for interaction. The system is extremely effective and reliable, and the results are clearly 
followed by AFM. Their consistency suggests that our system could be further evolved for 
the study of other DNA repair enzymes. Even though, the complexity and high cost of the 
AFM technique hinders the application of this technology for the high throughput 
evaluation of potential inhibitors of hAGT.  
As a result of the high impact achieved by the publication of this work, our group 
was invited to write a review on the state of the art of DNA nanotechnology. This work is 
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included as an annex of this chapter. In this review we examine recent progresses towards 
the potential use of DNA nanostructures for molecular and cellular biology.  
In parallel, we developed a second fluorescence assay which tried to address the 
limitations found before (chapter 4). Studying the mechanism of action of hAGT and some 
reports in the literature where it is described that hAGT is more active over double 
stranded DNA,[31] we decided to use a double stranded oligonucleotide with a labelled 
alkylated guanine which could be transferred to the active site of hAGT upon DNA repair 
and could be quantified. This would represent a direct measurement of the activity of the 
protein and could be used to evaluate the effect of potential inhibitors. We synthesized a 
double stranded oligonucleotide where one of the two strands incorporated an alkyl-
guanosine chemically modified in the O6 position with an aminobenzyl group. We used this 
group because O6-benzylguanine is reported to be the most efficiently repaired bulky 
adduct by hAGT[31-32] and the free amino group in the para position allowed the post-
synthetic chemical introduction of a fluorophore (fluorescein isothiocyanate, FITC). This 
work implied the design of a novel synthetic route for the properly protected O6-
benzylguanosine to incorporate it to the automatized DNA synthesis cycle. This O6-
benzylguanosine was prepared from 2’-deoxyguanosine and the corresponding protected 
4-aminomethylbenzyl alcohol through a Mitsunobu reaction.[33] Prior to the setting up of 
the fluorescence assay, we conducted HPLC studies of the repair capability of hAGT of this 
O6-benzylguanine with the attached fluorescein, to ensure that this bulky substituent can 
be accommodated in the active site of the protein. Post-synthetically, we attached a 
fluorophore to this aminobenzyl group to follow the repair reaction by means of 
fluorescence. We incorporated a nucleotide modified with a quencher group in the 
complementary strand to reach very low basal fluorescence when the two strands are 
annealed. Two options were explored to ensure the maximal quenching of fluorescence for 
the background conditions of the assay: in one case, the quencher was placed in the exact 
complementary position, and in the other, at one nucleotide shift in the complementary 
sequence. The placement of the quencher in the complementary base of the modified 
guanosine provokes a mismatch in the sequence, due to the fact that there is no 
commercially available cytidine covalently modified with the dabcyl group and the use of a 
thymidine was required. In the case of the complementary duplex, we expected that the 
fluorescence extinction would remain efficient even if the quencher was not placed in the 
complementary position. As spatial orientation of this bulky substituents remains unclear, 
both were studied in terms of thermal stability and capacity to enter hAGT’s active site , 
and finally the complementary duplex was used for the fluorescence assays because it 
remained stable at the temperature range required for the efficient reaction of hAGT. As 
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expected, once hAGT repaired the O6 alkylguanine, it transferred the fluorophore to its 
active site together with the alkyl group, bringing it apart from the quencher. This resulted 
in an immediate increase in fluorescence that could be detected and correlated to hAGT 
activity. In contrast with the previous methods, and as it has been mentioned before, this 
system uses a double stranded oligonucleotide, which is the real substrate for the activity 
of hAGT in vivo and thus increases the efficiency of the repair reaction. In addition, as the 
variation in fluorescence is increasing upon activity, it is easier to quantify than the loss of 
fluorescence measured before. This method is currently ready to be used for the study of 
potential hAGT inhibitors, and some preliminary results are shown in the annex 4. These 
results point to compound 8 as a promising candidate to inhibit hAGT in vitro, which is in 
consonance with the results obtained in chapter 1, where it was found to form a specific 
complex with hAGT, to be non-toxic per se and to produce a significant enhancement of 
carmustine toxicity. 
A similar approach had been described for the preparation of a fluorescent 
derivative of O6-benzylguanine to be used in the detection of the hAGT activity in cells.[34] 
In these experiments, the O6-alkylnucleobase is allowed to enter the cells by passive 
diffusion and after a certain time the excess of the fluorescent nucleobase is washed away 
and the remaining fluorescence measured. This remaining fluorescence inside the cells 
corresponds to the hAGT which has reacted, becoming fluorescently labeled. In our case, 
we need to evaluate in real-time the activity of hAGT and for this reason, we had to 
introduce the fluorescently labeled nucleoside in a DNA sequence, as well as we require 
the quencher molecule to be in the complementary sequence to enhance the change of 
fluorescence when the fluorescein molecule is transferred to hAGT. Our approach 
represents a more complex system which allows to measure in vitro the activity of hAGT in 
real-time. 
Following with the nanotechnology, and during a short stay in the Department of 
Food, Environmental and Nutrition Sciences of the University of Milan, we studied the use 
of gold-coated magnetic nanoparticles for molecular biosensing. Binding of α-thrombin to 
these nanoparticles conjugated with two aptamers which recognize different sites of the 
protein causes aggregation,[35] a phenomenon that can be detected by three different 
techniques: UV, DLS and MRI. These techniques discriminate even a single methylation in 
one of the aptamers, preventing aggregation due to the inability of α-thrombin to 
recognize it. This system can be further developed for the detection of the activity of DNA 
repair proteins which have alkylated guanines as substrate. 
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We conjugated the thrombin binding aptamers 1 and 2 to gold nanoparticles 
(AuNPs) iron-oxide nanoparticles (SPION) and gold-coated iron-oxide (AuSPION) 
nanoparticles, and then comparatively studied the ability of α-thrombin to recognize a 
mixture of methylated and unmethylated TBA-conjugated nanoparticles. The mixture 
containing unmodified TBAs was able to bind α-thrombin in its both recognizing sites, 
forming a molecular network. In contrast, the methylated TBA1 together with the 
unmodified TBA2 was unable to form the network, and the aggregation process did not 
occur. 
SPION and AuSPION allow the detection of α-thrombin by means of Magnetic 
Resonance Imagining, because they are contrast agents for image enhancement. The 
unmodified mixture of TBAs is able to interact with α-thrombin and a molecular network 
is formed, increasing the image contrast and its T2 value, as reported previously.[35] 
AuSPION and AuNP have a surface plasmon maximum at 520 nm that shifts to higher 
wavelengths when precipitation occurs, allowing the use of UV-spectroscopy as a 
detection method. Other works have previously exploited this feature to develop 
biosensors for lipase activity,[36] to monitor oxidative stress[37] or to detect blood 
cholesterol,[38] between others. And finally, precipitation of the three types of 
nanoparticles can be detected by Dynamic Light Scattering, measuring the main diameter 
of the nanoparticles before and after thrombin addition and finding a huge increase in the 
case of the unmodified mixture of nanoparticles. Aggregation detected by DLS has also 
been used before to develop sensors for cancer biomarkers,[39] or for the detection of small 
molecules in solution.[40] However, this is the first time that the same nanoparticles 
(AuSPIONs) can be used to detect a protein by the three techniques indistinguishably, due 
to the combination of features provided by the magnetic core and the gold coating. 
Given that the repair activity of this methylation by hAGT would imply an 
aggregation of the nanoparticles as a result of the dealkylation process, this platforms 
could be evolved to design a new methodology to detect hAGT activity. We have set the 
bases for this multidisciplinary methodology, allowing its use for a development of a new 
straight-forward and single-step assay for hAGT activity and for the testing of potential 
inhibitors. 
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CONCLUSIONS: 
- 10 compounds selected by a virtual screening study with potential inhibitory activity against hAGT have been analysed in vitro and in cell culture assays : 
 The analysis by mass spectrometry (ESI-MS) confirmed the complex formation of hAGT with 5 of them: compound 8 formed a specific complex and compounds 5, 6, 7 and 9 an unspecific one.  
 MTT cytotoxicity studies showed that 2 compounds (5 and 8) were non-toxic and the other 8 compounds presented different levels of toxicity per se. In addition, 5 compounds showed enhancement of carmustine toxicity (4, 5, 6, 7 and 8). Compounds 5 and 8 seem to be the best candidates for hAGT inhibition, as they enhance BCNU without being toxic by themselves. 
 Compounds 5, 6, 7 and 8 were further characterized by colony formation assays, which confirmed that compound 8 was non-toxic at long-term experiments and exhibited a stimulation effect of carmustine.  
- A new method to detect hAGT activity based on the conformational change of the thrombin binding aptamer and followed by FRET has been designed and set up successfully. This technology allows the quantification of hAGT activity in a single step and in a straightforward manner, avoiding radioactivity and reaching a detection limit of 0.5 pmols of hAGT. Furthermore, this method can be easily transferred to a high throughput experiment for the evaluation of small molecules as potential hAGT inhibitors.  
- The DNA origami platform has been exploited to design a new methodology to follow in real-time the repair activity of hAGT by Atomic Force Microscopy. This study combines the recognition capacity of α-thrombin, able to discriminate methyl-TBA and TBA, and the single-molecule features of the DNA origami technique, applied to the detection of DNA repair. The system is extremely effective and reliable, and the results are clearly followed by AFM, allowing the detection of single-molecule reactions, the highest detection limit possible. Their consistency suggests that our system could be further evolved to design hAGT activity assays for the identification of potential inhibitors as chemotherapy enhancers and for the study of other DNA repair enzymes.  
- A new assay to detect hAGT activity by the transfer of a fluorescent moiety from the substrate oligonucleotide to the active site of the protein has been described. For this purpose: 
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 We have described a novel route for synthesizing an O6-benzyl-2’-deoxyguanosine precursor which incorporated to an oligonucleotide sequence, can become a fluorescently labelled substrate for measuring hAGT repair activity.  
 Annealing with a complementary quencher strand produces a stable duplex confirmed by physicochemical methods which presents a low basal fluorescence.  
 We have tested the efficiency of the fluorescence substrate transfer to hAGT. This system allows the detection of 0.5 pmols of hAGT, the same obtained for the fluorescence assay based on the conformational change of a G-quadruplex. 
 On theses bases, we have developed a new rapid and straightforward assay to detect hAGT activity. The system uses a double-stranded oligonucleotide, the natural substrate for hAGT activity, improving efficiency and reliability due to its easy quantification of the fluorescence increase upon activity.  
 We have tested 9 compounds with potential inhibitory activity of hAGT, finding that compound 8 inhibits significantly the DNA repair activity of hAGT in vitro. This represents a proof of concept of the usability of our method, as well as confirms the results previously obtained in chapter 1.  
- Three types of nanoparticles (AuNPs, SPIONs and AuSPIONs) have been used to detect by different techniques (UV, DLS and MRI) a single methylation in G-quadruplex. We have proven the detection capacity of AuSPION as biosensors, demonstrating that their performance is comparable to AuNPs and SPIONs. The bases for setting up a new detection platform for hAGT activity over a nanoparticle system have been accomplished.  
240
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
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The O6-alkylguanine DNA alkyltransferase (hAGT or MGMT) is a DNA repair protein in charge of removing alkyl adducts from the O6 position of guanines, blocking their cytotoxic effects and playing an important role as a resistance mechanism to chemotherapy in cancer patients. For these reasons, it is considered relevant as a prognosis marker of cancer and represents a potential therapeutic target. Intense research efforts have been devoted to the identification of small molecules capable of inhibiting hAGT activity and enhancing the cytotoxic effect of the alkylating agents in tumour cells.  In this doctoral thesis, we have explored 10 compounds with potential inhibitory activity against hAGT. The analysis by mass spectrometry (ESI-MS) confirmed the complex formation of hAGT with 5 of them (compounds 5, 6, 7, 8 and 9). MTT cytotoxicity studies in cell culture showed that 2 compounds (5 and 8) were non-toxic and showed enhancement of carmustine toxicity. This compounds were further analysed by colony formation assays, which confirmed that compound 8 was non-toxic at long-term experiments and exhibited a stimulation effect of carmustine. Compound 8 seem to be the best candidates for hAGT inhibition, as it forms a complex with hAGT and it enhances BCNU without being toxic in MTT and colony formation assays. Due to the lack of a consistent in vitro assay for the activity of hAGT, we have devoted part of this doctoral thesis to the search of bio and nanotechnologies to detect hAGT activity which enable the evaluation of potential inhibitors of the protein. Chapter 2 describes the development of a new fluorescence method using the conformational change of a DNA G-quadruplex, the thrombin binding aptamer (TBA), as a molecular beacon for the detection of hAGT activity and the development of new inhibitor compounds.  The conformational change of TBA is further explored to develop a detection platform on DNA origami which allows de quantification of the repair activity of hAGT on a single molecules basis, through the direct visualization by AFM of the interaction of TBA 
with its target protein α-thrombin when its G-quadruplex structure is restored.  In addition, this work reports the synthesis of guanine derivatives modified at position 6 and properly functionalized for their incorporation into double stranded oligonucleotides that are used for the development of another novel fluorescence methodology to evaluate hAGT activity and to assess potential inhibitors as enhancers of chemotherapy. Finally, during a short stay in the University of Milan, we have developed a new sensor to detect a methylation in TBA using three types of nanoparticles: AuNPs, SPIONs and AuSPIONs. AuSPIONs combine the features of the gold coating and the magnetic core, 
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and exhibit similar performance as AuNPs and SPIONs in UV, DLS and MRI assays to detect thrombin and a single methylation in TBA. These results provide the basis for the development of a new straightforward method to study hAGT activity and to evaluate potential inhibitors.   
244
 RESUM 
La proteïna de reparació de l’ADN alquilguanina-ADN-O6-alquiltransferasa (hAGT) 
elimina productes d'alquilació en la posició O6 de les guanines, bloquejant la citotoxicitat 
dels agents alquilants i produint resistència a la quimioterapia. Es considera rellevant com 
a marcador de pronòstic en càncer i representa una potencial diana terapèutica.  
L’objectiu a llarg termini d’aquesta tesi doctoral és trobar inhibidors de l’activitat 
d’hAGT per millorar l'efecte de la quimioteràpia en pacients amb càncer. 
En primer lloc, es va avaluar la capacitat de 10 compostos, potencials inhibidors 
d’hAGT, de formar un complexe amb hAGT utilitzant espectrometria de masses, i es va 
estudiar la seva toxicitat en cultius cel·lulars a través d'assajos de MTT i de formació de 
colònies.  
A continuació, es desenvolupen diferents mètodes per a la detecció de l’activitat 
d’hAGT, per a avaluar inhibidors d’aquesta proteïna in vitro. Dos d’aquests mètodes 
utilitzen el canvi conformacional que es produeix en l’aptàmer d’unió a la trombina (TBA) 
en introduir una O6-metilguanina, substrat d’hAGT, en una de les seves tètrades centrals.  
En el primer mètode es va emprar el TBA per generar un sensor de fluorescencia 
incorporant un fluoròfor i un inhibidor de fluorescència a cadascun dels seus extrems. 
Aquest sensor permet la detecció de la disminució en la fluorescència deguda al canvi 
conformacional del TBA produit per l’activitat d’hAGT. 
Posteriorment, el canvi conformacional del TBA va permetre dissenyar un 
biosensor de l'activitat d'hAGT a nivell unimolecular sobre la superfice d’un origami 
d'ADN. La interacció del TBA amb la seva proteina diana, l’α-trombina, es va seguir per 
AFM per detectar que l’estructura de G-quàdruplex metilada es restableix per la reparació 
d’hAGT.  
El tercer mètode es basa en la transferència de fluorescència al centre actiu d’hAGT 
degut a la reparació d’un oligonucleòtid que conté una guanina modificada amb un grup 
alquil marcat amb un fluoròfor. Amb aquest objectiu, es va portar a terme la síntesi 
química d’aquesta guanina modificada. 
En el marc d’una estada en la Universitat de Milà, es descriu l’estudi de 
nanopartícules funcionalitzades amb TBAs per a detectar una metilació en una guanina 
utilitzant espectroscopia d’UV, DLS o MRI, amb l’objectiu de desenvolupar un nou assaig 
de l’activitat reparadora d’ADN d’hAGT. 
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